PMID- 9339686 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 0028-3878 (Print) VI - 49 IP - 4 DP - 1997 Oct TI - Higher neonatal cerebral blood flow correlates with worse childhood neurologic outcome. PG - 1035-41 AB - Cerebral blood flow (CBF) in newborn infants is often below levels necessary to sustain brain viability in adults. Controversy exists regarding the effects of such low CBF on subsequent neurologic function. We determined the current childhood neurologic status and IQ in 26 subjects who had measurements of CBF performed with PET in the neonatal period between 1983 and 1989 as part of a study of hypoxic-ischemic encephalopathy. Follow-up information at ages 4 to 12 years was obtained on all 26 subjects. Ten subjects had died. All 16 survivors underwent clinical neurologic evaluation, and 14 also underwent intelligence testing. Eight had abnormal clinical neurologic evaluations; eight were normal. The mean neonatal CBF in those with abnormal childhood neurologic outcome was significantly higher than in those with normal childhood neurologic outcome (35.64 +/- 11.80 versus 18.26 +/- 8.62 mL 100 g(-1) min(-1), t = 3.36, p = 0.005). A significant negative correlation between neonatal CBF and childhood IQ was demonstrated (Spearman rank correlation r = -0.675, p = 0.008). Higher CBF was associated with lower IQ. The higher CBF in subjects with worse neurologic and intellectual outcome may reflect greater loss of cerebrovascular autoregulation or other vascular regulatory mechanisms due to more severe brain damage. AD - Department of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, MO 63110, USA. FAU - Rosenbaum, J L AU - Rosenbaum JL FAU - Almli, C R AU - Almli CR FAU - Yundt, K D AU - Yundt KD FAU - Altman, D I AU - Altman DI FAU - Powers, W J AU - Powers WJ LA - eng GR - NS06833/NS/NINDS GR - NS32568/NS/NINDS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Neurology JT - Neurology JID - 0401060 SB - AIM SB - IM MH - Cerebrovascular Circulation/*physiology MH - *Child Development MH - Follow-Up Studies MH - Humans MH - Infant, Newborn MH - Intelligence MH - *Nervous System Physiology MH - Neurologic Examination MH - Tomography, Emission-Computed EDAT- 1997/10/27 MHDA- 1997/10/27 00:01 PST - ppublish SO - Neurology. 1997 Oct;49(4):1035-41. PMID- 9357896 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0003-3022 (Print) VI - 87 IP - 4 DP - 1997 Oct TI - Bupivacaine inhibition of L-type calcium current in ventricular cardiomyocytes of hamster. PG - 926-34 AB - BACKGROUND: The local anesthetic bupivacaine is cardiotoxic when accidentally injected into the circulation. Such cardiotoxicity might involve an inhibition of cardiac L-type Ca2+ current (ICa,L). This study was designed to define the mechanism of bupivacaine inhibition of ICa,L. METHODS: Cardiomyocytes were enzymatically dispersed from hamster ventricles. Certain voltage- and time-dependencies of ICa,L were recorded using the whole-cell patch clamp method in the presence and absence of different concentrations of bupivacaine. RESULTS: Bupivacaine, in a concentration-dependent manner (10-300 microM), tonically inhibited the peak amplitude of ICa,L. The inhibition was characterized by an increase in the time of recovery from inactivation and a negative-voltage shift of the steady-state inactivation curve. The inhibition was shown to be voltage-dependent, and the peak amplitude of ICa,L could not be restored to control levels by a wash from bupivacaine. CONCLUSIONS: The inhibition of ICa,L appears, in part, to result from bupivacaine predisposing L-type Ca channels to the inactivated state. Data from washout suggest that there may be two mechanisms of inhibition at work. Bupivacaine may bind with low affinity to the Ca channel and also affect an unidentified metabolic component that modulates Ca channel function. AD - Department of Anesthesiology, Winthrop-University Hospital, Mineola, New York, USA. krossner@epo.som.sunysb.edu FAU - Rossner, K L AU - Rossner KL FAU - Freese, K J AU - Freese KJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Anesthesiology JT - Anesthesiology JID - 1300217 RN - 0 (Anesthetics, Local) RN - 0 (Calcium Channels) RN - 0 (Calcium Channels, L-Type) RN - 2180-92-9 (Bupivacaine) SB - AIM SB - IM MH - Anesthetics, Local/*pharmacology MH - Animals MH - Bupivacaine/*pharmacology MH - Calcium Channels/*drug effects MH - Calcium Channels, L-Type MH - Cricetinae MH - Dose-Response Relationship, Drug MH - Heart/*drug effects MH - Male EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Anesthesiology. 1997 Oct;87(4):926-34. PMID- 9298188 OWN - NLM STAT- MEDLINE DA - 19971117 DCOM- 19971117 LR - 20061115 PUBM- Print IS - 0003-6072 (Print) VI - 72 IP - 2 DP - 1997 Aug TI - Formation of formate and hydrogen, and flux of reducing equivalents and carbon in Ruminococcus flavefaciens FD-1. PG - 101-9 AB - A pathway for conversion of the metabolic intermediate phosphoenolpyruvate (PEP) and the formation of acetate, succinate, formate, and H2 in the anaerobic cellulolytic bacterium Ruminococcus flavefaciens FD-1 was constructed on the basis of enzyme activities detected in extracts of cells grown in cellulose- or cellobiose-limited continuous culture. PEP was converted to acetate and CO2 (via pyruvate kinase, pyruvate dehydrogenase, and acetate kinase) or carboxylated to form succinate (via PEP carboxykinase, malate dehydrogenase, fumarase, and fumarate reductase). Lactate was not formed even during rapid growth (batch culture, mu = 0.35/h). H2 was formed by a hydrogenase rather than by cleavage of formate, and 13C-NMR and 14C-exchange reaction data indicated that formate was produced by CO2 reduction, not by a cleavage of pyruvate. The distribution of PEP into the acetate and succinate pathways was not affected by changing extracellular pH and growth rates within the normal growth range. However, increasing growth rate from 0.017/h to 0.244/h resulted in a shift toward formate production, presumably at the expense of H2. This shift suggested that reducing equivalents could be balanced through formate or H2 production without affecting the yields of the major carbon-containing fermentation endproducts. AD - Department of Bacteriology, University of Wisconsin-Madison 53706, USA. FAU - Shi, Y AU - Shi Y FAU - Weimer, P J AU - Weimer PJ FAU - Ralph, J AU - Ralph J LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - NETHERLANDS TA - Antonie Van Leeuwenhoek JT - Antonie van Leeuwenhoek JID - 0372625 RN - 0 (Acetates) RN - 0 (Bacterial Proteins) RN - 0 (Formates) RN - 110-15-6 (Succinic Acid) RN - 124-38-9 (Carbon Dioxide) RN - 127-17-3 (Pyruvic Acid) RN - 1333-74-0 (Hydrogen) RN - 16462-44-5 (Cellobiose) RN - 50-21-5 (Lactic Acid) RN - 73-89-2 (Phosphoenolpyruvate) RN - 9004-34-6 (Cellulose) RN - EC 1.18.99.1 (Hydrogenase) SB - IM MH - Acetates/*metabolism MH - Anaerobiosis MH - Bacterial Proteins/analysis/metabolism MH - Carbon Dioxide/metabolism MH - Cellobiose/metabolism MH - Cellulose/metabolism MH - Fermentation MH - Formates/*metabolism MH - Gram-Positive Cocci/enzymology/growth & development/*metabolism MH - Hydrogen/*metabolism MH - Hydrogen-Ion Concentration MH - Hydrogenase/metabolism MH - Lactic Acid/metabolism MH - Phosphoenolpyruvate/metabolism MH - Pyruvic Acid/metabolism MH - Succinic Acid/*metabolism EDAT- 1997/08/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - Antonie Van Leeuwenhoek. 1997 Aug;72(2):101-9. PMID- 9263049 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20031114 PUBM- Print IS - 0021-8812 (Print) VI - 75 IP - 8 DP - 1997 Aug TI - Approximate confidence intervals for heritability from method R estimates. PG - 2041-6 AB - Method R estimates of heritability (h2) and associated confidence intervals (CI) were obtained from simulated data using a single trait, direct effects, full animal model, with 50% subsampling. Five hundred data sets were simulated for each of five levels of h2 (.10, .20, .30, .40, and .50) and two types of pedigree structure (random pedigree structure [N = 2,000] that varied over simulations, or the pedigree structure from a real data set [N = 2,644] that was constant for all simulations). The first 10, 20, and all 50 h2 estimates were used to obtain 80, 90, 95, and 99% CI for each data set. The variance of h2 estimates within data sets approximated the sampling variance of the h2 estimates. The Box-Cox transformation was used to normalize the distribution of estimates from each data set. Confidence intervals were computed on the transformed scale as CI = mu +/- (T x sigma), where mu and sigma = the mean and SD of the N transformed h2 estimates, respectively, and T = the critical value from the T distribution for a 1-alpha CI, with df = N-1. Upper and lower CI bounds were converted back to the original scale by reversing the transformation. The percentages of CI containing the true h2 value, pooled across all levels of h2, types of pedigree, and number of estimates used to obtain CI, for 80, 90, 95, and 99% CI were 81.14, 90.96, 95.27, and 98.76%, respectively. These results suggested that Method R h2 estimates can be used to obtain reliable CI. AD - Department of Statistics, Colorado State University, Fort Collins 80523, USA. FAU - Mallinckrodt, C H AU - Mallinckrodt CH FAU - Golden, B L AU - Golden BL FAU - Reverter, A AU - Reverter A LA - eng PT - Journal Article PL - UNITED STATES TA - J Anim Sci JT - Journal of animal science JID - 8003002 SB - IM MH - Analysis of Variance MH - Animals MH - Animals, Domestic/*genetics MH - Confidence Intervals MH - Female MH - *Genetics/statistics & numerical data MH - Male MH - *Models, Genetic MH - Phenotype MH - Time Factors EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 PST - ppublish SO - J Anim Sci. 1997 Aug;75(8):2041-6. PMID- 9308130 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20060504 PUBM- Print IS - 0277-6715 (Print) VI - 16 IP - 18 DP - 1997 Sep 30 TI - rhDNase as an example of recurrent event analysis. PG - 2029-47 AB - We consider counting process methods for analysing time-to-event data with multiple or recurrent outcomes, using the models developed by Anderson and Gill, Wei, Lin and Weissfeld and Prentice, Williams and Peterson. We compare the methods, and show how to implement them using popular statistical software programs. By analysing three data sets, we illustrate the strengths and pitfalls of each method. The first example is simulated and involves the effect of a hidden covariate. The second is based on a trial of gamma interferon, and behaves remarkably like the first. The third and most interesting example involves both multiple events and discontinuous intervals at risk, and the three approaches give dissimilar answers. We recommend the AG and marginal models for the analysis of this type of data. AD - Mayo Clinic, Rochester, MI, USA. FAU - Therneau, T M AU - Therneau TM FAU - Hamilton, S A AU - Hamilton SA LA - eng PT - Journal Article PL - ENGLAND TA - Stat Med JT - Statistics in medicine JID - 8215016 RN - 0 (Expectorants) RN - 0 (Interferon-gamma, Recombinant) RN - 0 (Recombinant Proteins) RN - EC 3.1.21.1 (DNASE1 protein, human) RN - EC 3.1.21.1 (Deoxyribonuclease I) SB - IM MH - Adult MH - Analysis of Variance MH - Child MH - Cystic Fibrosis/*drug therapy MH - Data Collection/statistics & numerical data MH - Deoxyribonuclease I/*therapeutic use MH - Double-Blind Method MH - Expectorants/*therapeutic use MH - Granulomatous Disease, Chronic/*therapy MH - Humans MH - Interferon-gamma, Recombinant/*therapeutic use MH - *Mathematical Computing MH - *Models, Statistical MH - Randomized Controlled Trials/*statistics & numerical data MH - Recombinant Proteins/therapeutic use MH - Risk MH - *Software MH - *Survival Analysis MH - Treatment Outcome EDAT- 1997/10/06 17:35 MHDA- 2000/06/20 09:00 AID - 10.1002/(SICI)1097-0258(19970930)16:18<2029::AID-SIM637>3.0.CO;2-H [pii] PST - ppublish SO - Stat Med. 1997 Sep 30;16(18):2029-47. PMID- 9317033 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0019-9567 (Print) VI - 65 IP - 10 DP - 1997 Oct TI - Involvement of p21racA, phosphoinositide 3-kinase, and vacuolar ATPase in phagocytosis of bacteria and erythrocytes by Entamoeba histolytica: suggestive evidence for coincidental evolution of amebic invasiveness. PG - 4243-9 AB - Trophozoites of Entamoeba histolytica, the protozoan parasite that causes amebic dysentery, phagocytose bacteria in the colonic lumen and erythrocytes (RBC) in host tissues. Because tissue invasion is an evolutionary dead end, it is likely that amebic pathogenicity is coincidentally selected, i.e., the same methods used to kill bacteria in the colonic lumen are used by parasites to damage host cells and cause disease. In support of this idea, the amebic lectin and pore-forming peptide are involved in binding and killing, respectively, bacteria and host epithelial cells. Here amebic phagocytosis of bacteria, RBC, and mucin-coated beads was disrupted by overexpression of E. histolytica p21(racA-V12), a ras-family protein involved in selection of sites of actin polymerization, which had been mutated to eliminate its GTPase activity. p21(racA-V12) transformants were also defective in capping and cytokinesis, while pinocytosis of fluorescent dextrans was not affected. Wortmannin, a fungal inhibitor of phosphoinositide 3-kinase, markedly inhibited phagocytosis of bacteria, RBC, and mucin-coated beads by wild-type amebae. In contrast to p21(racA-V12) overexpression, wortmannin abolished amebic pinocytosis of dextrans but had no inhibitory effects on capping. Inhibition of amebic vacuolar acidification by bafilomycin also decreased bacterial and RBC uptake. These results, which demonstrate similarities between mechanisms of phagocytosis of bacteria and RBC by amebae and macrophages, support the idea of coincidental selection of amebic genes encoding proteins that mediate destruction of host cells. AD - Department of Tropical Public Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA. FAU - Ghosh, S K AU - Ghosh SK FAU - Samuelson, J AU - Samuelson J LA - eng GR - AI-33492/AI/NIAID PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Infect Immun JT - Infection and immunity JID - 0246127 RN - 0 (Androstadienes) RN - 0 (Anti-Bacterial Agents) RN - 0 (Cysteine Proteinase Inhibitors) RN - 0 (Macrolides) RN - 12125-02-9 (Ammonium Chloride) RN - 17090-79-8 (Monensin) RN - 19545-26-7 (wortmannin) RN - 61-90-5 (Leucine) RN - 66701-25-5 (E 64) RN - EC 2.7.1.137 (1-Phosphatidylinositol 3-Kinase) RN - EC 3.6.1.- (GTP-Binding Proteins) RN - EC 3.6.5.2 (rac GTP-Binding Proteins) SB - IM MH - 1-Phosphatidylinositol 3-Kinase/genetics/*metabolism MH - Ammonium Chloride/pharmacology MH - Androstadienes/pharmacology MH - Animals MH - Anti-Bacterial Agents/pharmacology MH - Bacteria MH - Cysteine Proteinase Inhibitors/pharmacology MH - Entamoeba histolytica/cytology/genetics/*pathogenicity MH - Erythrocytes MH - Evolution MH - GTP-Binding Proteins/genetics/*metabolism MH - Hydrogen-Ion Concentration MH - Immunologic Capping MH - Leucine/analogs & derivatives/pharmacology MH - Macrolides MH - Macrophages/physiology MH - Models, Biological MH - Monensin/pharmacology MH - Mutation MH - Phagocytosis/*physiology MH - Pinocytosis MH - Transformation, Genetic MH - Vacuoles/physiology MH - rac GTP-Binding Proteins EDAT- 1997/10/08 MHDA- 1997/10/08 00:01 PST - ppublish SO - Infect Immun. 1997 Oct;65(10):4243-9. PMID- 9331038 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20041117 PUBM- Print IS - 0301-620X (Print) VI - 79 IP - 5 DP - 1997 Sep TI - Intra-articular local anaesthesia for pain after hip arthroplasty. PG - 796-800 AB - We investigated 15 patients with painful hip arthroplasties using intra-articular injection of bupivicaine. Fourteen had pain relief and 13 of them were subsequently found to have loosening of one or both components. The relief of pain after total hip arthroplasty by intra-articular injection of bupivicaine indicates that a satisfactory result is probable after revision surgery with refixation of the components. AD - Princess Elizabeth Orthopaedic Hospital, Exeter, UK. FAU - Crawford, R W AU - Crawford RW FAU - Ellis, A M AU - Ellis AM FAU - Gie, G A AU - Gie GA FAU - Ling, R S AU - Ling RS LA - eng PT - Journal Article PL - ENGLAND TA - J Bone Joint Surg Br JT - The Journal of bone and joint surgery. British volume JID - 0375355 RN - 0 (Anesthetics, Local) RN - 2180-92-9 (Bupivacaine) SB - AIM SB - IM MH - Aged MH - Aged, 80 and over MH - Anesthetics, Local/*therapeutic use MH - Arthrography MH - Bupivacaine/*therapeutic use MH - Female MH - Follow-Up Studies MH - Hip Prosthesis/*adverse effects MH - Humans MH - Injections, Intra-Articular MH - Male MH - Middle Aged MH - Pain Measurement MH - Pain, Postoperative/*drug therapy/*etiology/radiography MH - Prosthesis Failure EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - J Bone Joint Surg Br. 1997 Sep;79(5):796-800. PMID- 9382160 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20070214 PUBM- Print IS - 0250-8095 (Print) VI - 17 IP - 5 DP - 1997 TI - Determinants of type of initial hemodialysis vascular access. PG - 425-7 AB - Vascular access thrombosis is more common with polytetrafluoroethylene (PTFE) grafts than with native arteriovenous fistulae (AVF). Recent studies report an unexplained excess vascular access morbidity in women on hemodialysis. We studied 92 consecutive end-stage renal disease (ESRD) patients receiving their first permanent hemodialysis vascular access at initiation of hemodialysis to identify variables that determine assignment of either a PTFE graft or a native AVF. Independent variables included: age, gender, race, etiology of ESRD, and whether or not access surgery was electively planned before need for dialytic therapy. The 51 women and 41 men included 65 blacks, 13 Hispanics, 11 whites, and 3 Orientals aged 50 +/- (SD) 16 years. Of the 92 subjects, 54 (59%) received an AVF, while 38 (41%) received a PTFE graft. 36 (94%) of 38 PTFE grafts were placed in the upper arm as compared with 9 (17%) of 54 AVF (p = 0.0001). Also, 45 (83%) of 54 AVF were placed in the forearm as compared with only 2 (6%) of 38 PTFE grafts (p = 0.0001). Women were more likely to receive a PTFE graft - 28 (55%) of 51 - than men - 10 (24%) of 41 (p = 0.003). By contrast, men were more likely to get an AVF - 31 (76%) of 41 - than women - 23 (45 %) of 51 (p = 0.003). The log linear analysis confirmed that this finding was significant (p = 0.0018) for the coefficient of interaction between gender and type of vascular access. No other independent variable had a significant relationship with type of vascular access. We conclude that women with ESRD are more likely to receive a PTFE graft for hemodialysis, while men are more likely to get an AVF. These findings may explain, in part, the reported excess vascular access morbidity in women on hemodialysis. AD - Department of Medicine, Scientific and Academic Computing Center, State University of New York Health Science Center, Brooklyn 11203, USA. FAU - Ifudu, O AU - Ifudu O FAU - Macey, L J AU - Macey LJ FAU - Homel, P AU - Homel P FAU - Hyppolite, J C AU - Hyppolite JC FAU - Hong, J AU - Hong J FAU - Sumrani, N AU - Sumrani N FAU - Distant, D AU - Distant D FAU - Sommer, B G AU - Sommer BG FAU - Friedman, E A AU - Friedman EA LA - eng PT - Comparative Study PT - Journal Article PL - SWITZERLAND TA - Am J Nephrol JT - American journal of nephrology JID - 8109361 RN - 9002-84-0 (Polytetrafluoroethylene) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - *Arteriovenous Shunt, Surgical/adverse effects MH - *Catheters, Indwelling/adverse effects MH - Decision Making MH - Female MH - Graft Occlusion, Vascular/etiology MH - Humans MH - Kidney Failure, Chronic/therapy MH - Male MH - Middle Aged MH - Polytetrafluoroethylene/adverse effects MH - Prospective Studies MH - Renal Dialysis/*methods MH - Sex Factors MH - Thrombosis/epidemiology/etiology EDAT- 1997/01/01 00:00 MHDA- 1997/10/27 00:01 PST - ppublish SO - Am J Nephrol. 1997;17(5):425-7. PMID- 9301125 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0916-8451 (Print) VI - 61 IP - 8 DP - 1997 Aug TI - Pradimicin, a mannose-binding antibiotic, induced carbohydrate-mediated apoptosis in U937 cells. PG - 1408-10 AB - Pradimicin (PRM), a mannose-binding antifungal antibiotic, recognizes a D-mannoside in the presence of calcium. We demonstrated that BMY-28864, a semi-synthetic analog of PRM, induced apoptosis in U937 cells which had been incubated with 1-deoxymannojirimycin (DMJ). Characteristic morphological changes such as formation of apoptotic bodies and DNA fragmentation were observed in apoptotic cells. AD - Toyama Prefectural University, Biotechnology Research Center, Japan. oki@pu-toyama.ac.jp FAU - Oki, T AU - Oki T FAU - Yamazaki, Y AU - Yamazaki Y FAU - Furumai, T AU - Furumai T FAU - Igarashi, Y AU - Igarashi Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - JAPAN TA - Biosci Biotechnol Biochem JT - Bioscience, biotechnology, and biochemistry JID - 9205717 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Antigens, Surface) RN - 0 (Carbohydrates) RN - 0 (DNA, Neoplasm) RN - 0 (Oligosaccharides) RN - 19130-96-2 (1-Deoxynojirimycin) RN - 31103-86-3 (Mannose) SB - B MH - 1-Deoxynojirimycin/pharmacology MH - Anti-Bacterial Agents/*pharmacology MH - Antibiotics, Antineoplastic/*pharmacology MH - Antigens, Surface/biosynthesis MH - Apoptosis/*drug effects MH - Carbohydrates/*physiology MH - Cell Line MH - DNA, Neoplasm/biosynthesis/chemistry MH - Electrophoresis, Agar Gel MH - Humans MH - Leukemia, Myeloid/metabolism MH - Mannose/metabolism MH - Oligosaccharides/biosynthesis EDAT- 1997/08/01 00:00 MHDA- 1997/09/25 00:01 PST - ppublish SO - Biosci Biotechnol Biochem. 1997 Aug;61(8):1408-10. PMID- 9378488 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0019-2805 (Print) VI - 91 IP - 4 DP - 1997 Aug TI - TCR alpha beta+ CD4- CD8- T cells differentiate extrathymically in an lck-independent manner and participate in early response against Listeria monocytogenes infection through interferon-gamma production. PG - 511-9 AB - T-cell receptor (TCR) alpha beta+ CD4- CD8- (double-negative; DN) T cells appear in the peritoneal cavity at an early stage of intraperitoneal (i.p.) infection with the intracellular pathogen Listeria monocytogenes. In the present report, we analysed the developmental pathway and functions of the TCR alpha beta+ DN T cells using the L. monocytogenes infection system. The TCR alpha beta+ DN T cells appeared in the peritoneal cavity after L. monocytogenes i.p. infection in adult-thymectomized lethally irradiated bone marrow chimeras and p56lck-deficient mice. The results demonstrated that the TCR alpha beta+ DN T cells can develop extrathymically in a p56lck-independent manner. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that the TCR alpha beta+ DN T cells expressed genes for interferon-gamma (IFN-gamma), the macrophage chemotactic factors MCP-1 and Eta-1, and granulocyte-macrophage colony-stimulating factor (GM-CSF) but lacked expression of genes for interleukin-2 (IL-2), IL-4 and IL-10. As expected from the RT-PCR analysis, the TCR alpha beta+ DN T cells produced IFN-gamma in response to anti-TCR beta monoclonal antibody (mAb), anti-CD3 mAb and L. monocytogenes-infected macrophages but IL-4 was undetectable after the stimulation. Furthermore, the intracellular cytokine staining analysis demonstrated that approximately half of the TCR alpha beta+ DN T cells detectable at the early stage of L. monocytogenes infection were IFN-gamma-producing cells. All of the results suggest that the TCR alpha beta+ DN T cells develop through a unique extrathymic p56lck-independent pathway and participate in early protection against bacterial infection through activation and accumulation of macrophages. AD - Department of Immunology, Kyushu University, Japan. FAU - Kadena, T AU - Kadena T FAU - Matsuzaki, G AU - Matsuzaki G FAU - Fujise, S AU - Fujise S FAU - Kishihara, K AU - Kishihara K FAU - Takimoto, H AU - Takimoto H FAU - Sasaki, M AU - Sasaki M FAU - Beppu, M AU - Beppu M FAU - Nakamura, S AU - Nakamura S FAU - Nomoto, K AU - Nomoto K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Immunology JT - Immunology JID - 0374672 RN - 0 (Antigens, CD4) RN - 0 (Antigens, CD8) RN - 0 (Cytokines) RN - 0 (Receptors, Antigen, T-Cell, alpha-beta) RN - 82115-62-6 (Interferon Type II) RN - EC 2.7.1.37 (Lymphocyte Specific Protein Tyrosine Kinase p56(lck)) SB - IM MH - Animals MH - Antigens, CD4/analysis MH - Antigens, CD8/analysis MH - Ascitic Fluid/immunology MH - Cell Culture Techniques MH - Cell Differentiation/immunology MH - Cytokines/genetics/metabolism MH - Female MH - Gene Expression MH - Interferon Type II/*biosynthesis MH - Listeria Infections/*immunology MH - Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*deficiency/immunology MH - Mice MH - Mice, Inbred Strains MH - Mice, Knockout MH - Polymerase Chain Reaction MH - Receptors, Antigen, T-Cell, alpha-beta/*analysis MH - T-Lymphocyte Subsets/*immunology EDAT- 1997/08/01 00:00 MHDA- 1997/10/24 00:01 PST - ppublish SO - Immunology. 1997 Aug;91(4):511-9. PMID- 9298438 OWN - NLM STAT- MEDLINE DA - 19971024 DCOM- 19971024 LR - 20061115 PUBM- Print IS - 0160-7715 (Print) VI - 20 IP - 4 DP - 1997 Aug TI - Identification of Beck Depression Inventory items related to multiple sclerosis. PG - 407-14 AB - The percentage contribution of each item on the Beck Depression Inventory (BDI) to the total BDI score was compared across patients with multiple sclerosis (MS), patients diagnosed with major depressive disorder, and normal college students. We considered an item to be confounded by MS-related symptoms if its percentage contribution to the total BDI score was significantly greater in the MS group than the major depression and control groups. Items measuring work difficulty, fatigue, and concerns about health met this criterion. These items accounted for 34, 17, and 19% of the total BDI score in the MS, major depression, and control groups, respectively. Using the 18-item BDI (BDI-18) which resulted from excluding the 3 confounded items, MS patients found to be were more depressed than controls but less depressed than the major depression group. The identification of signs of depression not confounded with MS which could be substituted for confounded signs was also discussed. AD - UCSF/Mt. Zion MS Center 94115-1642, USA. FAU - Mohr, D C AU - Mohr DC FAU - Goodkin, D E AU - Goodkin DE FAU - Likosky, W AU - Likosky W FAU - Beutler, L AU - Beutler L FAU - Gatto, N AU - Gatto N FAU - Langan, M K AU - Langan MK LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Behav Med JT - Journal of behavioral medicine JID - 7807105 SB - IM MH - Adult MH - Depressive Disorder/diagnosis/*psychology MH - Female MH - Humans MH - Male MH - Middle Aged MH - Multiple Sclerosis/diagnosis/*psychology MH - Personality Inventory/*statistics & numerical data MH - Psychometrics MH - Reproducibility of Results MH - Sick Role EDAT- 1997/08/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - J Behav Med. 1997 Aug;20(4):407-14. PMID- 9279722 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0163-4453 (Print) VI - 35 IP - 1 DP - 1997 Jul TI - Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine. PG - 37-40 AB - Sera from 30 subjects vaccinated with the Pasteur Merieux Serums & Vaccins (PM) inactivated hepatitis A vaccine, and from 30 subjects vaccinated with the Smithkline Beecham (SB) inactivated hepatitis A vaccine, were tested in two laboratories in order to provide comparative data on neutralizing activities of vaccine-induced antibodies. Sera were also evaluated by a modified radioimmunoassay (mRIA) and results were compared to neutralization assays results. Neutralizing antibody titres provided by the two laboratories correlated well (coefficient or correlation 0.42, P < 0.001). Neutralizing antibodies were detected after vaccination with both vaccines, and the kinetics of neutralizing antibody were the same with both vaccines. The titres gradually increased between the second week after the first dose and the post-booster dose (week 28). A strong booster effect of the booster vaccine dose on neutralizing titres was observed. Significantly higher neutralizing antibody titres with the PM vaccine were observed as early immune response on week 2 titres on both series of results. Vaccine-induced neutralizing antibody titres and vaccine-induced antibody mRIA titres correlated well (coefficient of correlation 0.82 and 0.72, respectively, P < 0.0001 in both cases). These results demonstrate early appearance of neutralizing antibody at high titre with the PM vaccine. AD - Hygiene-Institut der Universitat Tubingen, Abteilung fur Medizinische Virologie und Epidemiologie der Viruskrankheiten, Germany. FAU - Flehmig, B AU - Flehmig B FAU - Staedele, H AU - Staedele H FAU - Xueref, C AU - Xueref C FAU - Vidor, E AU - Vidor E FAU - Zuckerman, J AU - Zuckerman J FAU - Zuckerman, A AU - Zuckerman A LA - eng PT - Clinical Trial PT - Comparative Study PT - Controlled Clinical Trial PT - Journal Article PL - ENGLAND TA - J Infect JT - The Journal of infection JID - 7908424 RN - 0 (Antibodies, Viral) RN - 0 (Hepatitis A Vaccines) RN - 0 (Vaccines, Inactivated) RN - 0 (Viral Hepatitis Vaccines) SB - IM MH - Adolescent MH - Adult MH - Antibodies, Viral/*analysis MH - Female MH - Hepatitis A/prevention & control MH - Hepatitis A Vaccines MH - Hepatitis A Virus, Human/*immunology MH - Humans MH - Male MH - Neutralization Tests MH - Radioimmunoassay MH - Vaccines, Inactivated/administration & dosage MH - Viral Hepatitis Vaccines/*administration & dosage EDAT- 1997/07/01 MHDA- 1997/07/01 00:01 AID - S0163-4453(97)90929-4 [pii] PST - ppublish SO - J Infect. 1997 Jul;35(1):37-40. PMID- 9366534 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20041117 PUBM- Print IS - 0009-9260 (Print) VI - 52 IP - 10 DP - 1997 Oct TI - MRI and CT of metastatic hepatocellular carcinoma causing spinal cord compression. PG - 755-60 AB - We report the imaging features in five patients with metastatic hepatocellular carcinoma causing spinal cord compression, three of which were biopsy proven and two were in patients with known diagnosis of hepatocellular carcinoma. The radiographic, magnetic resonance imaging (MRI) and computed tomography (CT) features are highlighted. Although the occurrence of metastatic disease in hepatocellular carcinoma is exceedingly rare, it may be increasingly encountered as survival of patients is improved with advancing methods of therapy, both surgical and palliative. It often accompanies local recurrence, and invariably signals a grave prognosis with extremely short life expectancy. Unusually, two of the five patients in this series presented initially with skeletal metastases which led to the diagnosis of hepatocellular carcinoma. AD - Department of Diagnostic Radiology & Organ Imaging, Chinese University of Hong Kong, Hong Kong. FAU - Yang, W T AU - Yang WT FAU - Yeo, W AU - Yeo W FAU - Leung, S F AU - Leung SF FAU - Chan, Y L AU - Chan YL FAU - Johnson, P J AU - Johnson PJ FAU - Metreweli, C AU - Metreweli C LA - eng PT - Case Reports PT - Journal Article PL - ENGLAND TA - Clin Radiol JT - Clinical radiology JID - 1306016 SB - IM MH - Adult MH - Bone Neoplasms/radiography/*secondary MH - Carcinoma, Hepatocellular/complications/diagnosis/*secondary MH - Fatal Outcome MH - Female MH - Humans MH - Liver Neoplasms/*pathology MH - *Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Spinal Cord Compression/*etiology MH - Spinal Neoplasms/complications/secondary MH - *Tomography, X-Ray Computed EDAT- 1997/11/20 MHDA- 1997/11/20 00:01 PST - ppublish SO - Clin Radiol. 1997 Oct;52(10):755-60. PMID- 9293364 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20041117 PUBM- Print IS - 0967-2109 (Print) VI - 5 IP - 3 DP - 1997 Jun TI - Transected thoracic aorta: age-specific differences in incidence and possible reasons. PG - 291-4 AB - The objective of this study was to determine the incidence of aortic transaction in relation to age, and to examine possible reasons for the observed differences. Data from the North Carolina Medical Database over a 7-year period were examined for the total number of motor vehicle accident victims and for the subset with aortic rupture, based on age at presentation. Data were then divided into 10-year intervals and the differences analyzed using chi-square analysis. Differences among various age groups were statistically significant (P = 0.0001). The highest rate was in the 21-30-year-old age group and average incidence for all ages was 0.7%. High incidence of aortic transaction in the 21-30-year-old group may be due to an increase in high-risk behaviors in such persons, to an improved survival compared with other age ranges, or to an inherent susceptibility of the aorta at this stage of life. These data have important implications for the diagnosis and treatment of aortic transaction and should be taken into account when developing practice guidelines for its management. AD - Department of Thoracic and Cardiovascular Surgery, Carolinas Heart Institute, Carolinas Medical Center, North Carolina, USA. FAU - Tripp, H F AU - Tripp HF FAU - Robicsek, F AU - Robicsek F FAU - Thomason, M AU - Thomason M FAU - Thubrikar, M AU - Thubrikar M LA - eng PT - Journal Article PL - ENGLAND TA - Cardiovasc Surg JT - Cardiovascular surgery (London, England) JID - 9308765 SB - IM MH - Accidents, Traffic/mortality MH - Adolescent MH - Adult MH - Age Factors MH - Aged MH - Aged, 80 and over MH - Aorta, Thoracic/*injuries/surgery MH - Aortic Rupture/etiology/mortality/*surgery MH - Child MH - Child, Preschool MH - Cross-Sectional Studies MH - Female MH - Humans MH - Incidence MH - Infant MH - Male MH - Middle Aged MH - North Carolina/epidemiology MH - Registries/statistics & numerical data MH - Risk Factors MH - Sex Factors MH - Survival Analysis MH - Thoracic Injuries/etiology/mortality/*surgery MH - Wounds, Nonpenetrating/etiology/mortality/*surgery EDAT- 1997/06/01 00:00 MHDA- 1997/09/18 00:01 AID - S0967-2109(97)00019-7 [pii] PST - ppublish SO - Cardiovasc Surg. 1997 Jun;5(3):291-4. PMID- 9377289 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20061115 PUBM- Print IS - 0210-0010 (Print) VI - 25 IP - 145 DP - 1997 Sep TI - [Clinical variability of bilateral paramedian thalamic infarcts] PG - 1353-62 AB - INTRODUCTION: Thalamic infarcts in paramedian artery territory are seen fairly frequently owing to certain peculiarities of the vascularization of the thalamus. However, clinical diagnosis is usually difficult because of the many varieties and peculiarities of the symptomatology. MATERIAL AND METHODS: We present a review of twelve cases of bilateral paramedian infarcts of the thalamus seen in our Department of Neurology and in a private surgery. We analyze the symptoms and their relationship to the neuro-radiological findings. Finally we compare our observations with the descriptions published by other authors and seek and anatomo-functional relationship for each of the symptoms and signs observed. RESULTS: The usual clinical outline in our patients included disorders of consciousness, different types of oculomotor disorders and cerebellar symptoms, mainly of gait. Other less common findings were memory disorders and abnormal movements. In no case were there sensory changes and pyramidal signs were rare in the absence of significant extra-thalamic lesions. CONCLUSIONS: Our findings, although generally comparable to those described in the literature consulted, were somewhat different with regard to cerebellar symptoms and the absence of sensory and pyramidal signs. We also emphasize the marked differences seen between the individual patients in our series. A good knowledge of the possible clinical variants of these lesions is necessary for a correct initial diagnostic approach in the study of these patients. AD - Servicio de Neurologia, Hospital Ntra. Sra. de Aranzazu, San Sebastian, Guipuzcoa, Espana. FAU - Martinez Perez-Balsa, A AU - Martinez Perez-Balsa A FAU - Marti-Masso, J F AU - Marti-Masso JF FAU - Carrera, N AU - Carrera N FAU - Urtasun, M AU - Urtasun M LA - spa PT - Case Reports PT - English Abstract PT - Journal Article TT - Variabilidad clinica de los infartos talamicos paramedianos bilaterales. PL - SPAIN TA - Rev Neurol JT - Revista de neurologia JID - 7706841 SB - IM MH - Adult MH - Aged MH - Amnesia/etiology MH - Ataxia/etiology MH - Basal Ganglia Diseases/etiology MH - Cerebellum/pathology MH - *Cerebral Infarction/complications/pathology MH - Consciousness Disorders/etiology MH - Dysarthria/etiology MH - Female MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Middle Aged MH - Ocular Motility Disorders/etiology MH - Thalamus/*blood supply/pathology EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Rev Neurol. 1997 Sep;25(145):1353-62. PMID- 9379299 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20031114 PUBM- Print IS - 0022-3395 (Print) VI - 83 IP - 5 DP - 1997 Oct TI - Ascarophis marina n. comb. (Nematoda: cystidicolidae) from the fishes Parona signata (Carangidae) and Urophycis brasiliensis (Gadidae) in the southwestern Atlantic. PG - 917-21 AB - The taxonomic position of Cystidicola marina Szidat, 1961 is revised, based on the re-examination of type and new specimens collected from the type host, Urophycis brasiliensis (Gadidae), and a new host, Parona signata (Carangidae), in the southwestern Atlantic. The species is redescribed and transferred to Ascarophis as A. marina n. comb. It is distinguished from other species of Ascarophis by the following combination of characters: body length (male: 10.2-22.5 mm, female: 32.8-44.2 mm), number of egg filaments (2 on each pole), egg size (0.030-0.039 mm x 0.015-0.021 mm), and left spicule length (0.4-0.6 mm). AD - Centro de Estudios Parasitologicos y de Vectores (CEPAVE-CONICET), La Plata, Buenos Aires, Argentina. FAU - Ivanov, V A AU - Ivanov VA FAU - Navone, G T AU - Navone GT FAU - Martorelli, S R AU - Martorelli SR LA - eng PT - Journal Article PL - UNITED STATES TA - J Parasitol JT - The Journal of parasitology JID - 7803124 SB - IM MH - Animals MH - Female MH - Fish Diseases/*parasitology MH - Fishes MH - Male MH - Microscopy, Electron, Scanning MH - Nematoda/anatomy & histology/*classification/ultrastructure MH - Nematode Infections/parasitology/*veterinary EDAT- 1997/10/29 MHDA- 1997/10/29 00:01 PST - ppublish SO - J Parasitol. 1997 Oct;83(5):917-21. PMID- 9314714 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0033-3182 (Print) VI - 38 IP - 5 DP - 1997 Sep-Oct TI - Use of medical services by veterans with mental disorders. PG - 451-8 AB - This study examined timeliness, access, and intensity of outpatient medical service use in a national sample of veterans with comorbid medical disorders discharged from Veterans Affairs (VA) psychiatric units (N = 44,533). The factors that predicted decreased use of medical services included diagnosis of schizophrenia, posttraumatic stress disorder, and substance abuse. The factors associated with increased use of medical services included proximity to a VA outpatient clinic, receipt of VA compensation payments, discharge from a facility with greater resources devoted to medical-surgical care, and prompt outpatient mental health follow-up. Better integration of medical and psychiatric services may help improve access to medical care for the severely mentally ill. AD - Northeast Program Evaluation Center, Department of Veterans Affairs, West Haven, Connecticut, USA. FAU - Druss, B G AU - Druss BG FAU - Rosenheck, R A AU - Rosenheck RA LA - eng GR - 15783/PHS PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Psychosomatics JT - Psychosomatics JID - 0376506 SB - IM MH - Adult MH - Aged MH - Ambulatory Care/utilization MH - Community Mental Health Services/*utilization MH - Comorbidity MH - Cross-Sectional Studies MH - Female MH - Health Services Accessibility/*statistics & numerical data MH - Humans MH - Incidence MH - Male MH - Mental Disorders/diagnosis/*epidemiology/psychology MH - Middle Aged MH - Patient Discharge/statistics & numerical data MH - United States MH - Veterans/*psychology/statistics & numerical data EDAT- 1997/10/07 MHDA- 1997/10/07 00:01 PST - ppublish SO - Psychosomatics. 1997 Sep-Oct;38(5):451-8. PMID- 9293538 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20041117 PUBM- Print IS - 1320-5463 (Print) VI - 47 IP - 8 DP - 1997 Aug TI - Ameloblastic fibrosarcoma arising de novo in the maxilla. PG - 564-8 AB - An ameloblastic fibrosarcoma (AFS) arising in the maxilla of a 14-year-old male is described. The tumor originated from the alveolar bone of the right maxilla with no apparent history of pre-existing lesion. Histologically, the lesion was composed of benign-appearing epithelial islands and strands scattered within an exceedingly cellular mass of mesenchymal tissue comprising a large number of stellate-and spindle-shaped fibroblast-like cells with marked pleomorphism. Occasional cementum-like calcification was also noted. Immunohistochemically, the neoplastic mesenchymal cells were positive only for vimentin, whereas the ameloblast-like epithelial component showed a distinctly positive reaction for wide-spectrum keratin and squamous cytokeratin. Clinicopathological features of the current case, as well as previously reported examples of AFS originating from the maxilla, are briefly discussed. AD - Department of Oral Pathology, Meikai University School of Dentistry, Saitama, Japan. FAU - Tajima, Y AU - Tajima Y FAU - Utsumi, N AU - Utsumi N FAU - Suzuki, S AU - Suzuki S FAU - Fujita, K AU - Fujita K FAU - Takahashi, H AU - Takahashi H LA - eng PT - Case Reports PT - Journal Article PL - AUSTRALIA TA - Pathol Int JT - Pathology international JID - 9431380 SB - IM MH - Adolescent MH - Biopsy MH - Fatal Outcome MH - Humans MH - Male MH - Maxilla/pathology MH - Maxillary Neoplasms/*pathology MH - Odontogenic Tumors/*pathology EDAT- 1997/08/01 00:00 MHDA- 1997/09/18 00:01 PST - ppublish SO - Pathol Int. 1997 Aug;47(8):564-8. PMID- 9346183 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20041117 PUBM- Print IS - 0893-3952 (Print) VI - 10 IP - 10 DP - 1997 Oct TI - Solitary fibrous tumor of soft tissue: a report of 15 cases, including 5 malignant examples with light microscopic, immunohistochemical, and ultrastructural data. PG - 1028-37 AB - We describe 15 soft tissue solitary fibrous tumors (SFTs) occurring in patients 24 to 78 years old (average, 50.6 yr). Ten tumors were benign and arose in the head and neck area (three tumors), thigh (two), vulva (two), upper arm (one), lower leg (one), and retroperitoneum (one). Five tumors were histologically malignant and arose in the thigh (two), abdominal wall (one), buttock (one), and retroperitoneum (one). All of the tumors were grossly well circumscribed. The benign tumors measured from 2 to 10 cm (average, 4.8 cm) and the malignant ones from 3 to 5.5 cm (average, 4.3 cm) in greatest diameter. Microscopically, the benign tumors showed areas of hypercellularity with variable amounts of collagenous and myxoid stroma; one had amianthoid fibers. The malignant tumors were composed of cytologically atypical cells enmeshed in a collagenous or myxoid extracellular matrix. Ultrastructural study of three benign and three malignant tumors showed fibroblastic differentiation; one benign tumor showed myofibroblastic differentiation. Immunohistochemically, all of the tumors examined were immunoreactive for vimentin, and seven of nine were positive for CD34, including all of the malignant ones. There was focal staining for muscle actin in two benign tumors and for Leu-7 in one benign tumor; there was no staining for cytokeratin, desmin, S-100 protein, epithelial membrane antigen, or smooth muscle actin in any of the examined tissues. Follow-up was available for eight patients for 6 to 21 months (average, 12 mo). No tumor recurred locally or metastasized. The SFTs reported herein support the experiences of others who recently described these tumors in the somatic soft tissues. In addition, our series highlights the occurrence of malignant SFTs in the soft tissues. SFTs should be separated from other spindle cell sarcomas, with which they can be confused. AD - The James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA. FAU - Nielsen, G P AU - Nielsen GP FAU - O'Connell, J X AU - O'Connell JX FAU - Dickersin, G R AU - Dickersin GR FAU - Rosenberg, A E AU - Rosenberg AE LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Mod Pathol JT - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JID - 8806605 RN - 0 (Tumor Markers, Biological) SB - IM MH - Abdominal Muscles/pathology MH - Adult MH - Aged MH - Buttocks/pathology MH - Cell Nucleus/ultrastructure MH - Endoplasmic Reticulum, Rough/ultrastructure MH - Extremities/pathology MH - Female MH - Fibroma/chemistry/*pathology/ultrastructure MH - Head and Neck Neoplasms/pathology MH - Humans MH - Immunohistochemistry MH - Male MH - Middle Aged MH - Retroperitoneal Neoplasms/pathology MH - Soft Tissue Neoplasms/chemistry/*pathology/ultrastructure MH - Tumor Markers, Biological/analysis MH - Vulvar Neoplasms/pathology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Mod Pathol. 1997 Oct;10(10):1028-37. PMID- 9325071 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0090-1229 (Print) VI - 85 IP - 1 DP - 1997 Oct TI - Plasma effects on phagocytic activity and hydrogen peroxide production by polymorphonuclear leukocytes in neonates. PG - 67-72 AB - To elucidate the defense mechanism in neonates against bacterial infections, phagocytic activity and hydrogen peroxide (H2O2) production by polymorphonuclear leukocytes (PMNs) in the whole blood and the effects of plasma on these functions were investigated on 44 healthy mature neonates (term 37 to 41 weeks) and 15 premature neonates (term 30 to 36 weeks) using two color flow cytometric analysis. The results were compared to those of a healthy adult control group (n = 10). PMN phagocytic activity was low in both mature and premature neonates. H2O2 production of PMN with phorbol myristate acetate (PMA) stimulation and following phagocytosis was augmented in both mature and premature neonates. When plasma and PMNs of adults and neonates were separated and combined differently, phagocytic activity and H2O2 production of PMNs appeared to be principally regulated by the plasma employed. This finding indicates that plasma has major effects on both phagocytosis and H2O2 production by PMNs of newborn neonates. AD - Department of Pediatrics, Kansai Medical University, Osaka, Japan. FAU - Fujiwara, T AU - Fujiwara T FAU - Kobayashi, T AU - Kobayashi T FAU - Takaya, J AU - Takaya J FAU - Taniuchi, S AU - Taniuchi S FAU - Kobayashi, Y AU - Kobayashi Y LA - eng PT - In Vitro PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Clin Immunol Immunopathol JT - Clinical immunology and immunopathology JID - 0356637 RN - 16561-29-8 (Tetradecanoylphorbol Acetate) RN - 7722-84-1 (Hydrogen Peroxide) SB - IM MH - Adult MH - Age Factors MH - *Blood Bactericidal Activity MH - Fetal Blood/cytology/*immunology/*metabolism MH - Humans MH - Hydrogen Peroxide/*blood MH - Infant, Newborn MH - Infant, Premature MH - Neutrophils/drug effects/*immunology/*metabolism MH - *Phagocytosis MH - Plasma/*immunology MH - Tetradecanoylphorbol Acetate/pharmacology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0090122997944032 [pii] PST - ppublish SO - Clin Immunol Immunopathol. 1997 Oct;85(1):67-72. PMID- 9379259 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0736-0266 (Print) VI - 15 IP - 4 DP - 1997 Jul TI - Forearm muscle oxygenation decreases with low levels of voluntary contraction. PG - 507-11 AB - The purpose of our investigation was to determine if the near infrared spectroscopy technique was sensitive to changes in tissue oxygenation at low levels of isometric contraction in the extensor carpi radialis brevis muscle. Nine subjects were seated with the right arm abducted to 45 degrees, elbow flexed to 85 degrees, forearm pronated 45 degrees, and wrist and forearm supported on an armrest throughout the protocol. Altered tissue oxygenation was measured noninvasively with near infrared spectroscopy. The near infrared spectroscopy probe was placed over the extensor carpi radialis brevis of the subject's right forearm and secured with an elastic wrap. After 1 minute of baseline measurements taken with the muscle relaxed, four different loads were applied just proximal to the metacarpophalangeal joint such that the subjects isometrically contracted the extensor carpi radialis brevis at 5, 10, 15, and 50% of the maximum voluntary contraction for 1 minute each. A 3-minute recovery period followed each level of contraction. At the end of the protocol, with the probe still in place, a value for ischemic tissue oxygenation was obtained for each subject. This value was considered the physiological zero and hence 0% tissue oxygenation. Mean tissue oxygenation (+/-SE) decreased from resting baseline (100% tissue oxygenation) to 89 +/- 4, 81 +/- 8, 78 +/- 8, and 47 +/- 8% at 5, 10, 15, and 50% of the maximum voluntary contraction, respectively. Tissue oxygenation levels at 10, 15, and 50% of the maximum voluntary contraction were significantly lower (p < 0.05) than the baseline value. Our results indicate that tissue oxygenation significantly decreases during brief, low levels of static muscle contraction and that near infrared spectroscopy is a sensitive technique for detecting deoxygenation noninvasively at low levels of forearm muscle contraction. Our findings have important implications in occupational medicine because oxygen depletion induced by low levels of muscle contraction may be directly linked to muscle fatigue. AD - Ergonomics Laboratory, University of California, Berkeley, USA. FAU - Murthy, G AU - Murthy G FAU - Kahan, N J AU - Kahan NJ FAU - Hargens, A R AU - Hargens AR FAU - Rempel, D M AU - Rempel DM LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - J Orthop Res JT - Journal of orthopaedic research : official publication of the Orthopaedic Research Society JID - 8404726 SB - IM SB - S MH - Adult MH - Exertion/physiology MH - Female MH - Forearm MH - Human Engineering MH - Humans MH - Male MH - Muscle Contraction/*physiology MH - Muscle Fatigue/physiology MH - Muscle, Skeletal/*physiology MH - Oxygen Consumption/*physiology MH - Spectroscopy, Near-Infrared MH - Volition/physiology OTO - NASA OT - NASA Center ARC OT - NASA Discipline Musculoskeletal IR - Hargens AR FIR - Hargens, A R IRAD- ARC EDAT- 1997/07/01 00:00 MHDA- 1997/10/23 00:01 AID - 10.1002/jor.1100150405 [doi] PST - ppublish SO - J Orthop Res. 1997 Jul;15(4):507-11. PMID- 9085387 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20041117 PUBM- Print IS - 0091-7435 (Print) VI - 26 IP - 2 DP - 1997 Mar-Apr TI - Educational and informational strategies to reduce pesticide risks. Council on Scientific Affairs. PG - 191-200 AB - BACKGROUND: In 1993, the American Medical Association (AMA) requested its Council on Scientific Affairs to investigate issues and concerns related to (1) improving public notification of pesticide applications and (2) improving educational programs for commercial and farm pesticide applicators and increasing enforcement of licensing examination requirements. This report was presented at the 1994 Interim Meeting of the AMA House of Delegates as Report 4 of the Council on Scientific Affairs. METHODS: Information for the report was derived from published literature and from personal communications with state and federal regulatory officials, physicians, and representatives of pest control, lawn care, and farm organizations. Some information about state certification and training programs was obtained from telephone conversations with pesticide applicator training program coordinators from California, Florida, Illinois, Iowa, Michigan, Missouri, Nebraska, New Jersey, New York, Texas, Washington, and Wisconsin. These states were selected because they contain large agricultural or urban populations that are likely to require the services of trained professional pesticide applicators. RESULTS: Current surveillance systems are inadequate to characterize potential exposure problems related either to pesticide usage or to pesticide related illnesses. The effectiveness of applicator certification and training programs and public notification programs could not be determined because of a lack of federal and state survey data for making useful assessments. CONCLUSIONS: Considering current data gaps, it is prudent for homeowners, farmers, and workers to limit pesticide exposures to themselves and others. LA - eng PT - Journal Article PT - Review PL - UNITED STATES TA - Prev Med JT - Preventive medicine JID - 0322116 RN - 0 (Pesticides) SB - IM MH - Certification/standards MH - Environmental Exposure/adverse effects/legislation & jurisprudence/*prevention & control MH - *Environmental Health/legislation & jurisprudence/standards MH - Government Agencies/legislation & jurisprudence/standards MH - Humans MH - Pest Control/standards MH - Pesticides/*adverse effects MH - Sentinel Surveillance MH - United States RF - 59 EDAT- 1997/03/01 MHDA- 1997/03/01 00:01 AID - S009174359690122X [pii] PST - ppublish SO - Prev Med. 1997 Mar-Apr;26(2):191-200. PMID- 9376959 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20051116 PUBM- Print IS - 1052-5157 (Print) VI - 7 IP - 4 DP - 1997 Oct TI - Angiographic evaluation and management of nonvariceal upper gastrointestinal bleeding. PG - 703-16 AB - Endoscopy is the primary diagnostic and therapeutic tool used in the evaluation and treatment of patients with upper gastrointestinal bleeding. When endoscopy is unsuccessful in identifying or controlling GI hemorrhage, however, arteriography is useful in both the evaluation and treatment of upper GI hemorrhage. AD - Dotter Interventional Institution, Oregon Health Sciences University, Portland, OR 97201, USA. FAU - Hamlin, J A AU - Hamlin JA FAU - Petersen, B AU - Petersen B FAU - Keller, F S AU - Keller FS FAU - Rosch, J AU - Rosch J LA - eng PT - Case Reports PT - Journal Article PT - Review PL - UNITED STATES TA - Gastrointest Endosc Clin N Am JT - Gastrointestinal endoscopy clinics of North America JID - 9202792 SB - IM MH - Adult MH - Angiography/*methods MH - Diagnosis, Differential MH - Esophageal and Gastric Varices/radiography/therapy MH - Gastrointestinal Hemorrhage/*radiography/therapy MH - Humans MH - Male MH - Middle Aged MH - Peptic Ulcer Hemorrhage/radiography/therapy MH - Postoperative Hemorrhage/radiography MH - Sensitivity and Specificity RF - 35 EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Gastrointest Endosc Clin N Am. 1997 Oct;7(4):703-16. PMID- 9327223 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20051116 PUBM- Print IS - 1040-8746 (Print) VI - 9 IP - 5 DP - 1997 Sep TI - HIV-associated lymphomas. PG - 450-4 AB - Intermediate and high-grade non-Hodgkin's lymphomas (NHL) with a B-cell phenotype are AIDS-defining illnesses. The incidence of systemic NHL increased greatly and primary central nervous system NHL increased even more in the HIV-infected population. Further increases in frequency are anticipated as HIV-infected individuals survive longer in an immunosuppressed state with improved antiretroviral treatment and treatment of opportunistic infections. Unusual types of NHL and manifestations of Hodgkin's disease are seen in HIV-infected individuals also. The pathologic and clinical features of the HIV-associated lymphomas and treatment approaches and results are the subjects of this review. Other articles in this issue discuss epidemiology and pathogenesis. AD - Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. FAU - Straus, D J AU - Straus DJ LA - eng PT - Clinical Trial PT - Journal Article PT - Review PL - UNITED STATES TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 SB - IM SB - X MH - Central Nervous System Neoplasms/pathology MH - Humans MH - Lymphoma, AIDS-Related/*pathology/therapy MH - Lymphoma, Non-Hodgkin/pathology RF - 46 EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Curr Opin Oncol. 1997 Sep;9(5):450-4. PMID- 9339895 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 1016-8478 (Print) VI - 7 IP - 4 DP - 1997 Aug 31 TI - Hinnavin I, an antibacterial peptide from cabbage butterfly, Artogeia rapae. PG - 509-13 AB - We have previously isolated four antibacterial peptides from the immune haemolymph of the fifth instar larvae of cabbage butterfly, Artogeia rapae [Yoe, S. M., Bang, I. S., Kang, C. S., and Kim, H. J. (1996) Mol. Cells 6, 609-614]. They were induced by live, nonpathogenic gram negative bacteria. One of these novel antibacterial peptides was named hinnavin I. Hinnavin I is heat stable; its activity was retained after 60 min incubation at 100 degrees C, being effective against gram negative and/or gram positive bacteria. Hinnavin I and lysozyme II showed a powerful synergistic effect on the inhibition of bacterial growth. Amino acid composition was analyzed and the molecular weight was determined to be 4,139.94+/-10.91 Da by the ESI mass spectrometer. To elucidate the primary structure of hinnavin I, the amino acid sequence of this peptide was determined by N-terminal sequencing techniques. The amino-terminal half of the molecule was rich in charged amino acids and was hydrophilic, whereas the carboxyl-terminal half was hydrophobic. AD - Department of Biological Sciences, Dankook University, Cheonan, Korea. FAU - Bang, I S AU - Bang IS FAU - Son, S Y AU - Son SY FAU - Yoe, S M AU - Yoe SM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - KOREA TA - Mol Cells JT - Molecules and cells JID - 9610936 RN - 0 (Amino Acids) RN - 0 (Anti-Bacterial Agents) RN - 0 (Growth Inhibitors) RN - 0 (Insect Proteins) RN - 0 (Peptides) RN - 0 (hinnavin I protein, Artogeia rapae) RN - EC 3.2.1.17 (Muramidase) SB - IM MH - Amino Acid Sequence MH - Amino Acids/analysis MH - Animals MH - Anti-Bacterial Agents/*chemistry/isolation & purification/pharmacology MH - Butterflies/*chemistry MH - Drug Synergism MH - Escherichia coli/drug effects/growth & development MH - Growth Inhibitors/pharmacology MH - Hemolymph/chemistry MH - Insect Proteins/*chemistry/isolation & purification/pharmacology MH - Molecular Sequence Data MH - Molecular Weight MH - Muramidase/pharmacology MH - Peptides/*chemistry/isolation & purification/pharmacology MH - Sequence Analysis EDAT- 1997/08/31 00:00 MHDA- 1997/10/27 00:01 PST - ppublish SO - Mol Cells. 1997 Aug 31;7(4):509-13. PMID- 9307842 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20061115 PUBM- Print IS - 0361-090X (Print) VI - 21 IP - 5 DP - 1997 TI - DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance. PG - 391-405 AB - DNA adducts are covalent complexes formed between genotoxic carcinogens and DNA bases, and constitute a critical early intermediate on the pathway of chemical carcinogenesis. Their accumulation in different tissues reflects the amount of activated carcinogen reaching DNA, and can therefore serve as an index of the biologically relevant dose reaching the target tissues or cells. Methylating agents are of interest in view of their occurrence in the environment and their use as cytotoxic drugs in cancer chemotherapy. Current evidence indicates that O6-methylguanine plays a particularly important role in the mutagenic, carcinogenic, and cytotoxic activities of methylating agents. O6-Methylguanine is repaired efficiently by the enzyme O6-alkylguanine-DNA alkyltransferase (AGT). Lack of this enzyme results in excessive accumulation of O6-methylguanine and recent evidence suggests that significant quantitative effects on adduct accumulation may be linked to conditions of very low AGT levels. This would be important from the point of view of clinical practice, since modulation of AGT is under investigation as a means of enhancing the therapeutic efficacy of clinical agents acting via the production of O6-methylguanine and related adducts, such as, for example, procarbazine, dacarbazine, and some nitrosoureas. The measurement of O6-methylguanine in human DNA has been employed as a tool to investigate the role of environmental methylating agents in human carcinogenesis. While the nature and origin of the methylating agents responsible for these adducts is currently unknown, recent studies in patas monkeys have shown that N-nitrosodimethylamine, a methylating carcinogen to which human exposure is well documented, is capable of efficiently generating O6-methylguanine in most tissues, including fetal tissues. Furthermore, it has been found that this damage is substantially enhanced by the coadministration of ethyl alcohol which acts by inhibiting the liver first-pass metabolism of the carcinogen, an observation which supports the hypothesis that alcohol consumption may act as a risk factor in human carcinogenesis by augmenting the action of nitrosamines. AD - National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, Athens, Greece. FAU - Kyrtopoulos, S A AU - Kyrtopoulos SA FAU - Anderson, L M AU - Anderson LM FAU - Chhabra, S K AU - Chhabra SK FAU - Souliotis, V L AU - Souliotis VL FAU - Pletsa, V AU - Pletsa V FAU - Valavanis, C AU - Valavanis C FAU - Georgiadis, P AU - Georgiadis P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - UNITED STATES TA - Cancer Detect Prev JT - Cancer detection and prevention JID - 7704778 RN - 0 (Antineoplastic Agents) RN - 0 (Carcinogens) RN - 0 (Carcinogens, Environmental) RN - 0 (DNA Adducts) RN - 0 (Nitroso Compounds) RN - 138-89-6 (4-nitrosodimethylaniline) RN - 20535-83-5 (O-(6)-methylguanine) RN - 62-75-9 (Dimethylnitrosamine) RN - 64-17-5 (Ethanol) RN - 671-16-9 (Procarbazine) RN - 73-40-5 (Guanine) SB - IM MH - Animals MH - Antineoplastic Agents/adverse effects/metabolism MH - Carcinogens/*metabolism/toxicity MH - Carcinogens, Environmental/metabolism/toxicity MH - DNA Adducts/*metabolism MH - DNA Damage MH - *DNA Methylation MH - Dimethylnitrosamine/metabolism/toxicity MH - Erythrocebus patas MH - Ethanol/pharmacology MH - Female MH - Guanine/analogs & derivatives/metabolism/toxicity MH - Humans MH - Leukocytes/drug effects MH - Liver/metabolism MH - Mice MH - Mice, Transgenic MH - Neoplasms/chemically induced/drug therapy MH - Nitroso Compounds/metabolism/toxicity MH - Procarbazine/metabolism/toxicity RF - 111 EDAT- 1997/01/01 00:00 MHDA- 1997/10/06 00:01 PST - ppublish SO - Cancer Detect Prev. 1997;21(5):391-405. PMID- 9385099 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20041117 PUBM- Print IS - 1380-7870 (Print) VI - 1 IP - 2 DP - 1995 TI - Product-limit survival functions with correlated survival times. PG - 171-86 AB - A simple variance estimator for product-limit survival functions is demonstrated for survival times with nested errors. Such data arise whenever survival times are observed within clusters of related observations. Greenwood's formula, which assumes independent observations, is not appropriate in this situation. A robust variance estimator is developed using Taylor series linearized values and the between-cluster variance estimator commonly used in multi-stage sample surveys. A simulation study shows that the between-cluster variance estimator is approximately unbiased and yields confidence intervals that maintain the nominal level for several patterns of correlated survival times. The simulation study also shows that Greenwood's formula underestimates the variance when the survival times are positively correlated within a cluster and yields confidence intervals that are too narrow. Extension to life table methods is also discussed. AD - Research Triangle Institute, NC 27709-2194, USA. willy@rti.org FAU - Williams, R L AU - Williams RL LA - eng PT - Journal Article PL - UNITED STATES TA - Lifetime Data Anal JT - Lifetime data analysis JID - 9516348 SB - IM MH - Angina Pectoris MH - Animals MH - Avoidance Learning MH - Exercise Test MH - Female MH - Humans MH - Life Tables MH - Linear Models MH - Male MH - Rodentia MH - *Survival Analysis EDAT- 1995/01/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Lifetime Data Anal. 1995;1(2):171-86. PMID- 9350074 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0036-5513 (Print) VI - 57 IP - 6 DP - 1997 Oct TI - Minimal residual disease in B-lymphoproliferative disorders by PCR detection of immunoglobulin heavy chain gene recombination. PG - 541-7 AB - We amplified and sequenced the rearranged immunoglobulin heavy chain VDJ genomic unit in B-leukemias and used it as a clone-specific marker for the molecular monitoring of the patients during and after therapeutic treatment. The method described is patient-specific rather than disorder-specific, more sensitive and less time-consuming than other conventional techniques for the detection of minimal residual disease. We propose reproducible and quick procedures, from DNA extraction to Southern blotting, that can be easily performed in any clinical laboratory and also applied to other kinds of investigation. AD - Dipartimento di Scienze Biomediche e Oncologia Umana, Universita di Torino, Ospedale San Luigi Gonzaga, Turin, Italy. FAU - Petroni, D AU - Petroni D FAU - Saglio, G AU - Saglio G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NORWAY TA - Scand J Clin Lab Invest JT - Scandinavian journal of clinical and laboratory investigation JID - 0404375 RN - 0 (DNA, Neoplasm) RN - 0 (Immunoglobulin Heavy Chains) SB - IM MH - Base Sequence MH - Blotting, Southern MH - DNA, Neoplasm/analysis MH - Gene Rearrangement MH - Humans MH - Immunoglobulin Heavy Chains/*genetics MH - Leukemia, B-Cell, Chronic/*genetics/immunology MH - Leukemia, Hairy Cell/*genetics/immunology MH - Leukemia, Lymphocytic, Acute/*genetics/immunology MH - Molecular Sequence Data MH - Neoplasm, Residual/*diagnosis/genetics/immunology MH - *Polymerase Chain Reaction EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Scand J Clin Lab Invest. 1997 Oct;57(6):541-7. PMID- 9342465 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20041117 PUBM- Print IS - 0390-6663 (Print) VI - 24 IP - 2 DP - 1997 TI - Amniotic fluid index variations after amniocentesis, amnioinfusion and amnioreduction: preliminary data. PG - 70-3 AB - We studied the relationship between the ultrasonographically measurable variations in the amniotic fluid index (AFI) and actual changes in the amniotic fluid volume induced by three differing invasive procedures: genetic amniocentesis, amnioinfusion and amnioreduction. We examined 50 patients, all between the 15th and 34th weeks of pregnancy, subdivided into three groups. The first group consisted of 33 women who underwent genetic amniocentesis, the second was of 11 patients submitted to amnioinfusion for oligohydramnios (AFI < 5 cm), and the third was composed of 6 patients affected by hydramnios (AFI > 20 cm) and treated with amnioreduction. In all cases AFI was measured before and after the invasive procedures and their variations (delta AFI) were correlated to the actual quantities of liquid infused or extracted. All the procedures gave rise to statistically significant AFI changes. After genetic amniocentesis, the mean change was from 12.0 to 10.9 cm (p < 0.005), after amnioinfusion from 3.1 to 10.6 cm (p < 0.0001) and after amnioreduction from 33.1 to 22.0 cm. (p < 0.005). However, a significant linear correlation between delta AFI and the fluid volume variations actually induced was found for amnioinfusion (y = 0.236537 + 0.031465x; R2 = 44.4%; p < 0.05) and for amnioreduction (y = -0.0584294 + 0.012008x; R2 = 89.8%. p < 0.00001). Only for amnioreduction is it possible, as proved by a multiple regression analysis, to improve the predictability of delta AFI, taking into consideration together with the quantity of fluid aspirated, the value of the preprocedure AFI (R2 = 92%; p < 0.05). AD - Department of Obstetrics and Gynecology, University of Parma, Italy. FAU - Gramellini, D AU - Gramellini D FAU - Piantelli, G AU - Piantelli G FAU - Di Marino, O AU - Di Marino O FAU - Avanzini, A AU - Avanzini A FAU - Vadora, E AU - Vadora E LA - eng PT - Journal Article PL - ITALY TA - Clin Exp Obstet Gynecol JT - Clinical and experimental obstetrics & gynecology JID - 7802110 SB - IM MH - *Amniocentesis MH - Amniotic Fluid/*physiology/ultrasonography MH - Female MH - Humans MH - Oligohydramnios/*therapy MH - Polyhydramnios/*therapy MH - Pregnancy MH - Reference Values MH - Regression Analysis EDAT- 1997/01/01 00:00 MHDA- 1997/10/29 00:01 PST - ppublish SO - Clin Exp Obstet Gynecol. 1997;24(2):70-3. PMID- 9304708 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20061115 PUBM- Print IS - 0080-0015 (Print) VI - 144 DP - 1998 TI - Applications of gene transfer in hematologic malignancy. PG - 60-9 AB - Although gene transfer was originally conceived as a means to replace or correct defective genes in patients with inherited disorders, the process has shown broad potential for intervention in hematologic malignancy and for study of hematopoietic stem cell biology. Gene transfer strategies now under investigation for these applications include 1) repair of one or more genetic defects associated with the malignant process, 2) delivery of a prodrug-metabolizing enzyme that causes tumor cells to become sensitive to the corresponding anticancer drug, 3) modification of immune responses to the cancer, and 4) introduction of drug resistance genes to increase the therapeutic index of cytotoxic agents. Finally, by marking normal or malignant cells with readily detectable genes, one can monitor the efficacy of therapy or study the dynamics of stem cell behavior in vivo. At present these applications are limited by the quality of vectors, but as transduction efficiencies and gene regulatory mechanisms improve, gene transfer can be expected to evolve into a major therapeutic modality in its own right. AD - Cell and Gene Therapy Program, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. FAU - Brenner, M K AU - Brenner MK LA - eng GR - CA 20180/CA/NCI GR - CA 21765/CA/NCI PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PT - Review PL - GERMANY TA - Recent Results Cancer Res JT - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer JID - 0044671 SB - IM MH - Drug Resistance, Neoplasm MH - *Gene Therapy MH - *Gene Transfer Techniques MH - Hematologic Neoplasms/genetics/immunology/*therapy MH - Hematopoietic Stem Cells MH - Humans MH - T-Lymphocytes, Cytotoxic/immunology RF - 37 EDAT- 1997/09/26 MHDA- 1997/09/26 00:01 PST - ppublish SO - Recent Results Cancer Res. 1998;144:60-9. PMID- 9365353 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20061115 PUBM- Print IS - 0003-9993 (Print) VI - 78 IP - 11 DP - 1997 Nov TI - Concentric and eccentric isokinetic assessment of flexor-extensor torque ratios at the hip, knee, and ankle in a sample population of healthy subjects. PG - 1224-30 AB - OBJECTIVE: To establish the relationship between the flexor/extensor torque ratios in the hip, knee, and ankle. DESIGN: Case series. SETTING: Laboratory of a university rehabilitation department. PARTICIPANTS: From a group of 158 healthy volunteers, 138 subjects completed all the tests in concentric mode, and 65 in eccentric mode. MAIN OUTCOME MEASURE: The flexor/extensor torque ratios of the hip, knee, and ankle were analyzed by means of isokinetic concentric and eccentric tests. Analysis of variance was carried out to compare the mean values of the ratios obtained between the male and female populations and between the right and left sides, and correlation analysis between the values of the joints. RESULTS: The flexor/extensor torque ratios differed significantly according to sex and angular velocities, but not according to side except for the ankle. No significant relationship was found between the flexor/extensor torque ratios in the hip, knee, and ankle joints. CONCLUSIONS: The flexor-extensor torque ratio of the knee and hip can be used as a reference point during rehabilitation of the contralateral side. Our results demonstrating the absence of correlation between the flexor/extensor torque ratio in each joint of the same limb, however, call for further longitudinal studies to be made under specific circumstances, such as training or immobilization of one joint, to follow the course of agonist/antagonist ratios and the synergistic activity between the joints. AD - Department of Physical Medicine and Rehabilitation, Lisfranc School of Medicine, Saint-Etienne University, France. FAU - Calmels, P M AU - Calmels PM FAU - Nellen, M AU - Nellen M FAU - van der Borne, I AU - van der Borne I FAU - Jourdin, P AU - Jourdin P FAU - Minaire, P AU - Minaire P LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Arch Phys Med Rehabil JT - Archives of physical medicine and rehabilitation JID - 2985158R SB - AIM SB - IM SB - S MH - Adult MH - Aged MH - Analysis of Variance MH - Ankle Joint/*physiology MH - Biomechanics MH - Exercise Test MH - Female MH - Hip Joint/*physiology MH - Humans MH - Knee Joint/*physiology MH - Male MH - Middle Aged MH - Muscle Contraction/*physiology MH - Physical Medicine/methods MH - Posture/physiology MH - Range of Motion, Articular/physiology MH - Reference Values MH - Reproducibility of Results MH - Tensile Strength/physiology MH - Torque EDAT- 1997/11/20 MHDA- 1997/11/20 00:01 AID - S0003-9993(97)90336-1 [pii] PST - ppublish SO - Arch Phys Med Rehabil. 1997 Nov;78(11):1224-30. PMID- 9327207 OWN - NLM STAT- MEDLINE DA - 19971103 DCOM- 19971103 LR - 20051116 PUBM- Print IS - 1062-4821 (Print) VI - 6 IP - 5 DP - 1997 Sep TI - The rise and fall of atrial natriuretic peptide for acute renal failure. PG - 474-6 AB - Atrial natriuretic peptide can increase glomerular filtration rate and filtration fraction and can promote natriuresis, effects that would logically seem to improve renal function after acute tubular necrosis from ischemic or toxic injury. Early human trials suggested a beneficial effect of atrial natriuretic peptide on creatinine clearance, and a reduction in the need for dialysis in treated patients. However, randomized, placebo-controlled trials have failed to show a clinically relevant benefit on survival, dialysis-free survival, or renal function in patients treated with this agent. AD - Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. FAU - Brenner, R M AU - Brenner RM FAU - Chertow, G M AU - Chertow GM LA - eng PT - Journal Article PT - Review PL - UNITED STATES TA - Curr Opin Nephrol Hypertens JT - Current opinion in nephrology and hypertension JID - 9303753 RN - 85637-73-6 (Atrial Natriuretic Factor) SB - IM MH - Atrial Natriuretic Factor/*therapeutic use MH - Clinical Trials MH - Humans MH - Kidney Failure, Acute/*drug therapy MH - Randomized Controlled Trials RF - 24 EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Curr Opin Nephrol Hypertens. 1997 Sep;6(5):474-6. PMID- 9324068 OWN - NLM STAT- MEDLINE DA - 19971024 DCOM- 19971024 LR - 20061115 PUBM- Print IS - 0024-3205 (Print) VI - 61 IP - 13 DP - 1997 TI - Transplacental transfer of naltrexone in rats. PG - 1261-7 AB - Extracts of fetal (20 days gestation) brain, heart, and liver were evaluated for naltrexone in rats 1 hour following maternal injection of 50 mg/kg opioid antagonist; adult plasma from the pregnant rats was analyzed. Samples were prepared by ultrafiltration, lyophilized, reconstituted in mobile phase, and separated by reversed phase high-performance liquid chromatography with ultraviolet detection. This qualitative analysis revealed the presence of naltrexone in all fetal tissues, as well as in adult plasma. These results indicate naltrexone, maternally administered, passes through the placenta and enters the fetus. The data would suggest that reports concerning somatic and neurobiological acceleration in offspring exposed to naltrexone during gestation may be the result of a direct opioid antagonist action in the fetus. AD - Department of Neuroscience and Anatomy, The Pennsylvania State University College of Medicine, Hershey 17033, USA. FAU - Zagon, I S AU - Zagon IS FAU - Hurst, W J AU - Hurst WJ FAU - McLaughlin, P J AU - McLaughlin PJ LA - eng GR - HL-53557/HL/NHLBI GR - NS-20500/NS/NINDS PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - ENGLAND TA - Life Sci JT - Life sciences JID - 0375521 RN - 0 (Narcotic Antagonists) RN - 16590-41-3 (Naltrexone) SB - IM MH - Animals MH - Brain/embryology/metabolism MH - Chromatography, High Pressure Liquid MH - Female MH - Heart/embryology MH - Kinetics MH - Liver/embryology/metabolism MH - Male MH - *Maternal-Fetal Exchange MH - Myocardium/metabolism MH - Naltrexone/*pharmacokinetics MH - Narcotic Antagonists/*pharmacokinetics MH - Placenta/*metabolism MH - Pregnancy MH - Rats MH - Rats, Sprague-Dawley EDAT- 1997/01/01 00:00 MHDA- 1997/11/04 00:01 AID - S0024320597006711 [pii] PST - ppublish SO - Life Sci. 1997;61(13):1261-7. PMID- 9322764 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0378-1119 (Print) VI - 196 IP - 1-2 DP - 1997 Sep 1 TI - Prevalence and chromosomal map location of Staphylococcus aureus adhesin genes. PG - 249-59 AB - Using genomic DNA from 25 unrelated strains and probes specific for each gene, we assessed the prevalence of the Staphylococcus aureus (Sa) adhesion genes cna, fnbA, fnbB, fib, clfA, fbpA, ebpS and map. All 25 strains encoded fib, clfA, ebpS, map and at least one of the fnb genes. fbpA and coa appeared to be allelic variants of the same gene with the fbpA variant being present in only four of 25 isolates. cna was present in 10 of 25 strains. Using Southern blot analysis of SmaI-digested genomic DNA resolved by pulsed-field gel electrophoresis, the adhesion genes were mapped to SmaI fragments A (ebpS), B (fib and clfA), C (fnbA/fnbB), E (fbpA), F (map) and G (cna). Despite variations in SmaI restriction profiles, co-localization of adhesin genes with genes known to map to specific SmaI fragments in the Sa 8325-4 chromosome strains suggests that the chromosomal location of each adhesin gene is conserved. AD - Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock 72205, USA. msmeltzer@biomed.uams.edu FAU - Smeltzer, M S AU - Smeltzer MS FAU - Gillaspy, A F AU - Gillaspy AF FAU - Pratt, F L Jr AU - Pratt FL Jr FAU - Thames, M D AU - Thames MD FAU - Iandolo, J J AU - Iandolo JJ LA - eng GR - AI 37729/AI/NIAID PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - NETHERLANDS TA - Gene JT - Gene JID - 7706761 RN - 0 (Adhesins, Bacterial) RN - 0 (Bacterial Proteins) RN - 0 (Carrier Proteins) RN - 0 (Fib protein, Staphylococcus aureus) RN - 0 (Receptors, Cell Surface) RN - 0 (adhesin, Staphylococcus aureus) RN - 0 (elastin-binding proteins) RN - EC 3.1.21.- (endodeoxyribonuclease XmaI) RN - EC 3.1.21.4 (Deoxyribonucleases, Type II Site-Specific) SB - IM MH - Adhesins, Bacterial/*genetics MH - Bacterial Proteins/genetics MH - Carrier Proteins/genetics MH - Chromosome Mapping MH - *Chromosomes, Bacterial MH - Deoxyribonucleases, Type II Site-Specific/genetics/metabolism MH - Receptors, Cell Surface/genetics MH - Staphylococcus aureus/*genetics EDAT- 1997/10/10 16:17 MHDA- 2001/03/28 10:01 PST - ppublish SO - Gene. 1997 Sep 1;196(1-2):249-59. PMID- 9237552 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0006-8993 (Print) VI - 760 IP - 1-2 DP - 1997 Jun 20 TI - Iron deposits in multiple sclerosis and Alzheimer's disease brains. PG - 298-303 AB - Iron may contribute to the pathogenesis of neurological diseases by promoting oxidative damage. The localization of iron in multiple sclerosis (MS) and Alzheimer's disease (AD) brains was investigated to further the understanding of its pathogenic role in these disease states. Earlier studies, utilizing a standard Perls' stain, yielded conflicting reports regarding the distribution of iron deposits in MS brains, and a previous study on AD brains utilized a diaminobenzidine (DAB) enhanced version of this stain. In the present study, a modified version of the DAB-enhanced stain was used; it utilizes sodium borohydride, proteinase K, Triton X-100 and xylenes to increase the accessibility of tissue iron to histochemical reagents. This modified method can reveal iron deposits that are missed by the Perls' or DAB-enhanced Perls' stains. In addition to its normal deposition in oligodendrocytes and myelin, iron was detected in reactive microglia, ameboid microglia and macrophages in MS brains. In AD brains, three types of plaques were stained: dense core, clear core and amorphous plaques. Punctate staining was also observed in neurons in the corticies of AD brains. The structure accounting for punctate labeling may be damaged mitochondria, lipofuscin or amyloid deposits. Dense core plaques, clear plaques and punctate labeling were not detected in the previous AD study which utilized only the DAB-enhanced Perls' stain. The labeling of these additional structures illustrates the benefit of the modified method. In summary, the localization of iron deposition in MS and AD brains indicates potential sites where iron could promote oxidative damage in these disease states. AD - Department of Physiology and the Smith Mental Retardation Research Center, University of Kansas Medical Center, Kansas City 66160, USA. slevine@kumc.edu FAU - LeVine, S M AU - LeVine SM LA - eng GR - HD 02528/HD/NICHD GR - NS 33596/NS/NINDS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - NETHERLANDS TA - Brain Res JT - Brain research JID - 0045503 RN - 7439-89-6 (Iron) SB - IM MH - Alzheimer Disease/*pathology MH - Brain/*pathology MH - Humans MH - Iron/*metabolism MH - Multiple Sclerosis/*pathology EDAT- 1997/06/20 MHDA- 1997/06/20 00:01 AID - S0006-8993(97)00470-8 [pii] PST - ppublish SO - Brain Res. 1997 Jun 20;760(1-2):298-303. PMID- 9344613 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20061115 PUBM- Print IS - 0014-4827 (Print) VI - 236 IP - 1 DP - 1997 Oct 10 TI - Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines. PG - 321-9 AB - The expression of prostaglandin H synthases can be induced by many stimuli and is likely to be important in control of the cell cycle. The analysis of prostaglandin H synthase-1 and -2 expression in colon adenocarcinoma cell lines is a useful model system for studying the function of the prostaglandin H synthases, especially with regard to proliferation and adhesion. Prostaglandin H synthase-1 protein is not found in any of eight human colon adenocarcinoma cell lines. Expression of prostaglandin H synthase-2 is variable for the eight cell lines: three constitutively expressed active protein, four did not express this gene at all, and one had mRNA but no active protein. Thus, five colorectal adenocarcinoma cell lines exhibit "null" expression of prostaglandin synthase-2. The three cell lines with constitutive expression of prostaglandin H synthase-2 produce PGE2. Prostaglandin E2 production could be inhibited by aspirin and NS398 without inhibiting proliferation, while direct addition of prostaglandin E2 inhibits proliferation. Adhesion to collagen IV and fibronectin was stronger in those cell lines that expressed prostaglandin H synthase-2. The constitutive expression of prostaglandin H synthase-2 is associated with increased adhesion to extracellular matrix components and a potential inhibition of proliferation through the production of prostaglandin E2. The absence of PGH synthase-2 expression in some cell lines may result from the original tumor's need to inactivate these associated functions. Our evidence suggests that PGH synthase-2 is a possible candidate for a tumor suppressor gene at 1q23-qter. AD - Division of Hematology/Oncology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City 37614-0622, USA. FAU - Parker, J AU - Parker J FAU - Kaplon, M K AU - Kaplon MK FAU - Alvarez, C J AU - Alvarez CJ FAU - Krishnaswamy, G AU - Krishnaswamy G LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Cyclooxygenase Inhibitors) RN - 0 (DNA, Neoplasm) RN - 0 (Extracellular Matrix Proteins) RN - 0 (Nitrobenzenes) RN - 0 (Prostaglandins) RN - 0 (RNA, Messenger) RN - 0 (Sulfonamides) RN - 123653-11-2 (N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) RN - 50-78-2 (Aspirin) RN - EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases) SB - IM MH - Adult MH - Aged MH - Aspirin/pharmacology MH - Blotting, Southern MH - Caco-2 Cells/cytology/*enzymology MH - Cell Adhesion/physiology MH - Cell Division/physiology MH - Cyclooxygenase Inhibitors/pharmacology MH - DNA, Neoplasm/analysis MH - Extracellular Matrix Proteins/metabolism MH - Female MH - Gene Expression Regulation, Enzymologic/drug effects/physiology MH - Gene Expression Regulation, Neoplastic/drug effects/physiology MH - HT29 Cells/cytology/*enzymology MH - Humans MH - Male MH - Middle Aged MH - Nitrobenzenes/pharmacology MH - Prostaglandin-Endoperoxide Synthases/*genetics/metabolism MH - Prostaglandins/biosynthesis MH - RNA, Messenger/metabolism MH - Sulfonamides/pharmacology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0014-4827(97)93741-1 [pii] AID - 10.1006/excr.1997.3741 [doi] PST - ppublish SO - Exp Cell Res. 1997 Oct 10;236(1):321-9. PMID- 9345238 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 1078-5884 (Print) VI - 14 IP - 3 DP - 1997 Sep TI - A paper for debate: vein versus PTFE for critical limb ischaemia--an unfair comparison? PG - 191-4 AB - INTRODUCTION: There is a widely held view that vein grafts for infrainguinal arterial reconstruction perform much better than prosthetic conduits, the best of which seems to be PTFE. Many randomised studies have been conducted which confirm this opinion, but is the difference as large as it is thought to be? One interesting feature of published trials is that the results for obligatory PTFE (when no vein is available) were much worse than the results for randomised PTFE grafts. The only way to explain this is that these groups of patients were not similar, and there are probably other factors which contribute to the difference in results when vein and PTFE grafts are compared. MATERIALS AND METHODS: A consecutive series of 109 femoro-infrapopliteal grafts undertaken for critical limb ischaemia was analysed to see the difference between vein and PTFE with vein cuff grafts. RESULTS: Vein grafts were superior to PTFE grafts when the whole cohort was included (p = 0.0038); however, there was no significant difference when the patients were stratified for inflow and runoff status. CONCLUSIONS: The difference between vein and PTFE has probably been exaggerated in the past, due to differences in risk factors and in the extent of arterial disease between the two groups of patients. The advantage of vein becomes more significant with time. AD - Department of Surgery, Guy's Hospital, London, U.K. FAU - Panayiotopoulos, Y P AU - Panayiotopoulos YP FAU - Taylor, P R AU - Taylor PR LA - eng PT - Comparative Study PT - Journal Article PL - ENGLAND TA - Eur J Vasc Endovasc Surg JT - European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery JID - 9512728 RN - 9002-84-0 (Polytetrafluoroethylene) SB - IM MH - Blood Vessel Prosthesis MH - *Blood Vessel Prosthesis Implantation MH - Cohort Studies MH - Graft Occlusion, Vascular/epidemiology MH - Humans MH - Ischemia/*surgery MH - Leg/*blood supply MH - *Polytetrafluoroethylene MH - Risk Factors MH - Treatment Outcome MH - Vascular Patency MH - Veins/*transplantation EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Eur J Vasc Endovasc Surg. 1997 Sep;14(3):191-4. PMID- 9336588 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 0002-8223 (Print) VI - 97 IP - 10 Suppl 2 DP - 1997 Oct TI - The ketogenic diet revisited. PG - S192-4 AB - The ketogenic diet is a high-fat diet that maintains the body's starvation mechanism, with exogenous fat provided for metabolism in lieu of stored fat. Mild dehydration is important to prevent dilution of the level of ketones in circulation at any given time. It is not known why or how ketosis affects seizure activity, so the principles behind the therapy have been developed from years of clinical experience and theoretical assumptions. Dietitians are essential providers of ketosis therapy, but the dietitian must work with a physician who understands the theories behind the therapy and is an active member of the ketosis therapy team. AD - Hermann Children's Hospital, University of Texas Medical School, Houston, USA. FAU - Berryman, M S AU - Berryman MS LA - eng PT - Journal Article PL - UNITED STATES TA - J Am Diet Assoc JT - Journal of the American Dietetic Association JID - 7503061 SB - AIM SB - IM MH - Diet/adverse effects/*methods MH - Humans MH - Ketosis/*etiology MH - Seizures/*diet therapy EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - J Am Diet Assoc. 1997 Oct;97(10 Suppl 2):S192-4. PMID- 9336566 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 0002-8223 (Print) VI - 97 IP - 10 Suppl 2 DP - 1997 Oct TI - Research competencies in the dietetics curricula. PG - S102-6 AB - Investment in dietetics research has the potential to improve general health; increase work performance and learning capacity; extend disease-free life; reduce birth defects, infections, and chronic diseases; and decrease health care costs. Opportunities exist for research in the areas of solid waste management, global environment, health care reform, and foodservice systems management. Research efforts can focus on cost-effectiveness and medical efficacy of dietary services to improve third-party reimbursement. Educators have a stake in creating the future by conducting research, teaching research to dietetic students, and investigating the effectiveness of education. AD - Veterans Affairs New Jersey Health Care Systems, East Orange 07108-1095, USA. FAU - Hynak-Hankinson, M T AU - Hynak-Hankinson MT FAU - Martin, S AU - Martin S FAU - Wirth, J AU - Wirth J LA - eng PT - Journal Article PL - UNITED STATES TA - J Am Diet Assoc JT - Journal of the American Dietetic Association JID - 7503061 SB - AIM SB - IM MH - Clinical Competence MH - *Curriculum MH - Data Collection/methods MH - Dietetics/*education MH - Humans MH - *Research MH - United States EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - J Am Diet Assoc. 1997 Oct;97(10 Suppl 2):S102-6. PMID- 9323515 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20051117 PUBM- Print IS - 0392-0461 (Print) VI - 18 IP - 4 DP - 1997 Aug TI - Recurrent external ophthalmoparesis during hormonal therapy after thyroid ablation. Case report. PG - 215-6 AB - We here report the case of a patient who had undergone total thyroid ablation for Graves' disease. After the beginning of oral therapy with 1-thyroxine, she developed a left external ophthalmoparesis that remitted with the discontinuation of the drug and recurred whenever the replacement therapy (1-thyroxine or tri-iodothyronine) was reintroduced. AD - Divisione di Neurologia, Ospedale Civile di Belluno, Italy. FAU - Ferracci, F AU - Ferracci F FAU - Conte, F AU - Conte F FAU - Marini, B AU - Marini B FAU - Fassetta, G AU - Fassetta G LA - eng PT - Case Reports PT - Journal Article PL - ITALY TA - Ital J Neurol Sci JT - Italian journal of neurological sciences JID - 8006502 RN - 0 (Thyroid Hormones) SB - IM MH - Aged MH - Combined Modality Therapy MH - Female MH - Graves Disease/drug therapy/surgery/*therapy MH - Humans MH - Recurrence MH - Thyroid Gland/*surgery MH - Thyroid Hormones/*therapeutic use EDAT- 1997/08/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Ital J Neurol Sci. 1997 Aug;18(4):215-6. PMID- 9380370 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20061115 PUBM- Print IS - 1040-5488 (Print) VI - 74 IP - 9 DP - 1997 Sep TI - Evaluation of Kojima-Matsubara color vision test plates: validity in young children. PG - 726-31 AB - PURPOSE: We examined a pseudoisochromatic color plate test by Kojima and Matsubara for young children which uses drawings of familiar objects rather than letters or numbers. First, we evaluated the test's efficacy as a color deficiency screener and its validity in classifying the types of color deficiencies by comparing its results with those from the Moreland anomaloscope. Second, we eliminated the chromatic factor and evaluated the functional ability of young children to perform the task by determining how many correct responses were obtained using modified black/white replicas of the test plates. METHODS: Part 1: Twenty color-normal and 13 color-deficient adults were diagnosed and classified with the Ishihara test, Panel D-15 test, and anomaloscope. Subjects were then tested with the Kojima-Matsubara test and result were compared with those from the anomaloscope. Part 2: Fifty children aged 3 to 7 years were tested with modified black/white test plate replicas. The number of correct responses for each plate was determined for five different age groups. RESULTS: Part 1: Among the 20 color-normal subjects, 18 read all 10 plates correctly and 2 subjects missed 1 of the 10. Only 1 of the 13 color-deficient subjects exhibited the expected responses for plates 2 to 6 (used for color deficiency screening). The color-deficient subjects' responses for plates 7 to 10, which are used to classify red-green defects, were varied and only the protanomalous subjects (n = 2) followed the expected response pattern. Part 2: Of the 10 black/white modified plates, only 2 were correctly identified by all 50 children. The other plates had a recognition rate that ranged from 32 to 98%. CONCLUSIONS: Because the response patterns given by most of the color-deficient adult subjects were different from those in the test manual, ambiguous results would occur if the Kojima-Matsubara test were used for color vision screening or the diagnosis of color deficiency. In addition, the difficulty that many of the young children exhibited in identifying the objects in the black/white replica plates suggests that there would be a large number of false positive errors (classifying a color normal as color deficient) when using this test in young children. AD - Illinois College of Optometry, Chicago, USA. FAU - Lee, D Y AU - Lee DY FAU - Cotter, S A AU - Cotter SA FAU - French, A L AU - French AL LA - eng PT - Comparative Study PT - Journal Article PL - UNITED STATES TA - Optom Vis Sci JT - Optometry and vision science : official publication of the American Academy of Optometry JID - 8904931 SB - IM MH - Adult MH - Aging/physiology MH - Child MH - Child, Preschool MH - Color Perception/*physiology MH - Color Perception Tests/*methods MH - Color Vision Defects/diagnosis MH - Evaluation Studies MH - Humans MH - Reproducibility of Results MH - Vision Screening/*methods EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Optom Vis Sci. 1997 Sep;74(9):726-31. PMID- 9333208 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0031-9384 (Print) VI - 62 IP - 5 DP - 1997 Nov TI - Behavioral and physiological sex differences observed in an animal model of fulminant hepatic encephalopathy in the rat. PG - 1113-24 AB - Hepatic encephalopathy is characterized by a number of neuropsychiatric and motor disturbances observed in patients with liver dysfunction. The purpose of this study is to fully characterize behavioral and physiological sex differences in an animal model of fulminant hepatic encephalopathy (FHE). Male and female rats were administered thioacetamide (600 mg/kg) via i.p. (intraperitoneal) injection at Hours 0 and 24 and allowed to progress into the four stages of FHE. Male rats reached all four stages of FHE significantly earlier than female rats (p < 0.05). The performance of the male rats deteriorated more quickly (p < 0.05) than that of the females in all of the sensory and motor behavioral tests. Sex differences were observed in the liver enzymes of the FHE rats. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase were significantly greater (p < 0.05) in male rats in all four stages of FHE. Significant increases were also observed in the levels of direct and total bilirubin (p < 0.05). Neuronal damage was observed in the CA1 and CA2 regions of the hippocampus. In the CA1 region, male rats displayed greater pathological changes in Stages III and IV (p < 0.05) than female rats. The damage in the CA2 region was only observed in Stage IV male rats. Our data indicate that observable behavioral and physiological sex differences occur in thioacetamide-induced FHE in the rat. AD - Department of Oral Biology, School of Dentistry, Creighton University, Omaha, NE 68178, USA. Nsnorton@creighton.edu FAU - Norton, N S AU - Norton NS FAU - McConnell, J R AU - McConnell JR FAU - Rodriguez-Sierra, J F AU - Rodriguez-Sierra JF LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Physiol Behav JT - Physiology & behavior JID - 0151504 RN - 62-55-5 (Thioacetamide) SB - IM MH - Animals MH - Behavior, Animal/drug effects/*physiology MH - Brain Mapping MH - Female MH - Hepatic Encephalopathy/chemically induced/pathology/*physiopathology MH - Hippocampus/drug effects/pathology/physiopathology MH - Injections, Intraperitoneal MH - *Liver Function Tests MH - Male MH - Neurons/drug effects/pathology/physiology MH - Rats MH - Rats, Sprague-Dawley MH - Sex Factors MH - Thioacetamide EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0031-9384(97)00267-9 [pii] PST - ppublish SO - Physiol Behav. 1997 Nov;62(5):1113-24. PMID- 9297630 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0895-8696 (Print) VI - 8 IP - 3 DP - 1997 Jun TI - Corticotropin-releasing factor and glucocorticoid receptor (GR) gene expression in the paraventricular nucleus of immune-challenged transgenic mice expressing type II GR antisense ribonucleic acid. PG - 165-79 AB - The purpose of this study was to investigate the effect of the immune activator lipopolysaccharide (LPS) on the expression of corticotropin-releasing factor (CRF) and glucocorticoid receptor (GR) mRNA in the paraventricular nucleus (PVN) of transgenic mice with impaired GR function caused by endogenous expression of GR antisense RNA. At 3 and 8 wk of age, control and transgenic mice were sacrificed 4.5 h after a single ip administration of LPS (100 micrograms/100 g of body wt) or vehicle. Frozen brains were mounted on a microtome and cut in 20-microns sections. mRNAs encoding CRF and GR were assayed by in situ hybridization histochemistry using 35S-labeled riboprobes, and localization of Fos-immunoreactive (Fos-ir) nuclei was determined by immunocytochemistry. Basal expression of CRF mRNA in the PVN, central nucleus of the amygdala (CeA), and geniculate complex (GN) was similar in the control and transgenic mice. LPS induced a comparable neuronal activation in the PVN of control and transgenic mice as revealed by the number of Fos-ir neurons. Moreover, the endotoxin caused a significant increase in the CRF mRNA levels within the PVN and CeA, an effect observed in both animal models. The endotoxin did not notably modulate CRF expression in other regions, such as GN. Although GR mRNA was expressed in the PVN of control mice under basal conditions, this transcript was not detected in this hypothalamic structure in LPS-treated and transgenic animals. This indicated that endogenous Type II GR mRNA is decreased in the PVN of mice expressing Type II GR antisense RNA and that gene is downregulated by LPS. Hybridization signal for CRF and GR transcripts was not notably altered by the age of mice. These results provide evidence that the basal expression of CRF and the increase of neuroendocrine CRF transcription in response to immunogenic challenges are not significantly affected by impairment of the Type II GR function. AD - Laboratory of Molecular Endocrinology, Laval University, Quebec, Canada. FAU - Laflamme, N AU - Laflamme N FAU - Barden, N AU - Barden N FAU - Rivest, S AU - Rivest S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Mol Neurosci JT - Journal of molecular neuroscience : MN JID - 9002991 RN - 0 (Lipopolysaccharides) RN - 0 (Proto-Oncogene Proteins c-fos) RN - 0 (RNA, Antisense) RN - 0 (RNA, Messenger) RN - 0 (Receptors, Glucocorticoid) RN - 9015-71-8 (Corticotropin-Releasing Hormone) SB - IM MH - Animals MH - Brain/drug effects/metabolism MH - Corticotropin-Releasing Hormone/*genetics MH - *Gene Expression MH - Humans MH - In Situ Hybridization MH - Lipopolysaccharides/pharmacology MH - Mice MH - Mice, Transgenic MH - Paraventricular Hypothalamic Nucleus/immunology/*metabolism MH - Proto-Oncogene Proteins c-fos/genetics/metabolism MH - RNA, Antisense/*biosynthesis/metabolism MH - RNA, Messenger/metabolism MH - Rats MH - Receptors, Glucocorticoid/*genetics EDAT- 1997/06/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - J Mol Neurosci. 1997 Jun;8(3):165-79. PMID- 9378611 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0074-7742 (Print) VI - 41 DP - 1997 TI - Cerebellar output channels. PG - 61-82 AB - The cerebellum has long been regarded as involved in the control of movement, in part through its connections with the cerebral cortex. These connections were thought to combine inputs from widespread regions of the cerebral cortex and "funnel" them into the motor system at the level of the primary motor cortex. Retrograde transneuronal transport of herpes simplex virus type I has recently been used to identify areas of the cerebral cortex that are "directly" influenced by the output of the cerebellum. Results suggest that cerebellar output projects via the thalamus to multiple cortical areas, including premotor and prefrontal cortex, as well as the primary motor cortex. In addition, the projections to different cortical areas appear to originate from distinct regions of the deep cerebellar nuclei. These observations have led to the proposal that cerebellar output is composed of a number of separate "output channels." Evidence from functional imaging studies in humans and single neuron recording studies in monkeys suggests that individual output channels are concerned with different aspects of motor or cognitive behavior. AD - Veterans Administration Medical Center, Syracuse, New York, USA. FAU - Middleton, F A AU - Middleton FA FAU - Strick, P L AU - Strick PL LA - eng GR - MH11262/MH/NIMH GR - NS24328/NS/NINDS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PT - Review PL - UNITED STATES TA - Int Rev Neurobiol JT - International review of neurobiology JID - 0374740 SB - IM MH - Animals MH - Brain Mapping/*methods MH - Cerebellum/*physiology MH - Humans MH - Magnetic Resonance Imaging MH - Motor Cortex/*physiology MH - Neural Pathways/physiology MH - Neurons/physiology MH - Prefrontal Cortex/physiology MH - Primates/physiology RF - 66 EDAT- 1997/01/01 00:00 MHDA- 1997/09/26 00:01 PST - ppublish SO - Int Rev Neurobiol. 1997;41:61-82. PMID- 9348568 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0890-9091 (Print) VI - 11 IP - 9 Suppl 10 DP - 1997 Sep TI - 5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca. PG - 48-9 AB - This phase III study compares leucovorin plus fluorouracil (5-FU) 425 mg/m2, days 1 through 5, 28-day cycle, with oral leucovorin plus oral UFT (tegafur and uracil) 300 mg/m2, days 1 through 28, 35-day cycle, in terms of efficacy, safety, quality of life, and pharmacoeconomics. Eligible patients have not been treated previously and have measurable or evaluable metastatic colorectal cancer, an Eastern Cooperative Oncology Group performance status of 2 or less, and adequate bone marrow, liver, and renal functions. Patients are evaluated for response clinically and by computed tomography. Responses are determined by World Health Organization criteria. The study is nearing completion, with no toxicity issues requiring protocol modification. The results of this study could lead to a change to oral therapy as the standard of care for metastatic colorectal cancer, providing the efficacy and toxicity of UFT/leucovorin are at least equivalent due to the ease of administration and patient preference for oral regimens. AD - QE II Health Sciences Centre, Halifax, Nova Scotia, Canada. FAU - Skillings, J R AU - Skillings JR LA - eng PT - Clinical Trial PT - Clinical Trial, Phase III PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - UNITED STATES TA - Oncology (Williston Park) JT - Oncology (Williston Park, N.Y.) JID - 8712059 RN - 0 (Antidotes) RN - 0 (Drug Combinations) RN - 0 (UFT(R) drug) RN - 17902-23-7 (Tegafur) RN - 51-21-8 (Fluorouracil) RN - 58-05-9 (Leucovorin) RN - 66-22-8 (Uracil) SB - IM MH - Adult MH - Antidotes/*administration & dosage MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Colorectal Neoplasms/*drug therapy MH - Drug Combinations MH - Drug Therapy, Combination MH - Fluorouracil/administration & dosage MH - Humans MH - Leucovorin/*administration & dosage MH - Tegafur/administration & dosage MH - Uracil/administration & dosage EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):48-9. PMID- 9313184 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20041117 PUBM- Print IS - 0884-2175 (Print) VI - 26 IP - 5 DP - 1997 Sep-Oct TI - Women's sense of well-being before and after hysterectomy. PG - 540-8 AB - OBJECTIVE: To describe women's perceived sense of well-being before and after hysterectomy by examining a broad array of outcomes experienced by women undergoing hysterectomies for benign conditions. DESIGN: Prospective, descriptive. SETTING: A regional tertiary care facility in central Texas. PARTICIPANTS: One hundred seventy-eight women presenting for hysterectomies for nononcologic reasons who completed all three periods of data collection. MAIN OUTCOME MEASURES: Subjects completed a questionnaire assessing information pertinent to their current gynecologic health and the SF-36 Health Survey before surgery and of 4 and 11 months after surgery. The women also completed the Zung Self-Rating Depression Scale preoperatively and at 4 months postoperatively. Additional demographic and medical information was extracted from the medical record. RESULTS: In the initial period after surgery, the patients experienced an improved health status. In addition, the women reported on improvement in their psychologic well-being, including less depression and improved sexual functioning. Relationships with others also improved after the surgery. CONCLUSIONS: Outcomes for these women undergoing hysterectomy for nononcologic reasons were generally positive. This information is vital for preoperative counseling by nurses of women contemplating or about to undergo this surgery. AD - Children's Health Center, Scott and White Clinic, Temple, TX 76508, USA. FAU - Lambden, M P AU - Lambden MP FAU - Bellamy, G AU - Bellamy G FAU - Ogburn-Russell, L AU - Ogburn-Russell L FAU - Preece, C K AU - Preece CK FAU - Moore, S AU - Moore S FAU - Pepin, T AU - Pepin T FAU - Croop, J AU - Croop J FAU - Culbert, G AU - Culbert G LA - eng PT - Journal Article PL - UNITED STATES TA - J Obstet Gynecol Neonatal Nurs JT - Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG JID - 8503123 SB - IM SB - N MH - Adult MH - Attitude to Health MH - Depression MH - Female MH - *Health Status MH - Humans MH - *Hysterectomy/psychology MH - Middle Aged MH - *Patient Satisfaction MH - Prospective Studies MH - Sexuality MH - Treatment Outcome MH - Uterine Diseases/*surgery EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - J Obstet Gynecol Neonatal Nurs. 1997 Sep-Oct;26(5):540-8. PMID- 9298185 OWN - NLM STAT- MEDLINE DA - 19971117 DCOM- 19971117 LR - 20061115 PUBM- Print IS - 0003-6072 (Print) VI - 72 IP - 2 DP - 1997 Aug TI - Seasonal occurrence of yeasts and yeast-like organisms in the river Danube. PG - 77-80 AB - One hundred and seventy yeast strains belonging to 14 genera and 29 species were isolated from 112 water samples of the river Danube in the area of Bratislava. The samples were collected through the year from April to March. Saccharomyces cerevisiae, Candida maltosa, Aureobasidium pullulans, Cystofilobasidium capitatum, Rhodotorula glutinis, Geotrichum candidum, and Candida krusei were the most frequent. The basidiomycetous yeasts and yeast-like organisms with oxidative metabolism were present in approximately equal numbers to those with fermentative metabolism. Saccharomyces cerevisiae was the dominant yeast and was isolated from 50% of all samples examined and represented approximately one quarter of the yeast community. Yeast densities ranged from 100 to 21,100 CFU per litre. The highest population density was observed in October. Cryptococcus albidus, Saccharomyces cerevisiae, Rhodotorula glutinis, and Aureobasidium pullulans formed the main part of the yeast population in this month. AD - Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia. FAU - Slavikova, E AU - Slavikova E FAU - Vadkertiova, R AU - Vadkertiova R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - Antonie Van Leeuwenhoek JT - Antonie van Leeuwenhoek JID - 0372625 RN - 0 (Culture Media) SB - IM MH - Aerobiosis MH - Ascomycota/*isolation & purification MH - Bacteriological Techniques MH - Basidiomycota/*isolation & purification MH - Colony Count, Microbial MH - Culture Media/metabolism MH - Ecology MH - Environmental Microbiology MH - Fermentation MH - Saccharomyces cerevisiae/isolation & purification MH - Seasons MH - Slovakia MH - *Water Microbiology EDAT- 1997/08/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - Antonie Van Leeuwenhoek. 1997 Aug;72(2):77-80. PMID- 9346625 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 1074-3022 (Print) VI - 2 IP - 1 DP - 1996 Jan TI - The influence of prostaglandin E1 on platelet adherence and injury in preserved rat liver allografts. PG - 23-36 AB - We have previously shown that part of the injury sustained by cold-preserved livers on reperfusion is the consequence of platelet adhesion to sinusoidal endothelium. The purpose of the present study was to determine whether prostaglandin E1 (PGE1) can reduce the injury and if so, how to maximize this beneficial effect. Rat livers were cold-preserved in University of Wisconsin solution for 30 hours then subjected to 1-hour warm ischemia after which they were reperfused at 37 degrees C with oxygenated Krebs-Henseleit solution with or without isolated platelets. PGE1 was used to treat the donor liver during harvesting, cold preservation, and reperfusion. In some studies, PGE1 was used to pretreat platelets before exposing them to the liver, and in other studies, both liver and platelets were treated. Pretreatment of platelets with paraformaldehyde, which inactivates them, or ADP, which activates them, was also studied. Treatment of livers with PGE1 significantly decreased preservation injury when livers were reperfused in the absence of platelets. However, when platelets were added to the perfusate, prior treatment of the liver with PGE1 had relatively minor beneficial effects. Pretreatment of platelets alone with PGE1 was also beneficial, but again the effect was small. However, when both liver and platelets were treated with PGE1 there was a highly significant decrease in the extent of liver injury and platelet adhesion. Perfusate transaminase levels were lower, bile flow was improved, and histologically, livers appeared less injured. Pretreatment of platelets with paraformaldehyde produced similar results to pretreatment with PGE1. When platelets were preactivated with adenosine diphosphate, extensive hepatic injury occurred upon reperfusion despite PGE1 treatment of the liver. PGE1 can lessen preservation-reperfusion injury impressively when administered to both liver and platelets but has little effect when platelets have been preactivated. AD - Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. FAU - Cywes, R AU - Cywes R FAU - Harvey, P R AU - Harvey PR FAU - Packham, M A AU - Packham MA FAU - Cameron, R AU - Cameron R FAU - Strasberg, S M AU - Strasberg SM LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Liver Transpl Surg JT - Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JID - 9502504 RN - 745-65-3 (Alprostadil) SB - IM MH - Alprostadil/*pharmacology MH - Animals MH - Liver/pathology MH - *Liver Transplantation MH - Male MH - *Organ Preservation MH - Platelet Adhesiveness/*drug effects MH - Rats MH - Rats, Wistar MH - Reperfusion Injury/*prevention & control MH - Transplantation, Homologous EDAT- 1996/01/01 00:00 MHDA- 1997/11/05 00:01 AID - S1527646596000044 [pii] PST - ppublish SO - Liver Transpl Surg. 1996 Jan;2(1):23-36. PMID- 9237858 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20041117 PUBM- Print IS - 0014-4835 (Print) VI - 65 IP - 1 DP - 1997 Jul TI - Description and function of the ciliary nerves--some historical remarks on choroidal innervation. PG - 1-5 AB - The earliest accounts of the eye recognized its main function as providing vision, but the mechanism of how the eye functioned remained obscure for many centuries. The aim of the following work is to outline these changes in the understanding of a particular structure and function of the human body, namely, the ciliary nerves supplying the uveoscleral part of the eye. In the extensive study on the history of ophthalmology by Hirschberg (published between 1899 and 1918), the ciliary nerves and choroidal innervation are only sparsely mentioned. AD - Department of Anatomy II, Friedrich Alexander University Erlangen-Nuernberg, Erlangen, 91054, Germany. FAU - May, C A AU - May CA LA - eng PT - Historical Article PT - Journal Article PL - ENGLAND TA - Exp Eye Res JT - Experimental eye research JID - 0370707 SB - IM MH - Choroid/cytology/*injuries MH - Ciliary Body/*injuries MH - Ganglia MH - History, 16th Century MH - History, 17th Century MH - History, 18th Century MH - History, 19th Century MH - History, Ancient MH - History, Medieval MH - Humans MH - Nerve Fibers EDAT- 1997/07/01 MHDA- 1997/07/01 00:01 AID - S0014-4835(97)90312-2 [pii] AID - 10.1006/exer.1997.0312 [doi] PST - ppublish SO - Exp Eye Res. 1997 Jul;65(1):1-5. PMID- 9343384 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0270-7306 (Print) VI - 17 IP - 11 DP - 1997 Nov TI - Elimination of defective alpha-factor pheromone receptors. PG - 6236-45 AB - This report compares trafficking routes of a plasma membrane protein that was misfolded either during its synthesis or after it had reached the cell surface. A temperature-sensitive mutant form of the yeast alpha-factor pheromone receptor (ste2-3) was found to provide a model substrate for quality control of plasma membrane proteins. We show for the first time that a misfolded membrane protein is recognized at the cell surface and rapidly removed. When the ste2-3 mutant cells were cultured continuously at 34 degrees C, the mutant receptor protein (Ste2-3p) failed to accumulate at the plasma membrane and was degraded with a half-life of 4 min, compared with a half-life of 33 min for wild-type receptor protein (Ste2p). Degradation of both Ste2-3p and Ste2p required the vacuolar proteolytic activities controlled by the PEP4 gene. At 34 degrees C, Ste2-3p comigrated with glycosylated Ste2p on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, indicating that Ste2-3p enters the secretory pathway. Degradation of Ste2-3p did not require delivery to the plasma membrane as the sec1 mutation failed to block rapid turnover. Truncation of the C-terminal cytoplasmic domain of the mutant receptors did not permit accumulation at the plasma membrane; thus, the endocytic signals contained in this domain are unnecessary for intracellular retention. In the pep4 mutant, Ste2-3p accumulated as series of high-molecular-weight species, suggesting a potential role for ubiquitin in the elimination process. When ste2-3 mutant cells were cultured continuously at 22 degrees C, Ste2-3p accumulated in the plasma membrane. When the 22 degrees C culture was shifted to 34 degrees C, Ste2-3p was removed from the plasma membrane and degraded by a PEP4-dependent mechanism with a 24-min half-life; the wild-type Ste2p displayed a 72-min half-life. Thus, structural defects in Ste2-3p synthesized at 34 degrees C are recognized in transit to the plasma membrane, leading to rapid degradation, and Ste2-3p that is preassembled at the plasma membrane is also removed and degraded following a shift to 34 degrees C. AD - Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, Worcester 01655-0122, USA. jennessd@ummed.edu FAU - Jenness, D D AU - Jenness DD FAU - Li, Y AU - Li Y FAU - Tipper, C AU - Tipper C FAU - Spatrick, P AU - Spatrick P LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Mol Cell Biol JT - Molecular and cellular biology JID - 8109087 RN - 0 (Fungal Proteins) RN - 0 (Receptors, Mating Factor) RN - 0 (Receptors, Peptide) RN - 0 (Transcription Factors) SB - IM MH - Biological Transport MH - Cell Compartmentation MH - Cell Membrane/metabolism MH - Cloning, Molecular MH - Fungal Proteins/chemistry/genetics/*metabolism MH - Models, Molecular MH - Mutation MH - Protein Conformation MH - Protein Folding MH - Receptors, Mating Factor MH - Receptors, Peptide/chemistry/genetics/*metabolism MH - Reproduction MH - Saccharomyces cerevisiae/metabolism MH - Sequence Analysis, DNA MH - *Transcription Factors MH - Vacuoles/metabolism EDAT- 1997/10/29 MHDA- 1997/10/29 00:01 PST - ppublish SO - Mol Cell Biol. 1997 Nov;17(11):6236-45. PMID- 9259380 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0148-7299 (Print) VI - 74 IP - 4 DP - 1997 Jul 25 TI - Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder: differences by diagnosis and family history. PG - 432-8 AB - The distribution of obsessive compulsive symptoms was compared in 16 individuals with primary obsessive compulsive disorder (OCD) and 16 individuals with Gilles de la Tourette syndrome (GTS) and associated obsessive compulsive behaviors (OCB). The two groups showed significant differences in the distribution of OC symptomatology. Furthermore, those OCD probands who shared a similar symptom profile with GTS individuals all had a positive family history of OCD. All of the other OCD probands were isolated cases. Implications of this finding on the etiology and pathogenesis of the two disorders are discussed. AD - Department of Psychiatry, University of London, United Kingdom. FAU - Eapen, V AU - Eapen V FAU - Robertson, M M AU - Robertson MM FAU - Alsobrook, J P 2nd AU - Alsobrook JP 2nd FAU - Pauls, D L AU - Pauls DL LA - eng GR - MH-00508/MH/NIMH PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Am J Med Genet JT - American journal of medical genetics JID - 7708900 RN - 50-67-9 (Serotonin) RN - 51-61-6 (Dopamine) SB - IM MH - Adolescent MH - Adult MH - Basal Ganglia/physiopathology MH - Child MH - *Compulsive Behavior MH - Dopamine/physiology MH - Female MH - Frontal Lobe/physiopathology MH - Gyrus Cinguli/physiopathology MH - Humans MH - Male MH - Middle Aged MH - *Obsessive Behavior MH - Obsessive-Compulsive Disorder/etiology/genetics/physiopathology/*psychology MH - Psychological Tests MH - Serotonin/physiology MH - Thalamus/physiopathology MH - Tourette Syndrome/etiology/genetics/physiopathology/*psychology EDAT- 1997/07/25 MHDA- 2000/06/20 09:00 AID - 10.1002/(SICI)1096-8628(19970725)74:4<432::AID-AJMG15>3.0.CO;2-J [pii] PST - ppublish SO - Am J Med Genet. 1997 Jul 25;74(4):432-8. PMID- 9379007 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20061115 PUBM- Print IS - 0022-1767 (Print) VI - 159 IP - 9 DP - 1997 Nov 1 TI - Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. PG - 4150-3 AB - C-C chemokines play an important role in recruitment of T lymphocytes to inflammatory sites. T lymphocytes secrete chemokines, but the activation requirements for chemokine production by T cells are uncertain. We studied the regulation of C-C chemokine production by CD28 costimulatory signals by murine T lymphocytes. Splenocytes from BALB/c mice cultured with anti-CD3 mAb expressed macrophage-inflammatory protein (MIP)-1alpha mRNA and secreted MIP-1alpha, which was inhibited by anti-B7-1 plus anti-B7-2 mAbs. MIP-1alpha production by Ag-stimulated T cells from DO.11.10 TCR transgenic mice was augmented by anti-CD28 mAb and increased compared with DO.11.10/CD28(-/-) cells. When T cell costimulation was provided by IL-2, MIP-1alpha was not enhanced. Studies with IL-2, IL-4, STAT4, and STAT6 knock-out mice suggested that chemokine production is controlled by pathways different from those regulating T cell differentiation. Thus, CD28 costimulation may amplify an immune response by stimulating T cell survival, proliferation, and production of chemokines that recruit T cells to inflammatory sites. AD - Department of Medicine, The University of Illinois at Chicago, 60612, USA. kherold@uic.edu FAU - Herold, K C AU - Herold KC FAU - Lu, J AU - Lu J FAU - Rulifson, I AU - Rulifson I FAU - Vezys, V AU - Vezys V FAU - Taub, D AU - Taub D FAU - Grusby, M J AU - Grusby MJ FAU - Bluestone, J A AU - Bluestone JA LA - eng GR - AI41071/AI/NIAID GR - DK49799/DK/NIDDK PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Immunol JT - Journal of immunology (Baltimore, Md. : 1950) JID - 2985117R RN - 0 (Antigens, CD28) RN - 0 (Antigens, CD80) RN - 0 (Chemokines, CC) RN - 0 (Receptors, Antigen, T-Cell) SB - AIM SB - IM MH - Animals MH - Antigens, CD28/*immunology MH - Antigens, CD80/*immunology MH - Cells, Cultured MH - Chemokines, CC/*biosynthesis/immunology MH - Mice MH - Mice, Inbred BALB C MH - Mice, Transgenic MH - Receptors, Antigen, T-Cell/genetics/immunology MH - Signal Transduction/immunology MH - T-Lymphocytes/*immunology EDAT- 1997/10/31 MHDA- 1997/10/31 00:01 PST - ppublish SO - J Immunol. 1997 Nov 1;159(9):4150-3. PMID- 9376099 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20061115 PUBM- Print IS - 0269-9370 (Print) VI - 11 Suppl 1 DP - 1997 Sep TI - Risk behavior and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. PG - S35-42 AB - OBJECTIVE: To characterize HIV seroprevalence and risk behavior among injecting drug users (IDUs) in Rio de Janeiro, Brazil, between 1990 and 1996. DESIGN: We report data from three separate cross-sectional samples of IDUs in Rio de Janeiro: the World Health Organization (WHO) sample (n = 479), the Proviva sample (n = 138) and the Brasil sample (n = 110). These data provide the most comprehensive view available, to date, of this understudied population in Rio. METHODS: Demographic characteristics, HIV/AIDS risk behavior and HIV seroprevalence were compared across the three samples and combined analyses were performed to determine the factors associated with injecting risk behavior, sexual risk behavior and HIV seropositivity. RESULTS: The overall HIV seroprevalence among IDUs was 25%. Two encouraging findings of the present analysis were the lower levels of needle-sharing among participants recruited in the latest years (1995-1996) and the lower HIV seroprevalence in the Proviva sample composed mainly of less educated, poorer IDUs living in deprived neighborhoods. No trends toward safer behavior were found for sexual risk, younger age being the principal factor associated with high risk. CONCLUSIONS: Levels of needle-sharing and sexual risk among IDUs in Rio remain high, demonstrating the urgent need to increase the limited preventive measures undertaken so far. Seroprevalence levels for HIV remain significantly lower in the most deprived sample, arguing for the fundamental importance of prompt and effective prevention strategies to keep infection rates from rising among the poorest and largest strata of Rio's IDUs. AD - Nucleo de Estudos e Pesquisa em Atencao ao uso de Drogas, State University of Rio de Janeiro, Brazil. FAU - Telles, P R AU - Telles PR FAU - Bastos, F I AU - Bastos FI FAU - Guydish, J AU - Guydish J FAU - Inciardi, J A AU - Inciardi JA FAU - Surratt, H L AU - Surratt HL FAU - Pearl, M AU - Pearl M FAU - Hearst, N AU - Hearst N LA - eng GR - UO1DA08510/DA/NIDA PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - AIDS JT - AIDS (London, England) JID - 8710219 SB - IM SB - J SB - X MH - Adolescent MH - Adult MH - Brazil/epidemiology MH - Female MH - HIV Seropositivity/*epidemiology MH - *HIV-1 MH - Humans MH - Male MH - Prevalence MH - Substance Abuse, Intravenous OID - PIP: 128472 OID - POP: 00269176 OTO - PIP OT - Americas OT - Behavior OT - Brazil OT - *Cross Sectional Analysis OT - Demographic Factors OT - Developing Countries OT - Diseases OT - Drug Usage OT - *Hiv Infections OT - *Iv Drug Users OT - Latin America OT - Population OT - Population Characteristics OT - Research Methodology OT - *Research Report OT - *Risk Behavior OT - *Sex Behavior OT - South America OT - *Urban Population OT - Viral Diseases GN - PIP: TJ: AIDS. EDAT- 1997/10/31 MHDA- 1997/10/31 00:01 PST - ppublish SO - AIDS. 1997 Sep;11 Suppl 1:S35-42. PMID- 9332329 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20061115 PUBM- Print IS - 0007-1048 (Print) VI - 98 IP - 3 DP - 1997 Sep TI - A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. PG - 711-8 AB - One hundred and thirty-four adults and 204 children were randomized in two prospective, parallel comparative multicentre trials to receive either conventional amphotericin B 1 mg/kg/d (c-AMB), liposomal amphotericin B 1 mg/kg/d(L-AMB1) or liposomal amphotericin B 3 mg/ kg/d (L-AMB3). Patients were entered if they had a pyrexia of unknown origin (PUO) defined as temperature of 38 degrees C or more, not responding to 96 h of systemic broad-spectrum antibiotic treatment, and neutropenia (< 0.5 x 10(9)/l). The safety and toxicity of liposomal amphotericin B was compared with that of conventional amphotericin B. Efficacy of treatment was assessed, with success defined as resolution of fever for 3 consecutive days (< 38 degrees C) without the development of any new fungal infection. Clinical and laboratory parameters were collected for safety analysis. In both the paediatric and adult populations, L-AMB treated patients had a 2-6-fold decrease in the incidence (P < or = 0.01) of test-drug-related side-effects, compared to c-AMB. Severe trial-drug-related side-effects were seen in 1% of L-AMB treated patients, in contrast to 12% of patients on c-AMB (P < 0.01). Nephrotoxicity, in the patient subset not receiving concomitant nephrotoxic agents, defined as a doubling from the patients baseline serum creatinine level, was not observed in the L-AMB1 arm whereas the incidence was 3% in patients on L-AMB3 and 23% in those on c-AMB (P < 0.01). Moreover, time to develop nephrotoxicity was longer in both L-AMB arms than c-AMB (P < 0.01). Severe hypokalaemia was observed less frequently in both L-AMB arms (P < 0.01). Analysis was by intention-to-treat and included all patients randomized. Success was defined by a minimum of 3 consecutive days with fever (< 38 degrees C) continuing to study end indicated by recovery of neutrophils to 0.5 x 10(9)/l. Addition of systemic antifungal therapy or development of systemic fungal infection were failures as was persistent fever to study end. Efficacy assessments indicated success in 49% of the total group treated with c-AMB, 58% of patients responded to L-AMB1 and 64% to L-AMB3. A statistically significant difference was found between c-AMB and L-AMB3 (P = 0.03) but a Kaplan-Meier analysis of time to differvescence of fever showed there was no significant difference between the arms. It was concluded that liposomal amphotericin at either 1 or 3 mg/kg/d was significantly safer than conventional amphotericin B in children and adults. The main aim of this open-label study was to compare safety between the three trial arms. However, we provide evidence for an equivalent or possibly superior efficacy of liposomal amphotericin with regard to resolution of fever of unknown origin. Subsequent trials should compare amphotericin preparations in defined fungal infections. AD - Royal Free Hospital and School of Medicine, London. FAU - Prentice, H G AU - Prentice HG FAU - Hann, I M AU - Hann IM FAU - Herbrecht, R AU - Herbrecht R FAU - Aoun, M AU - Aoun M FAU - Kvaloy, S AU - Kvaloy S FAU - Catovsky, D AU - Catovsky D FAU - Pinkerton, C R AU - Pinkerton CR FAU - Schey, S A AU - Schey SA FAU - Jacobs, F AU - Jacobs F FAU - Oakhill, A AU - Oakhill A FAU - Stevens, R F AU - Stevens RF FAU - Darbyshire, P J AU - Darbyshire PJ FAU - Gibson, B E AU - Gibson BE LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Br J Haematol JT - British journal of haematology JID - 0372544 RN - 0 (AmBisome) RN - 0 (Antibiotics, Antifungal) RN - 1397-89-3 (Amphotericin B) SB - IM MH - Adult MH - Amphotericin B/*therapeutic use MH - Antibiotics, Antifungal/*therapeutic use MH - Child MH - Female MH - Fever of Unknown Origin/complications/*drug therapy MH - Humans MH - Male MH - Mycoses/*drug therapy MH - Neutropenia/*complications MH - Prospective Studies EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Br J Haematol. 1997 Sep;98(3):711-8. PMID- 9377966 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0009-479X (Print) VI - 62 IP - 3 DP - 1997 TI - [Treatment of complex fractures within the hand with external fixation] PG - 205-9 AB - External fixation with the use of bone cement was employed in treatment for 22 metacarpal and phalangeal fractures in 18 patients. Open fractures prevailed (70%). A frame or "V" construction was used. Metal implants were connected with balls of bone cement. The average hand function loss in cases of metacarpal fractures associated with nerves and tendons lesion was 25%. AD - Osrodka Replantacji Konczyn, Mikrochirurgii, Chirurgii Reki i Chirurgii Ogolnej w Trzebnicy. FAU - Jablecki, J AU - Jablecki J FAU - Domanasiewicz, A AU - Domanasiewicz A FAU - Chelmonski, A AU - Chelmonski A LA - pol PT - Clinical Trial PT - English Abstract PT - Journal Article TT - Leczenie skomplikowanych zlaman w obrebie reki stabilizacja zewnetrzna. PL - POLAND TA - Chir Narzadow Ruchu Ortop Pol JT - Chirurgia narzadow ruchu i ortopedia polska JID - 2985137R RN - 0 (Bone Cements) SB - IM MH - Adolescent MH - Adult MH - Bone Cements MH - *External Fixators MH - Female MH - Fractures, Open/*therapy MH - Humans MH - Male MH - Metacarpophalangeal Joint/*injuries MH - Middle Aged MH - Prosthesis Implantation MH - Treatment Outcome EDAT- 1997/01/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Chir Narzadow Ruchu Ortop Pol. 1997;62(3):205-9. PMID- 9303406 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print IS - 0066-4804 (Print) VI - 41 IP - 9 DP - 1997 Sep TI - Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). PG - 2019-22 AB - HMR 3647 (RU 66647) and HMR 3004 (RU 64004), two ketolides, had MICs at which 50% of the strains are inhibited (MIC50s) of 0.06 to 0.125 microg/ml and MIC90s of 16.0 microg/ml against 352 anaerobes. MIC50s and MIC90s of erythromycin, azithromycin, clarithromycin, and roxithromycin were 0.5 to 2.0 microg/ml and 32.0 to >64.0 microg/ml, respectively. HMR 3647 and HMR 3004 were more active against non-Bacteroides fragilis-group anaerobes (other than Fusobacterium mortiferum, Fusobacterium varium, and Clostridium difficile). AD - Department of Pathology (Clinical Microbiology), Hershey Medical Center, Pennsylvania 17033, USA. FAU - Ednie, L M AU - Ednie LM FAU - Jacobs, M R AU - Jacobs MR FAU - Appelbaum, P C AU - Appelbaum PC LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Antimicrob Agents Chemother JT - Antimicrobial agents and chemotherapy JID - 0315061 RN - 0 (Anti-Bacterial Agents) RN - 0 (Ketolides) RN - 0 (Macrolides) RN - 0 (RU 64004) RN - 0 (telithromycin) RN - 114-07-8 (Erythromycin) RN - 124-38-9 (Carbon Dioxide) RN - 80214-83-1 (Roxithromycin) RN - 81103-11-9 (Clarithromycin) RN - 83905-01-5 (Azithromycin) SB - IM MH - Anti-Bacterial Agents/*pharmacology MH - Azithromycin/pharmacology MH - Bacteria, Anaerobic/*drug effects MH - Carbon Dioxide/metabolism MH - Clarithromycin/pharmacology MH - Erythromycin/pharmacology MH - Hydrogen-Ion Concentration MH - *Ketolides MH - *Macrolides MH - Microbial Sensitivity Tests MH - Roxithromycin/pharmacology EDAT- 1997/09/26 MHDA- 1997/09/26 00:01 PST - ppublish SO - Antimicrob Agents Chemother. 1997 Sep;41(9):2019-22. PMID- 9357967 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0301-472X (Print) VI - 25 IP - 12 DP - 1997 Nov TI - Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. PG - 1240-5 AB - We studied the effect of recombinant canine stem cell factor (rcSCF) on hematopoietic recovery, incidence of graft failure, graft-vs.-host disease (GVHD), and survival after marrow transplantation from dog leukocyte antigen (DLA)-identical canine littermates. Ten animals received 100 microg rcSCF/kg/day b.i.d. by subcutaneous injection on days 1 through 10 after 920 cGy total body irradiation and transplantation of a mean of 3.7x10(8) marrow cells/kg body weight. None of the dogs received GVHD prophylaxis. All animals showed hematopoietic engraftment. The median number of days to achieve 1000 neutrophils/mm3 was 9; 100 monocytes/mm3 were reached after 15 days, 500 lymphocytes/mm3 after 21 days, and 20,000 platelets/mm3 after 16 days. One animal developed GVHD involving skin, gut, and liver and died of bacterial pneumonia 21 days after transplantation. The remaining nine dogs were observed for a median of 37 days (range 29-84 days) posttransplantation until they were killed. Facial edema was seen in three dogs during the first 2-3 days of rcSCF administration. These results show that within the limits of this study it appears to be safe to administer SCF after DLA-identical littermate marrow transplants in dogs. Comparison with previously published data in the same model showed that neutrophil and monocyte recovery was significantly faster in dogs receiving SCF treatment compared with dogs without growth factor treatment (recovery to achieve 1000 neutrophils/mm3: median 9 days vs. 13 days, p = 0.002; recovery to 100 monocytes/mm3: median 15 days vs. 105 days, p = 0.0002). Otherwise, no significant differences were seen. Results obtained with SCF treatment were similar to those previously obtained in the same model with recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment except that recovery of lymphocytes to 500/mm3 appeared to be more rapid in G-CSF-treated dogs (median 15 days vs. 21 days, p = 0.03). AD - The University of Wisconsin, Madison, USA. FAU - Schuening, F G AU - Schuening FG FAU - von Kalle, C AU - von Kalle C FAU - Kiem, H P AU - Kiem HP FAU - Appelbaum, F R AU - Appelbaum FR FAU - Deeg, H J AU - Deeg HJ FAU - Pepe, M AU - Pepe M FAU - Gooley, T AU - Gooley T FAU - Graham, T C AU - Graham TC FAU - Hackman, R C AU - Hackman RC FAU - Storb, R AU - Storb R LA - eng GR - CA15704/CA/NCI GR - CA18221/CA/NCI GR - DK42716/DK/NIDDK GR - etc. PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Exp Hematol JT - Experimental hematology JID - 0402313 RN - 0 (Recombinant Proteins) RN - 0 (Stem Cell Factor) RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) SB - IM MH - Animals MH - Bone Marrow Transplantation/immunology/*veterinary MH - Dogs MH - Female MH - Graft Survival MH - Graft vs Host Disease/etiology MH - Granulocyte Colony-Stimulating Factor/pharmacology MH - Hematopoiesis/*drug effects MH - Histocompatibility MH - Male MH - Recombinant Proteins/pharmacology MH - Stem Cell Factor/*pharmacology MH - Time Factors EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Exp Hematol. 1997 Nov;25(12):1240-5. PMID- 9326217 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0006-4971 (Print) VI - 90 IP - 7 DP - 1997 Oct 1 TI - Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. PG - 2529-34 AB - We previously showed that a peptide (PR1) derived from the primary granule enzyme proteinase 3 induced peptide specific cytotoxic T lymphocytes (CTL) in a normal HLA-A2.1+ individual. These CTL showed HLA-restricted cytotoxicity to myeloid leukemias (which overexpress proteinase 3). To further investigate their antileukemic potential, we studied the ability of PR1-specific CTL, derived from two HLA-A2.1+ normal individuals, to inhibit colony-forming unit granulocyte-macrophage (CFU-GM) from normal and leukemic individuals. CTL from 20 day PR1 peptide-pulsed lymphocyte cultures showed 89% to 98% HLA-A2.1-restricted colony inhibition of chronic myeloid leukemia targets. Colony formation in normal HLA-A2.1+ bone marrow or HLA-A2.1- CML cells was not inhibited. Sequencing of the exon encoding PR1 showed that colony inhibition was not caused by polymorphic differences in proteinase 3 between effectors and targets. Analysis by flow cytometry showed that proteinase 3 was overexpressed in the leukemia targets compared with normal marrow targets (median channel fluorescence 1,399 v 298, P = .009). These results show that PR1-specific allogeneic T cells preferentially inhibit leukemic CFU-GM based on overexpression of proteinase 3, and that proteinase 3-specific CTL could be used for leukemia-specific adoptive immunotherapy. AD - Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. FAU - Molldrem, J J AU - Molldrem JJ FAU - Clave, E AU - Clave E FAU - Jiang, Y Z AU - Jiang YZ FAU - Mavroudis, D AU - Mavroudis D FAU - Raptis, A AU - Raptis A FAU - Hensel, N AU - Hensel N FAU - Agarwala, V AU - Agarwala V FAU - Barrett, A J AU - Barrett AJ LA - eng PT - Journal Article PL - UNITED STATES TA - Blood JT - Blood JID - 7603509 RN - 0 (HLA-A2 Antigen) RN - 0 (Neoplasm Proteins) RN - 0 (Peptide Fragments) RN - EC 3.4.21.- (Serine Endopeptidases) RN - EC 3.4.21.76 (Myeloblastin) SB - AIM SB - IM MH - Bone Marrow/pathology MH - Cells, Cultured MH - Cytotoxicity, Immunologic MH - Exons/genetics MH - HLA-A2 Antigen/immunology MH - Humans MH - Immunotherapy, Adoptive MH - Leukemia, Myeloid, Chronic/*immunology/pathology MH - Myeloblastin MH - Neoplasm Proteins/chemistry/genetics/*immunology MH - Peptide Fragments/genetics/*immunology MH - Serine Endopeptidases/chemistry/genetics/*immunology MH - T-Lymphocytes, Cytotoxic/*immunology MH - Tumor Cells, Cultured MH - Tumor Stem Cell Assay MH - Tumor Stem Cells/enzymology/*immunology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Blood. 1997 Oct 1;90(7):2529-34. PMID- 9382507 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0385-0684 (Print) VI - 24 IP - 12 DP - 1997 Sep TI - [Intraoperative radiotherapy in carcinoma of the body and tail of the pancreas] PG - 1687-90 AB - The prognosis for patients with carcinoma of the body and tail of the pancreas is extremely poor. We analyzed the effectiveness of intraoperative radiotherapy (IOR) from the viewpoint of the cumulative survival rate and pain relief. The prognosis of patients who underwent IOR with/without resection was significantly longer than for patients without IOR (p < 0.0001). Better pain relief was obtained by IOR. Although a randomized prospective study is required, resection and IOR will be the central treatment modalities for carcinoma of the body and tail of the pancreas. AD - Dept. of Surgery I, Tohoku University School of Medicine. FAU - Egawa, S AU - Egawa S FAU - Fukuyama, S AU - Fukuyama S FAU - Sunamura, M AU - Sunamura M FAU - Kobari, M AU - Kobari M FAU - Matsuno, S AU - Matsuno S LA - jpn PT - English Abstract PT - Journal Article PL - JAPAN TA - Gan To Kagaku Ryoho JT - Gan to kagaku ryoho. Cancer & chemotherapy JID - 7810034 SB - IM MH - Aged MH - Combined Modality Therapy MH - Humans MH - *Intraoperative Care MH - Middle Aged MH - Pain Measurement MH - Pain, Postoperative/physiopathology MH - Pancreatic Neoplasms/mortality/*radiotherapy/surgery MH - Radiotherapy Dosage MH - Radiotherapy, Adjuvant MH - Retrospective Studies MH - Survival Rate EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Gan To Kagaku Ryoho. 1997 Sep;24(12):1687-90. PMID- 9325342 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0021-9258 (Print) VI - 272 IP - 41 DP - 1997 Oct 10 TI - Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. PG - 26049-55 AB - The full-length cDNA for the rat recombinant synaptic vesicle monoamine transporter (rVMAT2) containing a COOH-terminal polyhistidine epitope was engineered into baculovirus DNA for expression in Spodoptera frugiperda (Sf9) cells. Using this recombinant baculovirus and cultured Sf9 cells, rVMAT2 has been expressed to high levels and purified to >95% homogeneity using immobilized Ni2+-affinity chromatography followed by lectin (concanavalin A) chromatography. Purified transporter was photolabeled using [125I]-7-azido-8-iodoketanserin ([125I]AZIK) and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine ([125I]TBZ-AIPP). Both [125I]AZIK and [125I]TBZ-AIPP photoaffinity labeling of purified rVMAT2 were protectable by 10 microM tetrabenazine (TBZ), 10 microM 7-aminoketanserin, and 1 mM concentrations of the transporter substrates dopamine, norepinephrine, and serotonin. Radiolabeled peptides were generated using enzymatic and chemical methods, purified using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and NH2-terminal microsequenced. Radiosequencing of [125I]AZIK-labeled rVMAT2 indicated derivatization of Lys-20 in the NH2 terminus, just prior to putative transmembrane domain 1 (TMD1). [125I]TBZ-AIPP derivatized a segment of rVMAT2 between Gly-408 and Cys-431 in TMD10 and 11. These data implicate juxtaposition of TMD1 and 10/11. AD - Department of Pharmacology, University of Wisconsin Medical School, Madison, Wisconsin 53706, USA. FAU - Sievert, M K AU - Sievert MK FAU - Ruoho, A E AU - Ruoho AE LA - eng GR - NS33650-02/NS/NINDS PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (2-N-((3'-iodo-4'-azidophenyl)propionyl)tetrabenazine) RN - 0 (Affinity Labels) RN - 0 (Azides) RN - 0 (Iodine Radioisotopes) RN - 0 (Membrane Glycoproteins) RN - 0 (Membrane Transport Proteins) RN - 0 (Neuropeptides) RN - 0 (Neurotransmitter Agents) RN - 0 (Recombinant Proteins) RN - 0 (Vesicular Biogenic Amine Transport Proteins) RN - 136769-36-3 (azidoiodoketanserin) RN - 58-46-8 (Tetrabenazine) RN - 74050-98-9 (Ketanserin) SB - IM MH - Affinity Labels/chemistry/*metabolism MH - Animals MH - Azides/chemistry/*metabolism MH - Binding Sites MH - Biological Transport MH - Iodine Radioisotopes MH - Ketanserin/*analogs & derivatives/chemistry/metabolism MH - Membrane Glycoproteins/chemistry/*metabolism MH - *Membrane Transport Proteins MH - Models, Molecular MH - *Neuropeptides MH - Neurotransmitter Agents/chemistry/*metabolism MH - Peptide Mapping MH - Protein Binding MH - Rats MH - Recombinant Proteins/metabolism MH - Spodoptera MH - Synaptic Vesicles/chemistry/*metabolism MH - Tetrabenazine/*analogs & derivatives/chemistry/metabolism MH - Vesicular Biogenic Amine Transport Proteins EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - J Biol Chem. 1997 Oct 10;272(41):26049-55. PMID- 9301342 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print IS - 0003-066X (Print) VI - 52 IP - 9 DP - 1997 Sep TI - Politics, science, and the emergence of a new disease. The case of chronic fatigue syndrome. PG - 973-83 AB - Chronic fatigue syndrome (CFS) emerged as a diagnostic category during the last decade. Initial research suggested that CFS was a relatively rare disorder with a high level of psychiatric comorbidity. Many physicians minimized the seriousness of this disorder and also interpreted the syndrome as being equivalent to a psychiatric disorder. These attitudes had negative consequences for the treatment of CFS. By the mid-1990s, findings from more representative epidemiological studies indicated considerably higher CFS prevalence rates. However, the use of the revised CFS case definition might have produced heterogeneous patient groups, possibly including some patients with pure psychiatric disorders. Social scientists have the expertise to more precisely define this syndrome and to develop appropriate and sensitive research strategies for understanding this disease. AD - Department of Psychology, DePaul University, Chicago, IL 60614, USA. FAU - Jason, L A AU - Jason LA FAU - Richman, J A AU - Richman JA FAU - Friedberg, F AU - Friedberg F FAU - Wagner, L AU - Wagner L FAU - Taylor, R AU - Taylor R FAU - Jordan, K M AU - Jordan KM LA - eng GR - AI36295/AI/NIAID PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Am Psychol JT - The American psychologist JID - 0370521 SB - IM CIN - Am Psychol. 1998 Sep;53(9):1080-2. PMID: 9841580 MH - *Attitude of Health Personnel MH - Comorbidity MH - Diagnosis, Differential MH - *Fatigue Syndrome, Chronic/classification/diagnosis/epidemiology/psychology MH - Humans MH - Mental Disorders/diagnosis/epidemiology MH - Prevalence MH - *Terminology MH - United States/epidemiology EDAT- 1997/09/25 MHDA- 1997/09/25 00:01 PST - ppublish SO - Am Psychol. 1997 Sep;52(9):973-83. PMID- 9353195 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0036-8075 (Print) VI - 278 IP - 5340 DP - 1997 Nov 7 TI - A low-barrier hydrogen bond in the catalytic triad of serine proteases? Theory versus experiment. PG - 1128-32 AB - Cleland and Kreevoy recently advanced the idea that a special type of hydrogen bond (H-bond), termed a low-barrier hydrogen bond (LBHB), may account for the "missing" transition state stabilization underlying the catalytic power of many enzymes, and Frey et al. have proposed that the H-bond between aspartic acid 102 and histidine 57 in the catalytic triad of serine proteases is an example of a catalytically important LBHB. Experimental facts are here considered regarding the aspartic acid-histidine and cis-urocanic H-bonds that are inconsistent with fundamental tenets of the LBHB hypothesis. The inconsistencies between theory and experiment in these paradigm systems cast doubt on the existence of LBHBs, as currently defined, within enzyme active sites. AD - Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA. FAU - Ash, E L AU - Ash EL FAU - Sudmeier, J L AU - Sudmeier JL FAU - De Fabo, E C AU - De Fabo EC FAU - Bachovchin, W W AU - Bachovchin WW LA - eng GR - GM27927/GM/NIGMS PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Science JT - Science JID - 0404511 RN - 0 (Boronic Acids) RN - 0 (Oligopeptides) RN - 0 (Protons) RN - 0 (Serine Proteinase Inhibitors) RN - 104-98-3 (Urocanic Acid) RN - 56-84-8 (Aspartic Acid) RN - 71-00-1 (Histidine) RN - 94242-73-6 (O-methyl-succinyl-alanyl-alanyl-prolyl-borovaline) RN - EC 3.4.21.- (Serine Endopeptidases) RN - EC 3.4.21.- (Subtilisins) RN - EC 3.4.21.12 (myxobacter alpha-lytic proteinase) SB - IM MH - Aspartic Acid/chemistry MH - Binding Sites MH - Boronic Acids/metabolism MH - Catalysis MH - Histidine/chemistry MH - Hydrogen Bonding MH - Hydrogen-Ion Concentration MH - Magnetic Resonance Spectroscopy MH - Oligopeptides/metabolism MH - Protons MH - Serine Endopeptidases/*chemistry/metabolism MH - Serine Proteinase Inhibitors/metabolism MH - Subtilisins/chemistry MH - Temperature MH - Urocanic Acid/chemistry EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Science. 1997 Nov 7;278(5340):1128-32. PMID- 9315221 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 0019-5189 (Print) VI - 35 IP - 2 DP - 1997 Feb TI - Enterotoxicity, haemolytic activity and antibiotic susceptibility of Aeromonas eucrenophila strains isolated from water and infected fish. PG - 144-7 AB - Strains of A. eucrenophila isolated from fresh water (2 strains) and infected fish (4 strains) were tested for haemolytic activity and enterotoxicity and any correlation between them. Also, the resistance patterns of A. eucrenophila were tested especially in relation to ampicillin. None of the A. eucrenophila strains caused fluid accumulation in the initial tests, however, they did so only after one to four sequential passages through the gut of a susceptible host. All the strains of A. eucrenophila showed beta-haemolytic activities. Production of beta-haemolysin could be correlated with enterotoxicity. Since all the strains of A. eucrenophila were resistant to ampicillin, media containing this antibiotic may be used for their isolation from diverse sources. AD - Department of Microbiology, Banaras Hindu University, Varanasi, India. FAU - Singh, D V AU - Singh DV FAU - Sanyal, S C AU - Sanyal SC LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - INDIA TA - Indian J Exp Biol JT - Indian journal of experimental biology JID - 0233411 SB - IM MH - Aeromonas/*drug effects/isolation & purification MH - Animals MH - Digestive System/microbiology MH - Fish Diseases/microbiology MH - Fishes/*microbiology MH - Gram-Negative Bacterial Infections/pathology/veterinary MH - Hemolysis MH - Microbial Sensitivity Tests MH - Rabbits MH - *Water Microbiology EDAT- 1997/02/01 00:00 MHDA- 1997/10/07 00:01 PST - ppublish SO - Indian J Exp Biol. 1997 Feb;35(2):144-7. PMID- 9335460 OWN - NLM STAT- MEDLINE DA - 19971105 DCOM- 19971105 LR - 20041117 PUBM- Print IS - 0003-276X (Print) VI - 249 IP - 2 DP - 1997 Oct TI - Immunohistochemical and ultrastructural investigation of the human vestibular dark cell area: roles of subepithelial capillaries and T lymphocyte-melanophage interaction in an immune surveillance system. PG - 153-62 AB - BACKGROUND: The aim of the present study was to morphologically characterize the structure of the subepithelial blood vessels in the dark cell area of the human vestibular organs, and to determine whether immunocompetent cells such as macrophages and lymphocytes could be found around these small blood vessels. MATERIALS AND METHODS: All 31 surgical specimens (semicircular canals and utricles) were obtained from patients with vestibular schwannoma. Formalin fixed specimens were stained with hematoxylin and eosin (H&E), and with antibodies to von Willebrand Factor (vWF), leukocyte common antigen (LCA), and UCHL-1, and were examined with light microscope. Specimens fixed with glutaraldehyde were examined with a transmission electron microscope (TEM). OBJECTIVES: Subepithelial blood vessels stained positive for vWF. By TEM observation, these blood vessels were observed to be capillaries that consisted of non-fenestrated endothelium, occasional pericytes, and a basement membrane. They were usually accompanied by melanophages with a number of secondary lysosomes containing phagocytosed degraded melanosomes and lipid droplets. Moreover, melanocytes and their cell processes directly surrounded these subepithelial capillaries. The fact that cells which were positively stained with LCA and UCHL-1 were present both in the intra- and subepithelial layer of the specimens, and that by TEM the intra- and subepithelial mononuclear cells with a lymphoid appearance had clustered dense bodies in their cytoplasm, suggested that they were a population of T lymphocytes. CONCLUSIONS: Results suggested the possibility of a T lymphocyte-melanophage (macrophage) interaction, both originating from and harbored around subepithelial capillaries, which suggests the presence of an immune surveillance system in the human vestibular organs. AD - Department of Otorhinolaryngology, Keio University, School of Medicine, Tokyo, Japan. FAU - Masuda, M AU - Masuda M FAU - Yamazaki, K AU - Yamazaki K FAU - Kanzaki, J AU - Kanzaki J FAU - Hosoda, Y AU - Hosoda Y LA - eng PT - Journal Article PL - UNITED STATES TA - Anat Rec JT - The Anatomical record JID - 0370540 RN - 0 (Antigens, CD45) RN - 0 (von Willebrand Factor) SB - IM SB - S MH - Adult MH - Aged MH - Antigens, CD45/analysis MH - Capillaries/immunology/ultrastructure MH - Ear Neoplasms/blood supply/immunology/pathology MH - Epithelium/blood supply/immunology/ultrastructure MH - Female MH - Humans MH - Immunohistochemistry MH - *Immunologic Surveillance MH - Macrophages/*immunology MH - Male MH - Middle Aged MH - Neurilemmoma/blood supply/immunology/pathology MH - Semicircular Canals/cytology MH - T-Lymphocytes/*immunology MH - Vestibule/*blood supply/cytology/immunology MH - von Willebrand Factor/analysis EDAT- 1997/10/23 22:33 MHDA- 2000/06/20 09:00 AID - 10.1002/(SICI)1097-0185(199710)249:2<153::AID-AR1>3.0.CO;2-Z [pii] PST - ppublish SO - Anat Rec. 1997 Oct;249(2):153-62. PMID- 9331078 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0008-5472 (Print) VI - 57 IP - 19 DP - 1997 Oct 1 TI - Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. PG - 4214-6 AB - Epidermodysplasia verruciformis (EV) is regarded as a model for cutaneous oncogenesis associated with specific human papillomaviruses (HPVs). Because genital HPV-associated carcinogenesis is a very long-lasting process requiring 20-30 years and epidemiological studies of this type for HPV-associated skin cancers are impossible in such a rare disease as EV, we observed for up to 20 years EV patients having surgery for carcinomas with consecutive autografts from uninvolved and non-sun-exposed skin. We noticed the appearance of premalignant and malignant changes around the grafts, whereas within the grafted skin, only benign macular lesions started to develop several years after transplantation. Thus, skin HPV-associated carcinogenesis appears to be a very slow process comparable to the genital carcinogenesis associated with high risk HPVs. AD - Department of Dermatology, Warsaw School of Medicine, Poland. FAU - Majewski, S AU - Majewski S FAU - Jablonska, S AU - Jablonska S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Cancer Res JT - Cancer research JID - 2984705R SB - IM MH - Adult MH - Aged MH - Cell Transformation, Neoplastic MH - Cell Transformation, Viral MH - Epidermodysplasia Verruciformis/pathology/*surgery/virology MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Papillomaviridae/*pathogenicity MH - Papillomavirus Infections/pathology/*surgery/virology MH - Precancerous Conditions/pathology/*surgery/virology MH - Skin Neoplasms/*etiology/pathology MH - Skin Transplantation/*pathology MH - Time Factors MH - Transplantation, Autologous MH - Tumor Virus Infections/pathology/*surgery/virology EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Cancer Res. 1997 Oct 1;57(19):4214-6. PMID- 9325282 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0021-9258 (Print) VI - 272 IP - 41 DP - 1997 Oct 10 TI - Covalent modification of the regulatory domain irreversibly stimulates cystic fibrosis transmembrane conductance regulator. PG - 25617-22 AB - The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel is regulated by three cytosolic domains, the regulatory domain (R domain) and two nucleotide binding domains. To learn more about how the cytosolic domains regulate channel activity, we used chemical modification to probe their structure. When we applied the sulfhydryl-modifying reagent N-ethylmaleimide (NEM) and other N-substituted maleimides to the cytosolic domains, we found that they rapidly and irreversibly stimulated channel activity. CFTR contains 14 intracellular cysteine residues that might be targets for NEM modification. We identified one, Cys832, that was essential for the response. Cys832 is located in the R domain. Single channel studies showed that NEM stimulated CFTR by increasing the duration of bursts of activity and by shortening the closed interval between bursts. At the single channel level, CFTR in which Cys832 was mutated to alanine behaved identically to wild-type CFTR, except that it failed to respond to NEM. Additional studies showed that NEM modification increased the potency of ATP-mediated stimulation. Previous work has shown that modification of the R domain by phosphorylation, which introduces negative charge, or replacement of multiple serines by negatively charged aspartates stimulates the channel. Our current data show that covalent modification of the R domain with a neutral, hydrophobic adduct at a site that is not phosphorylated can also stimulate CFTR. This finding suggests that an alteration in the conformation of the R domain may be a key feature that regulates channel activity. AD - Howard Hughes Medical Institute and the Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA. FAU - Cotten, J F AU - Cotten JF FAU - Welsh, M J AU - Welsh MJ LA - eng GR - HL29851/HL/NHLBI GR - HL42385/HL/NHLBI PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (CFTR protein, human) RN - 126880-72-6 (Cystic Fibrosis Transmembrane Conductance Regulator) RN - 128-53-0 (Ethylmaleimide) RN - 52-90-4 (Cysteine) RN - 56-41-7 (Alanine) RN - 56-65-5 (Adenosine Triphosphate) RN - EC 2.7.1.37 (Cyclic AMP-Dependent Protein Kinases) SB - IM MH - Adenosine Triphosphate/metabolism MH - Alanine/metabolism MH - Binding Sites MH - Cyclic AMP-Dependent Protein Kinases/metabolism MH - Cysteine/metabolism MH - Cystic Fibrosis Transmembrane Conductance Regulator/*chemistry/genetics/metabolism MH - Cytoplasm/drug effects/metabolism MH - Ethylmaleimide/pharmacology MH - Humans MH - Models, Chemical MH - Mutagenesis, Site-Directed MH - Transfection EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - J Biol Chem. 1997 Oct 10;272(41):25617-22. PMID- 9382073 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20041117 PUBM- Print IS - 0002-9270 (Print) VI - 92 IP - 10 DP - 1997 Oct TI - Multifocal hepatic lesions in AIDS: an unusual presentation of steatosis. PG - 1934-6 AB - Patients infected with HIV frequently have abnormal results on liver tests, leading to radiographic evaluation for hepatic lesions. The etiology of these lesions in patients infected with HIV is most often secondary to infections or tumors. Occasionally, focal abnormalities in the liver are identified in asymptomatic patients. The etiology and clinical course in this subset of patients are not known. However, because of concerns of tumor, an evaluation is usually warranted. We report an unusual case of multifocal hepatic steatosis presenting as multiple liver lesions in an HIV-positive patient with cutaneous Kaposi's sarcoma. This case emphasizes the importance of obtaining a tissue diagnosis in this patient population. AD - Department of Medicine, University Hospitals of Cleveland, Ohio, USA. FAU - Sterling, R K AU - Sterling RK FAU - Herbener, T E AU - Herbener TE FAU - Jacobs, G H AU - Jacobs GH FAU - Post, A B AU - Post AB FAU - Carey, J T AU - Carey JT FAU - Haaga, J R AU - Haaga JR LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Am J Gastroenterol JT - The American journal of gastroenterology JID - 0421030 SB - IM SB - X MH - Acquired Immunodeficiency Syndrome/*complications MH - Fatty Liver/*complications/radiography MH - Humans MH - Liver/radiography MH - Male MH - Middle Aged MH - Sarcoma, Kaposi/complications MH - Skin Neoplasms/complications MH - Tomography, X-Ray Computed EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Am J Gastroenterol. 1997 Oct;92(10):1934-6. PMID- 9377881 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20061115 PUBM- Print IS - 0090-3493 (Print) VI - 25 IP - 10 DP - 1997 Oct TI - Patient-ventilator flow dyssynchrony: flow-limited versus pressure-limited breaths. PG - 1671-7 AB - OBJECTIVES: Patient-ventilator flow dyssynchrony occurs when ventilator flow delivery is insufficient to meet patient demands. If sufficiently severe, flow dyssynchrony can produce significant imposed loads on ventilatory muscles. Flow dyssynchrony can be improved by increasing ventilator flow delivery. We hypothesized that the variable flow pressure-limited breath would be a better approach for matching patient flow demands than adjusting a set flow on a conventional volume-cycled breath. DESIGN: Clinical interventional study. SETTING: Medical intensive care unit. PATIENTS: Sixteen stable, mechanically ventilated patients receiving volume-cycled assist-control ventilation. INTERVENTIONS: Flow dyssynchrony was produced by reducing the set flow by 50%. Dyssynchrony was quantified by measuring the esophageal pressure time product during the assisted breath. Two strategies were then employed in an attempt to reduce the dyssynchrony. One strategy was to increase flow back to the initial set flow and then further increase flow by an additional 25% (VI strategy). The other strategy was to use a pressure-limited breath feature coupled to a volume assist breath (the P strategy). With the P strategy, the pressure limit was set at 75% and 100% of the static elastic recoil pressure at end-inspiration. MEASUREMENTS AND MAIN RESULTS: Pressure time product, intrinsic positive end-expiratory pressure, and the ventilatory pattern were measured with each strategy and were analyzed by analysis of variance. Induced baseline flow dyssynchrony, as measured by the pressure time product, was > 5 cm H2O/sec in ten of 16 patients. This dyssynchrony was significantly reduced by both the VI strategy and the P strategy, although the P strategy appeared to be more effective in those patients with the greatest baseline dyssynchrony. Baseline inspiratory time was also shortened by both the VI strategy and the P strategy; the VI strategy shortened baseline inspiratory time more than the P strategy. Baseline tidal volume, frequency, and intrinsic positive end-expiratory pressure were only minimally affected by either strategy. CONCLUSION: The pressure-limited, variable-flow approach to ventilator gas delivery appears to be more responsive to a vigorous patient effort than a fixed-flow approach. AD - Duke University Medical Center, Durham, NC, USA. FAU - MacIntyre, N R AU - MacIntyre NR FAU - McConnell, R AU - McConnell R FAU - Cheng, K C AU - Cheng KC FAU - Sane, A AU - Sane A LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Crit Care Med JT - Critical care medicine JID - 0355501 SB - AIM SB - IM CIN - Crit Care Med. 1997 Oct;25(10):1630. PMID: 9377872 MH - Adult MH - Aged MH - Airway Obstruction/physiopathology/therapy MH - Analysis of Variance MH - Female MH - Humans MH - Linear Models MH - Male MH - Middle Aged MH - Monitoring, Physiologic/instrumentation MH - Positive-Pressure Respiration, Intrinsic/physiopathology/therapy MH - Respiration, Artificial/*methods/statistics & numerical data MH - Respiratory Distress Syndrome, Adult/physiopathology/therapy MH - *Work of Breathing EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Crit Care Med. 1997 Oct;25(10):1671-7. PMID- 9315229 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20051117 PUBM- Print IS - 0019-5189 (Print) VI - 35 IP - 4 DP - 1997 Apr TI - Ets oncogene family. PG - 315-22 AB - First member of Ets gene family was discovered a decade ago by studying avian erythroblastosis virus, E26. This virus encodes a tripartite protein gag-myb-ets with a molecular weight of 135 kDa. Subsequently, a series of cellular Ets genes were isolated (Ets-1, Ets-2, Erg, Elk-1, Sap-1, PEA-3, PU.1, Fli-1, Pok/Yan, Etv-1 etc.). These genes share sequence homology to E26 Ets gene (v-ets or viral ets). Ets genes are highly conserved in phylogenetically divergent species from Drosophila to man. Mammalian Ets genes are located on different chromosomes. Ets gene products are transcriptionally active sequence-specific DNA binding proteins and are differentially regulated. Ets genes are involved in certain chromosomal translocations leading to the formation of chimeric fusion proteins that are associated with certain leukemias and soft tissue cancers. Ets genes also have a role in T-cell development and molecular and genetic analysis of Down Syndrome patients have implicated the human Ets-2 and Erg genes in the disease. Down Syndrome afflicted patients have immunologic and thymic disorders as well as a greater risk for leukemic disease. Thus, Ets genes having homology to viral oncogenes, may be instrumental in regulating cellular growth and differentiation, as well as organismal development. Alteration of these genes and their products may cause deregulation of normal cell growth and differentiation and result in a disease. AD - Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104, USA. FAU - Dhulipal, P D AU - Dhulipal PD LA - eng PT - Journal Article PT - Review PL - INDIA TA - Indian J Exp Biol JT - Indian journal of experimental biology JID - 0233411 RN - 0 (ETS1 protein, human) RN - 0 (Proto-Oncogene Protein c-ets-1) RN - 0 (Proto-Oncogene Proteins) RN - 0 (Proto-Oncogene Proteins c-ets) RN - 0 (Retroviridae Proteins, Oncogenic) RN - 0 (Transcription Factors) RN - 0 (oncogene proteins v-ets) RN - 9007-49-2 (DNA) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Binding Sites/genetics MH - DNA/genetics/metabolism MH - Humans MH - Molecular Sequence Data MH - Multigene Family MH - *Oncogenes MH - Proto-Oncogene Protein c-ets-1 MH - Proto-Oncogene Proteins/*genetics/metabolism MH - Proto-Oncogene Proteins c-ets MH - Retroviridae Proteins, Oncogenic/*genetics/metabolism MH - Trans-Activation (Genetics) MH - Transcription Factors/*genetics/metabolism RF - 79 EDAT- 1997/04/01 00:00 MHDA- 1997/10/07 00:01 PST - ppublish SO - Indian J Exp Biol. 1997 Apr;35(4):315-22. PMID- 9261855 OWN - NLM STAT- MEDLINE DA - 19971105 DCOM- 19971105 LR - 20060328 PUBM- Print IS - 8755-6863 (Print) VI - 24 IP - 1 DP - 1997 Jul TI - Massive hemoptysis as the presenting manifestation in a child with histoplasmosis. PG - 57-60 AB - A previously healthy and asymptomatic 7-year-old white boy presented with a history of two episodes of hemoptysis productive of bright red blood in the 5 days preceding admission. After admission he developed massive hemoptysis that, on bronchoscopy, was noted to be emanating from the right lower lobe. An emergency right lower lobe resection was done. Pathological examination revealed hilar adenopathy and peripheral lesions with caseating granulomas containing yeast, morphologically consistent with Histoplasma capsulatum. AD - Department of Pediatrics, Ohio State University Medical Center, Columbus 43210, USA. FAU - Shaffer, J P AU - Shaffer JP FAU - Barson, W AU - Barson W FAU - Luquette, M AU - Luquette M FAU - Groner, J I AU - Groner JI FAU - Hogan, M J AU - Hogan MJ FAU - Allen, E AU - Allen E LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Pediatr Pulmonol JT - Pediatric pulmonology JID - 8510590 RN - 0 (Antibiotics, Antifungal) RN - 0 (Antifungal Agents) RN - 1397-89-3 (Amphotericin B) RN - 84625-61-6 (Itraconazole) SB - IM MH - Amphotericin B/therapeutic use MH - Antibiotics, Antifungal/therapeutic use MH - Antifungal Agents/therapeutic use MH - Bronchoscopy MH - Child MH - Drug Therapy, Combination MH - Hemoptysis/*etiology/surgery MH - Histoplasmosis/complications/*diagnosis/drug therapy/pathology MH - Humans MH - Itraconazole/therapeutic use MH - Lung/pathology MH - Lung Diseases, Fungal/complications/*diagnosis/drug therapy/pathology MH - Male MH - Pneumonectomy MH - Recurrence EDAT- 1997/07/01 MHDA- 2000/06/22 10:00 AID - 10.1002/(SICI)1099-0496(199707)24:1<57::AID-PPUL10>3.0.CO;2-9 [pii] PST - ppublish SO - Pediatr Pulmonol. 1997 Jul;24(1):57-60. PMID- 9336559 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print IS - 0002-8223 (Print) VI - 97 IP - 10 DP - 1997 Oct TI - Review of self-efficacy and locus of control for nutrition- and health-related behavior. PG - 1122-32 AB - This article reviews several cognitive predictors of health- and diet-related behaviors commonly used in theories and models of nutrition and health behavior change. Constructs such as self-efficacy, self-esteem, outcome expectancies, health value, and locus of control are examined. Self-efficacy has repeatedly been a good predictor of health behavior, sometimes explaining more than 50% of variability. Research on locus of control and other predictive factors has been less conclusive. The take-home message is threefold: (a) task specificity of self-efficacy and domain specificity of locus of control are crucial for unraveling their effects on behavior; (b) careful segmentation of different population groups under study may explain the inconsistencies in previous research; and (c) especially when studying dietary behavior, these predictors of behavior change should not be used alone or in place of one another but should be used simultaneously to explain complex food and diet-related behaviors. We recommend that nutritionists systematically integrate available theories and models and explore new areas for studying human behavior, such as sociology and anthropology, to form a more powerful, comprehensive model for behavior change. AD - Department of Nutrition, Pennsylvania State University, University Park 16802, USA. FAU - AbuSabha, R AU - AbuSabha R FAU - Achterberg, C AU - Achterberg C LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - UNITED STATES TA - J Am Diet Assoc JT - Journal of the American Dietetic Association JID - 7503061 SB - AIM SB - IM MH - *Feeding Behavior/psychology MH - *Health Behavior MH - Humans MH - *Internal-External Control MH - *Nutrition Physiology MH - *Self Concept RF - 95 EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0002-8223(97)00273-3 [pii] AID - 10.1016/S0002-8223(97)00273-3 [doi] PST - ppublish SO - J Am Diet Assoc. 1997 Oct;97(10):1122-32. PMID- 9281438 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0022-2828 (Print) VI - 29 IP - 8 DP - 1997 Aug TI - Different responses of non-ischemic and post-ischemic myocardium towards Ca2+ sensitization. PG - 2053-66 AB - We tested whether decreased Ca2+ sensitivity is a major cause for dysfunctional stunned myocardium. The experiments employed a novel Ca2+ sensitizing agent: the thiadiazinone derivative EMD 60 263. Experiments were done on 14 isolated, blood-perfused rabbit hearts. After control, seven hearts were subjected to 20 min no-flow ischemia, and then allowed to recover during 30 min reperfusion. Thereafter, EMD 60 263 was administered (3, 10 and 30 microm). For comparison, the effect of the same doses was investigated in seven non-ischemic hearts. At the low dose, the agent improved ventricular systolic function in the post-ischemic group significantly (LVPmax: 65+/-13 v 91+/-17 mmHg; dP/dtmax: 845+/-235 v 1300+/-350 mmHg/s), and non-significantly in the non-ischemic group (LVPmax: 115+/-35 v 132+/-39 mmHg; dP/dtmax: 1415+/-545 v 1885+/-720 mmHg/s). Early relaxation (dP/dtmin) was slightly improved in both groups (800+/-225 v 1050+/-220 mmHg/s post-ischemic; 1120+/-315 v 1205+/-285 mmHg/s non-ischemic). Heart rate was increased (151+/-35 v 175+/-45 beats/min) in the post-ischemic group and was unaffected in the non-ischemic group. At the higher dose, systolic ventricular function in the post-ischemic group was further improved (LVPmax: 109+/-17 mmHg, dP/dtmax: 1330+/-180 mmHg/s), but tended to decrease in the non-ischemic group (LVPmax: 121+/-40 mmHg, dP/dtmax: 1605+/-680 mmHg/s). This dose decreased heart rate in both groups (133+/-34 and 134+/-23 beats/min). 30 microm EMD 60 263 had deleterious effects in both groups. The different responses towards Ca2+ sensitization suggest that a decrease in Ca2+ sensitivity might play a role in dysfunctional stunned myocardium. Therefore, Ca2+ sensitizing agents of the thiadiazinone type could be useful to recruit a positive inotropic reserve in stunned myocardium. AD - Institute of Experimental Surgery, University of Dusseldorf, Dusseldorf, Germany. FAU - Korbmacher, B AU - Korbmacher B FAU - Sunderdiek, U AU - Sunderdiek U FAU - Selcan, G AU - Selcan G FAU - Arnold, G AU - Arnold G FAU - Schipke, J D AU - Schipke JD LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - J Mol Cell Cardiol JT - Journal of molecular and cellular cardiology JID - 0262322 RN - 0 (Cardiotonic Agents) RN - 0 (Thiadiazines) RN - 158623-12-2 (EMD 60263) RN - 7440-70-2 (Calcium) SB - IM MH - Action Potentials/drug effects MH - Animals MH - Arrhythmia/prevention & control MH - Bradycardia/chemically induced MH - Calcium/*metabolism MH - Cardiotonic Agents/*pharmacology/toxicity MH - Drug Resistance MH - Heart Rate/drug effects MH - Male MH - Myocardial Contraction/*drug effects MH - Myocardial Ischemia/complications/*metabolism MH - Myocardial Reperfusion MH - Myocardial Reperfusion Injury/*metabolism MH - Myocardial Stunning/etiology/*metabolism MH - Oxygen Consumption/drug effects MH - Rabbits MH - Systole/drug effects MH - Thiadiazines/*pharmacology/toxicity EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 AID - S0022-2828(97)90440-5 [pii] AID - 10.1006/jmcc.1997.0440 [doi] PST - ppublish SO - J Mol Cell Cardiol. 1997 Aug;29(8):2053-66. PMID- 9313157 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20031114 PUBM- Print IS - 0022-0302 (Print) VI - 80 IP - 9 DP - 1997 Sep TI - Effect of starch on the bioavailability of glutamine and leucine in the dairy cow. PG - 2143-8 AB - This experiment was designed to quantify changes in utilization of Gln and Leu by the gut wall as a result of changes in the starch supply to the duodenum. Four dairy cows fitted with cannulas in the rumen and the distal duodenum were adapted for 3 wk to starch infusion, either into the rumen (600 g/d of flaked maize) or into the duodenum (300 g/d of flaked maize plus 300 g/d of maize meal), in a 2 x 2 crossover design. Absorption and elimination kinetics and the relative bioavailability of Gln and Leu were measured during wk 4 and 5. After infusion of 50 g of Gln or 10 g of Leu into the duodenum or jugular vein, blood samples were taken from the jugular vein at 0.5-h intervals up to 4 h after infusion. Concentrations of Gln and Leu in plasma fitted best to an open, one-compartment model (duodenal infusion) or to an open, two-compartment model (i.v. infusion). Both amino acids were rapidly absorbed; half-life times were less than 20 min. The amount of Gln trapped in the splanchnic bed was higher than the amount of Leu trapped in the splanchnic bed. Site of starch infusion did not affect the relative bioavailability of amino acids. AD - Department of Ruminant Nutrition, Institute for Animal Science and Health, Lelystad, The Netherlands. FAU - Meijer, G A AU - Meijer GA FAU - Bontempo, V AU - Bontempo V FAU - Van Vuuren, A M AU - Van Vuuren AM FAU - Van der Meulen, J AU - Van der Meulen J LA - eng PT - Journal Article PL - UNITED STATES TA - J Dairy Sci JT - Journal of dairy science JID - 2985126R RN - 56-85-9 (Glutamine) RN - 61-90-5 (Leucine) RN - 9005-25-8 (Starch) SB - IM MH - Absorption MH - Animals MH - Biological Availability MH - Cattle/*physiology MH - Duodenum/metabolism MH - Female MH - Glutamine/*pharmacokinetics MH - Half-Life MH - Kinetics MH - Leucine/*pharmacokinetics MH - Rumen/metabolism MH - Starch/administration & dosage/*pharmacology EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - J Dairy Sci. 1997 Sep;80(9):2143-8. PMID- 9344581 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20061115 PUBM- Print IS - 0014-4827 (Print) VI - 236 IP - 1 DP - 1997 Oct 10 TI - Inhibition of retinoic acid receptor function in normal human mammary epithelial cells results in increased cellular proliferation and inhibits the formation of a polarized epithelium in vitro. PG - 16-28 AB - The expression of retinoic acid receptor-beta (RAR beta) mRNA is absent or down-regulated in a majority of breast cancers, suggesting that loss of retinoic acid receptor function may be a critical event in breast cancer carcinogenesis. We developed an in vitro system to investigate whether the loss of retinoic acid receptor (RAR) function might affect the proliferation and structural differentiation of normal cultured human mammary epithelial cells (HMECs). Utilizing a truncated retinoic acid receptor (RAR)-alpha construct exhibiting dominant-negative activity against retinoic acid receptor isoforms alpha, beta, and gamma (DNRAR), we inhibited normal retinoic acid receptor function in HMECs. Suppression of RAR function in HMECs resulted in reduced growth inhibition mediated by all-trans-retinoic acid (ATRA). Moreover, the doubling time of HMECs expressing the DNRAR was significantly shortened, associated with a decrease in the percentage of cells in G1 and an increase in the percentage of cells in S-phase relative to controls. In addition, HMECs expressing the DNRAR cultured in prepared extracellular matrix exhibited a loss of extracellular matrix-induced growth arrest and formation of a polarized ductal epthelium. Our results suggest that ATRA and RARs may play an important role in regulating the proliferation of HMECs and in promoting differentiation. AD - Division of Medical Oncology, University of Washington, Seattle 98195, USA. vseewald@u.washington.edu FAU - Seewaldt, V L AU - Seewaldt VL FAU - Caldwell, L E AU - Caldwell LE FAU - Johnson, B S AU - Johnson BS FAU - Swisshelm, K AU - Swisshelm K FAU - Collins, S J AU - Collins SJ FAU - Tsai, S AU - Tsai S LA - eng GR - 2P30 DK 35816-11/DK/NIDDK GR - DK-48622/DK/NIDDK GR - KO8 CA 68210-01/CA/NCI PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Exp Cell Res JT - Experimental cell research JID - 0373226 RN - 0 (Extracellular Matrix Proteins) RN - 0 (Growth Substances) RN - 0 (Receptors, Retinoic Acid) RN - 0 (Viral Fusion Proteins) RN - EC 2.3.1.6 (Choline O-Acetyltransferase) SB - IM MH - Breast/*cytology MH - Cell Aging/physiology MH - Cell Division/drug effects/physiology MH - Cell Line MH - Cell Polarity/*physiology MH - Choline O-Acetyltransferase/genetics MH - Down-Regulation/physiology MH - Epithelial Cells/*chemistry/cytology/ultrastructure MH - Extracellular Matrix Proteins/pharmacology MH - Genes, Reporter MH - Growth Substances/pharmacology MH - Humans MH - Microscopy, Electron MH - Mutagenesis/physiology MH - Receptors, Retinoic Acid/*genetics/metabolism MH - Retroviridae/genetics MH - Transformation, Genetic MH - Viral Fusion Proteins/physiology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0014-4827(97)93694-6 [pii] AID - 10.1006/excr.1997.3694 [doi] PST - ppublish SO - Exp Cell Res. 1997 Oct 10;236(1):16-28. PMID- 9380472 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20041117 PUBM- Print IS - 0891-3668 (Print) VI - 16 IP - 10 DP - 1997 Oct TI - Concentration of cefuroxime in middle ear effusion of children with acute otitis media. PG - 959-62 AB - BACKGROUND: Antibiotic concentrations in serum and middle ear effusion are important in determining therapeutic success in acute otitis media. For beta-lactams the most relevant pharmacokinetic index for clinical efficacy is the time for which serum concentrations exceed the minimum inhibitory concentration (MIC) of the pathogen, which should be at least 40 to 50% of the dosing interval. METHODS: In this open, single center study, the concentration of cefuroxime achieved in the serum and middle ear effusion of pediatric acute otitis media patients with purulent effusion was assessed between 2 and 5 h after a single oral dose of 15 mg/kg cefuroxime axetil suspension. RESULTS: Serum concentrations of cefuroxime ranged from 2.8 to 7.3 microg/ml and were consistent with the results of previous pharmacokinetic study. These results show that serum concentrations of cefuroxime remain above the MIC90 (2.0 microg/ml) for Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis for at least 5 h (42%) of the 12-h dosing interval. Cefuroxime was detected in 14 of 17 (82%) middle ear effusion samples and ranged from 0.2 to 3.6 microg/ml, indicating that cefuroxime penetrates well into the middle ear. CONCLUSIONS: Cefuroxime is well-absorbed and penetrates well into the middle ear after oral administration of cefuroxime axetil suspension. AD - Medical Clinic, Reykjavik, Iceland. FAU - Thoroddsen, E AU - Thoroddsen E FAU - Marr, C AU - Marr C FAU - Efthymiopoulos, C AU - Efthymiopoulos C FAU - Thorarinsson, H AU - Thorarinsson H LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PL - UNITED STATES TA - Pediatr Infect Dis J JT - The Pediatric infectious disease journal JID - 8701858 RN - 0 (Cephalosporins) RN - 55268-75-2 (Cefuroxime) SB - IM MH - Acute Disease MH - Administration, Oral MH - Cefuroxime/metabolism/*pharmacokinetics/therapeutic use MH - Cephalosporins/metabolism/*pharmacokinetics/therapeutic use MH - Child, Preschool MH - Humans MH - Infant MH - Microbial Sensitivity Tests MH - Otitis Media with Effusion/*drug therapy/metabolism EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Pediatr Infect Dis J. 1997 Oct;16(10):959-62. PMID- 9357761 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0002-9513 (Print) VI - 273 IP - 4 Pt 1 DP - 1997 Oct TI - Cloning and functional expression of a ClC Cl- channel from the renal cell line A6. PG - C1176-85 AB - Cl- channels are important for ion transport and cell volume regulation in A6 renal cells. In the present study, we used reverse transcriptase (RT)-polymerase chain reaction (PCR) and rapid amplification of cDNA ends (RACE) to identify proteins homologous to ClC Cl- channel proteins in A6 cells. Using degenerate primers designed on consensus sequences for members of the ClC family, we amplified an RT-PCR product that had significant homology to the ClC sequences. RACE-PCR was then used to isolate several full-length clones that had total lengths from 2,764 to 3,016 base pairs. Although the coding regions were identical, sequence differences occurred in the 5' noncoding regions. The amino acid sequences of the clones had high homologies to rat and human ClC-5 (85 and 84%, respectively, if the 5th methionine of the open reading frame represents the start codon). Three parts of the protein (53, 80, and 63 amino acids in length) were 97-100% homologous to the mammalian sequences. Ribonuclease protection assay analysis revealed mRNA for this protein in oocytes, kidney, intestine, liver, brain, and blood, with lower amounts in stomach, muscle, and skin. Expression of the clones in Xenopus laevis oocytes resulted in an outwardly rectifying Cl- current that was inhibited by 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid and possessed an anion selectivity of I- > Cl- >> gluconate. AD - Department of Physiology, University of Texas Medical Branch, Galveston 77555, USA. FAU - Lindenthal, S AU - Lindenthal S FAU - Schmieder, S AU - Schmieder S FAU - Ehrenfeld, J AU - Ehrenfeld J FAU - Wills, N K AU - Wills NK LA - eng SI - GENBANK/Y09940 PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Chloride Channels) RN - 0 (Chlorides) RN - 0 (DNA, Complementary) RN - 0 (Gluconates) RN - 0 (Iodides) RN - 0 (RNA Probes) RN - 526-95-4 (gluconic acid) RN - 53005-05-3 (4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid) SB - IM EIN - Am J Physiol 1998 Oct;275(4 Pt 1 MH - 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/pharmacology MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Cell Line MH - Chloride Channels/*biosynthesis/chemistry/*physiology MH - Chlorides/pharmacology MH - Cloning, Molecular MH - DNA, Complementary MH - Female MH - Gluconates/pharmacology MH - Humans MH - Iodides/pharmacology MH - Kidney/*metabolism MH - Membrane Potentials/drug effects MH - Molecular Sequence Data MH - Oocytes/physiology MH - Organ Specificity MH - Polymerase Chain Reaction MH - RNA Probes MH - Rats MH - Sequence Alignment MH - Sequence Homology, Amino Acid MH - Xenopus laevis EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Am J Physiol. 1997 Oct;273(4 Pt 1):C1176-85. PMID- 9285033 OWN - NLM STAT- MEDLINE DA - 19971104 DCOM- 19971104 LR - 20041117 PUBM- Print IS - 0304-4602 (Print) VI - 26 IP - 3 DP - 1997 May TI - Williams syndrome--the Singapore General Hospital experience. PG - 360-4 AB - Williams syndrome first described in 1961 is generally characterised by mental deficiency, gregarious personality, unusual "elfin" facies, supravalvular aortic stenosis and idiopathic infantile hypercalcaemia. Patients with Williams syndrome show a hemizygous submicroscopic deletion of 7q11.23 detectable by fluorescent in-situ hybridisation (FISH). The deleted portion of the chromosome corresponds to the Elastin gene. We report 3 girls with characteristics of Williams syndrome in whom the diagnosis was confirmed by demonstration of the hemizygous deletion of 7q11.23 in the karyotype by FISH. These patients, aged 6, 7 and 10 years, showed the characteristic facies and gregarious personalities. Some developmental delay with mild mental deficiency and dysmorphic facies were prominent features in the initial presentation. Cardiac lesions found in these patients were small patent ductus arteriosus which closed, pulmonary valvular stenosis and mitral valve prolapse associated with mitral regurgitation respectively. Hypercalcaemia was not documented in these patients. Learning difficulty was a major issue and all patients required special schooling. Chromosome analyses done on peripheral blood were found to be normal in all patients. FISH using the Elastin Williams Syndrome Chromosome Region (WSCR) probes (oncor) showed the hemizygous deletion of 7q11.23. Diagnosis of Williams syndrome can now be confidently confirmed with the help of FISH. AD - Department of Paediatric Medicine, Singapore General Hospital, Singapore. FAU - Teo, S H AU - Teo SH FAU - Chan, D K AU - Chan DK FAU - Yong, M H AU - Yong MH FAU - Ng, I S AU - Ng IS FAU - Wong, K Y AU - Wong KY FAU - Knight, L AU - Knight L FAU - Ho, L Y AU - Ho LY LA - eng PT - Case Reports PT - Journal Article PL - SINGAPORE TA - Ann Acad Med Singapore JT - Annals of the Academy of Medicine, Singapore JID - 7503289 SB - IM MH - Child MH - Chromosomes, Human, Pair 7 MH - Female MH - Gene Deletion MH - Humans MH - In Situ Hybridization, Fluorescence MH - Williams Syndrome/*diagnosis/genetics EDAT- 1997/05/01 MHDA- 1997/05/01 00:01 PST - ppublish SO - Ann Acad Med Singapore. 1997 May;26(3):360-4. PMID- 9287109 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20031114 PUBM- Print IS - 0014-5793 (Print) VI - 413 IP - 1 DP - 1997 Aug 11 TI - Functional cloning of a cDNA encoding Mei2-like protein from Arabidopsis thaliana using a fission yeast pheromone receptor deficient mutant. PG - 16-20 AB - To isolate Arabidopsis cDNAs that encode signal transducers and components involved in the regulation of meiosis, a trans-complementation analysis was performed using a Schizosaccharomyces pombe meiosis-defective mutant in which the genes for pheromone receptors were disabled. One cDNA obtained in this screening encodes a polypeptide, named AML1, that shows significant similarity to S. pombe Mei2 protein and has three putative RNA-recognition motifs like as Mei2. Mei2 is involved in the regulation of meiosis in fission yeast. Northern blot analysis showed that the AML1 gene is expressed in each organ. The possible functions of AML1 are discussed. AD - Laboratory of Plant Molecular Biology, Tsukuba Life Science Center, The Institute of Physical and Chemical Research (RIKEN), Ibaraki, Japan. takashih@sas.upenn.edu FAU - Hirayama, T AU - Hirayama T FAU - Ishida, C AU - Ishida C FAU - Kuromori, T AU - Kuromori T FAU - Obata, S AU - Obata S FAU - Shimoda, C AU - Shimoda C FAU - Yamamoto, M AU - Yamamoto M FAU - Shinozaki, K AU - Shinozaki K FAU - Ohto, C AU - Ohto C LA - eng SI - GENBANK/D86122 PT - Journal Article PL - NETHERLANDS TA - FEBS Lett JT - FEBS letters JID - 0155157 RN - 0 (AML1 protein, Arabidopsis) RN - 0 (Arabidopsis Proteins) RN - 0 (DNA, Fungal) RN - 0 (Fungal Proteins) RN - 0 (Nucleoproteins) RN - 0 (Plant Proteins) RN - 0 (RNA-Binding Proteins) RN - 0 (Receptors, Cell Surface) RN - 0 (Schizosaccharomyces pombe Proteins) RN - 0 (mei2 protein, S pombe) SB - IM MH - Amino Acid Sequence MH - Arabidopsis/*genetics MH - *Arabidopsis Proteins MH - Base Sequence MH - Blotting, Southern MH - Cells, Cultured MH - Chemoreceptors/*metabolism MH - Cloning, Molecular MH - DNA, Fungal/*genetics MH - Fungal Proteins/*genetics MH - *Genes, Fungal MH - Genetic Complementation Test MH - Meiosis MH - Molecular Sequence Data MH - Mutation MH - *Nucleoproteins MH - Plant Proteins/*genetics MH - RNA-Binding Proteins/*genetics MH - Receptors, Cell Surface/*genetics/metabolism MH - Schizosaccharomyces/genetics MH - *Schizosaccharomyces pombe Proteins MH - Sequence Homology, Amino Acid EDAT- 1997/08/11 MHDA- 1997/08/11 00:01 AID - S0014-5793(97)00871-5 [pii] PST - ppublish SO - FEBS Lett. 1997 Aug 11;413(1):16-20. PMID- 9381776 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0044-3220 (Print) VI - 135 IP - 4 DP - 1997 Jul-Aug TI - [The Holt-Oram syndrome. Review of the literature and current orthopedic treatment concepts] PG - 368-75 AB - PROBLEM: The clinical manifestation of the Holt-Oram-syndrome (HOS) shows congenital heart-disease and anomalies of the upper limb. The inheritance of this syndrome is autosomal dominant. The question arise, as to whether a contemporary orthopedic concept of treatment could developed based on own experiences and data from the literature. METHODS: We revised data from five patients with HOS treated at the Clinic for Orthopaedics of the University of Heidelberg. The review of the literature revealed a comprehensive and detailed picture of the clinical syndrome and, furthermore, information in respect to a comparative analysis of methods of treatments. RESULTS: Our patients showed characteristic cardiac anomalies, i.e. atrio and ventricular septal defects, and persisting Botall's duct (three cases). The types of malformation of the upper limb corresponded with those found in the literature. Furthermore the indication for amputation of rudimentary or hypoplastic fingers in the Heidelberg clinic was in accordance with the clinical treatments described worldwide. CONCLUSION: The type of treatment of the clubhand in cases with HOS depends on (1) the age and (2) the pattern and degree of accompanying malformations of the upper limb. For patients with aplasia of the thumb or amputation of a rudimental one we recommend pollicisation of the index finger to improve its function. AD - Orthopadische Universitatsklinik der RWTH Aachen. FAU - Weber, M AU - Weber M FAU - Wenz, W AU - Wenz W FAU - van Riel, A AU - van Riel A FAU - Kaufmann, A AU - Kaufmann A FAU - Graf, J AU - Graf J LA - ger PT - English Abstract PT - Journal Article PT - Review TT - Das Holt-Oram Syndrom (HOS). Literaturuberblick und aktuelle orthopadische Behandlungskonzepte. PL - GERMANY TA - Z Orthop Ihre Grenzgeb JT - Zeitschrift fur Orthopadie und ihre Grenzgebiete JID - 1256465 SB - IM MH - Child MH - Child, Preschool MH - Chromosome Aberrations/genetics MH - Chromosome Disorders MH - Ductus Arteriosus, Patent/genetics/radiography/surgery MH - Ectromelia/genetics/radiography/surgery MH - Female MH - Fingers/*abnormalities/radiography/surgery/transplantation MH - Genes, Dominant/genetics MH - Hand Deformities, Congenital/*genetics/radiography/surgery MH - Heart Defects, Congenital/*genetics/radiography/surgery MH - Heart Septal Defects, Atrial/genetics/radiography/surgery MH - Heart Septal Defects, Ventricular/genetics/radiography/surgery MH - Humans MH - Infant MH - Male MH - Retrospective Studies MH - Syndrome MH - Thumb/abnormalities/radiography/surgery RF - 36 EDAT- 1997/07/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Z Orthop Ihre Grenzgeb. 1997 Jul-Aug;135(4):368-75. PMID- 9306153 OWN - NLM STAT- MEDLINE DA - 19971104 DCOM- 19971104 LR - 20061115 PUBM- Print IS - 0192-0561 (Print) VI - 19 IP - 3 DP - 1997 Mar TI - Ouabain effects on activated lymphocytes: augmentation of CD25 expression on TPA-stimulated cells and of CD69 on PHA-and TPA-stimulated cells. PG - 143-8 AB - Ouabain (OUA) was capable of inhibiting peripheral blood lymphocyte (PBL) proliferation induced by phyothaemagglutinin (PHA) of phorbol ester (TPA), as measured by thymidine incorporation or cell cycle analysis. In this latter case it was possible to detect a block in the progression from G1 to S phase. This inhibition could not be reversed by interleukin (IL)-2 and was not due to an effect on CD 25 expression, as this molecule was only reduced in PHA cultures treated with OUA. Conversely, cultures activated by TPA and OUA showed an increased expression of CD25. The activation antigen CD69 was increased in both situation, suggesting that despite the absence of proliferative response the cells were being activated. The possibility that these cells were being deviated to the activation pathway leading to apoptosis is now under investigation. This study also suggested that CD25 induction may occur via different pathways, and that the selective effect of OUA for PHA-activated cells may become a useful tool for the understanding of the process. AD - Pathology Department, Hospital Antonio Pedro, Fluminense Federal University, Niteroi, Brazil. FAU - Pires, V AU - Pires V FAU - Harab, R C AU - Harab RC FAU - Olej, B AU - Olej B FAU - Rumjanek, V M AU - Rumjanek VM LA - eng PT - In Vitro PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Int J Immunopharmacol JT - International journal of immunopharmacology JID - 7904799 RN - 0 (Antigens, CD) RN - 0 (Antigens, Differentiation, T-Lymphocyte) RN - 0 (CD69 antigen) RN - 0 (Interleukin-2) RN - 0 (Phytohemagglutinins) RN - 0 (Receptors, Interleukin-2) RN - 16561-29-8 (Tetradecanoylphorbol Acetate) RN - 50-89-5 (Thymidine) RN - 630-60-4 (Ouabain) SB - IM MH - Antigens, CD/*biosynthesis MH - Antigens, Differentiation, T-Lymphocyte/*biosynthesis MH - Cell Cycle/drug effects MH - Flow Cytometry MH - Humans MH - Interleukin-2/pharmacology MH - Lymphocyte Activation/*drug effects MH - Lymphocytes/*drug effects/metabolism MH - Ouabain/*pharmacology MH - Phytohemagglutinins/*pharmacology MH - Receptors, Interleukin-2/*biosynthesis MH - Tetradecanoylphorbol Acetate/*pharmacology MH - Thymidine/blood EDAT- 1997/03/01 00:00 MHDA- 1997/11/05 00:01 AID - S0192056196000707 [pii] PST - ppublish SO - Int J Immunopharmacol. 1997 Mar;19(3):143-8. PMID- 9337957 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0007-1250 (Print) VI - 171 DP - 1997 Aug TI - Plasma noradrenaline response to electroconvulsive therapy in depressive illness. PG - 182-6 AB - BACKGROUND: Abnormalities of catecholaminergic function have been hypothesised to cause depressive illness. Plasma noradrenaline can be used as a marker of central noradrenergic activity. It is of interest to examine the change in resting plasma noradrenaline in patients with depressive illness over a course of electroconvulsive therapy (ECT) and relate this to their clinical state. METHOD: Patients referred for ECT who suffered from DSM-III-R major depressive disorder or dysthymia were recruited. Blood samples were taken before and after each treatment, during a course of ECT, to measure plasma noradrenaline and cortisol. Clinical ratings were carried out weekly during the course of ECT. RESULTS: Plasma noradrenaline fell significantly in those patients with melancholic/psychotic depressions but increased in those with non-melancholic depressive illness. There was a strong trend indicating that a fall in plasma noradrenaline was associated with improvement in depression ratings in the melancholic/psychotic patients only. CONCLUSIONS: Electroconvlusive therapy decreases plasma noradrenaline in melancholic/psychotic depressive illness and this shows a trend associated with clinical improvement. AD - Department of Mental Health, Queen's University of Belfast. FAU - Kelly, C B AU - Kelly CB FAU - Cooper, S J AU - Cooper SJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Br J Psychiatry JT - The British journal of psychiatry : the journal of mental science JID - 0342367 RN - 0 (Biological Markers) RN - 50-23-7 (Hydrocortisone) RN - 51-41-2 (Norepinephrine) SB - IM MH - Adult MH - Aged MH - Biological Markers/blood MH - Depressive Disorder/*blood/therapy MH - *Electroconvulsive Therapy MH - Female MH - Humans MH - Hydrocortisone/blood MH - Male MH - Middle Aged MH - Norepinephrine/*blood EDAT- 1997/08/01 00:00 MHDA- 1997/10/24 00:01 PST - ppublish SO - Br J Psychiatry. 1997 Aug;171:182-6. PMID- 9351726 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 0002-8703 (Print) VI - 134 IP - 4 DP - 1997 Oct TI - Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial infarction: data from a large HMO. PG - 608-13 AB - We investigated whether patients who do not undergo coronary angiography and therefore any form of revascularization after a myocardial infarction derive greater benefit from chronic beta-blocker therapy than patients who undergo coronary angiography. With multivariate analyses, treatment with beta-blockers was a much stronger predictor of survival in patients who did not undergo coronary angiography (relative risk = 0.38, p = 0.005) than in those patients who did undergo catheterization (p < 0.05 for interaction). Our findings provide direct support for the recommendation by the American College of Cardiology/American Heart Association task force that beta-blocker therapy should be initiated for all infarct survivors who do not undergo revascularization and who have no contraindications. AD - Department of Medicine, University of California, San Francisco, USA. barron@ep4.ucsf.edu FAU - Barron, H V AU - Barron HV FAU - Viskin, S AU - Viskin S FAU - Lundstrom, R J AU - Lundstrom RJ FAU - Wong, C C AU - Wong CC FAU - Swain, B E AU - Swain BE FAU - Truman, A F AU - Truman AF FAU - Selby, J V AU - Selby JV LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Am Heart J JT - American heart journal JID - 0370465 RN - 0 (Adrenergic beta-Antagonists) SB - AIM SB - IM MH - Adrenergic beta-Antagonists/*therapeutic use MH - Aged MH - Female MH - Health Maintenance Organizations MH - Humans MH - Male MH - Middle Aged MH - Myocardial Infarction/*drug therapy/*mortality MH - Odds Ratio MH - Retrospective Studies MH - Risk MH - San Francisco MH - Treatment Outcome EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 AID - S0002-8703(97)70042-5 [pii] PST - ppublish SO - Am Heart J. 1997 Oct;134(4):608-13. PMID- 9302538 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0278-6133 (Print) VI - 16 IP - 5 DP - 1997 Sep TI - Sexual assault history and health perceptions: seven general population studies. PG - 417-25 AB - This article uses data from 7 population surveys to evaluate the association of sexual assault history with health perceptions. It estimates the extent of generalizability across gender, ethnic groups, and studies; the extent to which depression accounts for or mediates the association; and whether some circumstances of assault are more strongly related to poor subjective health. Data from each of 18 subsamples of the surveys were analyzed (pooled N = 10,001; 7,550 women and 2,451 men), and results were combined by using meta-analysis. Assault was associated with poor subjective health (odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.36, 1.95) and this result was consistent regardless of gender, ethnicity, or sample. Controlling depression did not markedly change this result (OR = 1.46, 95% CI = 1.21, 1.77), indicating that depression did not account for or mediate the assault-health perceptions association. Multiple assaults and assaults by strangers or spouse were most strongly associated with poor subjective health. AD - Institute for Health & Aging, University of California, San Francisco 94143-0646, USA. FAU - Golding, J M AU - Golding JM FAU - Cooper, M L AU - Cooper ML FAU - George, L K AU - George LK LA - eng GR - R29-MH50005/MH/NIMH PT - Journal Article PT - Meta-Analysis PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Health Psychol JT - Health psychology : official journal of the Division of Health Psychology, American Psychological Association JID - 8211523 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - *Attitude to Health MH - Child MH - Child Abuse, Sexual/*psychology/statistics & numerical data MH - Depression/epidemiology/psychology MH - Ethnic Groups/psychology/statistics & numerical data MH - Female MH - Humans MH - Male MH - Middle Aged MH - Population Surveillance MH - Rape/*psychology/statistics & numerical data MH - United States/epidemiology EDAT- 1997/09/26 MHDA- 1997/09/26 00:01 PST - ppublish SO - Health Psychol. 1997 Sep;16(5):417-25. PMID- 9259208 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20031114 PUBM- Print IS - 0391-3988 (Print) VI - 20 IP - 6 DP - 1997 Jun TI - Development of intracoronary local adhesive delivery technique. PG - 319-26 AB - Acute coronary occlusion may occur in weak coronary atherosclerotic lesions, including dissection, ulceration or thrombus. In some cases of occlusion "bail-out" is performed by using recently developed New Devices. However, these have not yet completely solved the problem to this end, we designed a new method of coronary revascularization, the Intracoronary Local Adhesive Delivery Technique, utilizing antithrombotic and absorbable adhesive injected locally into the fragile and morbid arterial wall using a drug delivery PTCA catheter more flexible than the existing New Devices. This adhesive strengthened and hardened the lesions. In this study, we examined the efficacy of making an adhesive cylinder in arteries of similar size to the coronary, through acute animal experiments using the existing clinical adhesives and drug delivery PTCA catheters and 12 femoral arteries of adult goats. We were successful in forming firm tunnels along the inside of six arteries, infused with approximately 0.04 ml Cyanoacrylate. These tunnels were observed with intravascular ultrasound (IVUS) imaging and evaluated microscopically. These results suggest the feasibility of this method as a new approach for making synthetic resinous stents. AD - Department of Medical Engineering and Cardiology, Tokoku University, Sendai, Japan. FAU - Sonobe, T AU - Sonobe T FAU - Naganuma, S AU - Naganuma S FAU - Yambe, T AU - Yambe T FAU - Kobayashi, S I AU - Kobayashi SI FAU - Sizuka, K AU - Sizuka K FAU - Katahira, Y AU - Katahira Y FAU - Nitta, K AU - Nitta K FAU - Nitta, S I AU - Nitta SI LA - eng PT - Journal Article PL - ITALY TA - Int J Artif Organs JT - The International journal of artificial organs JID - 7802649 RN - 0 (Cyanoacrylates) RN - 0 (Fibrinolytic Agents) RN - 0 (Tissue Adhesives) SB - IM MH - Absorption MH - *Angioplasty, Transluminal, Percutaneous Coronary MH - Animals MH - Coronary Disease/etiology/*therapy MH - Cyanoacrylates/*administration & dosage/metabolism MH - Disease Models, Animal MH - Drug Delivery Systems/*standards MH - Feasibility Studies MH - Female MH - Fibrinolytic Agents/*administration & dosage/metabolism MH - Goats MH - Male MH - Myocardial Revascularization MH - Stents MH - Tissue Adhesives/standards/*therapeutic use EDAT- 1997/06/01 MHDA- 1997/06/01 00:01 PST - ppublish SO - Int J Artif Organs. 1997 Jun;20(6):319-26. PMID- 9325340 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0021-9258 (Print) VI - 272 IP - 41 DP - 1997 Oct 10 TI - Binding properties of neuroligin 1 and neurexin 1beta reveal function as heterophilic cell adhesion molecules. PG - 26032-9 AB - beta-Neurexins and neuroligins are plasma membrane proteins that are displayed on the neuronal cell surface. We have now investigated the interaction of neurexin 1beta with neuroligin 1 to evaluate their potential to function as heterophilic cell adhesion molecules. Using detergent-solubilized neuroligins and secreted neurexin 1beta-IgG fusion protein, we observed binding of these proteins to each other only in the presence of Ca2+ and in no other divalent cation tested. Only neurexin 1beta lacking an insert in splice site 4 bound neuroligins, whereas neurexin 1beta containing an insert was inactive. Half-maximal binding required 1-3 microM free Ca2+, which probably acts by binding to neuroligin 1 but not to neurexin 1beta. To determine if neurexin 1beta and neuroligin 1 can also interact with each other when present in a native membrane environment on the cell surface, we generated transfected cell lines expressing neuroligin 1 and neurexin 1beta. Upon mixing different cell populations, we found that cells aggregate only if cells expressing neurexin 1beta are mixed with cells expressing neuroligin 1. Aggregation was dependent on Ca2+ and was inhibited by the addition of soluble neurexin 1beta lacking an insert in splice site 4 but not by the addition of neurexin 1beta containing an insert in splice site 4. We conclude that neurexin 1beta and neuroligin 1 (and, by extension, other beta-neurexins and neuroligins) function as heterophilic cell adhesion molecules in a Ca2+-dependent reaction that is regulated by alternative splicing of beta-neurexins. AD - Department of Molecular Genetics and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA. FAU - Nguyen, T AU - Nguyen T FAU - Sudhof, T C AU - Sudhof TC LA - eng GR - R01-MH52804/MH/NIMH PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Biol Chem JT - The Journal of biological chemistry JID - 2985121R RN - 0 (Cations, Divalent) RN - 0 (Cell Adhesion Molecules) RN - 0 (Membrane Proteins) RN - 0 (Nerve Tissue Proteins) RN - 0 (neuroligin 1) RN - 156532-80-8 (neurexin Ibeta) RN - 7440-70-2 (Calcium) SB - IM MH - Animals MH - Brain/metabolism MH - Calcium/metabolism MH - Cations, Divalent/metabolism MH - Cell Adhesion MH - Cell Adhesion Molecules/*metabolism MH - Drosophila MH - Intercellular Junctions/metabolism MH - Membrane Proteins/genetics/*metabolism MH - Nerve Tissue Proteins/genetics/*metabolism MH - Neurons/metabolism MH - Protein Binding MH - Protein Folding MH - Rats MH - Transfection EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - J Biol Chem. 1997 Oct 10;272(41):26032-9. PMID- 9378512 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0019-5189 (Print) VI - 35 IP - 5 DP - 1997 May TI - Selective use of calcium chelators enhances the yield of calcium-tolerant myocytes from adult heart. PG - 451-6 AB - Isolation of viable and functional cells from adult heart remains an intriguing problem for investigators who choose to use the cardiomyocyte model for experimental studies. With a few modifications of the existing procedures we have been able to improve the yield of ventricular myocardial cells from the adult rat heart. Sarcolemmal damage leading to hypercontracture due to Ca2+ loading appears to be the major hindrance to the successful isolation of sufficient number of viable cells. The two crucial steps are found to be the pre-enzymatic perfusion for Ca(2+)-depletion and the final step of Ca(2+)-repletion in extracellular medium for the isolation of Ca(2+)-tolerant myocytes. Inclusion of EGTA and taurine during the initial perfusion of Ca(2+)-free medium and of trypsin during reintroduction of Ca2+ led to a considerable increase in the yield of Ca(2+)-tolerant myocytes. The contraction amplitude and speed of shortening and relaxation of isolated cells were measured using an edge detection device. Selective use of calcium ion chelators appears to have a beneficial effect on the isolation of Ca(2+)-tolerant myocytes. AD - Division of Cellular & Molecular Cardiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Trivandrum, India. FAU - Nair, P AU - Nair P FAU - Nair, R R AU - Nair RR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - INDIA TA - Indian J Exp Biol JT - Indian journal of experimental biology JID - 0233411 RN - 0 (Chelating Agents) RN - 7440-70-2 (Calcium) SB - IM MH - Animals MH - *Calcium MH - Chelating Agents/*pharmacology MH - Heart/*drug effects MH - Male MH - Myocardium/cytology MH - Rats MH - Rats, Wistar EDAT- 1997/05/01 00:00 MHDA- 1997/10/07 00:01 PST - ppublish SO - Indian J Exp Biol. 1997 May;35(5):451-6. PMID- 9300300 OWN - NLM STAT- MEDLINE DA - 19971104 DCOM- 19971104 LR - 20061115 PUBM- Print IS - 1045-3873 (Print) VI - 8 IP - 9 DP - 1997 Sep TI - Cultured adult rabbit myocytes: effect of adding supplements to the medium, and response to isoprenaline. PG - 1020-30 AB - INTRODUCTION: The aims of this study were to investigate: (1) the effect of supplementing the culture medium on preservation of L-type calcium channel current (1Ca,L) in adult rabbit ventricular myocytes cultured for 4 days; and (2) preservation of the ICa,L response in cultured myocytes to the beta-adrenergic agonist isoprenaline. METHODS AND RESULTS: Adult rabbit myocytes were cultured on laminin-pretreated glass coverslips. The basic, serum-free culture medium was supplemented with 2 mM L-carnitine, 5 mM creatine, and 5 mM taurine. Myocytes were whole cell patch-clamped, and the L-type Ca channel current was recorded selectively as Ba flux (IBa,L) via the channels. IBa,L density (i.e., IBa,L amplitude normalized to membrane capacitance) in myocytes maintained in supplemented medium did not change significantly during culture (P > 0.1). By comparison, IBa,L density in myocytes cultured in nonsupplemented medium declined by 36% after 24 hours in culture (day 1) and then recovered by the fourth day (day 4). There was no significant difference in the response to isoprenaline of acutely isolated myocytes and 4-day cultured myocytes. Isoprenaline 100 nM increased peak IBa,L by 149% +/- 32% (mean +/- SEM) in acutely isolated myocytes (n = 4 cells), and by 224% +/- 60% (n = 6 cells) and 159% +/- 24% (n = 8 cells) in day 1 and 4 cultured myocytes, respectively. CONCLUSIONS: Supplemented medium improved IBa,L density in cultured myocytes. beta-Adrenergic receptors and intracellular messenger pathways appear to remain intact in adult rabbit myocytes cultured for up to 4 days. AD - Department of Physiology, University of Bristol, School of Medical Sciences, United Kingdom. john.s.mitcheson@bristol.ac.uk FAU - Mitcheson, J S AU - Mitcheson JS FAU - Hancox, J C AU - Hancox JC FAU - Levi, A J AU - Levi AJ LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Cardiovasc Electrophysiol JT - Journal of cardiovascular electrophysiology JID - 9010756 RN - 0 (Adrenergic beta-Agonists) RN - 0 (Calcium Channels) RN - 0 (Culture Media, Serum-Free) RN - 7683-59-2 (Isoproterenol) SB - IM MH - Adrenergic beta-Agonists/pharmacology MH - Animals MH - Calcium Channels/drug effects MH - Cells, Cultured MH - Culture Media, Serum-Free/pharmacology MH - Heart/*drug effects/physiology MH - Heart Ventricles/cytology/drug effects MH - Isoproterenol/*pharmacology MH - Male MH - Membrane Potentials/drug effects MH - Myocardium/*cytology MH - Patch-Clamp Techniques MH - Rabbits EDAT- 1997/09/23 MHDA- 1997/09/23 00:01 PST - ppublish SO - J Cardiovasc Electrophysiol. 1997 Sep;8(9):1020-30. PMID- 9326653 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0027-8424 (Print) VI - 94 IP - 21 DP - 1997 Oct 14 TI - Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. PG - 11583-8 AB - Panhandle PCR amplifies genomic DNA with known 5' and unknown 3' sequences from a template with an intrastrand loop schematically shaped like a pan with a handle. We used panhandle PCR to clone MLL genomic breakpoints in two pediatric treatment-related leukemias. The karyotype in a case of treatment-related acute lymphoblastic leukemia showed the t(4;11)(q21;q23). Panhandle PCR amplified the translocation breakpoint at position 2158 in intron 6 in the 5' MLL breakpoint cluster region (bcr). The karyotype in a case of treatment-related acute myeloid leukemia was normal, but Southern blot analysis showed a single MLL gene rearrangement. Panhandle PCR amplified the breakpoint at position 1493 in MLL intron 6. Screening of somatic cell hybrid and radiation hybrid DNAs by PCR and reverse transcriptase-PCR analysis of the leukemic cells indicated that panhandle PCR identified a fusion of MLL intron 6 with a previously uncharacterized sequence in MLL intron 1, consistent with a partial duplication. In both cases, the breakpoints in the MLL bcr were in Alu repeats, and there were Alu repeats in proximity to the breakpoints in the partner DNAs, suggesting that Alu sequences were relevant to these rearrangements. This study shows that panhandle PCR is an effective method for cloning MLL genomic breakpoints in treatment-related leukemias. Analysis of additional pediatric cases will determine whether breakpoint distribution deviates from the predilection for 3' distribution in the bcr that has been found in adult cases. AD - Division of Oncology, Jr. Research Institute, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA. FAU - Megonigal, M D AU - Megonigal MD FAU - Rappaport, E F AU - Rappaport EF FAU - Jones, D H AU - Jones DH FAU - Kim, C S AU - Kim CS FAU - Nowell, P C AU - Nowell PC FAU - Lange, B J AU - Lange BJ FAU - Felix, C A AU - Felix CA LA - eng SI - GENBANK/AF024540 SI - GENBANK/AF024541 SI - GENBANK/AF024542 SI - GENBANK/AF024543 GR - 1R29CA66140-02/CA/NCI GR - 5R25CA4009/CA/NCI GR - CA42232/CA/NCI PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Proc Natl Acad Sci U S A JT - Proceedings of the National Academy of Sciences of the United States of America JID - 7505876 RN - 0 (DNA Primers) RN - 0 (DNA-Binding Proteins) RN - 0 (MLL protein, human) RN - 0 (Transcription Factors) RN - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein) SB - IM MH - Adult MH - Artificial Gene Fusion MH - Base Sequence MH - Bone Marrow/pathology MH - Child MH - Chromosome Mapping MH - *Chromosomes, Human, Pair 11 MH - *Chromosomes, Human, Pair 4 MH - DNA Primers MH - DNA-Binding Proteins/*genetics MH - Female MH - Gene Rearrangement MH - Humans MH - Introns MH - Leukemia/etiology/*genetics/pathology MH - Male MH - Molecular Sequence Data MH - Myeloid-Lymphoid Leukemia Protein MH - Neoplasms/*therapy MH - Neoplasms, Second Primary/*etiology/*genetics/pathology MH - Polymerase Chain Reaction/*methods MH - *Proto-Oncogenes MH - Repetitive Sequences, Nucleic Acid MH - *Transcription Factors MH - *Translocation, Genetic MH - Zinc Fingers EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11583-8. PMID- 9322741 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0378-1119 (Print) VI - 196 IP - 1-2 DP - 1997 Sep 1 TI - Isolation and expression pattern of hahr1, a homeobox-containing cDNA from Helianthus annuus. PG - 61-8 AB - A 2.5 kb homeobox (HB)-containing cDNA (hahr1) was isolated from a library prepared from rootlets of Helianthus annuus using a polymerase chain reaction (PCR)-based strategy. The putative protein product (77 kDa) contains the homeodomain (HD) and an acidic domain at the N-terminal region (residues 72-155). The deduced amino acid sequence of hahr1 shares a 53% sequence identity with GLABRA2, a HD protein associated with epidermal cell differentiation. Hahr1 expression was primarily found in dry seeds, hypocotyls and roots at stages associated with early developmental events. Expression was completely lacking in leaves and flowers. Evidence for the existence of one related gene expressed in sunflower stems was obtained by the presence of restriction fragment length polymorphism of amplified cDNA products. AD - Programa Multidisciplinario de Biologia Experimental (PROMUBIE), Facultad de Ciencias Bioquimicas y Farmaceuticas, UNR, Rosario, Argentina. FAU - Valle, E M AU - Valle EM FAU - Gonzalez, D H AU - Gonzalez DH FAU - Gago, G AU - Gago G FAU - Chan, R L AU - Chan RL LA - eng SI - GENBANK/L76588 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - Gene JT - Gene JID - 7706761 RN - 0 (Arabidopsis Proteins) RN - 0 (DNA, Complementary) RN - 0 (GL2 protein, Arabidopsis) RN - 0 (HAHR1 protein, plant) RN - 0 (Homeodomain Proteins) RN - 0 (Plant Proteins) RN - 0 (RNA, Messenger) SB - IM MH - Amino Acid Sequence MH - *Arabidopsis Proteins MH - Base Sequence MH - Cloning, Molecular MH - DNA, Complementary MH - *Gene Expression Regulation, Plant MH - Helianthus/*genetics/growth & development MH - Homeodomain Proteins/*genetics/*metabolism MH - Molecular Sequence Data MH - Plant Proteins/genetics/metabolism MH - Plant Roots/genetics/growth & development MH - Plant Stems/genetics MH - RNA, Messenger MH - Sequence Analysis, DNA MH - Sequence Homology, Amino Acid EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 AID - S0378-1119(97)00193-5 [pii] PST - ppublish SO - Gene. 1997 Sep 1;196(1-2):61-8. PMID- 9376223 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20061115 PUBM- Print IS - 0898-6568 (Print) VI - 9 IP - 6 DP - 1997 Sep TI - Agonist-mediated tyrosine phosphorylation of isoforms of the shc adapter protein by the delta opioid receptor. PG - 423-9 AB - Maximally effective concentrations of the opioid agonist D-ala2-D-leu5-enkephalin resulted in some 2-3-fold enhancement of tyrosine phosphorylation of the p52 Shc adapter protein in a clone of Rat-1 fibroblasts transfected to express stably the murine delta opioid receptor. More limited modifications of the tyrosine phosphorylation status of the p46 and p66 forms of Shc were observed in parallel. Epidermal growth factor caused some 10-12-fold enhancement of tyrosine phosphorylation of p52 Shc and marked increases in the p46 and p66 forms. The effect of D-ala2-D-leu5-enkephalin was prevented by pretreatment of the cells with pertussis toxin and was not observed in non-transfected parental fibroblasts whereas the effect of epidermal growth factor was still manifest in both these situations. Half-maximal effects of D-ala2-D-leu5-enkephalin on p52 Shc tyrosine phosphorylation were produced with sub-nanomolar concentrations, in agreement with previous results on the tyrosine phosphorylation of p44MAPK (Burt et al., 1996). p52 Shc became tyrosine phosphorylated more rapidly than p44MAPK in response to D-ala2-D-leu5-enkephalin and its enhanced tyrosine phosphorylation was maintained for at least 10 min. AD - Division of Biochemistry and Molecular Biology, University of Glasgow, Scotland, U.K. FAU - Mullaney, I AU - Mullaney I FAU - Carr, I C AU - Carr IC FAU - Burt, A R AU - Burt AR FAU - Wilson, M AU - Wilson M FAU - Anderson, N G AU - Anderson NG FAU - Milligan, G AU - Milligan G LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Cell Signal JT - Cellular signalling JID - 8904683 RN - 0 (Adaptor Proteins, Signal Transducing) RN - 0 (Adaptor Proteins, Vesicular Transport) RN - 0 (Proteins) RN - 0 (Receptors, Opioid, delta) RN - 0 (Src homology 2 domain-containing, transforming protein 1) RN - 0 (Virulence Factors, Bordetella) RN - 55520-40-6 (Tyrosine) RN - 62229-50-9 (Epidermal Growth Factor) RN - 63631-40-3 (Enkephalin, Leucine-2-Alanine) RN - EC 2.4.2.31 (Pertussis Toxin) RN - EC 2.7.1.112 (Receptor, Epidermal Growth Factor) RN - EC 2.7.1.37 (Mitogen-Activated Protein Kinase 1) SB - IM MH - *Adaptor Proteins, Signal Transducing MH - *Adaptor Proteins, Vesicular Transport MH - Animals MH - Clone Cells/chemistry/enzymology MH - Enkephalin, Leucine-2-Alanine/pharmacology MH - Epidermal Growth Factor/metabolism/pharmacology MH - Fibroblasts/chemistry/cytology/enzymology MH - Gene Expression/physiology MH - Isomerism MH - Mice MH - Mitogen-Activated Protein Kinase 1/metabolism MH - Pertussis Toxin MH - Phosphorylation MH - Proteins/chemistry/*metabolism MH - Rats MH - Receptor, Epidermal Growth Factor/agonists/genetics MH - Receptors, Opioid, delta/*agonists/genetics MH - Signal Transduction/drug effects/*physiology MH - Time Factors MH - Transfection MH - Tyrosine/*metabolism MH - Virulence Factors, Bordetella/pharmacology EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 AID - S0898-6568(96)00188-X [pii] PST - ppublish SO - Cell Signal. 1997 Sep;9(6):423-9. PMID- 9352845 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0016-5085 (Print) VI - 113 IP - 5 DP - 1997 Nov TI - Physician specialty and variations in the cost of treating patients with acute upper gastrointestinal bleeding. PG - 1443-8 AB - BACKGROUND & AIMS: Upper gastrointestinal tract bleeding is a frequent cause of hospitalization. The goal of this study was to assess whether the cost of treating patients with upper gastrointestinal bleeding varies among surgeons, internists, and gastroenterologists. METHODS: A retrospective study of 124 patients admitted with acute upper gastrointestinal hemorrhage was performed. Patients were stratified into three groups based on a validated risk score; length of stay and hospital costs were compared among patients primarily cared for by internists, surgeons, and gastroenterologists. RESULTS: The median length of stay (2 days) for patients admitted to the gastroenterology service was significantly shorter than for patients admitted under the care of other physicians (P < 0.05). The median hospitalization cost ($2856) for patients admitted to the gastroenterology service was significantly lower than for patients admitted to the other services (P < 0.01). There were no significant differences in the time to endoscopy among services. CONCLUSIONS: Patients admitted to an urban teaching hospital directly under the care of a gastroenterologist had shorter hospital stays that were significantly less costly than patients under the primary care of internists or surgeons. The difference in length of stay reflects the time interval between endoscopy and discharge. AD - Massachusetts General Hospital, and Department of Medicine, Harvard Medical School, Boston 02114, USA. FAU - Quirk, D M AU - Quirk DM FAU - Barry, M J AU - Barry MJ FAU - Aserkoff, B AU - Aserkoff B FAU - Podolsky, D K AU - Podolsky DK LA - eng GR - T32DK07191/DK/NIDDK PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Gastroenterology JT - Gastroenterology JID - 0374630 SB - AIM SB - IM CIN - Gastroenterology. 1997 Nov;113(5):1788-90. PMID: 9352886 MH - Acute Disease MH - Adult MH - Aged MH - Female MH - *Gastroenterology MH - Gastrointestinal Hemorrhage/*therapy MH - *Health Care Costs MH - Humans MH - Length of Stay MH - Male MH - Middle Aged MH - Regression Analysis MH - Retrospective Studies MH - Sex Factors MH - *Specialties, Medical EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 AID - S001650859700509X [pii] PST - ppublish SO - Gastroenterology. 1997 Nov;113(5):1443-8. PMID- 9312208 OWN - NLM STAT- MEDLINE DA - 19971117 DCOM- 19971117 LR - 20061115 PUBM- Print IS - 0022-2631 (Print) VI - 159 IP - 3 DP - 1997 Oct 1 TI - Red blood cells of a transgenic mouse expressing high levels of human hemoglobin S exhibit deoxy-stimulated cation flux. PG - 187-96 AB - Deoxy-stimulated cation fluxes have been implicated in the generation of the dense and irreversibly sickled red blood cells (RBCs) in patients homozygous for hemoglobin S (SS). We now report on the effect of short term deoxygenation on K+ and Na+ transport in RBCs from control mice (C57Bl/6J) and a transgenic (alphaHbetaS[betaMDD]) mouse line that expresses high levels of human alphaH and betaS-chains and has a small percent dense cells but does not exhibit anemia. In transgenic mouse RBCs (n = 5) under oxygenated conditions, K+ efflux was 0.22 +/- 0.01 mmol/L cell x min and Na+ influx was 0.17 +/- 0.02 mmol/L cell x min. Both fluxes were stimulated by 10 min deoxygenation in transgenic but not in control mice. The deoxy-stimulated K+ efflux from transgenic mouse RBCs was about 55% inhibited by 5 nm charybdotoxin (CTX), a blocker of the calcium activated K+-channel. To compare the fluxes between human and mouse RBCs, we measured the area of mouse RBCs and normalized values to area per liter of cells. The deoxy-simulated CTX-sensitive K+ efflux was larger than the CTX-sensitive K+ efflux observed in RBCs from SS patients. These results suggest that in transgenic mice, deoxygenation increases cytosolic Ca2+ to levels which open Ca2+-activated K+ channels. The presence of these channels was confirmed in both control and transgenic mice by clamping intracellular Ca2+ at 10 microM with the ionophore A23187 and measuring Ca2+-activated K+ efflux. Both types of mouse had similar maximal rates of CTX-sensitive, Ca2+-activated K+ efflux that were similar to those in human SS cells. The capacity of the mouse red cell membrane to regulate cytosolic Ca2+ levels was examined by measurements of the maximal rate of calmodulin activated Ca2+-ATPase activity. This activity was 3-fold greater than that observed in human RBCs thus indicating that mouse RBC membranes have more capacity to regulate cytosolic Ca2+ levels.In summary, transgenic mouse RBCs exhibit larger values of deoxy-stimulated K+ efflux and Na+ influx when compared to human SS cells. They have a similar Ca2+-activated K+ channel activity to human SS cells while expressing a very high Ca2+ pump activity. These properties may contribute to the smaller percent of very dense cells and to the lack of adult anemia in this animal model. AD - Endocrine-Hypertension Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA. FAU - Romero, J R AU - Romero JR FAU - Fabry, M E AU - Fabry ME FAU - Suzuka, S AU - Suzuka S FAU - Nagel, R L AU - Nagel RL FAU - Canessa, M AU - Canessa M LA - eng GR - HL-35664/HL/NHLBI GR - HL-38655/HL/NHLBI GR - HL-42120/HL/NHLBI PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Membr Biol JT - The Journal of membrane biology JID - 0211301 RN - 0 (Hemoglobin, Sickle) RN - 0 (Ionophores) RN - 0 (Potassium Channel Blockers) RN - 115422-61-2 (Charybdotoxin) RN - 52665-69-7 (Calcimycin) RN - 7440-09-7 (Potassium) RN - 7440-23-5 (Sodium) RN - EC 3.6.1.8 (Calcium-Transporting ATPases) SB - IM MH - Adult MH - Anemia, Sickle Cell/*blood MH - Animals MH - Calcimycin/pharmacology MH - Calcium-Transporting ATPases/blood MH - Charybdotoxin/pharmacology MH - Erythrocytes/*metabolism MH - Hemoglobin, Sickle/*metabolism MH - Humans MH - Ionophores/pharmacology MH - Mice MH - Mice, Inbred C57BL MH - Mice, Transgenic MH - Potassium/*blood MH - Potassium Channel Blockers MH - Sodium/*blood EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - J Membr Biol. 1997 Oct 1;159(3):187-96. PMID- 9298159 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 0001-5660 (Print) VI - 46 IP - 1 DP - 1997 TI - Abstraction skillfulness in monozygotic and dizygotic twin pairs. PG - 57-67 AB - The computerized version of the Wisconsin Card Sorting Test (WCST) was administered to a sample of 96 subjects (Ss), constituted in equal parts by monozygotic twins (MZ), dizygotic twins (DZ), unique children and couples of "almost contemporary" brothers. The statistic tests (Analysis of principal components, ANOVA) underline, as far as the rapidity to define a category is concerned, a statistically significant difference between DZ and singletons, independently from the fact that the latter may be unique children. A significant difference emerged neither between MZ and singletons, nor between MZ and DZ. AD - Dipartimento di Psicologia, Universita di Roma La Sapienza. FAU - Nicole, S AU - Nicole S FAU - Del Miglio, C AU - Del Miglio C LA - eng PT - Journal Article PT - Twin Study PL - ITALY TA - Acta Genet Med Gemellol (Roma) JT - Acta geneticae medicae et gemellologiae JID - 0370314 SB - IM MH - Adolescent MH - Adult MH - Analysis of Variance MH - *Cognition MH - Female MH - Humans MH - Intelligence Tests MH - Male MH - Twins, Dizygotic/*psychology MH - Twins, Monozygotic/*psychology EDAT- 1997/01/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - Acta Genet Med Gemellol (Roma). 1997;46(1):57-67. PMID- 9338089 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 1381-3455 (Print) VI - 103 IP - 2 DP - 1995 May TI - Treadmill chamber for studies of respiratory gas exchange in the rat during exercise. PG - 175-86 AB - A treadmill for studying gas exchange in small mammals during exercise is presented. The system consists of a motor-driven running mat enclosed in a gastight chamber that receives a measured flow of air from a compressed air cylinder. The gas flow and temperature, pressure and instantaneous gas composition of the chamber (oxygen, carbon dioxide and water) are measured continuously and the data are computed to include the effects on chamber atmosphere of the rat activity, either running or at rest. The system is completed with a shock delivery grid that stimulates the rat to run. The calculations are based on the changes in the composition of the gas in the chamber (constantly stirred by a small electric fan) induced by the rat instead of relying on the alterations induced in the outflowing gas. The consumption of oxygen, and production of carbon dioxide and water by the rat are computed in real time, giving a very fast response to physiological change induced by exercise. The chamber is custom-made from an aluminium block and a plexiglass lid; all other components are available commercially. The system, as described, allows for a detailed analysis of respiratory gas (and water) exchange by rats under varying exercise conditions, there is practically no time lag between changes in respiratory gases and the detection of these changes, and the buffering effect of the chamber size is practically eliminated because of the calculation approach used. AD - Departament de Bioquimica i Fisiologia, Facultat de Biologia, Universitat de Barcelona, Spain. FAU - Ardevol, A AU - Ardevol A FAU - Adan, C AU - Adan C FAU - Fernandez-Lopez, J A AU - Fernandez-Lopez JA FAU - Perez, J AU - Perez J FAU - Corts, J L AU - Corts JL FAU - Binagui, D AU - Binagui D FAU - Remesar, X AU - Remesar X FAU - Alemany, M AU - Alemany M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - Arch Physiol Biochem JT - Archives of physiology and biochemistry JID - 9510153 RN - 124-38-9 (Carbon Dioxide) RN - 7732-18-5 (Water) RN - 7782-44-7 (Oxygen) SB - IM MH - Animals MH - Carbon Dioxide/analysis MH - Exercise Test/*instrumentation/methods MH - Oxygen/analysis MH - Oxygen Consumption MH - Pressure MH - *Pulmonary Gas Exchange MH - Rats MH - Temperature MH - Water/analysis EDAT- 1995/05/01 00:00 MHDA- 1997/10/24 00:01 PST - ppublish SO - Arch Physiol Biochem. 1995 May;103(2):175-86. PMID- 9334930 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0146-6615 (Print) VI - 53 IP - 2 DP - 1997 Oct TI - Puumala virus and two genetic variants of Tula virus are present in Austrian rodents. PG - 174-81 AB - Puumala and Tula viruses are hantaviruses found in Europe and are associated with the rodents Clethrionomys glareolus and Microtus arvalis, respectively. Puumala virus is associated with the human disease nephropathia epidemica. In Austria, ten clinically diagnosed cases of nephropathia epidemica, presumably caused by Puumala virus infection, have been reported but not virologically confirmed [Leschinskaya et al., 1991; Aberle et al., 1996]. To identify the hantaviruses that are present in Austria, five species of rodents were trapped and screened for virus antibodies, antigen, and RNA. Hantaviruses were detected in two species, Cl. glareolus and M. arvalis, by reverse transcription-polymerase chain reaction (RT-PCR). RT-PCR products from Cl. glareolus tissues yielded a unique Puumala virus sequence distinct from Puumala virus sequences reported from other parts of Europe. RT-PCR products from M. arvalis tissues yielded two genetically distinct Tula virus sequences, one similar to sequences reported from Slovakia and the Czech Republic and another that appears to be a novel genetic variant of Tula virus. This is the first confirmed report of hantaviruses in Austria. AD - Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia, USA. MKB6@CDC.GOV FAU - Bowen, M D AU - Bowen MD FAU - Gelbmann, W AU - Gelbmann W FAU - Ksiazek, T G AU - Ksiazek TG FAU - Nichol, S T AU - Nichol ST FAU - Nowotny, N AU - Nowotny N LA - eng SI - GENBANK/U95302 SI - GENBANK/U95303 SI - GENBANK/U95304 SI - GENBANK/U95305 SI - GENBANK/U95306 SI - GENBANK/U95307 SI - GENBANK/U95308 SI - GENBANK/U95309 SI - GENBANK/U95310 SI - GENBANK/U95311 SI - GENBANK/U95312 SI - GENBANK/U95313 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Med Virol JT - Journal of medical virology JID - 7705876 RN - 0 (Antibodies, Viral) RN - 0 (Antigens, Viral) RN - 0 (RNA, Viral) SB - IM MH - Animals MH - Antibodies, Viral/blood MH - Antigens, Viral/analysis MH - Austria MH - Disease Reservoirs MH - Hantavirus/genetics/immunology/*isolation & purification MH - Lung/virology MH - Molecular Sequence Data MH - Muridae/*virology MH - *Phylogeny MH - RNA, Viral/analysis MH - Sequence Analysis, DNA EDAT- 1997/10/23 22:31 MHDA- 2000/06/20 09:00 AID - 10.1002/(SICI)1096-9071(199710)53:2<174::AID-JMV11>3.0.CO;2-J [pii] PST - ppublish SO - J Med Virol. 1997 Oct;53(2):174-81. PMID- 9342232 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0014-2956 (Print) VI - 248 IP - 3 DP - 1997 Sep 15 TI - Molecular cloning of the gene for mouse leukotriene-C4 synthase. PG - 807-13 AB - Leukotriene C4 (LTC4) synthase (LTC4S), an integral membrane protein, catalyzes the conjugation of leukotriene A4 with reduced glutathione to form LTC4, the biosynthetic parent of the additional cysteinyl leukotriene metabolites. An XmnI-digested fragment of a P1 clone from a 129 mouse ES library contained the full-length gene of 2.01 kb for mouse LTC4S. The mouse LTC4S gene is comprised of 5 exons of 122, 100, 71, 82 and 241 nucleotides, with intron sizes that range from 76 nucleotides to 937 nucleotides. The intron/exon boundaries are identical to those of the human genes for LTC4S and 5-lipoxygenase-activating protein (FLAP). Primer extension demonstrated a single transcription-initiation site 64 bp 5' of the ATG translation-start site. Nucleotide sequencing of 1.2 kb of the 5' flanking region revealed multiple putative sites for activating protein-2, CCAAT/enhancer-binding protein, and polyoma virus enhancer-3. Fluorescent in situ hybridization mapped the mouse LTC4S gene to mouse chromosome 11, in a region containing the genes for interleukin 13 and granulocyte/macrophage-colony-stimulating factor, and orthologous to the chromosomal location of 5q35 for the human LTC4S gene. Thus, the mouse LTC4S gene is similar in size, intron/exon organization and chromosomal localization to the human LTC4S gene. Recent mutagenic analysis of the conjugation function of human LTC4S has identified R51 and Y93 as critical for acid and base catalysis of LTA4 and reduced glutathione, respectively. A comparison across species for proteins that possess LTC4S activity reveals conservation of both of these residues, whereas R51 is absent in the FLAP molecules. Thus, within the glutathione S-transferase superfamily of genes, alignment of specific residues allows the separation of LTC4S family members from their most structurally similar counterparts, the FLAP molecules. AD - Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA. jpenrose@warren.med.harvard.edu FAU - Penrose, J F AU - Penrose JF FAU - Baldasaro, M H AU - Baldasaro MH FAU - Webster, M AU - Webster M FAU - Xu, K AU - Xu K FAU - Austen, K F AU - Austen KF FAU - Lam, B K AU - Lam BK LA - eng GR - AI-22531/AI/NIAID GR - AI-31599/AI/NIAID GR - AR-36308/AR/NIAMS GR - etc. PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - GERMANY TA - Eur J Biochem JT - European journal of biochemistry / FEBS JID - 0107600 RN - EC 2.5.1.18 (Glutathione Transferase) RN - EC 4.4.1.20 (leukotriene-C4 synthase) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Chromosome Mapping MH - Cloning, Molecular MH - Exons/genetics MH - Glutathione Transferase/*chemistry/*genetics MH - Humans MH - In Situ Hybridization, Fluorescence MH - Introns/genetics MH - Mice MH - Microsomes/enzymology MH - Models, Molecular MH - Molecular Sequence Data MH - Polymerase Chain Reaction MH - Sequence Analysis, DNA MH - Sequence Homology, Amino Acid MH - Transcription, Genetic EDAT- 1997/10/28 MHDA- 1997/10/28 00:01 PST - ppublish SO - Eur J Biochem. 1997 Sep 15;248(3):807-13. PMID- 9357854 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0002-9513 (Print) VI - 273 IP - 4 Pt 1 DP - 1997 Oct TI - Differential induction of c-fos, c-jun, and apoptosis in lung epithelial cells exposed to ROS or RNS. PG - L789-96 AB - Reactive oxygen (ROS) or nitrogen (RNS) species can affect epithelial cells to cause acute damage and an array of pulmonary diseases. The goal of this study was to determine patterns of early response gene expression and functional end points of exposure to nitric oxide (NO.), H2O2, or peroxynitrite (ONOO-) in a line of rat lung epithelial (RLE) cells. Our focus was on c-fos and c-jun protooncogenes, as these genes play an important role in proliferation or apoptosis, possible end points of exposure to reactive metabolites in lung. Our data demonstrate that NO. generated by spermine 1,3-propanediamine N-14-[1-(3-aminopropyl)-2-hydroxy-2-nitrosohydrazino]-butyl] or S-nitroso-N-acetylpenicillamine as well as H2O2 cause increased c-fos and c-jun mRNA levels, nuclear proteins, and complexes binding the activator protein-1 recognition sequence in RLE cells. These agents also lead to apoptosis and increased membrane permeability. In contrast, exogenously administered ONOO- or 3-morpholinosydnonimine do not induce protooncogenes or apoptosis in RLE cells despite nitration oftyrosines. We conclude that ROS and RNS can elicit distinct molecular and phenotypic responses in a target cell of pulmonary disease. AD - Department of Pathology, University of Vermont, Burlington 05405, USA. FAU - Janssen, Y M AU - Janssen YM FAU - Matalon, S AU - Matalon S FAU - Mossman, B T AU - Mossman BT LA - eng GR - ES-06499/ES/NIEHS GR - ES-07038/ES/NIEHS GR - HL-39469/HL/NHLBI GR - etc. PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Am J Physiol JT - The American journal of physiology JID - 0370511 RN - 0 (Nitrates) RN - 0 (Proto-Oncogene Proteins c-fos) RN - 0 (Proto-Oncogene Proteins c-jun) RN - 0 (RNA, Messenger) RN - 0 (Reactive Oxygen Species) RN - 10102-43-9 (Nitric Oxide) RN - 25717-80-0 (Molsidomine) RN - 26404-66-0 (peroxynitric acid) RN - 33876-97-0 (3-morpholino-sydnonimine) RN - 52-67-5 (Penicillamine) RN - 71-44-3 (Spermine) RN - 7722-84-1 (Hydrogen Peroxide) RN - 79032-48-7 (S-Nitroso-N-Acetylpenicillamine) SB - IM MH - Animals MH - Apoptosis/*drug effects/physiology MH - Cell Line MH - Epithelial Cells/drug effects/physiology MH - Genes, fos/drug effects MH - Genes, jun/drug effects MH - Hydrogen Peroxide/*pharmacology MH - Lung/*drug effects MH - Molsidomine/analogs & derivatives/pharmacology MH - Nitrates/*pharmacology MH - Nitric Oxide/*pharmacology MH - Penicillamine/analogs & derivatives/pharmacology MH - Proto-Oncogene Proteins c-fos/*biosynthesis MH - Proto-Oncogene Proteins c-jun/*biosynthesis MH - RNA, Messenger/biosynthesis MH - Rats MH - Reactive Oxygen Species MH - S-Nitroso-N-Acetylpenicillamine MH - Spermine/pharmacology MH - Transcription, Genetic/drug effects EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Am J Physiol. 1997 Oct;273(4 Pt 1):L789-96. PMID- 9315494 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20060703 PUBM- Print IS - 0955-9930 (Print) VI - 9 IP - 3 DP - 1997 Sep TI - Trazodone, a double blind trial for treatment of erectile dysfunction. PG - 163-5 AB - OBJECTIVE: to assess the effectiveness of oral trazodone 150 mg/d for treatment of erectile dysfunction. PATIENTS AND METHODS: A double-blind, placebo controlled, multicentre trial. A run-in period of two weeks was followed by four weeks of medication. Evaluation was done by patients diary, a questionnaire and Rigiscan nightly penile tumescence and rigidity (NPTR) measurements in the second and sixth week of the trial. RESULTS: 69 patients were randomised, two patients never returned for follow-up, nine patients stopped the medication due to side-effects, so 58 patients are evaluable for effect assessment. Half of the patients suffered psychogenic impotence. There was no significant difference in the subjective results of trazodone compared to placebo. Side effects occurred more often with the use of trazodone, but this was not statistically significant. CONCLUSION: In a group of patients, that was not selected on the basis of the etiology of the erectile dysfunction, nor selected on the duration of the complaint, the efficacy of trazodone 150 mg/d, could not be shown. AD - Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. FAU - Meinhardt, W AU - Meinhardt W FAU - Schmitz, P I AU - Schmitz PI FAU - Kropman, R F AU - Kropman RF FAU - de la Fuente, R B AU - de la Fuente RB FAU - Lycklama a Nijeholt, A A AU - Lycklama a Nijeholt AA FAU - Zwartendijk, J AU - Zwartendijk J LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PL - ENGLAND TA - Int J Impot Res JT - International journal of impotence research JID - 9007383 RN - 0 (Adrenergic alpha-Antagonists) RN - 0 (Placebos) RN - 0 (Serotonin Uptake Inhibitors) RN - 19794-93-5 (Trazodone) SB - IM MH - Adrenergic alpha-Antagonists/*therapeutic use MH - Double-Blind Method MH - Humans MH - Impotence/*drug therapy/psychology MH - Male MH - Placebos MH - Serotonin Uptake Inhibitors/*therapeutic use MH - Trazodone/administration & dosage/adverse effects/*therapeutic use MH - Treatment Outcome EDAT- 1997/10/07 MHDA- 1997/10/07 00:01 PST - ppublish SO - Int J Impot Res. 1997 Sep;9(3):163-5. PMID- 9322229 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 1359-4184 (Print) VI - 2 IP - 5 DP - 1997 Sep TI - Imprinted X-linked genes, 'feminine intuition' and the public (mis)understanding of science. PG - 385-6 AB - The report of an imprinted locus on the X chromosome influencing social behaviour was taken up with fervour by the media and reported in a way which neglected the reality of multifactorial complexity and the interplay between genetic and environmental contributors to gender differences. We summarize the background scientific details of the study and discuss the media reporting of those findings. AD - Department of Psychological Medicine, University of Wales College of Medicine, Cardiff, UK. ScourfieldJ@cardiff.ac.uk FAU - Scourfield, J AU - Scourfield J FAU - McGuffin, P AU - McGuffin P LA - eng PT - Journal Article PL - ENGLAND TA - Mol Psychiatry JT - Molecular psychiatry JID - 9607835 SB - IM MH - Humans MH - Intuition/*physiology MH - Linkage (Genetics)/*genetics MH - Science MH - *Social Behavior MH - X Chromosome/*genetics EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 PST - ppublish SO - Mol Psychiatry. 1997 Sep;2(5):385-6. PMID- 9237795 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0896-8411 (Print) VI - 10 IP - 4 DP - 1997 Aug TI - Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. PG - 323-9 AB - A peptide from the sequence of hsp60 molecule, designated p277, has been shown to be functionally involved in modulating the development of auto-immune diabetes in the NOD mouse: administration of p277 to NOD mice can arrest the diabetogenic autoimmune process, even when far advanced. Is p277 the only hsp60 peptide able to modulate the disease? We mapped T cell responses to peptides spanning the mouse hsp60 molecule and identified an immunogenic peptide, designated p12, that is also functional in arresting NOD diabetes. Although no spontaneous T cell reactivity to p12 could be detected in NOD mice, subcutaneous administration of 100 microg of p12 in mineral oil to 10-week-old female NOD mice, similar to treatment with p277, significantly prevented progression of the disease. Administration of other immunogenic peptides was not effective. A peptide from the glutamic acid decarboxylase (GAD65) sequence, GADp35, and a peptide from the myco-bacterial hsp60 molecule did not influence the development of diabetes. The effectiveness of hsp60 peptides p12 and p277 was associated with the induction of antibodies to the peptides of the IgG1 and IgG2b isotypes, antibodies which appear to be regulated by anti-inflammatory cytokines. There was a negative correlation between the amounts of antibodies induced by the hsp60 peptides and the level of blood glucose. Thus, more than one peptide of the hsp60 molecule can be used to inhibit the development of NOD diabetes, and the effect of peptide therapy appears to be associated with the induction of specific antibody isotypes. AD - Department of Immunology, The Weizmann Institute of Science, Rehovot, 76100, Israel. FAU - Bockova, J AU - Bockova J FAU - Elias, D AU - Elias D FAU - Cohen, I R AU - Cohen IR LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - J Autoimmun JT - Journal of autoimmunity JID - 8812164 RN - 0 (Chaperonin 60) RN - 0 (Immunoglobulin G) RN - 0 (Peptide Fragments) SB - IM SB - X MH - Amino Acid Sequence MH - Animals MH - Antibody Specificity MH - Autoimmunity MH - Chaperonin 60/genetics/*immunology/*therapeutic use MH - Diabetes Mellitus, Type 1/*immunology/prevention & control/*therapy MH - Female MH - Immunoglobulin G/biosynthesis MH - Lymphocyte Activation MH - Mice MH - Mice, Inbred NOD MH - Molecular Sequence Data MH - Peptide Fragments/genetics/*immunology/*therapeutic use MH - Peptide Mapping MH - T-Lymphocytes/immunology MH - Th2 Cells/*immunology EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 AID - S0896-8411(97)90150-5 [pii] AID - 10.1006/jaut.1997.0150 [doi] PST - ppublish SO - J Autoimmun. 1997 Aug;10(4):323-9. PMID- 9354327 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0896-6273 (Print) VI - 19 IP - 4 DP - 1997 Oct TI - Activity regulates the synaptic localization of the NMDA receptor in hippocampal neurons. PG - 801-12 AB - We describe here a novel effect of activity on the subcellular distribution of NMDA receptors in hippocampal neurons in culture. In spontaneously active neurons, NMDA receptors were clustered at a few synaptic and nonsynaptic sites. Chronic blockade of NMDA receptor activity induced a 380% increase in the number of NMDA receptor clusters and a shift to a more synaptic distribution. This effect was reversible. The distributions of the presynaptic marker synaptophysin, the AMPA-type glutamate receptor subunit GluR1, and the putative NMDA receptor clustering protein PSD-95 were not affected by blockade. Regulation of the synaptic localization of NMDA receptors by activity may define a novel mechanism by which input controls a neuron's ability to modify its synapses. AD - Department of Cell and Structural Biology, University of Illinois, Urbana 61801, USA. FAU - Rao, A AU - Rao A FAU - Craig, A M AU - Craig AM LA - eng GR - NS33184/NS/NINDS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Neuron JT - Neuron JID - 8809320 RN - 0 (Dlgh4 protein, rat) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Membrane Proteins) RN - 0 (Nerve Tissue Proteins) RN - 0 (Receptors, AMPA) RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 0 (Synaptophysin) RN - 0 (glutamate receptor ionotropic, AMPA 1) RN - 0 (postsynaptic density proteins) RN - 4368-28-9 (Tetrodotoxin) RN - 76726-92-6 (2-Amino-5-phosphonovalerate) SB - IM MH - 2-Amino-5-phosphonovalerate/pharmacology MH - Animals MH - Cells, Cultured MH - Embryo MH - Hippocampus/cytology/*physiology MH - Intracellular Signaling Peptides and Proteins MH - Membrane Proteins MH - Nerve Tissue Proteins/biosynthesis MH - Neurons/cytology/*physiology MH - Rats MH - Receptors, AMPA/biosynthesis MH - Receptors, N-Methyl-D-Aspartate/analysis/antagonists & inhibitors/*biosynthesis MH - Synapses/drug effects/*physiology/ultrastructure MH - Synaptophysin/analysis/biosynthesis MH - Tetrodotoxin/pharmacology MH - Up-Regulation/drug effects EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 AID - S0896-6273(00)80962-9 [pii] PST - ppublish SO - Neuron. 1997 Oct;19(4):801-12. PMID- 9297573 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print IS - 1023-3830 (Print) VI - 46 IP - 8 DP - 1997 Aug TI - Atypical association of H1 and H2 histamine receptors with signal transduction pathways during multistage mouse skin carcinogenesis. PG - 292-8 AB - OBJECTIVE: In the present work we studied the association of histamine receptors with second messengers during multistage carcinogenesis in Sencar mice skin. METHODS: 96 Sencar female mouse, divided into six groups were used. Tumors appeared only in the 7, 12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted group. Control groups received only TPA, or acetone or no treatment at all. Periodically during the promotion period, cAMP and inositol phosphate production were measured after stimulation with H1 or H2 agonists in samples from all groups. RESULTS: In non-treated skin, H1 receptors were coupled to phosphatidylinositol hydrolysis and H2 receptors mediated cAMP production. Conversely, in tumors H2 receptors were associated with phosphatidylinositol hydrolysis and H1 mediated a rise in cAMP levels. The skin among tumors and the skin from all control groups maintained the same coupling as non-treated skin. An increase in mast cell number, with a homogeneous subepithelial distribution and marked phenotypic changes, was also observed in promoted skin. CONCLUSIONS: These findings indicate an atypical association of histamine receptors with second messengers that could be a critical feature for the postulated action of histamine in tumor growth. AD - Laboratorio de Radiosotopos, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Argentina. FAU - Fitzsimons, C AU - Fitzsimons C FAU - Molinari, B AU - Molinari B FAU - Duran, H AU - Duran H FAU - Palmieri, M AU - Palmieri M FAU - Davio, C AU - Davio C FAU - Cricco, G AU - Cricco G FAU - Bergoc, R AU - Bergoc R FAU - Rivera, E AU - Rivera E LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - SWITZERLAND TA - Inflamm Res JT - Inflammation research : official journal of the European Histamine Research Society ... [et al.] JID - 9508160 RN - 0 (Histamine H1 Antagonists) RN - 0 (Histamine H2 Antagonists) RN - 0 (Phosphatidylinositols) RN - 0 (Receptors, Histamine H1) RN - 0 (Receptors, Histamine H2) RN - 16561-29-8 (Tetradecanoylphorbol Acetate) RN - 51481-61-9 (Cimetidine) RN - 57-97-6 (9,10-Dimethyl-1,2-benzanthracene) RN - 60-92-4 (Cyclic AMP) RN - 69014-14-8 (tiotidine) RN - 91-84-9 (Pyrilamine) SB - IM MH - 9,10-Dimethyl-1,2-benzanthracene MH - Animals MH - Cell Count MH - Cimetidine/analogs & derivatives/metabolism MH - Cyclic AMP/metabolism MH - Female MH - Histamine H1 Antagonists/metabolism MH - Histamine H2 Antagonists/metabolism MH - Hydrolysis MH - Mast Cells/pathology MH - Mice MH - Phosphatidylinositols/metabolism MH - Pyrilamine/metabolism MH - Receptors, Histamine H1/*physiology MH - Receptors, Histamine H2/*physiology MH - Second Messenger Systems MH - Signal Transduction/*physiology MH - Skin Neoplasms/chemically induced/pathology/*physiopathology MH - Tetradecanoylphorbol Acetate EDAT- 1997/08/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - Inflamm Res. 1997 Aug;46(8):292-8. PMID- 9335237 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 0193-1091 (Print) VI - 19 IP - 5 DP - 1997 Oct TI - Atypical lymphoid infiltrates arising in cutaneous lesions of connective tissue disease. PG - 446-55 AB - Atypical lymphoid infiltrates occurring in the setting of connective-tissue disease (CTD) comprise malignant neoplasms of B-cell or T-cell phenotypes and various reactive lymphoid hyperplasias, such as myoepithelial sialadenitis, lymphocytic thyroiditis, and lymphocytic interstitial pneumonitis. We describe 17 patients with atypical lymphoid infiltrates arising in cutaneous lesions of CTD, the spectrum of which included lupus erythematosus, dermatomyositis, relapsing polychondritis, and lichen sclerosus et atrophicus. There were two principal categories, pseudolymphoma and malignant lymphoma, the former representing 15 of the 17 cases. The clinical and histologic features and possible pathogenetic mechanisms are discussed. AD - Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School Pathology Services, Inc., Cambridge, Massachusetts, USA. FAU - Magro, C M AU - Magro CM FAU - Crowson, A N AU - Crowson AN FAU - Harrist, T J AU - Harrist TJ LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Am J Dermatopathol JT - The American Journal of dermatopathology JID - 7911005 SB - IM MH - Adult MH - Aged MH - B-Lymphocytes/pathology MH - Connective Tissue Diseases/*pathology MH - Dermatomyositis/pathology MH - Female MH - Follow-Up Studies MH - Humans MH - Lichen Sclerosus et Atrophicus/pathology MH - Lung Diseases, Interstitial/pathology MH - Lupus Erythematosus, Cutaneous/pathology MH - Lupus Erythematosus, Discoid/pathology MH - Lupus Erythematosus, Systemic/pathology MH - Lymphocytes/*pathology MH - Lymphoma/pathology MH - Lymphoma, T-Cell, Cutaneous/pathology MH - Male MH - Middle Aged MH - Phenotype MH - Polychondritis, Relapsing/pathology MH - Pseudolymphoma/pathology MH - Sialadenitis/pathology MH - Skin Diseases/*pathology MH - Skin Neoplasms/pathology MH - T-Lymphocytes/pathology MH - Thyroiditis, Autoimmune/pathology EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - Am J Dermatopathol. 1997 Oct;19(5):446-55. PMID- 9321417 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0022-2844 (Print) VI - 45 IP - 4 DP - 1997 Oct TI - Synonymous substitution rates in Drosophila: mitochondrial versus nuclear genes. PG - 378-91 AB - Synonymous substitution rates in mitochondrial and nuclear genes of Drosophila were compared. To make accurate comparisons, we considered the following: (1) relative synonymous rates, which do not require divergence time estimates, should be used; (2) methods estimating divergence should take into account base composition; (3) only very closely related species should be used to avoid effects of saturation; (4) the heterogeneity of rates should be examined. We modified the methods estimating synonymous substitution numbers to account for base composition bias. By using these methods, we found that mitochondrial genes have 1.7-3.4 times higher synonymous substitution rates than the fastest nuclear genes or 4.5-9.0 times higher rates than the average nuclear genes. The average rate of synonymous transversions was 2.7 (estimated from the melanogaster species subgroup) or 2.9 (estimated from the obscura group) times higher in mitochondrial genes than in nuclear genes. Synonymous transversions in mitochondrial genes occurred at an approximately equivalent rate to those in the fastest nuclear genes. This last result is not consistent with the hypothesis that the difference in turnover rates between mitochondrial and nuclear genomes is the major factor determining higher synonymous substitution rates in mtDNA. We conclude that the difference in synonymous substitution rates is due to a combination of two factors: a higher transitional mutation rate in mtDNA and constraints on nuclear genes due to selection for codon usage. AD - Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 06520-8106, USA. FAU - Moriyama, E N AU - Moriyama EN FAU - Powell, J R AU - Powell JR LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - J Mol Evol JT - Journal of molecular evolution JID - 0360051 RN - 0 (DNA, Mitochondrial) SB - IM MH - Animals MH - Cell Nucleus/genetics MH - DNA, Mitochondrial/genetics MH - Drosophila/*genetics MH - Drosophila melanogaster/genetics MH - Evolution, Molecular MH - *Genes, Insect MH - Models, Genetic MH - Mutation MH - Time Factors EDAT- 1997/10/08 MHDA- 1997/10/08 00:01 PST - ppublish SO - J Mol Evol. 1997 Oct;45(4):378-91. PMID- 9378240 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20061115 PUBM- Print IS - 0306-3623 (Print) VI - 29 IP - 3 DP - 1997 Sep TI - Vasodilation profile of CD-832, a novel dihydropyridine derivative in rabbit aorta. PG - 361-6 AB - 1. CD-832, nifedipine and nitrendipine, but not nitroglycerin and nicorandil, inhibited the KCl-induced contraction of rabbit aortas. 2. CD-832, nitroglycerin and nicorandil, but not nifedipine and nitrendipine, inhibited the norepinephrine-induced contraction of aortas. The inhibitory effects of these agents were either potentiated or inhibited by zaprinast or methylene blue, respectively. 3. On the KCl-induced contraction, the duration of CD-832-induced vasodilation was longer than that of nifedipine. Concerning the norepinephrine-induced contraction, the duration of CD-832-induced vasodilation was longer than that of nicorandil. 4. These results suggest that the mechanism of CD-832-induced vasodilation concerns both Ca(2+)-antagonistic action and a nitratelike action. Furthermore, the vasodilation is long lasting. AD - Pharmacology Laboratory, Taisho Pharmaceutical Co., Ltd., Saitama, Japan. FAU - Noguchi, K AU - Noguchi K FAU - Takahashi, K AU - Takahashi K FAU - Araki, H AU - Araki H FAU - Higuchi, S AU - Higuchi S LA - eng PT - In Vitro PT - Journal Article PL - ENGLAND TA - Gen Pharmacol JT - General pharmacology JID - 7602417 RN - 0 (Adrenergic alpha-Agonists) RN - 0 (CD 832) RN - 0 (Calcium Channel Blockers) RN - 0 (Vasodilator Agents) RN - 21829-25-4 (Nifedipine) RN - 39562-70-4 (Nitrendipine) RN - 51-41-2 (Norepinephrine) RN - 55-63-0 (Nitroglycerin) RN - 65141-46-0 (Nicorandil) RN - 7447-40-7 (Potassium Chloride) RN - 98-92-0 (Niacinamide) SB - IM MH - Adrenergic alpha-Agonists/pharmacology MH - Animals MH - Aorta, Thoracic/*drug effects MH - Calcium Channel Blockers/*pharmacology MH - Male MH - Muscle Contraction/drug effects MH - Muscle Relaxation/drug effects MH - Niacinamide/*analogs & derivatives/pharmacology MH - Nicorandil MH - Nifedipine/*analogs & derivatives/pharmacology MH - Nitrendipine/pharmacology MH - Nitroglycerin/pharmacology MH - Norepinephrine/antagonists & inhibitors/pharmacology MH - Potassium Chloride/antagonists & inhibitors/pharmacology MH - Rabbits MH - Vasodilation/*drug effects MH - Vasodilator Agents/pharmacology EDAT- 1997/09/01 MHDA- 1997/09/01 00:01 AID - S0306362396008130 [pii] PST - ppublish SO - Gen Pharmacol. 1997 Sep;29(3):361-6. PMID- 9356032 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0012-1797 (Print) VI - 46 IP - 11 DP - 1997 Nov TI - Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. PG - 1822-8 AB - Insulin resistance is a common feature in first-degree relatives of NIDDM patients. To explore the mechanism(s) behind this condition in more detail, a percutaneous muscle biopsy (vastus lateralis) was performed in 25 first-degree relatives of NIDDM patients and 21 control subjects to examine muscle fiber composition and capillary density. Insulin-stimulated glucose disposal (Rd) was determined employing a hyperinsulinemic-(insulin infusion rate 0.6 mU x kg[-1] x min[-1]) euglycemic clamp. Rd (5.76 +/- 0.35 vs. 8.06 +/- 0.36 mg x kg lean body weight [LBW]-1 x min[-], P < 0.001) and estimated VO2max (49.3 +/- 2.8 vs. 57.2 +/- 3.5 mg x kg LBW[-1] x min[-1], 0.05 < P < 0.10) were decreased in the relatives. The number of type IIb fibers (29.5 +/- 2.5 vs. 21.0 +/- 2.8%, P < 0.05) was increased in the relatives, whereas no significant differences were found in other fiber types or capillary density between the groups. Correlations were observed between number of type I fibers (positive), number of type IIb fibers (negative), and capillary density (positive) versus Rd as well as estimated VO2max (P < 0.05). In a multiple linear regression analysis with Rd as a dependent variable, estimated VO2max, family history of NIDDM, and number of type IIb fibers (P < 0.001, r2 = 0.64) significantly determined the level of Rd, whereas capillary density did not. In conclusion, insulin-resistant first-degree relatives of NIDDM patients are characterized by an increased number of type IIb muscle fibers. Whether this finding reflects a reduced physical activity level and fitness in the relatives or is of primary genetic origin remains to be determined. AD - Department of Medicine (Endocrinology and Diabetes), Institute for Experimental Clinical Research, University of Aarhus, Denmark. FAU - Nyholm, B AU - Nyholm B FAU - Qu, Z AU - Qu Z FAU - Kaal, A AU - Kaal A FAU - Pedersen, S B AU - Pedersen SB FAU - Gravholt, C H AU - Gravholt CH FAU - Andersen, J L AU - Andersen JL FAU - Saltin, B AU - Saltin B FAU - Schmitz, O AU - Schmitz O LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Diabetes JT - Diabetes JID - 0372763 SB - AIM SB - IM SB - S MH - Adult MH - Capillaries/anatomy & histology MH - Diabetes Mellitus, Type 2/*genetics MH - Female MH - Humans MH - Insulin Resistance/genetics/*physiology MH - Male MH - Middle Aged MH - Muscle Fibers, Fast-Twitch/*cytology MH - Muscle Fibers, Slow-Twitch/*cytology MH - Muscle, Skeletal/blood supply/cytology MH - Nuclear Family MH - Reference Values MH - Regression Analysis EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Diabetes. 1997 Nov;46(11):1822-8. PMID- 9379020 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20061115 PUBM- Print IS - 0022-1767 (Print) VI - 159 IP - 9 DP - 1997 Nov 1 TI - Transgenic expression of lymphotoxin restores lymph nodes to lymphotoxin-alpha-deficient mice. PG - 4252-60 AB - Lymphotoxin-alpha (LT alpha) has recently been demonstrated to be important in the development of lymph nodes (LN), Peyer's patches, and splenic organization, including the development of germinal centers. To elucidate the role of LT alpha in lymphoid organogenesis and the plasticity of the process, we examined LT alpha-/- mice in which an LT alpha transgene under the control of the rat insulin promoter (RIPLT) is expressed in the pancreas, kidney, and skin. The LT alpha transgene restored LN in LT alpha-/- mice. The reconstituted LN of RIPLT.LT alpha-/- mice had germinal center-like peanut agglutinin-positive regions, but lacked follicular dendritic cells. Although the LT alpha transgene did not restore Peyer's patches or splenic architecture, it restored the ability of the spleen to form germinal centers and follicular dendritic cell networks. Lymphocytes isolated from the reconstituted LN showed normal proliferative responses to T and B cell mitogens and were defective in their proliferative response to T-dependent Ag, and a decreased number of interdigitating dendritic cells was apparent in the RIPLT.LT alpha-/- mice LN. Expression of the RIPLT transgene in mice deficient in LT beta did not reconstitute LN, suggesting an important role for LT beta in the mechanisms that reconstitute LN in RIPLT.LT alpha-/- mice. These data are the first to demonstrate reconstitution of LN in LT alpha-/- mice and show that the process of LN restoration is amenable to manipulation with ectopic lymphotoxin. AD - Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA. FAU - Sacca, R AU - Sacca R FAU - Turley, S AU - Turley S FAU - Soong, L AU - Soong L FAU - Mellman, I AU - Mellman I FAU - Ruddle, N H AU - Ruddle NH LA - eng GR - GM33904/GM/NIGMS GR - R01AI34404/AI/NIAID GR - R01CA16885/CA/NCI GR - etc. PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Immunol JT - Journal of immunology (Baltimore, Md. : 1950) JID - 2985117R RN - 0 (Lymphotoxin-alpha) SB - AIM SB - IM MH - Animals MH - *Gene Expression Regulation MH - Lymph Nodes/*growth & development/immunology MH - Lymphotoxin-alpha/*genetics/immunology MH - Mice MH - *Mice, Transgenic MH - Peyer's Patches/growth & development/immunology MH - Rats EDAT- 1997/10/31 MHDA- 1997/10/31 00:01 PST - ppublish SO - J Immunol. 1997 Nov 1;159(9):4252-60. PMID- 9378367 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20061115 PUBM- Print IS - 0891-5849 (Print) VI - 23 IP - 6 DP - 1997 TI - Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. PG - 879-84 AB - Inflammatory conditions characterized by neutrophil activation are associated with a variety of chronic diseases. Reactive oxygen species are produced by activated neutrophils and produce DNA damage which may lead to tissue damage. Previous studies have shown that activated murine neutrophils induce DNA strand breaks in a target plasmacytoma cell, RIMPC 2394. We studied the effect of a water soluble nitroxide anti-oxidant, Tempol, on murine neutrophil induction of DNA strand breaks in this system. Murine neutrophils were isolated from the peritoneal cavity of BALB/cAn mice after an i.p. injection of pristane oil. Neutrophils were activated by the phorbol ester PMA and co-incubated with RIMPC 2394 cells. Control alkaline elution studies revealed progressive DNA strand breaks in RIMPC cells with time. The addition of Tempol to the incubation mixture prevented DNA damage in a dose dependent fashion. Five mM Tempol provided complete protection. Tempol protection against DNA strand breaks was similar for both stimulated neutrophils and exogenously added hydrogen peroxide. Measurement of hydrogen peroxide produced by stimulated neutrophils demonstrated that Tempol did not decrease hydrogen peroxide concentration. Oxidation of reduced metals, thereby interfering with the production of hydroxyl radical, is the most likely mechanism of nitroxide protection, although superoxide dismutase (SOD) like activity and scavenging of carbon-based free radicals may also account for a portion of the observed protection. The anti-oxidant activity of Tempol inhibited DNA damage by activated neutrophils. The nitroxides as a class of compounds may have a role in the investigation and modification of inflammatory conditions. AD - Radiation Biology Branch, National Cancer Institute, Bethesda, MD 20892, USA. FAU - Hahn, S M AU - Hahn SM FAU - Mitchell, J B AU - Mitchell JB FAU - Shacter, E AU - Shacter E LA - eng PT - Journal Article PL - UNITED STATES TA - Free Radic Biol Med JT - Free radical biology & medicine JID - 8709159 RN - 0 (Antioxidants) RN - 0 (Cyclic N-Oxides) RN - 0 (Reactive Oxygen Species) RN - 0 (Spin Labels) RN - 2226-96-2 (tempol) RN - 7722-84-1 (Hydrogen Peroxide) SB - IM MH - Animals MH - Antioxidants/*pharmacology MH - Cells, Cultured MH - Cyclic N-Oxides/*pharmacology MH - DNA Damage/*drug effects MH - Hydrogen Peroxide/*toxicity MH - Mice MH - Mice, Inbred BALB C MH - Neutrophil Activation/drug effects MH - Neutrophils/*drug effects/metabolism MH - Peritoneal Cavity/cytology MH - Plasmacytoma MH - Reactive Oxygen Species/metabolism MH - Respiratory Burst/drug effects MH - Spin Labels MH - Tumor Cells, Cultured EDAT- 1997/01/01 00:00 MHDA- 1997/09/23 00:01 AID - S0891-5849(97)00079-8 [pii] PST - ppublish SO - Free Radic Biol Med. 1997;23(6):879-84. PMID- 9326899 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print IS - 0022-0345 (Print) VI - 76 IP - 10 DP - 1997 Oct TI - Association between marginal bone loss around osseointegrated mandibular implants and smoking habits: a 10-year follow-up study. PG - 1667-74 AB - While many factors are conceivable, occlusal loading and plaque-induced inflammation are frequently stated as the most important ones negatively affecting the prognosis of oral implants. Currently, little is known about the relative importance of such factors. The aim of this study was to analyze the influence of smoking and other possibly relevant factors on bone loss around mandibular implants. The participants were 45 edentulous patients, 21 smokers and 24 non-smokers, who were followed for 10-year period after treatment with a fixed implant-supported prosthesis in the mandible. The peri-implant bone level was measured on intraoral radiographs, information about smoking habits was based on a careful interview, and oral hygiene was evaluated from clinical registration of plaque accumulation. Besides standard statistical methods, multiple linear regression models were constructed for estimation of the relative influence of some factors on peri-implant bone loss. The long-term results of the implant treatment were good, and only three implants (1%) were lost. The mean marginal bone loss around the mandibular implants was very small, about 1 mm for the entire 10-year period. It was greater in smokers than in non-smokers and correlated to the amount of cigarette consumption. Smokers with poor oral hygiene showed greater marginal bone loss around the mandibular implants than those with good oral hygiene. Oral hygiene did not significantly affect bone loss in non-smokers. Multivariate analyses showed that smoking was the most important factor among those analyzed for association with peri-implant bone loss. The separate models for smokers and non-smokers revealed that oral hygiene had a greater impact on peri-implant bone loss among smokers than among non-smokers. This study showed that smoking was the most important factor affecting the rate of peri-implant bone loss, and that oral hygiene also had an influence, especially in smokers, while other factors, e.g., those associated with occlusal loading, were of minor importance. These results indicate that smoking habits should be included in analyses of implant survival and peri-implant bone loss. AD - Department of Prosthetic Dentistry, Faculty of Odontology, Goteborg University, Sweden. FAU - Lindquist, L W AU - Lindquist LW FAU - Carlsson, G E AU - Carlsson GE FAU - Jemt, T AU - Jemt T LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Dent Res JT - Journal of dental research JID - 0354343 SB - D SB - IM MH - Adult MH - Alveolar Bone Loss/epidemiology/*etiology MH - Dental Prosthesis, Implant-Supported/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Jaw, Edentulous/complications/rehabilitation MH - Male MH - Mandible MH - Mandibular Diseases/epidemiology/*etiology MH - *Mandibular Prosthesis/statistics & numerical data MH - Middle Aged MH - Oral Hygiene MH - *Osseointegration MH - Prosthesis Failure MH - Smoking/*adverse effects MH - Time Factors EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - J Dent Res. 1997 Oct;76(10):1667-74. PMID- 9312211 OWN - NLM STAT- MEDLINE DA - 19971117 DCOM- 19971117 LR - 20061115 PUBM- Print IS - 0022-2631 (Print) VI - 159 IP - 3 DP - 1997 Oct 1 TI - Characterization of a chloride-selective channel from rough endoplasmic reticulum membranes of rat hepatocytes: evidence for a block by phosphate. PG - 219-29 AB - We have characterized the conduction and blocking properties of a chloride channel from rough endoplasmic reticulum membranes of rat hepatocytes after incorporation into a planar lipid bilayer. Our experiments revealed the existence of a channel with a mean conductance of 164 +/- 5 pS in symmetrical 200 mm KCl solutions. We determined that the channel was ten times more permeable for Cl- than for K+, calculated from the reversal potential using the Goldman-Hodgkin-Katz equation. The channel was voltage dependent, with an open probability value ranging from 0.9 at -20 mV to 0.4 at +60 mV. In addition to its fully open state, the channel could also enter a flickering state, which appeared to involve rapid transitions to zero current level. Our results showed a decrease of the channel mean open time combined with an increase of the channel mean closed time at positive potentials. An analysis of the dwell time distributions for the open and closed intervals led to the conclusion that the observed fluctuation pattern was compatible with a kinetic scheme containing a single open state and a minimum of three closed states. The permeability sequence for test halides determined from reversal potentials was Br- > Cl- > I- approximately F-. The voltage dependence of the open probability was modified by the presence of halides in trans with a sequence reflecting the permeability sequence, suggesting that permeant anions such as Br- and Cl- have access to an internal site capable of controlling channel gating. Adding NPPB to the cis chamber inhibited the channel activity by increasing fast flickering and generating long silent periods, whereas channel activity was not affected by 50 microM DNDS in trans. The channel was reversibly inhibited by adding phosphate to the trans chamber. The inhibitory effect of phosphate was voltage-dependent and could be reversed by addition of Cl-. Our results suggest that channel block involves the interaction of HPO2-4 with a site located at 70% of the membrane span. AD - Department of Physiology, Membrane Transport Research Group, University of Montreal, C.P. 6128, Succ. Centre-ville, Montreal Canada H3C 3J7. FAU - Eliassi, A AU - Eliassi A FAU - Garneau, L AU - Garneau L FAU - Roy, G AU - Roy G FAU - Sauve, R AU - Sauve R LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Membr Biol JT - The Journal of membrane biology JID - 0211301 RN - 0 (Chloride Channels) RN - 0 (Lipid Bilayers) RN - 0 (Nitrobenzoates) RN - 0 (Phosphates) RN - 0 (Stilbenes) RN - 107254-86-4 (5-nitro-2-(3-phenylpropylamino)benzoic acid) RN - 128-42-7 (4,4'-dinitro-2,2'-stilbenedisulfonic acid) RN - 1333-74-0 (Hydrogen) RN - 7440-09-7 (Potassium) RN - 7440-70-2 (Calcium) SB - IM MH - Animals MH - Calcium/metabolism MH - Chloride Channels/drug effects/*metabolism MH - Endoplasmic Reticulum, Rough/drug effects/*metabolism MH - Hydrogen/metabolism MH - Hydrogen-Ion Concentration MH - Intracellular Membranes/drug effects/metabolism MH - Kinetics MH - Lipid Bilayers/metabolism MH - Liver/*metabolism/ultrastructure MH - Nitrobenzoates/pharmacology MH - Phosphates/*pharmacology MH - Potassium/metabolism MH - Rats MH - Stilbenes/pharmacology EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - J Membr Biol. 1997 Oct 1;159(3):219-29. PMID- 9342780 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0033-3158 (Print) VI - 133 IP - 2 DP - 1997 Sep TI - The effects of kainic acid lesions on dopaminergic responses to haloperidol and clozapine. PG - 142-51 AB - The antipsychotic drugs haloperidol and clozapine have the common action of increasing dopamine metabolism in the striatum (nucleus accumbens, caudate-putamen) of the rat. Intracerebroventricular administration of kainic acid (KA) produces neuronal loss in limbic-cortical brain regions which project directly or indirectly to the striatum. In the present study, dopamine metabolism in subregions of the striatum was examined in rats with KA lesions after acute and chronic haloperidol or clozapine administration. The main findings was that the elevating effect of acute haloperidol treatment on the dopamine metabolite, DOPAC, was blocked in the nucleus accumbens shell and diminished in medial and laterodorsal caudate-putamen of the KA-lesioned rats. In addition, the elevating effects of both acute and chronic haloperidol treatment on dopamine turnover were attenuated in the laterodorsal caudate-putamen of KA-lesioned rats. The levels of dopamine, DOPAC, and HVA after chronic clozapine treatment were greater in KA-lesioned than control rats. These results indicate that dopaminergic responses to haloperidol may be diminished by limbic-cortical neuropathology, while such pathology does not significantly alter dopaminergic responses to clozapine. AD - Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110-1093, USA. FAU - Bardgett, M E AU - Bardgett ME FAU - Salaris, S L AU - Salaris SL FAU - Jackson, J L AU - Jackson JL FAU - Harding, J AU - Harding J FAU - Csernansky, J G AU - Csernansky JG LA - eng GR - MH01109/MH/NIMH PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - GERMANY TA - Psychopharmacology (Berl) JT - Psychopharmacology JID - 7608025 RN - 0 (Dopamine Agonists) RN - 487-79-6 (Kainic Acid) RN - 51-61-6 (Dopamine) RN - 52-86-8 (Haloperidol) RN - 5786-21-0 (Clozapine) SB - IM MH - Animals MH - Caudate Nucleus/drug effects/metabolism MH - Clozapine/*pharmacology MH - Corpus Striatum/*drug effects/metabolism MH - Dopamine/*metabolism MH - Dopamine Agonists MH - Haloperidol/*pharmacology MH - Injections, Intraventricular MH - Kainic Acid/*toxicity MH - Male MH - Nucleus Accumbens/drug effects/metabolism MH - Putamen/drug effects/metabolism MH - Rats MH - Rats, Sprague-Dawley EDAT- 1997/10/29 MHDA- 1997/10/29 00:01 PST - ppublish SO - Psychopharmacology (Berl). 1997 Sep;133(2):142-51. PMID- 9376257 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0885-8195 (Print) VI - 12 IP - 3 DP - 1997 Fall TI - Outcomes study of a course in breast-cancer screening. PG - 179-84 AB - BACKGROUND: The Breast Cancer Screening Module is a professional training course within the Professional Education for Prevention and Early Detection (PEPED) program at the University of Texas M. D. Anderson Cancer Center. An outcomes study was done to determine the module's ability to improve screening practices crucial to breast-cancer control. METHODS: The five-day course combines 17 hours of class work with 20 hours of hands-on clinical training. Subjects were followed for one year post-training. Six outcome areas were evaluated: 1) knowledge about breast-cancer prevention; 2) clinical skills; 3) changes in routine practice; 4) numbers of patients screened, referred, and diagnosed; 5) trainee satisfaction with the course; and 6) barriers to implementing screening in routine practice. The study population was 63 subjects (all nurse professionals). RESULTS: Outcomes were positive in all six evaluation areas-significant gains in general and clinical knowledge tests (p < or = 0.05); a significant increase from 54.2% pre-training to 70.5% post-training in risk counseling (p < or = 0.05); a sustained increase in screening practices (4.3 times and 2.8 times greater at 6 and 12 months post-training, respectively); 72% rate of high course satisfaction; and barriers to improved screening practices, such as time limitations among 60.4% of subjects and 57.6% of their employers, were identified. CONCLUSIONS: This unique training enhances breast-cancer prevention and screening practices and early detection. AD - Department of Clinical Cancer Prevention, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA. FAU - Ford, M AU - Ford M FAU - Martin, R D AU - Martin RD FAU - Hilton, L W AU - Hilton LW FAU - Ewert-Flannagan, T AU - Ewert-Flannagan T FAU - Corrigan, G K AU - Corrigan GK FAU - Johnson, G AU - Johnson G FAU - Hernandez, M A AU - Hernandez MA FAU - Sbach, A AU - Sbach A FAU - Lippman, S M AU - Lippman SM LA - eng GR - CA 16413/CA/NCI PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Cancer Educ JT - Journal of cancer education : the official journal of the American Association for Cancer Education JID - 8610343 SB - IM MH - Breast Neoplasms/*prevention & control MH - Cancer Care Facilities MH - Clinical Competence MH - Counseling MH - Data Interpretation, Statistical MH - *Education, Nursing, Continuing MH - Evaluation Studies MH - Female MH - Follow-Up Studies MH - Health Knowledge, Attitudes, Practice MH - Humans MH - *Mass Screening MH - Outcome Assessment (Health Care) MH - Risk Factors MH - Time Factors EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - J Cancer Educ. 1997 Fall;12(3):179-84. PMID- 9380972 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0034-8376 (Print) VI - 49 IP - 3 DP - 1997 May-Jun TI - [Immunogenetic study in Mexican couples with recurrent spontaneous abortions] PG - 183-7 AB - AIM: To study the HLA markers in Mexican couples who have suffered three or more spontaneous abortions. DESIGN: The study included 24 couples with recurrent abortions and 32 with normal fertility. METHOD: HLA class I (A, B, C) and class II (DR, DQ) typing was done with a standard microlymphocytoxity test. The intergroup differences were evaluated by chi-square and the Fisher exact test. RESULTS: The frequency of the MHC markers in the males and females of couples with abortions were not significantly different from those in fertile couples. However, the abortion couples shared class I antigens more often than expected from random mating as compared to fertile couples, specially in the HLA-B locus. We also found a significantly decreased frequency of the HLA-B7 antigen in males belonging to the abortion group. CONCLUSION: These results suggest that HLA-B antigens may be markers for genes related to pregnancy outcome in Mexicans. AD - Departamento de Genetica, Hospital General de Mexico, SS, Mexico, D.F. FAU - Silva, B AU - Silva B FAU - Yamamoto-Furusho, J K AU - Yamamoto-Furusho JK FAU - Grether, P AU - Grether P FAU - Vargas-Alarcon, G AU - Vargas-Alarcon G FAU - Kofman, S AU - Kofman S FAU - Granados, J AU - Granados J LA - spa PT - English Abstract PT - Journal Article PT - Research Support, Non-U.S. Gov't TT - Estudio inmunogenetico en parejas mexicanas con abortos espontaneos recurrentes. PL - MEXICO TA - Rev Invest Clin JT - Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion JID - 9421552 RN - 0 (HLA Antigens) RN - 0 (HLA-B7 Antigen) SB - IM MH - Abortion, Habitual/epidemiology/genetics/*immunology MH - Adult MH - Disease Susceptibility MH - Female MH - Fertility/genetics/immunology MH - Gene Frequency MH - HLA Antigens/*analysis/genetics MH - HLA-B7 Antigen/analysis MH - Histocompatibility Testing MH - Humans MH - Male MH - Mexico/epidemiology MH - Pregnancy MH - Pregnancy Outcome EDAT- 1997/05/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Rev Invest Clin. 1997 May-Jun;49(3):183-7. PMID- 9354556 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20041117 PUBM- Print IS - 0003-4975 (Print) VI - 64 IP - 4 DP - 1997 Oct TI - Mitral valve repair in a patient with severe porcelain aorta. PG - 1179-81 AB - We repaired the mitral valve in a patient with severe porcelain aorta. Significant mitral regurgitation developed in a 66-year-old woman with heavy calcification throughout the whole aorta. At operation, cardiopulmonary bypass was properly established by combined axillary and femoral arterial cannulations for sufficient systemic flow. Likewise, the combination of a superior mitral approach and profound hypothermic fibrillatory arrest in conjunction with low-flow cardiopulmonary bypass allowed us to repair the mitral valve successfully. AD - Department of Cardiovascular Surgery, Tenri Hospital, Japan. FAU - Ogino, H AU - Ogino H FAU - Ueda, Y AU - Ueda Y FAU - Morioka, K AU - Morioka K FAU - Matsubayashi, K AU - Matsubayashi K FAU - Nomoto, T AU - Nomoto T LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Ann Thorac Surg JT - The Annals of thoracic surgery JID - 15030100R SB - AIM SB - IM MH - Aged MH - Aortic Diseases/*complications MH - Calcinosis/*complications MH - Cardiopulmonary Bypass MH - Female MH - Heart Arrest, Induced MH - Heart Valve Prosthesis Implantation/*methods MH - Humans MH - Mitral Valve/surgery MH - Mitral Valve Insufficiency/complications/*surgery EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 AID - S0003-4975(97)00824-2 [pii] PST - ppublish SO - Ann Thorac Surg. 1997 Oct;64(4):1179-81. PMID- 9335178 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0168-1656 (Print) VI - 58 IP - 1 DP - 1997 Oct 2 TI - Overproduction and purification of an agarase of bacterial origin. PG - 59-66 AB - The agarase gene from Streptomyces coelicolor has been cloned in the non-producer bacterium Streptomyces lividans under the control of its own set of promoters and under the control of a heterologous promoter that is functional only during exponential growth. The best level of overproduction was obtained when the strain containing the natural gene was cultivated in fed batch with mannitol as carbon source. The protein, with a relative molecular mass of 32 kDa, has been purified following an affinity purification method. Contaminating activities seem to be absent from the purified enzyme preparation that can be used to purify DNA from agarose gels. AD - Centro Nacional de Biotecnologia (CSIC), Campus de la Universidad Autonoma, Cantoblanco, Madrid, Spain. FAU - Parro, V AU - Parro V FAU - Vives, C AU - Vives C FAU - Godia, F AU - Godia F FAU - Mellado, R P AU - Mellado RP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - J Biotechnol JT - Journal of biotechnology JID - 8411927 RN - 0 (Bacterial Proteins) RN - 9007-49-2 (DNA) RN - EC 3.2.1.- (Glycoside Hydrolases) RN - EC 3.2.1.81 (agarase) SB - B MH - Bacterial Proteins/*biosynthesis MH - DNA/isolation & purification MH - Glycoside Hydrolases/*biosynthesis/genetics/isolation & purification MH - Promoter Regions (Genetics) MH - Streptomyces/*genetics EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0168-1656(97)00128-4 [pii] PST - ppublish SO - J Biotechnol. 1997 Oct 2;58(1):59-66. PMID- 9271786 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20041117 PUBM- Print IS - 0090-6980 (Print) VI - 54 IP - 1 DP - 1997 Jul TI - Oxidative stress and the mobilisation of arachidonic acid in stimulated human platelets: role of hydroxyl radical. PG - 493-509 AB - Platelet functions, including eicosanoid biosynthesis, can be significantly altered by exposure to reactive oxygen species. We utilised the redox properties of the phenazine derivative, pyocyanin, to generate low micromolar levels of reactive oxygen species in order to investigate the metabolism of arachidonic acid by human platelets under oxidative stress. Eicosanoid production by platelets, pre-labelled with [3H]arachidonic acid (AA) and stimulated with the calcium ionophore A23187, was inhibited in the presence of pyocyanin. In contrast, platelets pre-treated with pyocyanin and concurrently exposed to A23187 and AA showed no evidence of inhibition. Analysis of the free label content of labelled, pyocyanin-treated platelets after stimulation revealed diminished levels of total free label and a corresponding increase in labelled phospholipid. Prior treatment with the antioxidants, superoxide dismutase, catalase or the hydroxyl radical scavenger, mannitol, before the addition of pyocyanin afforded protection against loss of eicosanoid production and restored AA release. We conclude that hydroxyl radicals inhibit one or more steps in the cascade leading to phospholipase A2 activation and release of arachidonic acid from platelet phospholipid stores. AD - Centre for Infectious Diseases and Microbiology, University of Sydney, Westmead Hospital, NSW, Australia. FAU - Muller, M AU - Muller M FAU - Sorrell, T C AU - Sorrell TC LA - eng PT - Journal Article PL - UNITED STATES TA - Prostaglandins JT - Prostaglandins JID - 0320271 RN - 0 (Antioxidants) RN - 0 (Eicosanoids) RN - 0 (Phospholipids) RN - 0 (Reactive Oxygen Species) RN - 3352-57-6 (Hydroxyl Radical) RN - 506-32-1 (Arachidonic Acid) RN - 53-59-8 (NADP) RN - 69-65-8 (Mannitol) RN - 7722-84-1 (Hydrogen Peroxide) RN - 85-66-5 (Pyocyanine) SB - IM MH - Antioxidants/pharmacology MH - Arachidonic Acid/*metabolism MH - Blood Platelets/drug effects/*metabolism MH - Eicosanoids/metabolism MH - Humans MH - Hydrogen Peroxide/chemistry/metabolism MH - Hydroxyl Radical/*metabolism MH - Lipid Peroxidation MH - Mannitol/pharmacology MH - NADP/metabolism MH - *Oxidative Stress MH - Phospholipids/metabolism MH - Pyocyanine/metabolism/pharmacology MH - Reactive Oxygen Species/metabolism EDAT- 1997/07/01 MHDA- 1997/07/01 00:01 AID - S0090698097000609 [pii] PST - ppublish SO - Prostaglandins. 1997 Jul;54(1):493-509. PMID- 9329890 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061030 PUBM- Print IS - 0011-9059 (Print) VI - 36 IP - 8 DP - 1997 Aug TI - Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. PG - 593-8 AB - BACKGROUND: Chemotherapy-induced acral erythema is a distinct localized cutaneous response to certain systemic chemotherapeutic agents. METHODS: Between January 1990 and December 1994, from a total of 76 leukemic patients who have received combination chemotherapy consisting of cytosine arabinoside and anthracycline antibiotics, 15 patients developed chemotherapy-induced acral erythema. Fourteen of the patients had acute myelocytic leukemia, and one of them had chronic myelogenous leukemia in blast phase. Clinical features of these 15 patients have been analysed. Biopsy specimens obtained from eight of the patients were also evaluated for histopathologic alterations. RESULTS: The overall incidence of this reaction was found to be 19.7% in our group of patients receiving this chemotherapy protocol. The onset of reaction varied from the fourth to the seventeenth days of the chemotherapy and resolved within 2 weeks in most of the patients. Lesions appeared as well-defined erythema and edema involving the palmar surfaces in all of the patients. In nine of the patients the reaction recurred with subsequent chemotherapies. Scattered necrotic keratinocytes, vacuolar alterations of the basal layer, and mild to moderate perivascular lymphocytic infiltration in the dermis were the histopathologic findings observed in the biopsy specimens. CONCLUSIONS: Chemotherapy-induced acral erythema is a frequent reaction in patients who are receiving high-dose chemotherapy. For patients in whom this self-limited condition develops, reassurance is the mainstay of therapy. Awareness of this reaction is also important to be able to differentiate it from acute graft versus host disease in patients who receive bone marrow transplants. AD - Department of Dermatology, Marmara University School of Medicine, Istanbul, Turkey. FAU - Demircay, Z AU - Demircay Z FAU - Gurbuz, O AU - Gurbuz O FAU - Alpdogan, T B AU - Alpdogan TB FAU - Yucelten, D AU - Yucelten D FAU - Alpdogan, O AU - Alpdogan O FAU - Kurtkaya, O AU - Kurtkaya O FAU - Bayik, M AU - Bayik M LA - eng PT - Journal Article PL - UNITED STATES TA - Int J Dermatol JT - International journal of dermatology JID - 0243704 RN - 0 (Antibiotics, Antineoplastic) RN - 0 (Antimetabolites, Antineoplastic) RN - 0 (Immunosuppressive Agents) RN - 147-94-4 (Cytarabine) RN - 20830-81-3 (Daunorubicin) RN - 23214-92-8 (Doxorubicin) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Antibiotics, Antineoplastic/adverse effects/therapeutic use MH - Antimetabolites, Antineoplastic/adverse effects/therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols/*adverse effects MH - Cytarabine/adverse effects/therapeutic use MH - Daunorubicin/adverse effects/therapeutic use MH - Doxorubicin/adverse effects/therapeutic use MH - Erythema/*chemically induced/pathology MH - Female MH - Humans MH - Immunosuppressive Agents/adverse effects/therapeutic use MH - Leukemia, Myelocytic, Acute/complications/*drug therapy MH - Leukemia, Myeloid, Chronic/complications/*drug therapy MH - Male MH - Middle Aged MH - Prospective Studies MH - Recurrence EDAT- 1997/08/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Int J Dermatol. 1997 Aug;36(8):593-8. PMID- 9378393 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20041117 PUBM- Print IS - 0017-5749 (Print) VI - 41 IP - 3 DP - 1997 Sep TI - Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. PG - 366-70 AB - BACKGROUND: Many individuals have serum antibodies against Clostridium difficile toxins. Those with an impaired antitoxin response may be susceptible to recurrent, prolonged, or severe C difficile diarrhoea and colitis. AIMS: To examine whether treatment with intravenous immunoglobulin might be effective in patients with severe pseudomembranous colitis unresponsive to standard antimicrobial therapy. PATIENTS: Two patients with pseudomembranous colitis not responding to metronidazole and vancomycin were given normal pooled human immunoglobulin intravenously (200-300 mg/kg). METHODS: Antibodies against C difficile toxins were measured in nine immunoglobulin preparations by ELISA and by cytotoxin neutralisation assay. RESULTS: Both patients responded quickly as shown by resolution of diarrhoea, abdominal tenderness, and distension. All immunoglobulin preparations tested contained IgG against C difficile toxins A and B by ELISA and neutralised the cytotoxic activity of C difficile toxins in vitro at IgG concentrations of 0.4-1.6 mg/ml. CONCLUSION: Passive immunotherapy with intravenous immunoglobulin may be a useful addition to antibiotic therapy for severe, refractory C difficile colitis. IgG antitoxin is present in standard immunoglobulin preparations and C difficile toxin neutralising activity is evident at IgG concentrations which are readily achieved in the serum by intravenous immunoglobulin administration. AD - Section of Gastroenterology, Boston University School of Medicine, Massachusetts, USA. FAU - Salcedo, J AU - Salcedo J FAU - Keates, S AU - Keates S FAU - Pothoulakis, C AU - Pothoulakis C FAU - Warny, M AU - Warny M FAU - Castagliuolo, I AU - Castagliuolo I FAU - LaMont, J T AU - LaMont JT FAU - Kelly, C P AU - Kelly CP LA - eng PT - Case Reports PT - Journal Article PL - ENGLAND TA - Gut JT - Gut JID - 2985108R RN - 0 (Antibodies) RN - 0 (Bacterial Proteins) RN - 0 (Bacterial Toxins) RN - 0 (Enterotoxins) RN - 0 (Immunoglobulin G) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (tcdA protein, Clostridium difficile) RN - 0 (toxB protein, Clostridium difficile) SB - AIM SB - IM MH - Antibodies/analysis MH - *Bacterial Proteins MH - Bacterial Toxins/immunology MH - *Clostridium difficile MH - Enterocolitis, Pseudomembranous/*therapy MH - Enterotoxins/immunology MH - Enzyme-Linked Immunosorbent Assay MH - Female MH - Humans MH - Immunoglobulin G/analysis MH - *Immunoglobulins, Intravenous/chemistry MH - Male MH - Middle Aged EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Gut. 1997 Sep;41(3):366-70. PMID- 9380284 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20061115 PUBM- Print IS - 0375-9393 (Print) VI - 63 IP - 4 DP - 1997 Apr TI - [Precision of drug dilution techniques] PG - 115-8 AB - OBJECT: Evaluation of accuracy of three common dilution methods for drugs. EXPERIMENTAL PLAN: Perspective double blind investigation from March to June 1995. PLACE: Anaesthesia and Resuscitation Service of Children's Hospital of Iglesias (CA). METHODS: Forty dopamine at 2/1000 samples, obtained by dilution of dopamine at 40/1000 on sale with three different methods by five different operators, were analysed with a chromatography system in liquid phase at high pressure. RESULTS: Mean concentration with difference not exceeding 5% from the goal, are considered acceptable. Only one group of samples was found to be into these limits, but it was also the most dangerous for the high percentage of great mistakes in dilution. Although there are significant differences in the accuracy and safety of the three dilution methods, the highest and lowest final concentrations obtained differ very much from those estimated. CONCLUSIONS: It is suggested that drugs confections with proper dilution for different clinical uses might be on sale. AD - Servizio di Anestesia e Rianimazione, Azienda USL n. 7, Ospedale Pediatrico F.lli Crobu, di Iglesias, (Cagliari). FAU - Lai, A AU - Lai A FAU - Silvetti, L AU - Silvetti L FAU - Cossu, F AU - Cossu F FAU - Di Chiara, G AU - Di Chiara G FAU - Tanda, G AU - Tanda G FAU - Frau, R AU - Frau R LA - ita PT - English Abstract PT - Journal Article TT - Precisione dei metodi di diluizione dei farmaci. PL - ITALY TA - Minerva Anestesiol JT - Minerva anestesiologica JID - 0375272 SB - IM MH - *Indicator Dilution Techniques MH - Reproducibility of Results EDAT- 1997/04/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Minerva Anestesiol. 1997 Apr;63(4):115-8. PMID- 9322874 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20060421 PUBM- Print IS - 1043-0342 (Print) VI - 8 IP - 14 DP - 1997 Sep 20 TI - Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. PG - 1715-30 AB - Fanconi Anemia (FA) is a rare genetic disorder characterized by progress pancytopenia, congenial abnormalities, and a predisposition to malignancy. Therapy is currently limited to allogeneic marrow transplantation; patients lacking a suitable donor usually die from aplasia or acute leukemia. Recently, mutation in a novel gene named FACC (Fanconi anemia C-complementing) has been identified as causing one type of FA. FACC mutations, which introduce splicing errors or stop codons, have been identified in approximately 15% of FA patients. We have recently been successful in functional complementation of four FA cell lines using retroviral vectors to transfer a copy of the normal FACC gene. We also analyzed the ability of our viral vectors to functionally correct hematopoietic progenitor cells from a patient bearing a splice donor mutation. As for the lymphoid cell lines, these CD34-enriched cells were extremely sensitive to MMC. After infection of these progenitor cells with viral vectors bearing normal FACC, the progenitors gave rise to increased numbers of colonies both in the absence and presence of up to 5nM MMC, whereas control cells were completely destroyed by 1nM MMC. In summary, we have demonstrated that: (1) retroviral vectors can be engineered to transfer a normal FACC gene to FA(C) lymphoid cell lines and primary hematopoietic cells; (2) introduction of a normal FACC gene into CD34+ progenitors markedly enhances their growth in the absence and presence of MMC. This study is designed to determine whether hematopoietic progenitors transduced with the normal FACC gene can be reinfused safely into FA(C) patients. CD34+ cells obtained from G-CSF mobilized peripheral blood will be transduced ex vivo over a 72-hour period in the presence of IL-3, IL-6, and Stem Cell Factor with the FACC retroviral vector. These transduced cells will be reinfused into FA(C) patients. Patients will be monitored for toxicities as well as evidence of successful gene transfer and expression. The procedure will be repeated up to a total of 4 times with each treatment 2-4 months apart. Theoretically, these rescued stem cells should have a selective growth advantage within the hypoplastic FA marrow environment in vivo. FAU - Liu, J M AU - Liu JM FAU - Young, N S AU - Young NS FAU - Walsh, C E AU - Walsh CE FAU - Cottler-Fox, M AU - Cottler-Fox M FAU - Carter, C AU - Carter C FAU - Dunbar, C AU - Dunbar C FAU - Barrett, A J AU - Barrett AJ FAU - Emmons, R AU - Emmons R LA - eng PT - Clinical Trial PT - Journal Article PL - UNITED STATES TA - Hum Gene Ther JT - Human gene therapy JID - 9008950 RN - 0 (Cell Cycle Proteins) RN - 0 (DNA-Binding Proteins) RN - 0 (FANCC protein, human) RN - 0 (Fanconi Anemia Complementation Group C Protein) RN - 0 (Fanconi Anemia Complementation Group Proteins) RN - 0 (Nuclear Proteins) RN - 0 (Proteins) SB - IM MH - *Cell Cycle Proteins MH - Cell Transplantation MH - Clinical Protocols MH - *DNA-Binding Proteins MH - Fanconi Anemia/*therapy MH - Fanconi Anemia Complementation Group C Protein MH - Fanconi Anemia Complementation Group Proteins MH - Gene Therapy/methods MH - *Gene Transfer Techniques MH - Genetic Vectors/genetics MH - *Hematopoietic Stem Cells MH - Humans MH - *Nuclear Proteins MH - Pilot Projects MH - Proteins/*genetics MH - Retroviridae/genetics EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 PST - ppublish SO - Hum Gene Ther. 1997 Sep 20;8(14):1715-30. PMID- 9350014 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20041117 PUBM- Print IS - 0024-7758 (Print) VI - 42 IP - 10 DP - 1997 Oct TI - Serum CA-125 measurements > 65 U/mL. Clinical value. PG - 617-24 AB - OBJECTIVE: To review the prevalence of various conditions associated with serum CA-125 values > 65 U/mL, to calculate the odds ratios of different ranges of high CA-125 in predicting cancer and to study the effect of menopause and the presence of a mass on the predictive value of high serum CA-125. STUDY DESIGN: A retrospective review of the diagnoses in 313 consecutive women seen at the Cleveland Clinic Foundation whose serum CA-125 was > 65 U/mL was performed. Statistical analysis was performed using crosstabulation, chi 2, Fisher's exact test and the odds ratio. RESULTS: In patients with serum CA-125 > 65 U/mL, gynecologic cancers, nongynecologic cancers and non-malignant conditions constituted 74.3%, 10.2% and 13.1% of diagnoses, respectively. In patients with serum CA-125 > or = 1,000 U/mL, the same conditions were responsible for 89%, 7% and 3% of diagnoses, respectively. Endometriosis and metastatic breast cancer were the most common benign condition and nongynecologic cancer associated with serum CA-125 > 65 U/mL. The presence of an abdominopelvic mass significantly increased the risk of malignancy (P < .00005). Approximately 90% of patients with CA-125 > 65 U/mL and no mass had nonmalignant disease. The diagnoses of serum CA-125 values > 65 U/mL varied significantly in premenopausal versus postmenopausal patients. Postmenopausal patients had a higher incidence of gynecologic (P = .002) and nongynecologic (P = .0008) cancers and lower incidence of benign conditions (P < .0005). The odds ratio that CA-125 levels were associated with cancer increased as the level of CA-125 increased. The odds ratio of malignant versus benign disease was significantly higher in post-menopausal patients for all intervals of CA-125 levels until the level of > or = 1,000 U/mL was reached. CONCLUSION: In patients seen at a tertiary center, serum CA-125 measurements > 65 U/mL were associated with nonmalignant conditions in 13% of patients. Although higher serum CA-125 levels were more associated with gynecologic malignancies, no level of CA-125 occurred exclusively with gynecologic cancers. In postmenopausal patients with serum CA-125 values > 65 U/mL and in patients with serum CA-125 values > 65 U/mL and an abdominopelvic mass, subspecialty consultation should be considered before proceeding to surgery. AD - Department of Gynecology, Cleveland Clinic Foundation, Ohio, USA. FAU - Eltabbakh, G H AU - Eltabbakh GH FAU - Belinson, J L AU - Belinson JL FAU - Kennedy, A W AU - Kennedy AW FAU - Gupta, M AU - Gupta M FAU - Webster, K AU - Webster K FAU - Blumenson, L E AU - Blumenson LE LA - eng PT - Journal Article PL - UNITED STATES TA - J Reprod Med JT - The Journal of reproductive medicine JID - 0173343 RN - 0 (CA-125 Antigen) SB - IM CIN - J Reprod Med. 1998 Jul;43(7):635-6. PMID: 9693414 MH - Adult MH - Aged MH - Aged, 80 and over MH - CA-125 Antigen/*blood MH - Endometriosis/blood MH - Female MH - Genital Neoplasms, Female/*blood MH - Heart Failure, Congestive/blood MH - Humans MH - Liver Cirrhosis/blood MH - Middle Aged MH - Ovarian Neoplasms/blood MH - Peritoneal Neoplasms/blood MH - Postmenopause MH - Reference Values MH - Retrospective Studies EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - J Reprod Med. 1997 Oct;42(10):617-24. PMID- 9306294 OWN - NLM STAT- MEDLINE DA - 19971104 DCOM- 19971104 LR - 20041117 PUBM- Print IS - 0022-3956 (Print) VI - 31 IP - 3 DP - 1997 May-Jun TI - Physiological and behavioral responses to minor stressors in offspring of patients with panic disorder. PG - 365-76 AB - Nineteen children born to patients with panic disorder and a comparison group of 16 children born to unaffected, non-psychiatric patient subjects exposed to novel and mildly stressful situations (visiting an unfamiliar place and watching a movie containing anxiogenic scenes) were assessed for their behaviors, heart rate, respiratory rate and salivary cortisol secretion. At arrival children born to patients with panic disorder had significantly longer latency of first spontaneous verbal comment, fewer prosocial behavior, and increased distress and attachment behavior. During the projection of the movie, children of the two groups differed for attachment, distress, and exploration behaviors. During the anxiogenic scenes children born to patients with panic disorder showed increased behavioral inhibition and higher heart rate. Autonomic modulation, respiratory rates and cortisol secretion were similar in the two groups. Some distinct psychophysiological patterns may constitute early manifestations of the transmitted liability to panic disorder. AD - Istituto Scientifico H S. Raffaele, Department of Neuropsychiatric Sciences, University of Milan School of Medicine, Italy. FAU - Battaglia, M AU - Battaglia M FAU - Bajo, S AU - Bajo S FAU - Strambi, L F AU - Strambi LF FAU - Brambilla, F AU - Brambilla F FAU - Castronovo, C AU - Castronovo C FAU - Vanni, G AU - Vanni G FAU - Bellodi, L AU - Bellodi L LA - eng PT - Journal Article PL - ENGLAND TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 RN - 50-23-7 (Hydrocortisone) SB - IM MH - Adaptation, Psychological/physiology MH - Arousal/*genetics/physiology MH - Autonomic Nervous System/physiopathology MH - Child MH - Child of Impaired Parents/*psychology MH - Child, Preschool MH - Female MH - Heart Rate/genetics/physiology MH - Humans MH - Hydrocortisone/metabolism MH - Male MH - Panic Disorder/*genetics/physiopathology/psychology MH - Personality Assessment MH - Reference Values MH - Respiration/genetics/physiology MH - Risk Factors MH - Saliva/metabolism MH - Social Behavior MH - Stress, Psychological/*complications EDAT- 1997/05/01 00:00 MHDA- 1997/11/05 00:01 AID - S0022-3956(97)00003-4 [pii] PST - ppublish SO - J Psychiatr Res. 1997 May-Jun;31(3):365-76. PMID- 9305762 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20061115 PUBM- Print IS - 0378-1119 (Print) VI - 195 IP - 2 DP - 1997 Aug 22 TI - Rice lipid transfer protein (LTP) genes belong to a complex multigene family and are differentially regulated. PG - 177-86 AB - Several cDNA clones encoding three different lipid transfer proteins (LTPs) have been isolated from rice (Oryza sativa L.) in order to analyse the complexity, the evolution and the expression of the LTP gene family. The mature proteins deduced from three clones exhibited a molecular mass of 9 kDa, in agreement with the molecular mass of other LTPs from plants. The clones were shown to be homologous in the coding region, while the 3' non-coding regions diverged strongly between the clones. The occurrence of at least three small multigene families encoding these proteins in rice was confirmed by Southern blot analysis. When compared with each other and with LTPs from other plants, the cluster including rice LTPs and other cereal LTPs indicated that these genes duplicated rather recently and independently in the different plant phyla. The expression pattern of each gene family was also investigated. Northern blot experiments demonstrated that they are differentially regulated in the different tissues analysed. Components such as salt, salicylic acid and abscisic acid were shown to modulate Ltp gene expression, depending on tissues and gene classes, suggesting a complex regulation of these genes. AD - Laboratoire de Physiologie Cellulaire et Moleculaire, URA CNRS 1180, Universite de Paris VI, France. FAU - Vignols, F AU - Vignols F FAU - Wigger, M AU - Wigger M FAU - Garcia-Garrido, J M AU - Garcia-Garrido JM FAU - Grellet, F AU - Grellet F FAU - Kader, J C AU - Kader JC FAU - Delseny, M AU - Delseny M LA - eng SI - GENBANK/X83433 SI - GENBANK/X83434 SI - GENBANK/X83435 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - Gene JT - Gene JID - 7706761 RN - 0 (Antigens, Plant) RN - 0 (Carrier Proteins) RN - 0 (DNA, Plant) RN - 0 (Plant Proteins) RN - 0 (Salicylic Acids) RN - 0 (lipid transfer proteins, plant) RN - 21293-29-8 (Abscisic Acid) RN - 69-72-7 (Salicylic Acid) RN - 7647-14-5 (Sodium Chloride) SB - IM MH - Abscisic Acid/pharmacology MH - Amino Acid Sequence MH - Antigens, Plant MH - Base Sequence MH - Carrier Proteins/*genetics/metabolism MH - Chromosome Mapping MH - Cloning, Molecular MH - DNA, Plant/genetics MH - *Gene Expression Regulation, Plant MH - Genes, Plant MH - Molecular Sequence Data MH - Oryza sativa/*genetics/metabolism MH - Phylogeny MH - Plant Proteins MH - Salicylic Acid MH - Salicylic Acids/pharmacology MH - Sequence Alignment MH - Sequence Analysis, DNA MH - Sequence Homology, Amino Acid MH - Sodium Chloride/pharmacology EDAT- 1997/08/22 00:00 MHDA- 1997/09/26 00:01 AID - S0378-1119(97)00137-6 [pii] PST - ppublish SO - Gene. 1997 Aug 22;195(2):177-86. PMID- 9382350 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0302-4342 (Print) VI - 47 IP - 2 DP - 1997 Aug TI - [Risk factors in retinopathy of prematurity] PG - 172-6 AB - OBJECTIVE: The objective of this study was to determine the potential risk factors in acute retinopathy of prematurity (ROP). PATIENTS AND METHODS: A retrospective study of preterm infants with birth weights less than 1,501 g, or more if mechanical ventilation and oxygen administration were needed, was carried out. Indirect ophthalmoscopy (mydriasis) with indentation was done every 15 days from the fourth week. Fifteen factors were analyzed. Statistically significant differences between the groups with and without ROP were sought with Fisher's exact probability test, two-sample t-test, and the chi-square contingency-table. A logistic regression was done. RESULTS: Thirty-six of the 137 infants examined (26.2%) with birth weight < or = 1,500 g had acute ROP. Only 7.1% of the infants with birth weights > or = 1,501 g had retinopathy. There were significant differences (p < 0.05) in the following variables: birth weight, gestational age, blood transfusion, mechanical ventilation, FiO2 (fraction inspired oxygen) maximum, time of FiO2 > or = 0.60 (hours) and time of FiO2 > or = 0.21 (days). However, the birth-weight was the only independent risk factor related to ROP. CONCLUSIONS: Retinopathy of the premature has a multifactorial etiology. The low gestational age and the oxygen had influence on ROP; however, low birth weight was the independent risk factor. AD - Servicio de Oftalmologia, Hospital Son Dureta, Palma de Mallorca. FAU - Olea Vallejo, J L AU - Olea Vallejo JL FAU - Corretger Ruhi, F J AU - Corretger Ruhi FJ FAU - Salvat Serra, M AU - Salvat Serra M FAU - Frau Rotger, E AU - Frau Rotger E FAU - Galiana Ferre, C AU - Galiana Ferre C FAU - Fiol Jaume, M AU - Fiol Jaume M LA - spa PT - Comparative Study PT - English Abstract PT - Journal Article TT - Factores de riesgo en la retinopatia del prematuro. PL - SPAIN TA - An Esp Pediatr JT - Anales espanoles de pediatria JID - 0420463 SB - IM MH - Female MH - Humans MH - Infant, Newborn MH - Male MH - Oxygen Inhalation Therapy MH - Retinopathy of Prematurity/diagnosis/*epidemiology/therapy MH - Retrospective Studies MH - Risk Factors EDAT- 1997/08/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - An Esp Pediatr. 1997 Aug;47(2):172-6. PMID- 9376273 OWN - NLM STAT- MEDLINE DA - 19971112 DCOM- 19971112 LR - 20060424 PUBM- Print IS - 0007-0920 (Print) VI - 76 IP - 8 DP - 1997 TI - Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. PG - 1099-105 AB - Between 1984 and 1990, 94 women presenting to the Edinburgh Breast Unit with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) were given preoperative systemic therapy. Initially, all women received hormone therapy, with CHOP (cyclophosphamide 1 g m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2) to a maximum of 2 mg and prednisolone 40 mg per day orally for 5 days) chemotherapy being administered to those who failed to respond by 3 months. After April 1987, first-line hormone therapy was only offered to women with oestrogen receptor (ER)-moderate/-rich (> 20 fmol mg(-1) protein) tumours, and CHOP was reserved for those women whose tumours failed to respond to hormone therapy and for those with ER-negative/-poor tumours. Response data have been published previously (Anderson et al, 1991). After a median follow-up of 7.5 years, there is no difference in survival between those women given initial hormone therapy and those given chemotherapy, with neither group having yet reached its median survival. The two key factors that predicted for a poor survival were the number of involved axillary nodes after preoperative systemic therapy (P < 0.00001) and a lack of response to preoperative therapy (P < 0.05). These data suggest that many women with ER-moderate/-rich tumours will have a good prognosis after preoperative hormone therapy alone. However, it is possible to identify, by their post-systemic therapy axillary node status, a group of women who still have an appalling prognosis after preoperative chemotherapy or hormone therapy. AD - ICRF Medical Oncology Unit, Western General Hospital, Edinburgh, UK. FAU - Cameron, D A AU - Cameron DA FAU - Anderson, E D AU - Anderson ED FAU - Levack, P AU - Levack P FAU - Hawkins, R A AU - Hawkins RA FAU - Anderson, T J AU - Anderson TJ FAU - Leonard, R C AU - Leonard RC FAU - Forrest, A P AU - Forrest AP FAU - Chetty, U AU - Chetty U LA - eng PT - Clinical Trial PT - Journal Article PL - SCOTLAND TA - Br J Cancer JT - British journal of cancer JID - 0370635 RN - 0 (CHOP protocol) RN - 10540-29-1 (Tamoxifen) RN - 125-84-8 (Aminoglutethimide) RN - 23214-92-8 (Doxorubicin) RN - 50-18-0 (Cyclophosphamide) RN - 50-23-7 (Hydrocortisone) RN - 53-03-2 (Prednisone) RN - 566-48-3 (formestane) RN - 57-22-7 (Vincristine) RN - 63-05-8 (Androstenedione) RN - 65807-02-5 (Goserelin) SB - IM MH - Adult MH - Aged MH - Aminoglutethimide/administration & dosage MH - Androstenedione/administration & dosage/analogs & derivatives MH - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use MH - Axilla MH - Breast Neoplasms/drug therapy/surgery/*therapy MH - Combined Modality Therapy MH - Cyclophosphamide/administration & dosage MH - Doxorubicin/administration & dosage MH - Female MH - Follow-Up Studies MH - Goserelin/administration & dosage MH - Humans MH - Hydrocortisone/administration & dosage MH - Lymphatic Metastasis MH - Middle Aged MH - Neoplasms, Hormone-Dependent/drug therapy/surgery/*therapy MH - Ovariectomy MH - Prednisone/administration & dosage MH - Preoperative Care MH - Tamoxifen/administration & dosage MH - Treatment Outcome MH - Vincristine/administration & dosage EDAT- 1997/01/01 00:00 MHDA- 1997/11/04 00:01 PST - ppublish SO - Br J Cancer. 1997;76(8):1099-105. PMID- 9376966 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20051116 PUBM- Print IS - 1052-5149 (Print) VI - 7 IP - 3 DP - 1997 Aug TI - Central nervous system opportunistic infections. PG - 513-25 AB - The spectrum of opportunistic infections occurring in association with human-immunodeficiency virus, type 1, is very broad. These infections develop most frequently in the setting of advanced immunosuppression. There is no part of the neuraxis that is immune to these complications and the concurrence of more than one infectious illness may always be considered. The neuroimaging features, when coupled with the clinical and laboratory findings, often suggest the correct diagnosis and enable the physician to initiate therapy. AD - Department of Neurology, University of Kentucky College of Medicine, Lexington, USA. FAU - Wright, D AU - Wright D FAU - Schneider, A AU - Schneider A FAU - Berger, J R AU - Berger JR LA - eng PT - Journal Article PT - Review PL - UNITED STATES TA - Neuroimaging Clin N Am JT - Neuroimaging clinics of North America JID - 9211377 SB - IM SB - X MH - AIDS-Related Opportunistic Infections/*diagnosis/therapy MH - Brain Diseases/*diagnosis/microbiology/therapy/virology MH - Cytomegalovirus Infections/diagnosis MH - Deltaretrovirus Infections/diagnosis MH - *HIV-1 MH - Herpes Simplex/diagnosis MH - Herpes Zoster/diagnosis MH - Humans MH - Immune Tolerance MH - Immunocompromised Host MH - Leukoencephalopathy, Progressive Multifocal/diagnosis/virology MH - Meningitis, Cryptococcal/diagnosis MH - Mycobacterium Infections/diagnosis MH - Mycoses/diagnosis MH - Neurosyphilis/diagnosis MH - Toxoplasmosis, Cerebral/diagnosis RF - 106 EDAT- 1997/08/01 00:00 MHDA- 1997/10/23 00:01 PST - ppublish SO - Neuroimaging Clin N Am. 1997 Aug;7(3):513-25. PMID- 9332524 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20041117 PUBM- Print IS - 1058-4838 (Print) VI - 25 IP - 2 DP - 1997 Aug TI - Histoplasmosis and kidney disease in patients with AIDS. PG - 281-4 AB - Renal disease in patients infected with human immunodeficiency virus (HIV) often presents with significant proteinuria and progressive renal failure; focal glomerulosclerosis is the most common renal pathology identified. To our knowledge, we report the first case of nephrotic-range proteinuria and preserved renal function in an HIV-infected patient in association with disseminated histoplasmosis. The initial level of proteinuria was 12.5 g/24 h. The patient developed a concomitant lesion on his neck, which was biopsied and identified as Histoplasma capsulatum by fungal stains and culture. The serum CF titer of antibody against yeast antigens of H. capsulatum was 1:8. The level of serum albumin decreased to 2.0 g/dL, and the level of serum cholesterol increased to 284 mg/dL. Immunohistochemical staining of renal biopsy tissue demonstrated immune complexes within the mesangium; H. capsulatum antigen was also demonstrated in the mesangium. Therapy with oral itraconazole resulted in marked clinical improvement. The findings in this case emphasize the need to rule out treatable causes of the nephrotic syndrome in AIDS, especially in cases of immune-complex glomerulonephritis. AD - Department of Medicine, Case Western Reserve University, University Hospitals of Cleveland, Ohio 44106-5083, USA. FAU - Burke, D G AU - Burke DG FAU - Emancipator, S N AU - Emancipator SN FAU - Smith, M C AU - Smith MC FAU - Salata, R A AU - Salata RA LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (Antibodies, Fungal) RN - 0 (Antifungal Agents) RN - 0 (Antigen-Antibody Complex) RN - 0 (Serum Albumin) RN - 57-88-5 (Cholesterol) RN - 84625-61-6 (Itraconazole) SB - IM SB - X MH - AIDS-Related Opportunistic Infections/*microbiology MH - Administration, Oral MH - Antibodies, Fungal/analysis/blood MH - Antifungal Agents/administration & dosage/therapeutic use MH - Antigen-Antibody Complex/analysis MH - Biopsy MH - Cholesterol/analysis/blood MH - Diagnosis, Differential MH - Glomerulonephritis, Membranoproliferative/*diagnosis/microbiology MH - Histoplasmosis/*complications/drug therapy/immunology MH - Humans MH - Immunohistochemistry MH - Itraconazole/administration & dosage/therapeutic use MH - Kidney/immunology/pathology MH - Male MH - Middle Aged MH - Proteinuria/*diagnosis/microbiology MH - Serum Albumin/analysis EDAT- 1997/08/01 00:00 MHDA- 1997/10/23 00:01 PST - ppublish SO - Clin Infect Dis. 1997 Aug;25(2):281-4. PMID- 9341963 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20051116 PUBM- Print IS - 0923-7534 (Print) VI - 8 Suppl 3 DP - 1997 TI - Current strategies for pain control. PG - S21-4 AB - Pain is the most feared symptom for patients diagnosed with cancer. Although our understanding of cancer pain and its management has greatly improved in the past decade, an unacceptably large proportion of patients still do not receive adequate pain relief. Before commencing any form of treatment, patients must receive a thorough assessment in order to define the pain, causes and severity. The recommendations for progressing a patient from step 2 to step 3 of the WHO analgesic ladder are discussed here as well as the choice of strong opioid substitution. An overview of the benefits of considering alternative routes of administering strong opioids, such as the transdermal delivery of fentanyl (TTS fentanyl), and the use of opioid substitution in patients intolerant to the adverse effects of morphine are also included. Finally, newer approaches to relieving refractory pain, such as neuropathic and bone pain, are considered. AD - Department of Surgical and Anaesthetic Sciences, Royal Hallamshire Hospital, Sheffield, UK. FAU - Ahmedzai, S AU - Ahmedzai S LA - eng PT - Journal Article PT - Review PL - NETHERLANDS TA - Ann Oncol JT - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO JID - 9007735 RN - 0 (Analgesics, Non-Narcotic) RN - 0 (Analgesics, Opioid) RN - 437-38-7 (Fentanyl) SB - IM MH - Analgesics, Non-Narcotic/therapeutic use MH - Analgesics, Opioid/*therapeutic use MH - Bone Neoplasms/physiopathology MH - Fentanyl/*administration & dosage MH - Humans MH - Neoplasms/*physiopathology MH - Pain/*drug therapy MH - *Pain Measurement RF - 28 EDAT- 1997/01/01 00:00 MHDA- 1997/10/28 00:01 PST - ppublish SO - Ann Oncol. 1997;8 Suppl 3:S21-4. PMID- 9339616 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20041117 PUBM- Print IS - 0030-9982 (Print) VI - 47 IP - 8 DP - 1997 Aug TI - Prevalence and severity of viral hepatitis in Pakistani pregnant women: a five year hospital based study. PG - 198-201 AB - A hospital based observational study was carried out on pregnant women presenting with either acute hepatitis or fulminant hepatic failure (FHF), during the past years. Of 53 patients, 20 (38%) developed FHF.Non-A, Non-B was the commonest cause (62%) followed by hepatitis B in 17% and hepatitis A in 4% cases. Eight women expired (case fatality rate 15%) with a high maternal mortality (62%) caused by NANB hepatitis. Perinatal mortality was 30%. Poor prognostic factors identified were lack of antenatal care, severity of jaundice, history of somnolence, gastrointestinal bleeding and a high grade of encephalopathy. AD - Department of Obstetrics and Gynaecology, Aga Khan University Hospital, Karachi. FAU - Aziz, A B AU - Aziz AB FAU - Hamid, S AU - Hamid S FAU - Iqbal, S AU - Iqbal S FAU - Islam, W AU - Islam W FAU - Karim, S A AU - Karim SA LA - eng PT - Journal Article PL - PAKISTAN TA - J Pak Med Assoc JT - JPMA. The Journal of the Pakistan Medical Association JID - 7501162 SB - IM MH - Adult MH - Female MH - Hepatic Encephalopathy/epidemiology/etiology MH - Hepatitis, Viral, Human/complications/*epidemiology MH - Humans MH - Pakistan/epidemiology MH - Pregnancy MH - Pregnancy Complications, Infectious/*epidemiology MH - Prevalence EDAT- 1997/08/01 00:00 MHDA- 1997/10/27 00:01 PST - ppublish SO - J Pak Med Assoc. 1997 Aug;47(8):198-201. PMID- 9323036 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20061115 PUBM- Print IS - 0014-5793 (Print) VI - 414 IP - 3 DP - 1997 Sep 15 TI - Cloning and expression in Escherichia coli of a human gelatinase B-inhibitory single-chain immunoglobulin variable fragment (scFv). PG - 562-6 AB - The murine monoclonal antibody REGA-3G12 selectively and specifically inhibits the activity of human gelatinase B. The cDNA fragments which encode the variable regions of the light and heavy chains were isolated by PCR-mediated cloning and sequenced. Single-chain Fv expression constructs for Escherichia coli were generated in which c-myc tag sequences were encoded. Inducible expression of the scFv and secretion to the periplasm were obtained with higher yields when the c-myc tag sequence was positioned at the amino-terminal side. The inhibitory activity of purified scFv on neutrophil gelatinase B was tested in a gelatin degradation assay and it was found to possess a similar specific activity as that of the intact monoclonal antibody and of the pepsin-clipped F(ab')2 derivative. This shows for the first time that inhibition of soluble enzymes with scFv is possible and opens new perspectives for the treatment of diseases with excessive and detrimental enzyme production in the host. AD - Laboratory of Molecular Immunology, Rega Institute for Medical Research, University of Leuven, Belgium. FAU - Zhou, N AU - Zhou N FAU - Paemen, L AU - Paemen L FAU - Opdenakker, G AU - Opdenakker G FAU - Froyen, G AU - Froyen G LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NETHERLANDS TA - FEBS Lett JT - FEBS letters JID - 0155157 RN - 0 (Immunoglobulin Fragments) RN - 0 (Immunoglobulin Variable Region) RN - 0 (Recombinant Proteins) RN - EC 3.4.24.- (Collagenases) RN - EC 3.4.24.35 (Matrix Metalloproteinase 9) SB - IM MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Cloning, Molecular MH - Collagenases/*antagonists & inhibitors MH - Escherichia coli/*genetics MH - Humans MH - Immunoglobulin Fragments/*genetics/metabolism/*pharmacology MH - Immunoglobulin Variable Region/*genetics/metabolism/pharmacology MH - Matrix Metalloproteinase 9 MH - Mice MH - Molecular Sequence Data MH - Recombinant Proteins/genetics/metabolism MH - Sequence Analysis EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 AID - S0014-5793(97)01072-7 [pii] PST - ppublish SO - FEBS Lett. 1997 Sep 15;414(3):562-6. PMID- 9337362 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20041117 PUBM- Print IS - 0735-6757 (Print) VI - 15 IP - 6 DP - 1997 Oct TI - Emergency extracorporeal life support for patients with near-fatal status asthmaticus. PG - 566-9 AB - Extracorporeal life support (ECLS) was used to treat three patients with near-fatal status asthmaticus who did not respond to aggressive medical therapies and mechanical ventilation under controlled permissive hypercapnia. ECLS was instituted in patient 1 because PaCO2 was excessively high and pH was excessively low, in patient 2 because hypoxemia and shock were not responsive to treatment, and in patient 3 because of sustained severe hypotension. ECLS supported adequate gas exchange until pulmonary function improved, diminishing the need for mechanical ventilation and preventing pulmonary complications. Pulmonary dysfunction improved markedly after only 21 to 86 hours of ECLS. Aggressive medical treatments were continued during ECLS. Our findings indicate that ECLS is a useful method for preventing death in patients with near-fatal status asthmaticus. AD - Division of Intensive and Critical Care Medicine, Kumamoto University School of Medicine, Japan. FAU - Kukita, I AU - Kukita I FAU - Okamoto, K AU - Okamoto K FAU - Sato, T AU - Sato T FAU - Shibata, Y AU - Shibata Y FAU - Taki, K AU - Taki K FAU - Kurose, M AU - Kurose M FAU - Terasaki, H AU - Terasaki H FAU - Kohrogi, H AU - Kohrogi H FAU - Ando, M AU - Ando M LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 SB - IM MH - Adolescent MH - Adult MH - Algorithms MH - Blood Gas Analysis MH - Decision Trees MH - Emergencies MH - Extracorporeal Membrane Oxygenation/*methods MH - Female MH - Humans MH - Life Support Care/*methods MH - Lung Compliance MH - Middle Aged MH - Pulmonary Gas Exchange MH - Respiration, Artificial MH - Status Asthmaticus/physiopathology/*therapy EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0735-6757(97)90158-3 [pii] PST - ppublish SO - Am J Emerg Med. 1997 Oct;15(6):566-9. PMID- 9323783 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20061115 PUBM- Print IS - 0281-3432 (Print) VI - 15 IP - 3 DP - 1997 Sep TI - The prevalence of beta-haemolytic streptococci in throat specimens from healthy children and adults. Implications for the clinical value of throat cultures. PG - 149-55 AB - OBJECTIVE: To examine the influence of age and season of the year on the carrier rate of beta-haemolytic streptococci (BHS) in healthy individuals and patients with throat pain. DESIGN: The prevalence of BHS in throat specimens from healthy individuals was compared with that from patients with throat pain of the same age in a defined geographical area, collected during the same mid-winter and late summer periods. RESULTS: The prevalence of BHS in healthy individuals was low before the age of 3 years (1.9-7.1%) and in adults > or = 16 years (2.4-3.7%) and highest in the age group 3-15 years (5.0-21.2%). The difference in prevalence of BHS between healthy individuals and patients with throat pain was small during the late summer season and large during the mid-winter season. CONCLUSION: Prevalence of BHS varies with age and season in healthy individuals and patients with throat pain. During the summer, it is much more difficult to interpret the result of a throat culture in individuals aged < 16 years. AD - Department of Primary Health Care, Goteborg University, Sweden. FAU - Gunnarsson, R K AU - Gunnarsson RK FAU - Holm, S E AU - Holm SE FAU - Soderstrom, M AU - Soderstrom M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - NORWAY TA - Scand J Prim Health Care JT - Scandinavian journal of primary health care JID - 8510679 SB - IM MH - Adolescent MH - Adult MH - Age Factors MH - Carrier State/epidemiology/*microbiology MH - Child MH - Child Day Care Centers MH - Child, Preschool MH - Humans MH - Infant MH - Pharyngitis/*microbiology MH - Pharynx/*microbiology MH - Prevalence MH - Prospective Studies MH - Seasons MH - Serotyping MH - Streptococcal Infections/*microbiology MH - Streptococcus pyogenes/classification/growth & development/*isolation & purification EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Scand J Prim Health Care. 1997 Sep;15(3):149-55. PMID- 9344868 OWN - NLM STAT- MEDLINE DA - 19971117 DCOM- 19971117 LR - 20061115 PUBM- Print IS - 0006-291X (Print) VI - 239 IP - 2 DP - 1997 Oct 20 TI - High pressure modulation of Escherichia coli DNA gyrase activity. PG - 552-6 AB - Elevated pressures greater than 551 bar were found to inhibit the DNA supercoiling activity of Escherichia coli DNA gyrase. A large fraction of the inhibitory effect could be reproduced by preincubation of the enzyme at high pressure prior to enzymatic assay at 1 bar. It is proposed that elevated pressure influences gyrase structure, most likely by promoting the dissociation of its subunits, however, it is also possible that effects on enzyme activity exist. CI - Copyright 1997 Academic Press. AD - Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, La Jolla, California 92093, USA. FAU - Chilukuri, L N AU - Chilukuri LN FAU - Fortes, P A AU - Fortes PA FAU - Bartlett, D H AU - Bartlett DH LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - UNITED STATES TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (DNA, Superhelical) RN - EC 5.99.1.3 (DNA Topoisomerases, Type II) SB - IM MH - *Atmospheric Pressure MH - DNA Topoisomerases, Type II/*metabolism MH - DNA, Superhelical/metabolism MH - Electrophoresis, Agar Gel MH - Enzyme Activation MH - Escherichia coli/*enzymology MH - Plasmids/metabolism MH - Substrate Specificity EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0006-291X(97)97503-3 [pii] AID - 10.1006/bbrc.1997.7503 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 1997 Oct 20;239(2):552-6. PMID- 9323782 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20041117 PUBM- Print IS - 0281-3432 (Print) VI - 15 IP - 3 DP - 1997 Sep TI - Enterobius vermicularis and finger sucking in young Swedish children. PG - 146-8 AB - OBJECTIVE: To study the prevalence of Enterobius vermicularis and its association with finger sucking in young Swedish children. DESIGN: Cross-sectional survey with a questionnaire for symptoms of infestation with Enterobius vermicularis, and the children's habit of finger sucking (including fingernail biting). Perianal tape-test for identification of eggs of Enterobius vermicularis. SETTING: Primary care, day-care centres, and schools in a Swedish middle-sized town (approx. 80,000 inhabitants). PARTICIPANTS: 172 children of both sexes, 4-10 years old. MAIN OUTCOME MEASURES: The prevalence of Enterobius vermicularis and its association with finger sucking. RESULTS: 21% of the children were symptom-free carriers of Enterobius vermicularis, and finger sucking was strongly associated with a positive tape-test (p = 0.01). CONCLUSION: More children than previously known seemed to be symptom-free carriers of Enterobius vermicularis. Finger sucking should be considered when treating infested children and especially those with relapsing symptoms. AD - Primary Care Centre Hertig Knut, Central Hospital, Halmstad, Sweden. FAU - Herrstrom, P AU - Herrstrom P FAU - Fristrom, A AU - Fristrom A FAU - Karlsson, A AU - Karlsson A FAU - Hogstedt, B AU - Hogstedt B LA - eng PT - Journal Article PL - NORWAY TA - Scand J Prim Health Care JT - Scandinavian journal of primary health care JID - 8510679 SB - IM MH - Animals MH - Child MH - Child, Preschool MH - Enterobiasis/diagnosis/*epidemiology/prevention & control/*transmission MH - *Enterobius MH - Female MH - *Fingersucking MH - Humans MH - Male MH - Mass Screening MH - Prevalence MH - Sweden/epidemiology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Scand J Prim Health Care. 1997 Sep;15(3):146-8. PMID- 9327226 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20051117 PUBM- Print IS - 1040-8746 (Print) VI - 9 IP - 5 DP - 1997 Sep TI - Advances in gynecologic radiation oncology. PG - 471-7 AB - Radiation therapy is an important modality in the curative and palliative management of patients with gynecologic malignancies. However, the specific roles of radiation therapy continue to evolve in terms of specific indications, volumes treated, techniques, and integration with other modalities. Retrospective assessments of outcome and prospective clinical trials are necessary to answer questions, generate additional hypotheses, and guide further refinements in the application of radiation therapy. This article focuses on recent literature and ongoing clinical trials in this disease group. AD - Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis 46202, USA. FAU - Woodburn, R AU - Woodburn R FAU - Randall, M E AU - Randall ME LA - eng PT - Journal Article PL - UNITED STATES TA - Curr Opin Oncol JT - Current opinion in oncology JID - 9007265 RN - 0 (Antineoplastic Agents) SB - IM MH - Antineoplastic Agents/therapeutic use MH - Combined Modality Therapy MH - Female MH - Genital Neoplasms, Female/*radiotherapy/surgery MH - Humans MH - Ovarian Neoplasms/radiotherapy MH - Uterine Cervical Neoplasms/radiotherapy MH - Uterine Neoplasms/radiotherapy MH - Vaginal Neoplasms/radiotherapy MH - Vulvar Neoplasms/radiotherapy EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Curr Opin Oncol. 1997 Sep;9(5):471-7. PMID- 9344556 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20031114 PUBM- Print IS - 0014-4886 (Print) VI - 147 IP - 2 DP - 1997 Oct TI - GABA and glutamate levels in the substantia nigra reticulata following repetitive cerebral ischemia in gerbils. PG - 311-5 AB - Repetitive cerebral ischemia produces more severe damage than a similar single duration insult. We have previously shown that, in gerbils, damage in the substantia nigra reticulata (SNr) is seen with repetitive insults rather than a single insult. We have also shown that there is a progressive decrease in the extracellular GABA in the striatum in the days preceding such damage, speculating that a loss of GABA may be in part responsible for this damage. This study evaluates the GABA levels in the SNr in animals exposed to repetitive ischemic insults. Each animal received a total of three ischemic insults of 3-min duration at hourly intervals. In vivo microdialysis was carried out to analyze the GABA and glutamate dialysate levels on Days 1, 3, 5, 7, and 14 following the ischemic insult. In the control and treated (ischemic) animals, there was a significant increase in the GABA levels with the introduction of nipecotic acid on Days 1, 3, 5, and 14. However, on Day 7 there was a significant attenuation in the GABA response to nipecotic acid in the treated animals in comparison to the controls. The glutamate levels in the treated animals were similar to the control animals on Days 1, 3, 5, and 7. However, on Day 14 the glutamate levels were significantly lower than on previous days. Our experiments for the first time measure extracellular glutamate and GABA responses in the SNr in animals exposed to repetitive ischemic insults. Our experiments show that there is a significant decrease in the GABA concentrations at a time when ischemic damage is developing in this region. This confirms our hypothesis that a decrease in GABA may be one factor contributing to neuronal damage during the period following repetitive ischemic insults. Further, the rebound increase in GABA levels on Day 14 with a concomitant fall in glutamate levels would indicate that reparative processes are still active in the 2 weeks following the insult. AD - Department of Medicine, and Saskatchewan Stroke Research Centre, University of Saskatchewan, Saskatoon, Canada. FAU - Shuaib, A AU - Shuaib A FAU - Ijaz, M S AU - Ijaz MS FAU - Miyashita, H AU - Miyashita H FAU - Hussain, S AU - Hussain S FAU - Kanthan, R AU - Kanthan R LA - eng PT - Journal Article PL - UNITED STATES TA - Exp Neurol JT - Experimental neurology JID - 0370712 RN - 56-12-2 (gamma-Aminobutyric Acid) RN - 56-86-0 (Glutamic Acid) SB - IM MH - Animals MH - Brain Damage, Chronic/etiology/pathology MH - Brain Ischemia/complications/*metabolism/pathology MH - Chromatography, High Pressure Liquid MH - Convalescence MH - Gerbillinae MH - Glutamic Acid/*analysis MH - Male MH - Microdialysis MH - Recurrence MH - Substantia Nigra/*chemistry MH - Time Factors MH - gamma-Aminobutyric Acid/*analysis EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0014-4886(97)96588-2 [pii] AID - 10.1006/exnr.1997.6588 [doi] PST - ppublish SO - Exp Neurol. 1997 Oct;147(2):311-5. PMID- 9327635 OWN - NLM STAT- MEDLINE DA - 19971029 DCOM- 19971029 LR - 20041117 PUBM- Print IS - 0962-7480 (Print) VI - 47 IP - 6 DP - 1997 Aug TI - Occupational risk and toxicology evaluations of industrial water conditioning. PG - 337-40 AB - This study addresses the chemical and toxicological questions due to the wide use of chemical treatment programmes for industrial cooling water. First, natural problems encountered in cooling tower systems were presented and grouped into three categories: (i) scaling; (ii) corrosion and (iii) biofouling. Chemical solutions adopted in industrial plants were outlined for each one in order to minimize damage and categorized as shut-down, production loss, heat transfer reduction, upsets, etc. Above all, the purpose of the work was to identify the most dangerous chemicals normally used, which means sources of chemical risk for safety workers and their environment; thus, symptoms of exposure, prevention measures and protection tools are also described. AD - Occupational Medicine Institute, University of Messina, Italy. FAU - Broussard, G AU - Broussard G FAU - Bramanti, O AU - Bramanti O FAU - Marchese, F M AU - Marchese FM LA - eng PT - Journal Article PL - ENGLAND TA - Occup Med (Lond) JT - Occupational medicine (Oxford, England) JID - 9205857 RN - 0 (Disinfectants) RN - 0 (Oxidants) RN - 0 (Surface-Active Agents) RN - 7732-18-5 (Water) SB - IM MH - Corrosion MH - Disinfectants/*adverse effects MH - Humans MH - Occupational Diseases/chemically induced/prevention & control MH - Occupational Exposure/*adverse effects MH - Oxidants/adverse effects MH - Risk Factors MH - Safety MH - Surface-Active Agents/adverse effects MH - *Water MH - Water Softening/*adverse effects EDAT- 1997/08/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Occup Med (Lond). 1997 Aug;47(6):337-40. PMID- 9345269 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0006-291X (Print) VI - 239 IP - 1 DP - 1997 Oct 9 TI - Comparison of exocytotic mechanisms between acetylcholine- and catecholamine-containing vesicles in rat pheochromocytoma cells. PG - 57-62 AB - The molecular mechanisms of exocytosis from two types of secretory organelles, synaptic-like microvesicles and secretory vesicles, were compared by measuring acetylcholine (ACh) and catecholamine (CA) release from a newly isolated PC12 subclone, PC12-C3 which contains a high level of Ach. Digitonin-permeabilized PC12-C3 cells released both transmitters with similar Ca(2+)-dependency. Ca(2+)-evoked Ach and CA release from permeabilized cells were increased in the presence of MgATP, suggesting the existence of a MgATP-dependent priming step prior to the Ca(2+)-triggered fusion step in both ACh release and CA release. The non-hydrolyzable analogue of GTP guanosine 5'-(gamma-thio)triphosphate (GTP gamma S), produced both ACh and CA release from permeabilized cells in the absence of Ca2+. Pretreatment with a phorbol ester which activates protein kinase C, potentiated depolarization-induced ACh and CA release from unpermeabilized cells. These results indicated that exocytosis from two distinct vesicle populations are mediated by the same basic molecular mechanisms. AD - Mitsubishi Kasei Institute of Life Sciences, Tokyo, Japan. FAU - Nishiki, T AU - Nishiki T FAU - Shoji-Kasai, Y AU - Shoji-Kasai Y FAU - Sekiguchi, M AU - Sekiguchi M FAU - Iwasaki, S AU - Iwasaki S FAU - Kumakura, K AU - Kumakura K FAU - Takahashi, M AU - Takahashi M LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Catecholamines) RN - 37589-80-3 (Guanosine 5'-O-(3-Thiotriphosphate)) RN - 51-84-3 (Acetylcholine) RN - 56-65-5 (Adenosine Triphosphate) RN - 7440-09-7 (Potassium) RN - 7440-70-2 (Calcium) SB - IM MH - Acetylcholine/*metabolism MH - Adenosine Triphosphate/metabolism MH - Animals MH - Calcium/metabolism MH - Catecholamines/*metabolism MH - Chromatography, High Pressure Liquid MH - *Exocytosis MH - Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology MH - PC12 Cells MH - Potassium/metabolism MH - Rats MH - Synaptic Vesicles/drug effects/*metabolism EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0006291X97974271 [pii] PST - ppublish SO - Biochem Biophys Res Commun. 1997 Oct 9;239(1):57-62. PMID- 9297786 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0045-6535 (Print) VI - 35 IP - 5 DP - 1997 Sep TI - Species-specific alteration of hepatic glucose 6-phosphate dehydrogenase activity with coplanar polychlorinated biphenyl: evidence for an Ah-receptor-linked mechanism. PG - 951-8 AB - We examined the in vivo effect of a highly toxic coplanar polychlorinated biphenyl (PCB) on the hepatic activity of glucose 6-phosphate dehydrogenase (G6PDH) in aryl hydrocarbon (Ah)-responsive (C57/BL) and -less-responsive (DBA) strains of mice. The activity in the C57BL strain was moderately increased by 3,3',4,4',5-pentachlorobiphenyl (PCB 126) in a dose dependent manner. However, this was not observed in DBA mice although greater doses were injected. 2,2',5,5'-Tetrachlorobiphenyl (PCB 52) with a non-planar structure did not increase G6PDH activity. The increase in G6PDH activity with PCB 126 was also seen in rats, but not in guinea pigs. The activity in the latter species was decreased rather than increased. These results suggest that the induction of hepatic G6PDH by coplanar PCB is mediated by a mechanism involving the Ah receptor, and the response was highly species-specific. AD - Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. FAU - Hori, M AU - Hori M FAU - Kondo, H AU - Kondo H FAU - Ariyoshi, N AU - Ariyoshi N FAU - Yamada, H AU - Yamada H FAU - Oguri, K AU - Oguri K LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Chemosphere JT - Chemosphere JID - 0320657 RN - 0 (Polychlorinated Biphenyls) RN - 0 (Receptors, Aryl Hydrocarbon) RN - EC 1.1.1.49 (Glucosephosphate Dehydrogenase) SB - IM MH - Animals MH - Dose-Response Relationship, Drug MH - Enzyme Induction MH - Glucosephosphate Dehydrogenase/*biosynthesis MH - Guinea Pigs MH - Liver/*drug effects/enzymology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Inbred DBA MH - Polychlorinated Biphenyls/*toxicity MH - Rats MH - Rats, Wistar MH - Receptors, Aryl Hydrocarbon/*drug effects/metabolism MH - Species Specificity EDAT- 1997/09/23 MHDA- 1997/09/23 00:01 AID - S0045653597001811 [pii] PST - ppublish SO - Chemosphere. 1997 Sep;35(5):951-8. PMID- 9380946 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0034-1193 (Print) VI - 88 IP - 9 DP - 1997 Sep TI - [The maternal-fetal immune relationship in pregnancy] PG - 406-14 AB - The mother establishes with the fetus a special interaction in pregnancy allowing his normal survival in spite of the different HLA antigens. The main factors contributing to these favourable conditions for the fetus are an efficient local immunosuppression and the formation of a protective barrier between the mother and the fetus. A number of substances are responsible for the local immunosuppression and include cytokines, prostaglandins, hormones as well as various other proteins of pregnancy. In addition, cytokines produced by TH2 lymphocytes seem to be predominant with respect to those of TH1 cells. An effective protection is provided by the trophoblast layer, which not only forms a physical barrier between the mother and the fetus but evades the immune attack of the mother by expressing inhibitory molecules of the complement system and by down regulating the expression of HLA antigens. Data obtained from murine models and clinical observation in pathological pregnancies suggest that an abnormal immune response of the mother against the feto-placental unit may be responsible for the occurrence of recurrent spontaneous abortions. This is proved by the ability of the partner's lymphocytes administered to females in the mouse model prior to mating to reduce the incidence of abortions. Unfortunately, similar treatment in women with recurrent abortion does not appear to be very effective. AD - Dipartimento di Fisiologia e Patologia, Universita, Trieste. FAU - Tedesco, F AU - Tedesco F FAU - Pausa, M AU - Pausa M FAU - Bulla, R AU - Bulla R FAU - Melazzini, S AU - Melazzini S FAU - Guaschino, S AU - Guaschino S LA - ita PT - English Abstract PT - Journal Article PT - Review TT - Il rapporto immune materno-fetale in gravidanza. PL - ITALY TA - Recenti Prog Med JT - Recenti progressi in medicina JID - 0401271 RN - 0 (HLA Antigens) SB - IM MH - Abortion, Habitual/immunology MH - Animals MH - Decidua/immunology MH - Female MH - HLA Antigens/immunology MH - Humans MH - *Immunity, Maternally-Acquired MH - Pregnancy/*immunology MH - Pregnancy, Animal/*immunology MH - Trophoblasts/immunology RF - 61 EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Recenti Prog Med. 1997 Sep;88(9):406-14. PMID- 9347825 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20041117 PUBM- Print IS - 0038-4348 (Print) VI - 90 IP - 10 DP - 1997 Oct TI - Breast metastasis from non-small cell lung cancer. PG - 1063-4 AB - Breast is an unusual site for metastatic disease, particularly for non-small cell lung cancer. We report an unusual case of metastatic breast lesions from a primary anaplastic lung tumor and discuss the common and uncommon sites of metastasis from lung carcinomas. AD - Department of Respiratory Medicine, Leeds General Infirmary, England. FAU - Sadikot, R T AU - Sadikot RT FAU - Renwick, D S AU - Renwick DS FAU - DaCosta, P AU - DaCosta P FAU - Chalmers, A G AU - Chalmers AG FAU - Pearson, S B AU - Pearson SB LA - eng PT - Case Reports PT - Journal Article PL - UNITED STATES TA - South Med J JT - Southern medical journal JID - 0404522 SB - AIM SB - IM MH - Breast Neoplasms/*secondary MH - Carcinoma, Non-Small-Cell Lung/*secondary MH - Female MH - Humans MH - Lung Neoplasms/*pathology MH - Middle Aged EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - South Med J. 1997 Oct;90(10):1063-4. PMID- 9323766 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20051116 PUBM- Print IS - 0033-8397 (Print) VI - 69 IP - 1 DP - 1997 Sep-Oct TI - Repair of pseudoaneurysms via ultrasound-guided compression. PG - 55-61 AB - Pseudoaneurysm formation is one of the potential complications of arterial catheterization. In the past, surgery was the usual method of treatment for pseudoaneurysms. Although surgical repair is still indicated in some cases, a noninvasive procedure called ultrasound-guided compression repair (UGCR) often can be used instead of surgery. During UGCR, an ultrasound transducer is used to apply compression to the pseudoaneurysm, causing a clot to form. This article describes the UGCR procedure and discusses results that clinicians have attained using this method of pseudoaneurysm repair. AD - Putnam County Hospital, Greencastle, Ind., USA. FAU - Benassi, K G AU - Benassi KG FAU - Cox, L A AU - Cox LA FAU - Long, B W AU - Long BW LA - eng PT - Journal Article PT - Review PL - UNITED STATES TA - Radiol Technol JT - Radiologic technology JID - 0401256 SB - IM MH - Aneurysm, False/etiology/*therapy MH - Catheterization/adverse effects MH - Humans MH - Pressure MH - Transducers MH - *Ultrasonography, Doppler RF - 26 EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Radiol Technol. 1997 Sep-Oct;69(1):55-61. PMID- 9300992 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20061115 PUBM- Print IS - 0301-5629 (Print) VI - 23 IP - 6 DP - 1997 TI - Comparison of B-mode, M-mode and echo-tracking methods for measurement of the arterial distension waveform. PG - 879-87 AB - Measurements of arterial diameter throughout the cardiac cycle (i.e., the arterial distension waveform) are conducted increasingly to study mechanical properties of the arterial wall and changes associated with disease. The distension waveform of peripheral arteries can be measured noninvasively via ultrasonic echo tracking. M-mode imaging, and B-mode imaging. Of these, echo tracking is the most popular method because of its single micrometer resolution during continuous measurements under ideal conditions. However, high resolution within continuous measurements does not imply high reproducibility between measurements. Therefore, we compared repeated measurements of the amplitude of common carotid artery distension in 26 subjects, obtained sequentially in random order by: 1. Off-line echo tracking of digitized radiofrequency ultrasound; 2. M-mode imaging with automated edge detection; and 3. 30-Hz B-mode imaging with automated edge detection and model-based diameter estimation. In each case, the transducer was hand-held and was removed from the neck between repeated measurements. The amplitude of arterial distension was estimated from the serial diameter measurements by maximum likelihood (ML) estimation, by least-squares fit of a Fourier series model, and by application of a cubic smoothing spline. Within continuous measurements, the standard deviation of the ML distension amplitude for neighboring cardiac cycles was significantly smaller (p > 0.05) with echo-tracking (0.023 mm) than with the B-mode (0.036 mm) or M-mode (0.074 mm) methods. However, between discontinuous measurements on the same subject, the standard deviation of the ML distension amplitude was similar for the echo-tracking (0.076 mm) and B-mode (0.073 mm) methods. The Fourier series model and the cubic smoothing spline slightly reduced the standard deviation of the B-mode and M-mode distension amplitudes, but also reduced the mean amplitude estimate. On the basis of this relative comparison of methods, we conclude that, although echo tracking offers high resolution for continuous measurements, the reproducibility of discontinuous measurements of carotid artery distension is no better with echo tracking than can be obtained from 30-Hz B-mode images. AD - Boston Heart Foundation, Cambridge, MA 02142, USA. FAU - Stadler, R W AU - Stadler RW FAU - Taylor, J A AU - Taylor JA FAU - Lees, R S AU - Lees RS LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - Ultrasound Med Biol JT - Ultrasound in medicine & biology JID - 0410553 SB - IM MH - Adult MH - Aged MH - Carotid Artery, Common/physiology/*ultrasonography MH - Elasticity MH - Female MH - Fourier Analysis MH - Humans MH - Image Processing, Computer-Assisted/*methods MH - Male MH - Middle Aged MH - Reproducibility of Results EDAT- 1997/01/01 00:00 MHDA- 1997/09/25 00:01 AID - S0301562997000744 [pii] PST - ppublish SO - Ultrasound Med Biol. 1997;23(6):879-87. PMID- 9335407 OWN - NLM STAT- MEDLINE DA - 19971105 DCOM- 19971105 LR - 20031114 PUBM- Print IS - 0160-2446 (Print) VI - 30 IP - 4 DP - 1997 Oct TI - Hemodynamic responses to endothelin-1 and endothelin antagonists microinjected into the nucleus tractus solitarius in rats. PG - 475-80 AB - The role of endothelin-1 (ET-1) within the nucleus tractus solitarius (NTS) in central cardiovascular control was investigated by local microinjections of ET-1 and ET-receptor antagonists. In urethane-anesthetized Sprague-Dawley rats, a unilateral microinjection of ET-1 (1.0, 3.3, and 10.0 pmol) into the NTS significantly increased arterial pressure, left ventricular systolic pressure, and dP/dt(max) in a dose-dependent manner, and slightly decreased heart rate in a dose-independent manner. The pressor effect lasted >90 min. In normotensive rats, neither PD147953, a selective ETA-receptor antagonist, nor PD142893, a mixed ETA- and ETB-receptor antagonist, microinjected into the NTS elicited any changes in arterial pressure or heart rate. The pressor and bradycardic effects evoked by microinjection of ET-1 into the NTS could be blocked by local pretreatment with PD147953 and completely eliminated by intravenous pretreatment with the ganglionic blocker hexamethonium. The arterial baroreflex sensitivity was almost totally suppressed by microinjection of ET-1 (3.3 pmol) in alpha-chloralose-anesthetized Sprague-Dawley rats. A similar pattern of changes in the hemodynamic variables was elicited by microinjection of ET-1 (3.3 pmol) into the NTS in spontaneously hypertensive rats (SHRs) compared with Wistar-Kyoto (WKY) rats. In SHRs, microinjection of PD142893 did not elicit any changes in arterial pressure or heart rate. These results suggest that ET-1 modulates reflex control of hemodynamics by activation of autonomic nerve via ETA receptors in the NTS, and that the responsiveness of SHRs to ET-1 or PD142893 is similar to that of WKY rats. AD - Department of Pharmacology, Faculty of Basic Medicine, Second Military Medical University, Shanghai, P.R. China. FAU - Dai, S M AU - Dai SM FAU - Shan, Z Z AU - Shan ZZ FAU - Miao, C Y AU - Miao CY FAU - Yin, M AU - Yin M FAU - Su, D F AU - Su DF LA - eng PT - Journal Article PL - UNITED STATES TA - J Cardiovasc Pharmacol JT - Journal of cardiovascular pharmacology JID - 7902492 RN - 0 (Endothelin-1) RN - 0 (Oligopeptides) RN - 0 (Receptors, Endothelin) RN - 143037-36-9 (PD 142893) RN - 60-26-4 (Hexamethonium) SB - IM MH - Animals MH - Blood Pressure/*drug effects MH - Endothelin-1/*pharmacology MH - Heart Rate/*drug effects MH - Hexamethonium/pharmacology MH - Male MH - Microinjections MH - Oligopeptides/pharmacology MH - Rats MH - Rats, Inbred SHR MH - Rats, Inbred WKY MH - Rats, Wistar MH - Receptors, Endothelin/*antagonists & inhibitors MH - Solitary Nucleus/*drug effects/physiology EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - J Cardiovasc Pharmacol. 1997 Oct;30(4):475-80. PMID- 9378510 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0019-5189 (Print) VI - 35 IP - 5 DP - 1997 May TI - Effect of carbon tetrachloride on rat liver, following parathyroidectomy: histopathological observations. PG - 443-7 AB - Absence of centrilobular necrosis, cirrhosis and giant hepatic cells with a large nucleus were significant observations in the liver of CCl4 treated rats following unilateral parathyroidectomy. Increased number of mitochondria and presence of binucleated cells indicated hepatic regeneration in unilaterally parathyroidectomized and CCl4 treated rats. Focal necrosis, giant cells and presence of smooth endoplasmic reticulum around the nucleus reflect a slight impairment in regeneration of the liver following bilateral parathyroidectomy and CCl4 administration. The results show that parathyroidectomy interferes in the pathogenesis of necrosis and associated lesions in the liver of CCl4 treated rats. Overall results indicate that unilateral parathyroidectomy afforded better protection than bilateral parathyroidectomy. AD - Department of Zoology, Ch. C.S. University, Meerut, India. FAU - Rasgoti, S AU - Rasgoti S LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - INDIA TA - Indian J Exp Biol JT - Indian journal of experimental biology JID - 0233411 SB - IM MH - Animals MH - Carbon Tetrachloride Poisoning/*pathology MH - Liver/*drug effects/pathology MH - Male MH - Muridae/*anatomy & histology MH - Parathyroid Glands/*physiology MH - Parathyroidectomy EDAT- 1997/05/01 00:00 MHDA- 1997/10/07 00:01 PST - ppublish SO - Indian J Exp Biol. 1997 May;35(5):443-7. PMID- 9335288 OWN - NLM STAT- MEDLINE DA - 19971104 DCOM- 19971104 LR - 20061115 PUBM- Print IS - 0021-9193 (Print) VI - 179 IP - 20 DP - 1997 Oct TI - Three genes of a motility operon and their role in flagellar rotary speed variation in Rhizobium meliloti. PG - 6391-9 AB - The peritrichous flagella of Rhizobium meliloti rotate only clockwise and control directional changes of swimming cells by modulating flagellar rotary speed. Using Tn5 insertions, we have identified and sequenced a motility (mot) operon containing three genes, motB, motC, and motD, that are translationally coupled. The motB gene (and an unlinked motA) has been assigned by similarity to the Escherichia coli and Bacillus subtilis homologs, whereas motC and motD are new and without known precedents in other bacteria. In-frame deletions introduced in motB, motC, or motD each result in paralysis. MotD function was fully restored by complementation with the wild-type motD gene. By contrast, deletions in motB or motC required the native combination of motB and motC in trans for restoring normal flagellar rotation, whereas complementation with motB or motC alone led to uncoordinated (jiggly) swimming. Similarly, a motB-motC gene fusion and a Tn5 insertion intervening between motB and motC resulted in jiggly swimming as a consequence of large fluctuations in flagellar rotary speed. We conclude that MotC biosynthesis requires coordinate expression of motB and motC and balanced amounts of the two gene products. The MotC polypeptide contains an N-terminal signal sequence for export, and Western blots have confirmed its location in the periplasm of the R. meliloti cell. A working model suggests that interactions between MotB and MotC at the periplasmic surface of the motor control the energy flux or the energy coupling that drives flagellar rotation. AD - Lehrstuhl fur Genetik, Universitat Regensburg, Germany. FAU - Platzer, J AU - Platzer J FAU - Sterr, W AU - Sterr W FAU - Hausmann, M AU - Hausmann M FAU - Schmitt, R AU - Schmitt R LA - eng SI - GENBANK/L49337 PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Bacteriol JT - Journal of bacteriology JID - 2985120R RN - 0 (Bacterial Proteins) RN - 0 (DNA Transposable Elements) RN - 0 (Molecular Motor Proteins) RN - 0 (MotB protein, Bacteria) RN - 0 (MotC protein, Rhizobium meliloti) RN - 0 (MotD protein, Rhizobium meliloti) RN - 0 (Protein Sorting Signals) SB - IM MH - Amino Acid Sequence MH - Artificial Gene Fusion MH - Bacterial Proteins/chemistry/*genetics/physiology MH - Base Sequence MH - DNA Transposable Elements MH - Flagella/*physiology MH - Genetic Complementation Test MH - Molecular Motor Proteins MH - Molecular Sequence Data MH - Movement MH - Mutagenesis, Insertional MH - *Operon MH - Protein Sorting Signals MH - Restriction Mapping MH - Sequence Deletion MH - Sinorhizobium meliloti/*genetics/physiology EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 PST - ppublish SO - J Bacteriol. 1997 Oct;179(20):6391-9. PMID- 9350135 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0018-0661 (Print) VI - 126 IP - 3 DP - 1997 TI - The physical location of genes cdc2 and prh1 in maize (Zea mays L.). PG - 211-7 AB - A biotin-labelling in situ hybridization technique was first used to physically map two single copy genes, cdc2 and prh1, in maize. These two genes are metabolically interrelated genes. The full-length cDNA clones cdc2ZmA and ZmPPI of genes cdc2 and prh1 were adopted as the probes. They are 1.3 and 1.6 kb in size, respectively. Clone cdc2ZmA was physically mapped on the long arm of chromosomes 4, 8, and 9. The percent distances from centromere to detection site were 57.9 +/- 2.7, 28.4 +/- 1.5, and 88.2 +/- 3.3. The detection rate was 19.2%. Clone ZmPPI was physically mapped on the long arm of chromosomes 4, 6, and 8. The percent distances were 53.6 +/- 1.2, 60.8 +/- 2.9 and 17.1 +/- 1.6. The detection ratio was 18.5%. The technique of chromosome ISH and the relationship between the location and function of these two genes have been discussed. AD - Department of Genetics, College of Life Sciences, Wuhan University, Wuhan Hubei, People's Republic of China. FAU - Ren, N AU - Ren N FAU - Song, Y C AU - Song YC FAU - Bi, X Z AU - Bi XZ FAU - Ding, Y AU - Ding Y FAU - Liu, L H AU - Liu LH LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - SWEDEN TA - Hereditas JT - Hereditas JID - 0374654 RN - 0 (DNA Probes) RN - 0 (Genetic Markers) RN - EC 2.7.1.37 (CDC2 Protein Kinase) RN - EC 3.1.3.16 (Phosphoprotein Phosphatase) SB - IM MH - CDC2 Protein Kinase/*genetics MH - Centromere MH - *Chromosome Mapping MH - DNA Probes MH - Genetic Markers MH - Phosphoprotein Phosphatase/*genetics MH - Zea mays/*genetics EDAT- 1997/01/01 00:00 MHDA- 1997/11/14 00:01 PST - ppublish SO - Hereditas. 1997;126(3):211-7. PMID- 9306444 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20051116 PUBM- Print IS - 0740-9303 (Print) VI - 13 IP - 3 DP - 1997 Sep TI - Visual hallucinations after enucleation. PG - 221-5 AB - Visual phenomena are frequently reported in patients after ocular trauma, surgery or progressive visual degeneration. In particular, hallucinations are often seen by patients following enucleation. Whereas these visions can be verbally described to the physician, they can never actually be seen. This article focuses on the case of a female artist who experienced visual hallucinations after enucleation of her dominant right eye. In addition to her verbal descriptions, she was able to express these hallucinations visually on canvas. Her case offers insight to caregivers about the nature of visual hallucinations in patients with similar experiences. A review of the general characteristics and etiologies of such visual phenomena is also included. AD - Casey Eye Institute, Oregon Health Sciences University, Portland 97201, USA. FAU - Gross, N D AU - Gross ND FAU - Wilson, D J AU - Wilson DJ FAU - Dailey, R A AU - Dailey RA LA - eng PT - Case Reports PT - Journal Article PT - Review PL - UNITED STATES TA - Ophthal Plast Reconstr Surg JT - Ophthalmic plastic and reconstructive surgery JID - 8508431 SB - IM MH - Aged MH - Eye Enucleation/*adverse effects MH - Female MH - Hallucinations/*etiology/psychology MH - Humans MH - Postoperative Complications MH - Vision Disorders/*etiology/psychology RF - 18 EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Ophthal Plast Reconstr Surg. 1997 Sep;13(3):221-5. PMID- 9347706 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20041118 PUBM- Print IS - 1040-2446 (Print) VI - 72 IP - 10 DP - 1997 Oct TI - Reflections on death and dying. PG - 848-55 AB - Americans simultaneously worry about dying and about being tethered to machines that keep them alive beyond a point when life has any meaning. People living with terminal illness often feel isolated from life around them and a burden on those they love; they feel uncertain that their deaths will be relatively free of pain and suffering and that their dignity will be compromised as little as possible. These failings can be remedied. Traditional hospice care and integrating palliative care into the general medical setting are important, but they cannot alone occasion a better dying. The medical community must re-imagine dying and reflect about ways to transform image into reality in practice and in training colleagues and successors. Physicians and others know how to provide care and even improve living when cure is unlikely; the harder task is to respect such care as profoundly as curing. The exigencies of modern medicine, where time is a budgetable commodity, makes caring well for dying patients difficult. Medicine cannot have hegemony over dying and cannot singularly offer people a better death, but it cannot absent itself either. The almost single-minded focus on decision making that has infused conversations about dying and death may divert attention from the attentiveness and loving relationships that are as vital as life's end as at its beginning. Medicine has "colonized" death: It has transformed it into a place where progress in staving it off may appear to be unlimited, and thus it encourages forgetting that death is part of the human condition. The task before medicine, and academic medicine in particular, is to transform death back into a human scale. With all that is available to delay death--but not to make it optional--the most important task is to recover humbleness before an awesome moment and be with the patient, one human being to another, knowing that dying is not always open to solutions. AD - Park Ridge Center for the Study of Health, Faith, and Ethics, Chicago, Illinois 60611-3215, USA. martha@prchfe.org FAU - Holstein, M AU - Holstein M LA - eng PT - Journal Article PL - UNITED STATES TA - Acad Med JT - Academic medicine : journal of the Association of American Medical Colleges JID - 8904605 SB - AIM SB - E SB - IM CIN - Acad Med. 1998 Mar;73(3):221-2. PMID: 9526441 MH - Advance Directives MH - *Death MH - Dehumanization MH - Ethics MH - Home Care Services MH - Humans MH - Narration MH - Physician's Role MH - Physician-Patient Relations MH - Social Change MH - Sociology, Medical MH - Stress, Psychological MH - Terminal Care OID - KIE: 56617 OTO - KIE OT - Death and Euthanasia GN - KIE: KIE BoB Subject Heading: terminal care GN - KIE: Full author name: Holstein, Martha EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Acad Med. 1997 Oct;72(10):848-55. PMID- 9376763 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0869-2092 (Print) VI - 60 IP - 4 DP - 1997 Jul-Aug TI - [The pharmacokinetic interaction of cholinolytics and cholinesterase reactivators as a reflection of the modulation of their binding in blood plasma and in brain tissue] PG - 64-7 AB - Radioligand assay showed that the cholinesterase (ChE) reactivators dipiroxime and benzyxime, but not carboxime, modulate selective absorption of some cholinolytics (tributam, pediphen, aprophen) in rat brain. Significant suppression of the specific binding of muscarine antagonists was recorded after chlorophos (2.LD50) intoxication. Under such conditions, the ChE reactivators induce increase in the number of binding sites and in the parameters of the constant of cholinolytic absorption on the brain membranes. It was also established by equilibrium dialysis that the binding of cholinolytics in blood plasma under the effect of ChE reactivators is reduced, leading to redistribution of their free and bound fractures, which is most favorable for tissue sorption. FAU - Elaeva, N L AU - Elaeva NL FAU - Predtechenskii, M B AU - Predtechenskii MB FAU - Kul'bitskii, G N AU - Kul'bitskii GN FAU - Babaina, E V AU - Babaina EV FAU - Trefilov, V V AU - Trefilov VV LA - rus PT - English Abstract PT - Journal Article TT - Farmakokineticheskoe vzaimodeistvie kholinolitikov i reaktivatorov kholinesterazy kak otrazhenie moduliatsii ikh sviazyvaniia v plazme krovi i v tkani mozga. PL - RUSSIA TA - Eksp Klin Farmakol JT - Eksperimental'naia i klinicheskaia farmakologiia JID - 9215981 RN - 0 (Carbon Radioisotopes) RN - 0 (Cholinergic Antagonists) RN - 0 (Cholinesterase Reactivators) RN - 0 (Insecticides) RN - 10028-17-8 (Tritium) RN - 52-68-6 (Trichlorfon) SB - IM MH - Animals MH - Brain/*metabolism MH - Brain Chemistry MH - Carbon Radioisotopes MH - Cholinergic Antagonists/analysis/*pharmacokinetics/therapeutic use MH - Cholinesterase Reactivators/analysis/*pharmacokinetics/therapeutic use MH - Chromatography, High Pressure Liquid MH - Chromatography, Thin Layer MH - Drug Interactions MH - Insecticides/poisoning MH - Male MH - Plasma/chemistry/*metabolism MH - Poisoning/drug therapy/metabolism MH - Radioligand Assay MH - Rats MH - Time Factors MH - Trichlorfon/poisoning MH - Tritium EDAT- 1997/07/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Eksp Klin Farmakol. 1997 Jul-Aug;60(4):64-7. PMID- 9263063 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20061115 PUBM- Print IS - 0021-8812 (Print) VI - 75 IP - 8 DP - 1997 Aug TI - Use of a raw meat-based diet or a dry kibble diet for sand cats (Felis margarita). PG - 2154-60 AB - Limited information is available on the utilization of different types of diets by captive exotic felid species. Utilization of diets by small exotic felids may differ depending on the diet fed. Eight sand cats (Felis margarita), which are small, 2- to 4-kg cats, were used to examine the digestibility of two types of diets: a raw meat-based diet and a dry kibble diet. Dry matter, crude protein and energy intakes and digestibilities were evaluated. Digestibilities for dry matter, energy, and crude protein were 83.5 +/- 4.8, 89.6 +/- 5.2, 92.4 +/- 5.3% for the raw meat-based diet and 72.7 +/- 12.3, 76.8 +/- 14.5, and 77.9 +/- 13.5% for the kibble diet. Physiological variables also were examined and included plasma taurine, vitamin A, retinyl palmitate, beta-carotene, calcium, and phosphorus. Plasma taurine means were 91.4 +/- 8.4 mumol/L in cats consuming the raw meat-based diet and 248.0 +/- 23.2 mumol/L in cats consuming the kibble diet. Plasma phosphorus was 5.2 +/- .1 and 4.5 +/- .1 mg/dL, respectively, in cats consuming raw meat-based and kibble diets. beta-Carotene was 25.2 +/- 2.9 and 2.9 +/- .3 micrograms/dL, respectively, for cats consuming the raw meat-based and kibble diets. These results indicate that diets formulated for small captive exotic felid species should be evaluated with respect to diet type and nutrient utilization. AD - Daniel F. & Ada L. Rice Conservation Biology and Research Center, Chicago Zoological Society, Brookfield, IL 60513, USA. FAU - Crissey, S D AU - Crissey SD FAU - Swanson, J A AU - Swanson JA FAU - Lintzenich, B A AU - Lintzenich BA FAU - Brewer, B A AU - Brewer BA FAU - Slifka, K A AU - Slifka KA LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Anim Sci JT - Journal of animal science JID - 8003002 RN - 0 (Dietary Proteins) RN - 107-35-7 (Taurine) RN - 11103-57-4 (Vitamin A) RN - 7235-40-7 (beta Carotene) RN - 7440-70-2 (Calcium) RN - 7723-14-0 (Phosphorus) SB - IM MH - Animal Feed/standards MH - Animals MH - Body Mass Index MH - Calcium/blood MH - Carnivora/growth & development/metabolism/*physiology MH - Diet/*veterinary MH - Dietary Proteins/pharmacology MH - Digestion/physiology MH - Energy Intake/physiology MH - Energy Metabolism/physiology MH - Female MH - Male MH - *Meat/analysis MH - Phosphorus/blood MH - Taurine/blood MH - Vitamin A/blood MH - beta Carotene/analysis EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 PST - ppublish SO - J Anim Sci. 1997 Aug;75(8):2154-60. PMID- 9311427 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 0272-9490 (Print) VI - 51 IP - 9 DP - 1997 Oct TI - Clinical interpretation of "In-hand manipulation in young children: translation movements". PG - 729-32 AB - As a result of their study, Pehoski et al. (1997) have contributed to our knowledge of the development of in-hand manipulation skills in young children. Although knowledge of skill development in children who are typically developing must be applied with caution to children with disabilities, information about normal development provides us with at least the basis for evaluation and treatment planning. Children with moderate and severe problems with hand skills are very unlikely to be appropriate candidates for intervention for in-hand manipulation skills, but children with mild disabilities may be easier for the therapies to identify when using these data on developmental trends and descriptions of strategies for execution of in-hand manipulation skills. Such identification has the potential to lead to intervention that can positively influence the child's performance of a variety of functional tasks that rely on these skills. AD - Occupational Therapy Department, Towson University, Maryland 21252-7097, USA. FAU - Exner, C E AU - Exner CE LA - eng PT - Comment PT - Journal Article PL - UNITED STATES TA - Am J Occup Ther JT - The American journal of occupational therapy. : official publication of the American Occupational Therapy Association JID - 7705978 SB - IM CON - Am J Occup Ther. 1997 Oct;51(9):719-28. PMID: 9311426 MH - Adult MH - Child MH - Child Development/*physiology MH - Child, Preschool MH - Female MH - Functional Laterality/*physiology MH - Humans MH - Male MH - Motor Skills/*physiology MH - Occupational Therapy MH - Patient Care Planning MH - Psychomotor Disorders/physiopathology/rehabilitation MH - Psychomotor Performance/*physiology MH - Reference Values EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - Am J Occup Ther. 1997 Oct;51(9):729-32. PMID- 9323504 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20061115 PUBM- Print IS - 0391-3988 (Print) VI - 20 IP - 8 DP - 1997 Aug TI - Quantitating dialysis using two dialysate samples: a simple, practical and accurate approach for evaluating urea kinetics. PG - 422-7 AB - Urea kinetics is now widely used to determine the adequacy of dialysis. Several simplified formulae are currently in use but only a few have been accepted into clinical practice because of their simplicity and ease of calculation. A recent analysis of these formulae showed that for the same set of blood urea values the calculated Kt/V can range from 1.0 to 1.5. We have developed a new dialysate-based method (2DSM) to estimate the urea kinetic parameters using dialysate and blood samples taken at the beginning and at the end of dialysis. The total urea removed (TUR) was calculated from the geometric mean of the two dialysate samples, dialysate flow rate and the duration of dialysis. The Watson formula was used to determine the volume of distribution of urea. A comparison of the 2DSM and the direct dialysate quantification (DDQ) method showed the following results (mean +/- sd, n = 52): for total urea removal (TUR) 697 +/- 32 vs 722 +/- 37 mmol (p = 0.6, r2 = 0.928, y = 101 + 0.83 x, mean difference 25 +/- 76 mmol, see Bland-Altman plot), dialysate urea concentration (Durea) 5.55 +/- 0.25 vs 5.75 +/- 0.29 mmol/l (p = 0.6, r2 = 0.928, y = 0.8 + 0.82 x, mean difference 0.2 +/- 0.6 mmol, see Bland-Altman plot), dialyser clearance (K) 232 +/- 4.4 vs 235 +/- 5.6 ml/min (p = 0.54), Kt/V 1.42 +/- 0.04 vs 1.51 +/- 0.04 (p = 0.21), volume of distribution of urea (Vd) 40.14 +/- 1.04 vs 38.74 +/- 1.2 L, (p = 0.38), and PCR 64.6 +/- 2.6 vs 68.1 +/- 3.1 g/day. We have developed a simple method of determining dialysate-based urea kinetics which requires two dialysate samples, one at the beginning and one at the end of dialysis and a blood sample at the midpoint of dialysis. TUR can be calculated using the dialysate flow rate and the dialysis duration and once this is known all the other kinetic parameters can be calculated. AD - Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario. FAU - Raj, D S AU - Raj DS FAU - Tobe, S AU - Tobe S FAU - Saiphoo, C AU - Saiphoo C FAU - Manuel, M A AU - Manuel MA LA - eng PT - Comparative Study PT - Journal Article PL - ITALY TA - Int J Artif Organs JT - The International journal of artificial organs JID - 7802649 RN - 0 (Dialysis Solutions) RN - 57-13-6 (Urea) SB - IM MH - Blood Specimen Collection MH - Dialysis Solutions/*analysis MH - Female MH - Humans MH - Kidney Failure, Chronic/blood/*therapy MH - Kinetics MH - Linear Models MH - Male MH - *Renal Dialysis MH - Urea/*analysis/isolation & purification EDAT- 1997/08/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Int J Artif Organs. 1997 Aug;20(8):422-7. PMID- 9344906 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0042-6822 (Print) VI - 237 IP - 1 DP - 1997 Oct 13 TI - The HIV-1 matrix domain of Gag is required for Vpu responsiveness during particle release. PG - 46-55 AB - HIV-1 viral protein U (Vpu) facilitates virus particle release. To determine whether Gag is sufficient for generation of a target for Vpu-mediated particle release, we expressed HIV-1 Gag protein in the absence of the other viral genes. The resulting particles were still Vpu responsive. Mutational analysis of Gag indicated that the matrix domain (MA) is required for Vpu responsiveness. However, additional mutations in other domains of Gag, which affect the formation of stable virus particles, also abrogate Vpu responsiveness on total Gag release. Coexpression of the wild-type gag gene and a gag mutant lacking the MA domain renders the MA- mutant Vpu responsive. This indicates that Gag molecules lacking MA are still incorporated into particles through association with wild-type Gag molecules and that the resulting composite particles are sufficient for Vpu-mediated exit. CI - Copyright 1997 Academic Press. AD - McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, 1400 University Avenue, Madison, Wisconsin 53706, USA. FAU - Lee, Y H AU - Lee YH FAU - Schwartz, M D AU - Schwartz MD FAU - Panganiban, A T AU - Panganiban AT LA - eng GR - R01-AI36174/AI/NIAID PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Virology JT - Virology JID - 0110674 RN - 0 (Gene Products, gag) RN - 0 (Gene Products, vpu) RN - 0 (Viral Proteins) SB - IM SB - X MH - Binding Sites MH - Gene Deletion MH - Gene Products, gag/genetics/*metabolism MH - Gene Products, vpu/*metabolism MH - HIV-1/*physiology MH - Hela Cells MH - Humans MH - Protein Binding MH - Viral Proteins/metabolism MH - Virion/physiology MH - Virus Replication/*physiology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0042-6822(97)98711-0 [pii] AID - 10.1006/viro.1997.8711 [doi] PST - ppublish SO - Virology. 1997 Oct 13;237(1):46-55. PMID- 9267510 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0003-1488 (Print) VI - 211 IP - 4 DP - 1997 Aug 15 TI - Effects of parenteral administration of vitamin E on health of periparturient dairy cows. PG - 466-9 AB - OBJECTIVE: To determine the effect of administration of vitamin E (D-alpha-tocopherol) on the incidence of retained placenta, metritis, and clinical mastitis during early lactation and on tocopherol concentrations. DESIGN: Prospective randomized controlled study. ANIMALS: 420 Holstein cows. PROCEDURE: Vitamin E (3,000 mg, IM, once) was administered to 204 cows B to 14 days before expected parturition, and 216 control cows were not treated. The number of cows that had retained placenta, metritis, clinical mastitis, displaced abomasum, and clinically apparent acetonemia or hypocalcemia were recorded. Serum concentrations of tocopherol, the tocopherol:cholesterol ratio, and glutathione-peroxidase activity were determined from samples obtained before administration of vitamin E, 7 and 14 days after administration, and at 30 days after parturition from 36 treated and 36 control cows. RESULTS: Administration of vitamin E significantly decreased the incidence of retained placenta and metritis (13/204 [6.4%] and 8/204: [3.9%], respectively, for the vitamin E-treated group; 27/216 [12.5%] and 19/ 216 [8.8%], respectively, for the untreated group) but did not affect the incidence of clinical mastitis. Serum vitamin E concentration was significantly higher in treated than in control cattle at 7 and 14 days after administration, but serum tocopherol: cholesterol ratio was significantly higher only at 7 days after administration. CLINICAL IMPLICATIONS: Parenteral administration of a single injection of vitamin E before parturition may decrease the incidence of retained placenta and metritis in dairy cows but will increase serum concentrations for 7 to 14 days after administration. AD - Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824, USA. FAU - Erskine, R J AU - Erskine RJ FAU - Bartlett, P C AU - Bartlett PC FAU - Herdt, T AU - Herdt T FAU - Gaston, P AU - Gaston P LA - eng PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - J Am Vet Med Assoc JT - Journal of the American Veterinary Medical Association JID - 7503067 RN - 1406-18-4 (Vitamin E) SB - IM CIN - J Am Vet Med Assoc. 1997 Oct 15;211(8):979-81. PMID: 9410866 MH - Animals MH - Cattle MH - Cattle Diseases/epidemiology/*prevention & control MH - Endometritis/epidemiology/prevention & control/veterinary MH - Female MH - Incidence MH - Mastitis, Bovine/epidemiology/prevention & control MH - Placenta, Retained/epidemiology/prevention & control/veterinary MH - Pregnancy MH - Prospective Studies MH - Puerperal Disorders/epidemiology/prevention & control/*veterinary MH - Vitamin E/administration & dosage/blood/*therapeutic use EDAT- 1997/08/15 MHDA- 1997/08/15 00:01 PST - ppublish SO - J Am Vet Med Assoc. 1997 Aug 15;211(4):466-9. PMID- 9377678 OWN - NLM STAT- MEDLINE DA - 19971105 DCOM- 19971105 LR - 20061115 PUBM- Print IS - 1426-9686 (Print) VI - 2 IP - 11 DP - 1997 May TI - [Early and late complications after surgical gastric resection for peptic ulcer] PG - 313-4 AB - For evaluating early and late complications after partial gastrectomy in gastric and duodenal ulcer, performed in 1976-92 years, was investigated 585 patients. The surgery was carry out mutables Rydygier and Billroth-2 methods. The smallest complications early and late found after the operations Finney-Haberer and Billroth-2 with Braun anastomosis and vagotomy. AD - Oddzialu Chirurgicznego Szpitala w Jasle. FAU - Kleba, T AU - Kleba T LA - pol PT - Clinical Trial PT - English Abstract PT - Journal Article TT - Wczesne i pozne powiklania po operacjach resekcyjnych zoladka z powodu choroby wrzodowej. PL - POLAND TA - Pol Merkur Lekarski JT - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego JID - 9705469 SB - IM MH - Anastomosis, Surgical/methods MH - Female MH - Gastrectomy MH - Humans MH - Male MH - Middle Aged MH - Postoperative Complications/*epidemiology/prevention & control MH - Stomach Ulcer/*surgery MH - Time Factors MH - Vagotomy EDAT- 1997/05/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Pol Merkur Lekarski. 1997 May;2(11):313-4. PMID- 9322197 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20051117 PUBM- Print IS - 1059-1052 (Print) VI - 6 IP - 3 DP - 1997 Fall TI - Antibiotic prophylaxis and infection resistance of massive tumor endoprostheses during chemotherapy. PG - 180-5 AB - Fifty-five consecutively treated patients with malignant bone tumors had preoperative and postoperative chemotherapy by one oncologist. These same patients had massive bone resection and cemented endoprosthetic bone replacement by one orthopaedic oncologist. Despite 143 instances of documented fever and/or neutropenia in 45 of these 55 patients, no known deep periprosthetic infections developed in any patient during follow-up (mean, 29.4 months; median, 25 months; range, 5 months to 62 months). Broad spectrum antibiotics had been administered in at least 118 instances to these patients (intravenously in hospital, 9 times to 7 patients; intravenously at home, 38 times to 18 patients; and orally at home, 71 times to 26 patients). This study confirms the low infection rate of these massive endoprostheses, despite neutropenic and/or febrile episodes if the patient is given prophylactic broad spectrum antibiotics during the episodes. We support the continued use of massive endoprostheses for bone reconstruction in patients requiring chemotherapy. AD - Department of Orthopaedic Surgery, Bowman Gray School of Medicine of Wake Forest University, Winston-Salem, NC 27157-1070, USA. FAU - Ward, W G AU - Ward WG FAU - Johnston-Jones, K AU - Johnston-Jones K FAU - Lowenbraun, S AU - Lowenbraun S FAU - Dorey, F AU - Dorey F FAU - Rosen, G AU - Rosen G FAU - Eckardt, J J AU - Eckardt JJ LA - eng PT - Journal Article PL - UNITED STATES TA - J South Orthop Assoc JT - Journal of the Southern Orthopaedic Association JID - 9211289 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antineoplastic Agents) SB - IM MH - Adolescent MH - Adult MH - Anti-Bacterial Agents MH - *Antibiotic Prophylaxis MH - Antineoplastic Agents/administration & dosage/*adverse effects MH - Bone Neoplasms/drug therapy/*surgery MH - Chemotherapy, Adjuvant MH - Child MH - Child, Preschool MH - Drug Therapy, Combination/therapeutic use MH - Female MH - Follow-Up Studies MH - Fractures, Spontaneous/*surgery MH - Humans MH - Male MH - Middle Aged MH - Neutropenia/chemically induced/immunology MH - Prospective Studies MH - Prosthesis-Related Infections/immunology/*prevention & control MH - Surgical Wound Infection/immunology/*prevention & control EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 PST - ppublish SO - J South Orthop Assoc. 1997 Fall;6(3):180-5. PMID- 9299752 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20041117 PUBM- Print IS - 0301-486X (Print) VI - 137 IP - 1 DP - 1997 TI - Disseminated dermatophytosis caused by Microsporum gypseum in two patients with the acquired immunodeficiency syndrome. PG - 9-12 AB - Microsporum gypseum is not a common agent of human dermatophytosis. To the best of our knowledge, this fungus has not been described in human immunodeficiency virus (HIV)-infected patients. We report a tinea corporis infection with atypical presentation caused by M. gypseum in two patients with the acquired immunodeficiency syndrome (AIDS) studied at the Sao Paulo Hospital (Sao Paulo, Brazil). AD - Departamento de Dermatologia, Escola Paulista de Medicina, Univerisidade Federal de Sao Paulo, Brazil. FAU - Porro, A M AU - Porro AM FAU - Yoshioka, M C AU - Yoshioka MC FAU - Kaminski, S K AU - Kaminski SK FAU - Palmeira, M do C AU - Palmeira Mdo C FAU - Fischman, O AU - Fischman O FAU - Alchorne, M M AU - Alchorne MM LA - eng PT - Case Reports PT - Journal Article PL - NETHERLANDS TA - Mycopathologia JT - Mycopathologia JID - 7505689 RN - 0 (Antifungal Agents) RN - 0 (Piperazines) RN - 0 (Triazoles) SB - IM SB - X MH - Acquired Immunodeficiency Syndrome/*complications MH - Adult MH - Antifungal Agents/therapeutic use MH - Dermatomycoses/*complications/drug therapy/pathology MH - Female MH - Hand Dermatoses/pathology MH - Humans MH - Male MH - *Microsporum MH - Onychomycosis/pathology MH - Piperazines/therapeutic use MH - Skin/pathology MH - Triazoles/therapeutic use EDAT- 1997/01/01 00:00 MHDA- 1997/09/23 00:01 PST - ppublish SO - Mycopathologia. 1997;137(1):9-12. PMID- 9377115 OWN - NLM STAT- MEDLINE DA - 19971031 DCOM- 19971031 LR - 20061115 PUBM- Print VI - 44 IP - 3 DP - 1997 May-Jun TI - [Serous otitis media. Comparative study of carbinoxamine- pseudoephedrine vs astemizole-pseudoephedrine] PG - 70-3 AB - They were studied 48 children of 3 to 8 years old, of two sex (30 male and 18 female), that attended the external service of otolaryngology of the Hospital of the ISSSTE of Nuevo Laredo, Tamaulipas (Mexico) and the private practice of the Allergy Clinic and Otolaringol in Nuevo Laredo, Tamaulipas, of the month of November of 1995 to April of 1996. Some of the side effects observed in the patients treated in the group A (carbinoxamine-P) were: mild sedation and in some instances hyperexcitability and irritability. However, it was not necessary to discontinue the medication or to modify the dose. In the group B (astemizole-P) was observed only excitement and irritability in some instances by hypersensitivity to the pseudoephedrine. It is very important to consider that the adequate and timely treatment in a patient with otitis serous media will permit to avoid sequels that they can cause, in the long run, a meaningful impact in the language and intellectual development of the child. AD - Pediatra alergologa, Hospital San Jose, Nuevo Laredo, Tamps. FAU - Perez Carmona, N J AU - Perez Carmona NJ FAU - Garcia, M A AU - Garcia MA FAU - Fuentes Rejon, T AU - Fuentes Rejon T LA - spa PT - Clinical Trial PT - Comparative Study PT - Controlled Clinical Trial PT - English Abstract PT - Journal Article TT - Otitis media serosa. Estudio comparativo de carbinoxamina-pseudoefedrina vs astemizol-pseudoefedrina. PL - MEXICO TA - Rev Alerg Mex JT - Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) JID - 9438824 RN - 0 (Histamine H1 Antagonists) RN - 0 (Nasal Decongestants) RN - 0 (Pyridines) RN - 299-42-3 (Ephedrine) RN - 486-16-8 (carbinoxamine) RN - 68844-77-9 (Astemizole) SB - IM MH - Astemizole/administration & dosage/adverse effects/*therapeutic use MH - Child MH - Child, Preschool MH - Drug Therapy, Combination MH - Ephedrine/administration & dosage/adverse effects/*therapeutic use MH - Female MH - Histamine H1 Antagonists/administration & dosage/adverse effects/*therapeutic use MH - Humans MH - Hyperkinesis/chemically induced MH - Male MH - Nasal Decongestants/administration & dosage/adverse effects/*therapeutic use MH - Otitis Media with Effusion/*drug therapy MH - Pyridines/administration & dosage/adverse effects/*therapeutic use MH - Sleep Stages MH - Treatment Outcome EDAT- 1997/05/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Rev Alerg Mex. 1997 May-Jun;44(3):70-3. PMID- 9379424 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20041117 PUBM- Print IS - 0904-2512 (Print) VI - 26 IP - 8 DP - 1997 Sep TI - Immunohistochemical distribution of lymph capillaries and blood capillaries in the synovial membrane in cases of internal derangement of the temporomandibular joint. PG - 356-61 AB - The distribution of lymph capillaries and blood capillaries in the synovial membrane was examined immunohistologically with anti-human collagen IV antibody and anti-human von Willebrand factor in 26 human temporomandibular joint (TMJ) samples comprising discs with adjoining synovial membrane from 10 control TMJs and from 16 TMJs with internal derangement. Three different distribution types were observed in the synovial membrane. In the control samples, the occurrence of blood capillaries and lymph capillaries was rare. In mildly hyperplastic synovitis, lymph capillaries were observed just beneath the surface of the synovial membrane, whereas blood capillaries occurred in a little deeper layer of the synovial membrane. In a severely hyperplastic synovitis, both lymph and blood capillaries were observed frequently. The present results suggest that the different distribution patterns of lymph capillaries and blood capillaries reflect the degree of synovitis but can not be attributed to specific clinical symptoms. AD - Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kyoto University, Japan. FAU - Yoshida, H AU - Yoshida H FAU - Fujita, S AU - Fujita S FAU - Nishida, M AU - Nishida M FAU - Iizuka, T AU - Iizuka T LA - eng PT - Journal Article PL - DENMARK TA - J Oral Pathol Med JT - Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology JID - 8911934 RN - 0 (von Willebrand Factor) RN - 9007-34-5 (Collagen) SB - D SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Capillaries/*pathology MH - Collagen/analysis MH - Dislocations/*pathology MH - Female MH - Humans MH - Hyperplasia MH - Immunohistochemistry MH - Lymphatic System/*pathology MH - Male MH - Middle Aged MH - Osteoarthritis/pathology MH - Synovial Membrane/blood supply/*pathology MH - Synovitis/pathology MH - Temporomandibular Joint/blood supply/pathology MH - Temporomandibular Joint Disk/blood supply/*pathology MH - Temporomandibular Joint Disorders/pathology MH - von Willebrand Factor/analysis EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - J Oral Pathol Med. 1997 Sep;26(8):356-61. PMID- 9347012 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20061115 PUBM- Print IS - 0003-3898 (Print) VI - 55 IP - 5 DP - 1997 Sep-Oct TI - [Reference values of apolipoproteins A1 and B. Contribution of international standardization. Travail collaboratif entre la SFBC, l'Arcol et le SFRL] PG - 451-4 AB - The utilization of two WHO reference materials, liquid and lyophilized, permitted international standardization of apolipoprotein measurements. We report here the results of a collaborative study between Arcol, SFBC and SFRL in order to establish reference ranges for apo A1 and B on nine standardized systems. A population of 1027 men and women supposed healthy, 4 to 60 year old, have been selected in two Centers for Preventive Medicine. The serum samples were aliquoted frozen at -20 degrees C the day of sampling and analysed by the manufacturers with IFCC standardized calibrants. A specific quality control was performed using a frozen pool of sera. For apo A1, the centile 2.5 of the reference population varies from 1.04 to 1.16 g/l. The range values for the centile 97.5 varies from 1.87 to 2.24 g/l. For apoB, the centile 2.5 varies from 0.43 to 0.57 g/l, and the centile 97.5 from 1.30 to 1.39 g/l. Only one system has a problem of dispersion with an upper limit equal to 1.20 g/l. These results improve that international standardization allowed actually a good comparability of the results, especially for apoB. AD - Laboratoire du Centre de medecine preventive, Vandoeuvre-les-Nancy. FAU - Steinmetz, J AU - Steinmetz J FAU - Caces, E AU - Caces E FAU - Couderc, R AU - Couderc R FAU - Beucler, I AU - Beucler I FAU - Legrand, A AU - Legrand A FAU - Henny, J AU - Henny J LA - fre PT - English Abstract PT - Journal Article TT - Valeurs de reference des apolipoproteines A1 et B. Apport de la standardisation internationale. Travail collaboratif entre la SFBC, l'Arcol et le SFRL. PL - FRANCE TA - Ann Biol Clin (Paris) JT - Annales de biologie clinique JID - 2984690R RN - 0 (Apolipoprotein A-I) RN - 0 (Apolipoproteins B) SB - IM MH - Adolescent MH - Adult MH - Apolipoprotein A-I/blood/*standards MH - Apolipoproteins B/blood/*standards MH - Child MH - Child, Preschool MH - Female MH - Humans MH - *International Cooperation MH - Male MH - Middle Aged MH - Reference Standards MH - Reference Values EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Ann Biol Clin (Paris). 1997 Sep-Oct;55(5):451-4. PMID- 9315328 OWN - NLM STAT- MEDLINE DA - 19971105 DCOM- 19971105 LR - 20051117 PUBM- Print IS - 0895-3988 (Print) VI - 10 IP - 2-3 DP - 1997 Sep TI - Two new selenoproteins found in the prostatic glandular epithelium and in the spermatid nuclei. PG - 340-5 AB - After labeling of rats in vivo with 75Se and protein separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis more than 25 Se-containing bands could be distinguished. Of those proteins which were detected only in certain compartments and might therefore have tissue-specific functions, two were chosen for detailed investigation. A 15 kDa-protein was found in the prostatic epithelium where it accounted for about two thirds of the protein-bound 75Se. It was mainly present in the cytosol but was not released into the prostatic secretion. After gel chromatography it was found in the fraction which contained proteins with molecular masses of about 300 kDa. Using two-dimensional electrophoresis a pI-value of about 4.5 was determined. In the testis a specific Se-containing 34 kDa-protein was observed which appeared after the onset of puberty. It was localized in the spermatid nuclei where it contained about 80% of the Se tracer present and was found to be bound to the DNA. After extraction it partly disintegrated into a 20 kDa-protein. Both compounds contain Se in the form of selenocysteine. The fact that their formation had priority over that of glutathione peroxidase during insufficient Se intake is an indication of their biological significance. Special interest in the prostatic epithelial selenoprotein derives from a possible inverse relationship between the Se status and the incidence of prostate cancer observed in epidemiological studies, whereas with the 34 kDa-selenoprotein its appearance during the condensation phase of the spermatid nuclei might suggest its participation in some processes of sperm maturation. AD - Hahn-Meitner-Institut Berlin, Department Trace Elements in Health and Nutrition, Germany. FAU - Behne, D AU - Behne D FAU - Kyriakopoulos, A AU - Kyriakopoulos A FAU - Kalcklosch, M AU - Kalcklosch M FAU - Weiss-Nowak, C AU - Weiss-Nowak C FAU - Pfeifer, H AU - Pfeifer H FAU - Gessner, H AU - Gessner H FAU - Hammel, C AU - Hammel C LA - eng PT - Journal Article PL - UNITED STATES TA - Biomed Environ Sci JT - Biomedical and environmental sciences : BES JID - 8909524 RN - 0 (Proteins) RN - 0 (Selenoproteins) RN - 0 (Sep15 protein, rat) SB - IM MH - Animals MH - Cell Nucleus/*metabolism MH - Epithelial Cells/metabolism MH - Male MH - Prostate/*metabolism MH - Proteins/*isolation & purification/metabolism MH - Rats MH - Selenoproteins MH - Spermatids/*metabolism EDAT- 1997/10/07 MHDA- 1997/10/07 00:01 PST - ppublish SO - Biomed Environ Sci. 1997 Sep;10(2-3):340-5. PMID- 9341945 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20050518 PUBM- Print IS - 0940-9602 (Print) VI - 179 IP - 5 DP - 1997 Oct TI - Angioarchitectural classification of the fungiform papillae on the dorsal surface of the bullfrog tongue. PG - 393-7 AB - In this study, the three-dimensional anatomy of the microvascular structure of fungiform papillae (FuP) on the dorsal surface of the bullfrog tongue has been investigated using scanning electron microscopy (SEM), and angioarchitectural classification has been carried out by means of the capillary loop (L. s) and intra-bridge structure (I. b). FuP from 30 sound bullfrog tongues were used. The following research methods were applied: SEM observation on microvascular cast specimens (MVCS) of bullfrog tongue's FuP were injected with synthetic resin (Mercox). Observation of MVSC showed that the bullfrog tongue FuP consisted of an ascending branch (A. b), L. s, I. b and a descending branch (D. b). Based upon SEM observations of MVCS, FuP can be classified into four types: A, B, C, D types according to A. b, L. s, I. b and D. b. A-type (none I. b) formed from A. b, L. s, D. b only and with no I. b. B-type (one I. b) consisted of A. b, L. s, D. b and one I. b. C-type (two I. b) were composed of A. b, L. s, D. b and two I. b. D-type (three I. b) were composed of A. b, L. s, D. b and three I. b, A. b, L. s, I. b and D. b on each. A, B, C, D types were all same thickness. AD - Department of Physiology, School of Dentistry at Tokyo, Nippon Dental University, Japan. FAU - Ojima, K AU - Ojima K FAU - Takeda, M AU - Takeda M FAU - Saiki, C AU - Saiki C FAU - Takahashi, T AU - Takahashi T FAU - Matsumoto, S AU - Matsumoto S LA - eng PT - Journal Article PL - GERMANY TA - Ann Anat JT - Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft JID - 100963897 SB - IM MH - Animals MH - Capillaries/ultrastructure MH - Female MH - Male MH - Microcirculation/*ultrasonography MH - Microscopy, Electron, Scanning MH - Models, Structural MH - Rana catesbeiana/*anatomy & histology MH - Tongue/*anatomy & histology/*blood supply EDAT- 1997/10/28 MHDA- 1997/10/28 00:01 PST - ppublish SO - Ann Anat. 1997 Oct;179(5):393-7. PMID- 9378660 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20001218 PUBM- Print IS - 0017-9078 (Print) VI - 73 IP - 5 DP - 1997 Nov TI - A prioritization and analysis strategy for environmental surveillance results. PG - 826-30 AB - DOE facilities are required to conduct environmental surveillance to verify that facility operations are operated within the approved risk envelope and have not caused undue risk to the public and the environment. Given a reduced budget, a strategy for analyzing environmental surveillance data was developed to set priorities for sampling needs. The radiological and metal data collected at Sandia National Laboratories, New Mexico, were used to demonstrate the analysis strategy. Sampling locations were prioritized for further investigation and the needs for routine sampling. The process of data management, analysis, prioritization, and presentation has been automated through a custom-designed computer tool. Data collected over years can be analyzed and summarized in a short table format for prioritization and decision making. AD - Sandia National Laboratories, Albuquerque, NM 87185-0748, USA. FAU - Shyr, L J AU - Shyr LJ FAU - Herrera, H AU - Herrera H FAU - Haaker, R AU - Haaker R LA - eng PT - Journal Article PL - UNITED STATES TA - Health Phys JT - Health physics JID - 2985093R RN - 0 (Cesium Radioisotopes) RN - 0 (Metals) RN - 0 (Soil Pollutants) RN - 0 (Soil Pollutants, Radioactive) RN - 10028-17-8 (Tritium) SB - IM MH - Cesium Radioisotopes/analysis MH - Conservation of Natural Resources/*methods MH - Environmental Pollution/*prevention & control MH - Government Agencies MH - Metals/analysis MH - New Mexico MH - *Radiation Protection MH - Soil Pollutants/analysis MH - Soil Pollutants, Radioactive/*analysis MH - Tritium/analysis MH - United States EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Health Phys. 1997 Nov;73(5):826-30. PMID- 9380039 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20061115 PUBM- Print IS - 0026-895X (Print) VI - 52 IP - 4 DP - 1997 Oct TI - 21-Hydroxy-6,19-oxidoprogesterone: a novel synthetic steroid with specific antiglucocorticoid properties in the rat. PG - 749-53 AB - In the rat, the conformationally highly bent steroid 21-hydroxy-6, 19-oxidoprogesterone efficiently displaces [3H]corticosterone from thymus-glucocorticoid receptors and blocks type II receptors in kidney cytosols but competes with neither [3H]aldosterone for kidney-mineralocorticoid receptors nor [3H]progesterone for uterus-progesterone receptors. It evokes Na+ retention only at very high doses (approximately 100 microg/100 g of rat weight) and is unable to induce tyrosine aminotransferase or to increase glycogen deposits in rat liver. When coincubated with corticosterone or dexamethasone, 2.5 microM 21OH-6OP inhibits 80% of tyrosine aminotransferase induction. It may therefore be used experimentally as an antiglucocorticoid virtually lacking mineralocorticoid or glucocorticoid properties as well as affinity for mineralocorticoid or progesterone receptors. AD - Departamentos de Quimica Biologica, Universidad de Buenos Aires and PRHOM-Consejo Nacional de Investigaciones Cientificas y Tecnicas, Ciudad Universitaria, (1428) Buenos Aires, Argentina. FAU - Vicent, G P AU - Vicent GP FAU - Monteserin, M C AU - Monteserin MC FAU - Veleiro, A S AU - Veleiro AS FAU - Burton, G AU - Burton G FAU - Lantos, C P AU - Lantos CP FAU - Galigniana, M D AU - Galigniana MD LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Mol Pharmacol JT - Molecular pharmacology JID - 0035623 RN - 0 (21-hydroxy-6,19-oxidoprogesterone) RN - 0 (Androstanols) RN - 0 (Receptors, Glucocorticoid) RN - 0 (Receptors, Mineralocorticoid) RN - 10028-17-8 (Tritium) RN - 52-01-7 (Spironolactone) RN - 52-39-1 (Aldosterone) RN - 57-83-0 (Progesterone) RN - 74915-64-3 (11,17-dihydroxy-6-methyl-17-(1-propynyl)androsta-1,4,6-triene-3-one) RN - 84542-26-7 (ZK 91587) RN - 9010-38-2 (Transcortin) SB - IM MH - Aldosterone/metabolism MH - Androstanols/metabolism MH - Animals MH - Kidney/metabolism MH - Male MH - Progesterone/*analogs & derivatives/chemistry/metabolism/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Receptors, Glucocorticoid/*antagonists & inhibitors/metabolism MH - Receptors, Mineralocorticoid/metabolism MH - Spironolactone/analogs & derivatives/metabolism MH - Structure-Activity Relationship MH - Thymus Gland/metabolism MH - Transcortin/metabolism MH - Tritium EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 PST - ppublish SO - Mol Pharmacol. 1997 Oct;52(4):749-53. PMID- 9288441 OWN - NLM STAT- MEDLINE DA - 19971024 DCOM- 19971024 LR - 20051116 PUBM- Print IS - 0706-7437 (Print) VI - 42 Suppl 2 DP - 1997 Aug TI - Bipolar depression: treatment options. PG - 87S-91S AB - OBJECTIVE: To review studies on treatments for bipolar depression and make recommendations for practising clinicians treating patients with bipolar depression. METHOD: Studies that examined various treatments for bipolar depression were evaluated and rated for evidence of efficacy using Periodic Health Examination criteria. The rating for classification of recommendation for an intervention was made taking both the efficacy and the side effects into consideration. RESULTS: Mood stabilizers, cyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and electroconvulsive therapy (ECT) are all effective in treating bipolar depression. Almost all antidepressant treatments with the exception of mood stabilizers have been reported to induce a manic-hypomanic switch and rapid cycling. CONCLUSIONS: Mood stabilizers, lithium in particular, are recommended as the first-line treatment. Addition of a second mood stabilizer or a cyclic antidepressant would be an appropriate next step. Newer agents such as lamotrigine offer considerable promise in treating bipolar depressed patients. AD - Department of Psychiatry, University of British Columbia, Vancouver. yatham@unixg.ubc.ca FAU - Yatham, L N AU - Yatham LN FAU - Kusumakar, V AU - Kusumakar V FAU - Parikh, S V AU - Parikh SV FAU - Haslam, D R AU - Haslam DR FAU - Matte, R AU - Matte R FAU - Sharma, V AU - Sharma V FAU - Kennedy, S AU - Kennedy S LA - eng PT - Journal Article PT - Review PL - CANADA TA - Can J Psychiatry JT - Canadian journal of psychiatry. Revue canadienne de psychiatrie JID - 7904187 RN - 0 (Antidepressive Agents) SB - IM MH - Antidepressive Agents/adverse effects/*therapeutic use MH - Bipolar Disorder/*drug therapy/psychology MH - Combined Modality Therapy MH - Depressive Disorder/*drug therapy/psychology MH - Drug Therapy, Combination MH - Electroconvulsive Therapy MH - Humans MH - Treatment Outcome RF - 71 EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 PST - ppublish SO - Can J Psychiatry. 1997 Aug;42 Suppl 2:87S-91S. PMID- 9228551 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0162-3109 (Print) VI - 36 IP - 2-3 DP - 1997 Jun TI - Kallikrein gene therapy: a new strategy for hypertensive diseases. PG - 229-36 AB - The tissue kallikrein-kinin system has been postulated to play a role in blood pressure homeostasis and the pathogenesis of clinical hypertension. To demonstrate the potential therapeutic effects of somatic gene delivery in treating hypertension, we used spontaneously hypertensive rats (SHR) as a model. The gene encoding the human tissue kallikrein was used because of its powerful hypotensive action. The human kallikrein DNA constructs were placed under the control of the metallothionein metal response element, the cytomegalovirus promoter/enhancer or the Rous sarcoma virus 3'-LTR. The human tissue kallikrein DNA constructs were incorporated into adenoviral vectors via homologous recombination. The naked plasmid DNA constructs or adenovirus containing the kallikrein gene were first introduced into kidney 293 cells and the expression of human tissue kallikrein was identified by ELISA. The kallikrein gene was delivered into SHR via intramuscular, intravenous, portal vein, intraperitoneal, and intracerebroventricular routes. A single injection of naked human kallikrein DNA constructs caused a prolonged reduction of high blood pressure for up to 8 weeks. Adenoviral-mediated gene delivery results in high efficiency of human tissue kallikrein expression. Immunoreactive human kallikrein was detected in rat serum at the highest level at 1 day post gene delivery. Portal vein delivery of a reporter gene, AdCMV-LacZ, results in intense staining of beta-galactosidase in rat liver, suggesting that recombinant kallikrein is mainly produced in liver and secreted into the circulation. These results show that kallikrein gene delivery causes a sustained reduction of blood pressure in genetically hypertensive rats and provide important information for a potential gene therapy approach to human hypertension and related diseases. AD - Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425-2211, USA. FAU - Chao, J AU - Chao J FAU - Chao, L AU - Chao L LA - eng GR - HL 29397/HL/NHLBI GR - HL 56686/HL/NHLBI PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - NETHERLANDS TA - Immunopharmacology JT - Immunopharmacology JID - 7902474 RN - 0 (DNA, Viral) RN - 9038-94-2 (Metallothionein) RN - EC 3.2.1.23 (beta-Galactosidase) RN - EC 3.4.21.- (Kallikreins) RN - EC 3.4.21.35 (Tissue Kallikreins) SB - IM MH - Animals MH - Avian Sarcoma Viruses/genetics MH - Blood Pressure/drug effects/genetics/physiology MH - Cytomegalovirus/genetics MH - DNA, Viral/administration & dosage/metabolism MH - Gene Expression Regulation, Viral/genetics MH - *Gene Therapy MH - Genes, Reporter/genetics MH - Genetic Vectors/genetics MH - Humans MH - Hypertension/genetics/physiopathology/*therapy MH - Injections, Intramuscular MH - Injections, Intraperitoneal MH - Injections, Intravenous MH - Injections, Intraventricular MH - Kallikrein-Kinin System/*genetics MH - Kallikreins/administration & dosage/*genetics/pharmacology/therapeutic use MH - Lac Operon MH - Metallothionein/genetics MH - Plasmids MH - Promoter Regions (Genetics) MH - Rats MH - Rats, Inbred SHR MH - Time Factors MH - Tissue Kallikreins MH - beta-Galactosidase/metabolism EDAT- 1997/06/01 MHDA- 1997/06/01 00:01 PST - ppublish SO - Immunopharmacology. 1997 Jun;36(2-3):229-36. PMID- 9263235 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0899-9007 (Print) VI - 13 IP - 6 DP - 1997 Jun TI - Effects of growth hormone and insulin-like growth factor-1 on protein metabolism, gut morphology, and cell-mediated immunity in burned rats. PG - 540-6 AB - The effects of recombinant human growth hormone (GH) and insulin-like growth factor-1 (IGF-1) were investigated in burned rats. Sprague-Dawley rats were fed exclusively by total parenteral nutrition and were subjected to 20% third-degree scald burns. The rats were then divided into the following three groups: (1) the GH group received GH at a dose of 1 IU.kg-1.d-1 for 2d (n = 10); (2) the IGF group received IGF-1 at a dose of 4 mg.kg-1.d-1 for 2d (n = 19); and (3) the control group received saline (n = 17). Cumulative nitrogen balance increased significantly in the GH (P < 0.01) and IGF (P < 0.01) groups as compared with the control group. There were no differences in nitrogen balance between the GH and IGF groups. Blood glucose was decreased in the IGF group (P < 0.01) and increased in the GH group (P < 0.05) as compared with the control group. The intestinal villus height and wall thickness of the GH and IGF groups were significantly greater than those of the control group. Delayed-type hypersensitivity was enhanced in both the GH and the IGF groups as compared with the control group (both P < 0.01). Furthermore, the increase in the IGF group was significantly greater than that in the GH group (P < 0.05). It was concluded that both GH and IGF-1 improve protein metabolism and immune responsiveness, as well as promote proliferation of the intestinal mucosa. AD - First Department of Surgery, School of Medicine, Chiba University, Japan. FAU - Shimoda, N AU - Shimoda N FAU - Tashiro, T AU - Tashiro T FAU - Yamamori, H AU - Yamamori H FAU - Takagi, K AU - Takagi K FAU - Nakajima, N AU - Nakajima N FAU - Ito, I AU - Ito I LA - eng PT - Comparative Study PT - Journal Article PL - UNITED STATES TA - Nutrition JT - Nutrition (Burbank, Los Angeles County, Calif.) JID - 8802712 RN - 0 (Blood Glucose) RN - 0 (Dietary Proteins) RN - 0 (Recombinant Proteins) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 7727-37-9 (Nitrogen) RN - 9002-72-6 (Growth Hormone) SB - IM MH - Animals MH - Blood Chemical Analysis MH - Blood Glucose/analysis/drug effects/metabolism MH - Body Weight/physiology MH - Burns/*immunology/*metabolism MH - Dietary Proteins/*drug effects/*metabolism MH - Growth Hormone/*pharmacology MH - Humans MH - Hypersensitivity, Delayed/physiopathology MH - Immunity, Cellular/*drug effects MH - Insulin-Like Growth Factor I/*pharmacology MH - Intestine, Small/*anatomy & histology/*drug effects MH - Kidney/anatomy & histology MH - Male MH - Nitrogen/analysis/metabolism MH - Organ Size MH - Pancreas/anatomy & histology MH - Rats MH - Rats, Sprague-Dawley MH - Recombinant Proteins/pharmacology MH - Stomach/anatomy & histology MH - Thymus Gland/anatomy & histology EDAT- 1997/06/01 MHDA- 1997/06/01 00:01 PST - ppublish SO - Nutrition. 1997 Jun;13(6):540-6. PMID- 9325098 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0022-2836 (Print) VI - 272 IP - 3 DP - 1997 Sep 26 TI - The crystal structure of the catalytic core domain of endoglucanase I from Trichoderma reesei at 3.6 A resolution, and a comparison with related enzymes. PG - 383-97 AB - Cellulose is the most abundant polymer in the biosphere. Although generally resistant to degradation, it may be hydrolysed by cellulolytic organisms that have evolved a variety of structurally distinct enzymes, cellobiohydrolases and endoglucanases, for this purpose. Endoglucanase I (EG I) is the major endoglucanase produced by the cellulolytic fungus Trichoderma reesei, accounting for 5 to 10% of the total amount of cellulases produced by this organism. Together with EG I from Humicola insolens and T. reesei cellobiohydrolase I (CBH I), the enzyme is classified into family 7 of the glycosyl hydrolases, and it catalyses hydrolysis with a net retention of the anomeric configuration.The structure of the catalytic core domain (residues 1 to 371) of EG I from T. reesei has been determined at 3.6 A resolution by the molecular replacement method using the structures of T. reesei CBH I and H. insolens EG I as search models. By employing the 2-fold non-crystallographic symmetry (NCS), the structure was refined successfully, despite the limited resolution. The final model has an R-factor of 0.201 (Rfree 0.258).The structure of EG I reveals an extended, open substrate-binding cleft, rather than a tunnel as found in the homologous cellobiohydrolase CBH I. This confirms the earlier proposal that the tunnel-forming loops in CBH I have been deleted in EG I, which has resulted in an open active site in EG I, enabling it to function as an endoglucanase. Comparison of the structure of EG I with several related enzymes reveals structural similarities, and differences that relate to their biological function in degrading particular substrates. A possible structural explanation of the drastically different pH profiles of T. reesei and H. insolens EG I is proposed. CI - Copyright 1997 Academic Press Limited. AD - Biomedical Centre, Uppsala University, Uppsala, SE-751 24, Sweden. FAU - Kleywegt, G J AU - Kleywegt GJ FAU - Zou, J Y AU - Zou JY FAU - Divne, C AU - Divne C FAU - Davies, G J AU - Davies GJ FAU - Sinning, I AU - Sinning I FAU - Stahlberg, J AU - Stahlberg J FAU - Reinikainen, T AU - Reinikainen T FAU - Srisodsuk, M AU - Srisodsuk M FAU - Teeri, T T AU - Teeri TT FAU - Jones, T A AU - Jones TA LA - eng SI - PDB/1EG1 SI - PDB/R1EG1SF PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - J Mol Biol JT - Journal of molecular biology JID - 2985088R RN - 0 (Peptide Fragments) RN - 16462-44-5 (Cellobiose) RN - 9004-34-6 (Cellulose) RN - EC 3.2.1.4 (Cellulase) RN - EC 3.2.1.91 (Cellulose 1,4-beta-Cellobiosidase) SB - IM MH - Amino Acid Sequence MH - Bacillus/enzymology MH - Binding Sites MH - Cellobiose/metabolism MH - Cellulase/*chemistry MH - Cellulose/metabolism MH - Cellulose 1,4-beta-Cellobiosidase MH - Computer Simulation MH - Conserved Sequence MH - Crystallography, X-Ray MH - Mitosporic Fungi/enzymology MH - Models, Molecular MH - Molecular Sequence Data MH - Peptide Fragments/*chemistry MH - Protein Conformation MH - Protein Engineering MH - Sequence Deletion MH - Sequence Homology, Amino Acid MH - Species Specificity MH - Trichoderma/*enzymology EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 AID - S0022-2836(97)91243-2 [pii] AID - 10.1006/jmbi.1997.1243 [doi] PST - ppublish SO - J Mol Biol. 1997 Sep 26;272(3):383-97. PMID- 9305568 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0832-610X (Print) VI - 44 IP - 9 DP - 1997 Sep TI - Tacrine does not alter the potency of succinylcholine in the rat. PG - 1021-6 AB - PURPOSE: Tacrine is a cholinesterase inhibitor used to manage Alzheimer's dementia. Given iv, it prolongs succinylcholine blockade in humans but the effects of chronic oral tacrine are not known. METHODS: Groups of adult rats were given 2.5 mg.kg-1 tacrine (chronic groups) or l ml saline (control) twice daily by gavage for one, two, four or eight weeks. An additional (acute) group received 2.5 mg.kg-1 tacrine iv. Twelve to 18 hr after the last gavage of tacrine or saline, and -20 min after iv tacrine, cumulative dose-response curves of succinylcholine were determined in the tibialis and soleus muscles in anaesthetized, ventilated rats during monitoring of evoked twitch response to indirect (nerve) train-of-four stimulation. RESULTS: The ED50 and ED95 of succinylcholine in control rats were (mean +/- SD) 204 +/- 41 and 382 +/- 96 micrograms.kg-1, respectively in the tibialis muscle, and 280 +/- 52 and 629 +/- 168 micrograms.kg-1 in the soleus muscle (P < 0.05 between muscles). In the acute and chronic tacrine groups, the mean ED50 and ED95 ranged from 166-197 and 277-396 micrograms.kg-1., respectively, in the tibialis muscle, and 248-333 and 546-667 micrograms.kg-1, in the soleus muscle. Dose responses did not differ among acute and chronic tacrine groups and the control group. CONCLUSION: Chronic oral tacrine does not alter muscle response to succinylcholine in the rat. This may not apply to Alzheimer patients receiving chronic tacrine since the interaction between acute tacrine and succinylcholine in the rat differs from that in humans. AD - Department of Anaesthesia, Royal Victoria Hospital, Montreal, Quebec, Canada. FAU - Ibebunjo, C AU - Ibebunjo C FAU - Eshelby, D AU - Eshelby D FAU - Donati, F AU - Donati F FAU - Fox, G S AU - Fox GS FAU - Tchervenkov, J I AU - Tchervenkov JI LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - CANADA TA - Can J Anaesth JT - Canadian journal of anaesthesia = Journal canadien d'anesthesie JID - 8701709 RN - 0 (Cholinesterase Inhibitors) RN - 0 (Neuromuscular Depolarizing Agents) RN - 306-40-1 (Succinylcholine) RN - 321-64-2 (Tacrine) SB - IM MH - Administration, Oral MH - Alzheimer Disease/drug therapy MH - Animals MH - Cholinesterase Inhibitors/administration & dosage/*pharmacology MH - Dose-Response Relationship, Drug MH - Drug Interactions MH - Electric Stimulation MH - Evoked Potentials/drug effects MH - Female MH - Hindlimb MH - Humans MH - Injections, Intravenous MH - Muscle Contraction/drug effects MH - Muscle, Skeletal/drug effects/innervation MH - Neuromuscular Blockade MH - Neuromuscular Depolarizing Agents/administration & dosage/*pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Succinylcholine/administration & dosage/*pharmacology MH - Tacrine/administration & dosage/*pharmacology EDAT- 1997/09/26 MHDA- 1997/09/26 00:01 PST - ppublish SO - Can J Anaesth. 1997 Sep;44(9):1021-6. PMID- 9334875 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20041117 PUBM- Print IS - 0091-4150 (Print) VI - 45 IP - 1 DP - 1997 TI - Intergenerational perceptions of English speaking and Spanish speaking Mexican-American grandparents. PG - 1-21 AB - Hispanics are facing a number of problems, such as poverty, hunger, and a high dropout rate at school. Health-care reform and changes in Medicaid and Medicare are bound to further challenge the resiliency of minority families. To strengthen families from within, relevant programming should be implemented. Information regarding the strengths and needs of Mexican-American grandparents was obtained in order to adapt existing grandparenting programs for this population. Mexican-American grandparents (n = 181), parents (n = 148), and grandchildren (n = 173) provided information on grandparent satisfaction, success, teaching, difficulty, frustration, and information needs. Multivariate analyses of variance found differences for English and Spanish speaking grandparents. Spanish speaking grandparents reported a greater need for information than English speaking grandparents, and more frustration when dealing with adolescents than with younger children. For the English speaking grandparents, all of the generations agreed that grandparents under the age of sixty-one experienced more frustration than their older counterparts, and those who spent more than five hours a month with their grandchildren were more effective in their role. Possible factors that account for the findings are discussed and recommendations for establishing a grandparent program are presented. AD - College of Education, Division of Psychology in Education, Arizona State University, Tempe 85287-0611, USA. FAU - Strom, R D AU - Strom RD FAU - Buki, L P AU - Buki LP FAU - Strom, S K AU - Strom SK LA - eng PT - Journal Article PL - UNITED STATES TA - Int J Aging Hum Dev JT - International journal of aging & human development JID - 0370033 SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Arizona MH - Child MH - Communication MH - Curriculum MH - *Education MH - Female MH - Humans MH - *Intergenerational Relations MH - *Language MH - Male MH - Mexican Americans/*psychology MH - Mexico/ethnology MH - Middle Aged MH - Multivariate Analysis MH - Psychometrics MH - Questionnaires MH - Social Work/*organization & administration EDAT- 1997/01/01 00:00 MHDA- 1997/10/23 00:01 PST - ppublish SO - Int J Aging Hum Dev. 1997;45(1):1-21. PMID- 9350179 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20060424 PUBM- Print IS - 0955-7873 (Print) VI - 740 DP - 1997 TI - Treatment of childhood and adult acute lymphoblastic leukaemia. PG - 29-36 AB - In the last 30 years the treatment of acute lymphoblastic leukaemia has radically changed and intensified and has resulted in improvements in the chances of cure in children to up to 70% but in adults only 30% will achieve long-term disease-free survival. Data from large therapeutic trials have determined good and poor prognostic risk factors which have been of use in planning risk-directed treatment protocols and can influence the chance of cure. However intensification of treatment has also been associated with increased toxicity and significant late effects, particularly in children. In the future it will be necessary for more international collaboration and a more uniform approach to treatment in order to achieve continued improvements in the survival from this disease. In children it will be necessary to focus efforts on improving treatment of relapsed patients: chemotherapy protocols in those with a first remission of > 36 months, or for the high-risk patients with a shorter first remission, new transplantation approaches directed towards enhancing the graft-versus-leukaemia effect are going to be of increasing importance. In adults, continued efforts will be directed towards improving first remission rates with the use of increasingly intensive chemotherapeutic protocols and growth factors. The use of unrelated donor transplantation is also likely to increase, particularly in patients with 'poor-risk' disease. AD - Department of Haematology, University College London Hospitals, UK. FAU - Liesner, R AU - Liesner R FAU - Goldstone, A H AU - Goldstone AH LA - eng PT - Journal Article PT - Review PL - ENGLAND TA - J Intern Med Suppl JT - Journal of internal medicine. Supplement JID - 8912975 SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Bone Marrow Transplantation MH - Combined Modality Therapy MH - Humans MH - Leukemia, Lymphocytic, Acute, L1/genetics/immunology/*therapy MH - Leukemia, Lymphocytic, Acute, L2/genetics/immunology/*therapy MH - Remission Induction RF - 68 EDAT- 1997/01/01 00:00 MHDA- 1997/11/14 00:01 PST - ppublish SO - J Intern Med Suppl. 1997;740:29-36. PMID- 9326222 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0006-4971 (Print) VI - 90 IP - 7 DP - 1997 Oct 1 TI - The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. PG - 2565-73 AB - Thrombopoietin (TPO) was evaluated for efficacy in a placebo-controlled study in rhesus monkeys with concurrent administration of either granulocyte/macrophage colony-stimulating factor (GM-CSF) or granulocyte CSF, (G-CSF). Rhesus monkeys were subjected to 5 Gy total-body irradiation (TBI), resulting in 3 weeks of profound pancytopenia, and received either TPO 5 microg/kg intravenously (I.V.) at day 1 (n = 4), GM-CSF 25 microg/kg subcutaneously (S.C.) for 14 days (n = 4), TPO and GM-CSF (n = 4), G-CSF 10 microg/kg/d S.C. for 14 days (n = 3), TPO and G-CSF (n = 4), or placebo (carrier, n = 4; historical controls, n = 8). Single-dose I.V. treatment with TPO 1 day after TBI effectively counteracted the need for thrombocyte transfusions (provided whenever thrombocyte levels were <40 x 10(9)/L) and accelerated platelet reconstitution to normal levels 2 weeks earlier than placebo controls. TPO/GM-CSF was more effective than single-dose TPO alone in stimulating thrombocyte regeneration, with a less profound nadir and a further accelerated recovery to normal thrombocyte counts, as well as a slight overshoot to supranormal levels of thrombocytes. Monkeys treated with TPO/GM-CSF uniformly did not require thrombocyte transfusions, whereas those treated with GM-CSF alone needed two to three transfusions, similar to the placebo-treated monkeys, which required, on average, three transfusions. Also, reticulocyte production was stimulated by TPO and further augmented in monkeys treated with TPO/GM-CSF. TPO alone did not stimulate neutrophil regeneration, whereas GM-CSF shortened the period of neutrophil counts less than 0.5 x 10(9)/L by approximately 1 week; TPO/GM-CSF treatment elevated the neutrophil nadir, but did not further accelerate recovery to normal values. TPO also augemented the neturophil response to G-CSF, resulting in similar patterns of reconstitution following TPO/G-CSF and TPO/GM-CSF treatment. TPO/GM-CSF resulted in significantly increased reconstitution of CD34+ bone marrow cells and progenitor cells such as GM-CFU and BFU-E. Adverse effects of combining TPO with the CSFs were not observed. It is concluded that (1) a single I.V. administration of TPO is sufficient to prevent severe thrombocytopenia following myelosuppression, (2) TPO/G-CSF and TPO/GM-CSF treatment result in distinct response patterns, with TPO/GM-CSF being superior to TPO/G-CSF in stimulating thrombocyte and erythrocyte recovery while being equivalent in stimulating neutrophil recovery; and (3) TPO significantly improves the performance of CSFs in alleviating severe neutropenia. AD - Institute of Hematology, Erasmus University Rotterdam, The Netherlands. FAU - Neelis, K J AU - Neelis KJ FAU - Hartong, S C AU - Hartong SC FAU - Egeland, T AU - Egeland T FAU - Thomas, G R AU - Thomas GR FAU - Eaton, D L AU - Eaton DL FAU - Wagemaker, G AU - Wagemaker G LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Blood JT - Blood JID - 7603509 RN - 0 (Recombinant Proteins) RN - 143011-72-7 (Granulocyte Colony-Stimulating Factor) RN - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) RN - 9014-42-0 (Thrombopoietin) SB - AIM SB - IM MH - Animals MH - Blood Cell Count/drug effects MH - Bone Marrow/drug effects MH - Bone Marrow Diseases/*drug therapy/etiology/pathology/therapy MH - Combined Modality Therapy MH - Drug Administration Schedule MH - Drug Therapy, Combination MH - Erythropoiesis/drug effects MH - Granulocyte Colony-Stimulating Factor/*administration & dosage/pharmacology/therapeutic use MH - Granulocyte-Macrophage Colony-Stimulating Factor/*administration & dosage/pharmacology/therapeutic use MH - Hematopoiesis/*drug effects MH - Injections, Intravenous MH - Macaca mulatta MH - Male MH - Neutropenia/blood/drug therapy MH - Neutrophils MH - Platelet Transfusion MH - Radiation Injuries, Experimental/blood/drug therapy/pathology MH - Recombinant Proteins/administration & dosage/pharmacology/therapeutic use MH - Thrombopoietin/*administration & dosage/pharmacology/therapeutic use MH - Whole-Body Irradiation EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Blood. 1997 Oct 1;90(7):2565-73. PMID- 9251867 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20041117 PUBM- Print IS - 0269-9052 (Print) VI - 11 IP - 8 DP - 1997 Aug TI - The relationship between sexual abuse and mild traumatic brain injury. PG - 587-603 AB - It remains unclear why some individuals with mild traumatic brain injury (MTBI) complain of cognitive deficits many months after the injury. Given neuropathological changes associated with prolonged stress, such as occurs with repeated sexual abuse (SA), it seems possible that individuals who experienced SA might be predisposed to greater deficits after MTBI. Four groups of subjects were administered measures of cognitive and emotional functioning. These groups were those with MTBI (n = 10), those with a history of SA (n = 10), those with both MTBI and SA (n = 10), and normal control (NC) subjects (n = 10). Compared to the NC subjects, those with MTBI demonstrated deficits in working memory, those with SA demonstrated deficits in executive functioning, and those with both MTBI and SA demonstrated the greatest number of deficits which were in working memory, executive functioning and memory. Tests of anxiety, depression and post-traumatic stress disorder, while demonstrating significant symptoms in all clinical groups, did not correlate with the neuropsychological tests that differentiated the groups. AD - Department of Psychology, Trinity College, Hartford, CT 06106, USA. FAU - Raskin, S A AU - Raskin SA LA - eng PT - Journal Article PL - ENGLAND TA - Brain Inj JT - Brain injury : [BI] JID - 8710358 SB - IM MH - Adult MH - Affect MH - Brain Injuries/*complications/psychology MH - Child MH - Child Abuse, Sexual/*psychology MH - Child, Preschool MH - Cognition Disorders/etiology MH - Female MH - Humans MH - Neuropsychological Tests MH - Stress Disorders, Post-Traumatic/psychology EDAT- 1997/08/01 MHDA- 1997/08/01 00:01 PST - ppublish SO - Brain Inj. 1997 Aug;11(8):587-603. PMID- 9310011 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 1073-449X (Print) VI - 156 IP - 3 Pt 1 DP - 1997 Sep TI - The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. PG - 901-5 AB - The early bactericidal activity (EBA) of ciprofloxacin (CIP) was measured in 80 patients with previously untreated, smear-positive pulmonary tuberculosis by counting viable bacilli in sputum collections during the first 2 d of treatment. Groups of about 10 patients were treated daily with graded doses of CIP or with 300 mg isoniazid or with no drug. The mean EBA, defined as the fall in log CFU/ ml sputum/d, increased from -0.011 in the no drug group to 0.046, 0.092, 0.121, and 0.205 in the groups receiving 250, 500, 1,000, or 1,500 mg CIP, respectively, a highly significant trend. These results demonstrate the antimycobacterial activity of CIP in high dosage, though the mean EBAs of 0.55 and 0.66 in two groups receiving isoniazid were much higher. AD - South African National Tuberculosis Research Programme, Tygerberg, South Africa. FAU - Sirgel, F A AU - Sirgel FA FAU - Botha, F J AU - Botha FJ FAU - Parkin, D P AU - Parkin DP FAU - Van de Wal, B W AU - Van de Wal BW FAU - Schall, R AU - Schall R FAU - Donald, P R AU - Donald PR FAU - Mitchison, D A AU - Mitchison DA LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Am J Respir Crit Care Med JT - American journal of respiratory and critical care medicine JID - 9421642 RN - 0 (Anti-Infective Agents) RN - 0 (Antitubercular Agents) RN - 54-85-3 (Isoniazid) RN - 85721-33-1 (Ciprofloxacin) SB - AIM SB - IM MH - Adult MH - Anti-Infective Agents/*administration & dosage MH - Antitubercular Agents/*administration & dosage MH - Ciprofloxacin/*administration & dosage MH - Colony Count, Microbial MH - Drug Therapy, Combination MH - Female MH - Humans MH - Isoniazid/*administration & dosage MH - Male MH - Sputum/microbiology MH - Time Factors MH - Treatment Outcome MH - Tuberculosis, Pulmonary/*drug therapy/microbiology EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):901-5. PMID- 9350007 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0142-4319 (Print) VI - 18 IP - 5 DP - 1997 Oct TI - Coordinated fast-to-slow transitions of myosin and SERCA isoforms in chronically stimulated muscles of euthyroid and hyperthyroid rabbits. PG - 545-54 AB - Changes in the patterns of myosin heavy chain (MHC) isoforms, isomyosins, and Ca(2+)-ATPase (SERCA) isoforms were studied in long-term (72 d) stimulated fast-twitch extensor digitorum longus (EDL) and tibialis anterior (TA) muscles of euthyroid and hyperthyroid rabbits. The chronic low-frequency stimulation-induced fast-to-slow transitions in MHC isoforms, isomyosins and SERCA isoforms were pronounced in muscles from euthyroid rabbits, but less pronounced in muscles from hyperthyroid rabbits. Thus, hyperthyroidism counteracted to same extent the stimulation-induced fast-to-slow transition. Analyses of all parameters were performed on the same individual muscles, providing information on the co-ordinated expression of SERCA and myosin isoforms. A high correlation (r = 0.97) was detected between relative concentrations of slow SERCA2a and slow MHCI isoforms. This correlation persisted under all experimental conditions, suggesting a co-ordinated expression of slow myosin and Ca(2+)-ATPase isoforms. Conversely, fast SERCA1a was correlated to fast myosin isoforms as a whole. AD - Fakultat fur Biologie, Universitat Konstanz, Germany. FAU - Hamalainen, N AU - Hamalainen N FAU - Pette, D AU - Pette D LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - ENGLAND TA - J Muscle Res Cell Motil JT - Journal of muscle research and cell motility JID - 8006298 RN - 0 (Isoenzymes) RN - 0 (Myosin Heavy Chains) RN - 0 (Vanadates) RN - EC 3.6.1.4 (Myosins) RN - EC 3.6.1.8 (Calcium-Transporting ATPases) SB - IM SB - S MH - Animals MH - Calcium-Transporting ATPases/isolation & purification/*metabolism MH - Electric Stimulation MH - Electrophoresis, Polyacrylamide Gel MH - Hyperthyroidism/*physiopathology MH - Isoenzymes/isolation & purification/metabolism MH - Muscle Fibers, Fast-Twitch/*physiology MH - Muscle, Skeletal/*physiology/physiopathology MH - Myosin Heavy Chains/metabolism MH - Myosins/isolation & purification/*metabolism MH - Rabbits MH - Reference Values MH - Regression Analysis MH - Thyroid Gland/*physiology/physiopathology MH - Vanadates/pharmacology EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - J Muscle Res Cell Motil. 1997 Oct;18(5):545-54. PMID- 9283235 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20061115 PUBM- Print IS - 0033-2658 (Print) VI - 99 IP - 6 DP - 1997 TI - [Profiles of effects of traditional oriental herbal medicines on central nervous systems in humans--assessment of saiboku-to and saiko-ka-ryukotsu-borei-to using EEG and pharmacokinetics of herbal medicine-derived ingredients as indices] PG - 355-69 AB - To elucidate usefulness of traditional oriental herbal medicines in psychiatric fields, we investigated their influences on central nervous systems in humans by using EEG and pharmacokinetics of herbal medicine-derived ingredients as the indices. The subjects were 12 healthy male volunteers who received single oral administration and after that received repeated oral administrations at a daily dose of Saiko-ka-ryukotsu-borei-to or Saiboku-to; EEG was recorded before administration, 1, 3, 6 hours and 10 days after administration. On direct comparison of global field powers calculated from 19-lead EEG before and after administration, it was verified that Saiboku-to possessed effects on central nervous systems. For assessment of pharmacokinetics of ingredients derived from Saiboku-to, pre- and post-treatment serum samples were assayed by HPLC and two ingredients were detected, besides individual differences being observed in their pharmacokinetic profiles. Given that these pharmacokinetics could be interpreted as the phenomena associated with Sho (traditional physical status classifications of patients), the subjects were classified into groups according to individual differences whereby quantitative pharmaco-EEG were employed to elucidate neurotropic effects of Saiboku-to. As the result, following two groups were evidenced: (1) a group demonstrating the mood elevator type after a single administration despite of no changes after repeated administrations, and (2) a group with a shift from the mood elevator type to the nootropics type being observed over time, delineating overt differences in EEG profiles among groups. Consequently, individual differences were evidenced to be involved in onset of neurotropic effects of Saiboku-to, permitting prediction of possible responses following repeated administrations by using EEG profiles. It was also suggested that neurotropic effects of respective ingredients could be anticipated by monitoring the time-course changes of both EEG and plasma levels of these ingredients. In summary, once further studies on oriental herbal medicines might progress based on efficacy assessments of respective ingredients with a clue of the present study, it is conceivable that these findings would play an important role as the objective indices in clinical application of herbal medicines in psychiatric fields, resulting in broadening the usefulness of oriental herbal medicines. AD - Department of Neuropsychiatry, Kansai Medical University. FAU - Fukushima, M AU - Fukushima M LA - jpn PT - English Abstract PT - Journal Article PL - JAPAN TA - Seishin Shinkeigaku Zasshi JT - Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica JID - 9801787 RN - 0 (Drugs, Chinese Herbal) RN - 0 (saiboku-to) RN - 0 (saiko-ka-ryukotsu-borei-to) SB - IM MH - Adult MH - Brain/*drug effects MH - Chromatography, High Pressure Liquid MH - Drugs, Chinese Herbal/pharmacokinetics/*pharmacology MH - Electroencephalography/*drug effects MH - Humans MH - Male MH - *Medicine, Kampo EDAT- 1997/01/01 MHDA- 1997/01/01 00:01 PST - ppublish SO - Seishin Shinkeigaku Zasshi. 1997;99(6):355-69. PMID- 9335543 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20061115 PUBM- Print IS - 0006-2960 (Print) VI - 36 IP - 42 DP - 1997 Oct 21 TI - Calmodulin-binding autoinhibitory domain controls "pH-sensing" in the Na+/H+ exchanger NHE1 through sequence-specific interaction. PG - 12854-61 AB - The calmodulin (CaM)-binding domain reduces the affinity of the Na+/H+ exchanger NHE1 for intracellular H+ by exerting an autoinhibitory function in quiescent cells. We replaced this domain (aa 637-656) with homologous segments from other NHE isoforms (NHE2 and 4) or functionally similar regions from other sources (Na+/Ca2+ exchanger, CaM-dependent protein kinase II, plasma membrane Ca2+-pump, or CaM-binding peptide Trp3). The NHE-1-, NHE2-, and NHE4-segments bound CaM with Kds of 16, 130, and 27 nM, respectively. These chimeric molecules were expressed in the exchanger-deficient cell PS120. NHE1 with incorporated NHE2-segment was activated in response to Ca2+-mobilizing agents ionomycin and thrombin resulting in an alkaline shift of the intracellular pH (pHi)-dependence of 22Na+ uptake, as was the case with the intact rat NHE2. In contrast, incorporation of the NHE4-segment or other CaM-binding segments induced a constitutive alkaline shift of pHi-dependence with concomitant abolishment of Ca2+-dependent activation, indicating that these segments could not function as an autoinhibitory domain in NHE1. Detailed analyses revealed that Leu639, Lys651 and Tyr652, conserved in the NHE1- and NHE2-segments, but not in the NHE4-segment, are important for the autoinhibition. Furthermore, 125I-labeled CaM-binding peptide from NHE1 was efficiently crosslinked to the NHE1 protein, suggesting that the inhibitory domain physically interacts with part(s) of the molecule. Together, these findings support the notion that the reduction of H+ affinity in Na+/H+ exchange occurs through a mechanism involving a highly sequence-specific interaction of the inhibitory domain with its putative acceptor in NHE1. AD - Department of Molecular Physiology, National Cardiovascular Center Research Institute, Suita, Osaka 565, Japan. wak@ri.ncvc.go.jp FAU - Wakabayashi, S AU - Wakabayashi S FAU - Ikeda, T AU - Ikeda T FAU - Iwamoto, T AU - Iwamoto T FAU - Pouyssegur, J AU - Pouyssegur J FAU - Shigekawa, M AU - Shigekawa M LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Biochemistry JT - Biochemistry JID - 0370623 RN - 0 (Calmodulin) RN - 0 (Cross-Linking Reagents) RN - 0 (Peptide Fragments) RN - 0 (Recombinant Proteins) RN - 0 (Slc9a2 protein, rat) RN - 0 (Sodium-Hydrogen Antiporter) RN - 0 (growth factor-activatable Na-H exchanger NHE-1) RN - 0 (sodium-hydrogen exchanger 3) RN - 56092-81-0 (Ionomycin) SB - IM MH - Amino Acid Sequence MH - Amino Acid Substitution MH - Animals MH - Base Sequence MH - Binding Sites MH - Calmodulin/*metabolism/pharmacology MH - Cell Line MH - Cross-Linking Reagents MH - *Hydrogen-Ion Concentration MH - Ionomycin/pharmacology MH - Kinetics MH - Molecular Sequence Data MH - Mutagenesis, Site-Directed MH - Peptide Fragments/chemical synthesis/*chemistry/metabolism MH - Rats MH - Recombinant Proteins/antagonists & inhibitors/chemistry/metabolism MH - Sequence Deletion MH - Sequence Homology, Amino Acid MH - Sodium-Hydrogen Antiporter/antagonists & inhibitors/*chemistry/*metabolism MH - Transfection EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - 10.1021/bi9715472 [doi] AID - bi9715472 [pii] PST - ppublish SO - Biochemistry. 1997 Oct 21;36(42):12854-61. PMID- 9356063 OWN - NLM STAT- MEDLINE DA - 19971119 DCOM- 19971119 LR - 20031114 PUBM- Print IS - 0022-5282 (Print) VI - 43 IP - 4 DP - 1997 Oct TI - Cardiopulmonary physiology of primary blast injury. PG - 650-5 AB - OBJECTIVE: Bomb blast survivors are occasionally found in profound shock and hypoxic without external signs of injury. We investigated the cardiovascular and pulmonary responses of rats subjected to a blast pressure wave. DESIGN: Prospectively randomized, controlled animal study. MATERIALS AND METHODS: Rats were instrumented and subjected to a blast pressure wave of different intensities from a blast wave generator. Cardiopulmonary parameters were recorded for 3 hours or until death. MEASUREMENTS AND MAIN RESULTS: The cardiovascular response to a blast pressure wave was immediate bradycardia, hypotension, and low cardiac index. Three hours later, the rats developed hypotension, low cardiac index, and low stroke volume. Interestingly, systemic vascular resistance remained unchanged. The pulmonary response was a decreased PaO2 and stable PacO2, suggesting a ventilation-perfusion mismatch from massive pulmonary hemorrhage. CONCLUSIONS: Blast-induced circulatory shock resulted from immediate myocardial depression without a compensatory vasoconstriction. Hypoxia presumably resulted from a ventilation-perfusion mismatch caused by pulmonary hemorrhage. AD - Department of Surgery, University of Oklahoma Health Sciences Center, and Department of Veterans Affairs Medical Center, Oklahoma City 73126, USA. FAU - Irwin, R J AU - Irwin RJ FAU - Lerner, M R AU - Lerner MR FAU - Bealer, J F AU - Bealer JF FAU - Brackett, D J AU - Brackett DJ FAU - Tuggle, D W AU - Tuggle DW LA - eng PT - Journal Article PL - UNITED STATES TA - J Trauma JT - The Journal of trauma JID - 0376373 SB - AIM SB - IM MH - Animals MH - Blast Injuries/*physiopathology MH - Evaluation Studies MH - Heart Injuries/*physiopathology MH - Hemodynamic Processes MH - Lung/*injuries/*physiopathology MH - Male MH - Prospective Studies MH - Pulmonary Circulation MH - Random Allocation MH - Rats MH - Rats, Sprague-Dawley EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - J Trauma. 1997 Oct;43(4):650-5. PMID- 9323920 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20041117 PUBM- Print IS - 0250-636X (Print) VI - 18 IP - 2 DP - 1997 Apr-Jun TI - Differences in hepatitis B markers between clinical and preclinical health care personnel. PG - 69-71 AB - Hepatitis B virus (HBV) infection is an occupational risk for health care personnel (HCP). Vaccination is an important preventive measure but high cost of vaccination limits the feasibility of giving vaccine to all HCP. To find an optimum approach for vaccination we conducted a study on HCP in Maulana Azad Medical College and associated LNJPN hospital. A total of 162 subjects were screened. Eight were excluded because of prior vaccination against HBV. Two groups of subjects were selected namely preclinical and clinical. The preclinical group comprised first year medical students and the clinical group comprised of HCP who have been exposed to clinical departments. The subjects were screened for HBsAg, anti HBs and anti HBc viral markers. 86 subjects were screened in the preclinical group. Two (2.3%) were positive for HBsAG; 16 (18%) and 9 (10.4%) were positive for anti HBs and anti HBc respectively. In the clinical group a total of 68 subjects were screened. Amongst them 1.4% were positive for HBsAg; 47 (69%) and 38 (55%) were positive for anti HBs and anti HBc respectively. The study revealed that there was a significant difference in the titre of the viral markers in the preclinical group as compared to the clinical group. Seventy (82%) of preclinical subjects were at high risk for the infection as they moved into clinical departments. Few subjects will be excluded from the vaccination schedule based on anti HBs screening and hence screening prior to vaccination is not cost effective. However in the clinical group 69% will be excluded from the vaccination schedule based on anti HBs positivity and screening will save up to 60% of cost involved in vaccination. AD - Department of Medicine, Maulana Azad Medical College, New Delhi, India. FAU - Khurana, V AU - Khurana V FAU - Kar, P AU - Kar P FAU - Mansharamani, N AU - Mansharamani N FAU - Jain, V AU - Jain V FAU - Kanodia, A AU - Kanodia A LA - eng PT - Journal Article PL - INDIA TA - Trop Gastroenterol JT - Tropical gastroenterology : official journal of the Digestive Diseases Foundation JID - 8107122 RN - 0 (Biological Markers) RN - 0 (Hepatitis B Vaccines) SB - IM MH - Adolescent MH - Adult MH - Biological Markers/blood MH - Costs and Cost Analysis MH - Female MH - *Health Personnel MH - Hepatitis B/immunology/*prevention & control MH - *Hepatitis B Vaccines/economics MH - Humans MH - India MH - Male MH - Middle Aged MH - Occupational Diseases/immunology/*prevention & control EDAT- 1997/04/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Trop Gastroenterol. 1997 Apr-Jun;18(2):69-71. PMID- 9380133 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0028-2162 (Print) VI - 141 IP - 22 DP - 1997 May 31 TI - [Malignant pleural mesothelioma in general practice; complex pain problems] PG - 1081-5 AB - In three patients, men aged 67, 57 and 69 years, malignant pleural mesothelioma was diagnosed. All three had worked as coal miners and were presented with thoracic pain. They were among seven cases of malignant pleural mesothelioma diagnosed in a period of five years in one suburban general practice (adherence: 5600 patients) in the former mining area in the province of Limburg. The terminal phase of the disease was characterized by intractable pain. High doses of opioids and adjuvants were necessary to achieve acceptable pain relief. It is suggested that step one of the 'analgesic ladder for cancer pain management' of the WHO (non-opioids) should be followed soon by step three (strong opioids). Because the incidence of pleural mesothelioma is not yet decreasing, it is important to know that pain management remains a serious problem. AD - Universiteit Maastricht, vakgroep Huisartsgeneeskunde. FAU - Leclercq, R M AU - Leclercq RM FAU - Jongmans-Liedekerken, A W AU - Jongmans-Liedekerken AW LA - dut PT - Case Reports PT - English Abstract PT - Journal Article TT - Pleuramesothelioom in de huisartsenpraktijk; gecompliceerde pijnproblemen. PL - NETHERLANDS TA - Ned Tijdschr Geneeskd JT - Nederlands tijdschrift voor geneeskunde JID - 0400770 RN - 0 (Analgesics, Opioid) RN - 1332-21-4 (Asbestos) RN - 57-27-2 (Morphine) SB - IM CIN - Ned Tijdschr Geneeskd. 1997 Aug 9;141(32):1582-3. PMID: 9543758 CIN - Ned Tijdschr Geneeskd. 1997 Aug 9;141(32):1582; author reply 1583. PMID: 9543757 MH - Aged MH - Analgesics, Opioid/administration & dosage/*therapeutic use MH - Asbestos/adverse effects MH - Humans MH - Lung Neoplasms/*complications/etiology MH - Male MH - Mesothelioma/*complications/etiology MH - Middle Aged MH - Morphine/administration & dosage/*therapeutic use MH - Pain, Intractable/etiology/*prevention & control EDAT- 1997/05/31 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Ned Tijdschr Geneeskd. 1997 May 31;141(22):1081-5. PMID- 9303578 OWN - NLM STAT- MEDLINE DA - 19971027 DCOM- 19971027 LR - 20061115 PUBM- Print IS - 0028-1298 (Print) VI - 356 IP - 3 DP - 1997 Sep TI - The interaction of endothelin receptor responses in the isolated perfused rat lung. PG - 392-7 AB - To gain more insight into the complex pulmonary interactions of endothelins (ET), we studied airway and vascular responses to endothelins in isolated perfused rat lungs in the presence of the novel ET(B)-receptor antagonist BQ788. In particular we focused on airway responses and on prostacyclin release. The effectiveness of BQ788 in our system was shown by its ability to concentration-dependently prevent vasoconstriction (IC50 0.1 microM), bronchoconstriction (IC50 0.1 microM) and prostacyclin production (IC50 < 0.1 microM) induced by the ET(B)-receptor agonist IRL1620 (1 nmol). Airway responses to ET-1: ET-1-induced bronchoconstriction was aggravated by BQ123 (1 or 8 microM), while BQ788 pretreatment (1 or 8 microM) showed no significant effect. Simultaneous treatment with 8 microM BQ123 and BQ788 attenuated the ET-1-induced bronchoconstriction. Vascular responses to ET-1: ET-1 (1 nmol)-induced vasoconstriction was potentiated by BQ788 (1 or 8 microM), but attenuated by the ET(A)-receptor antagonist BQ123 (1 microM). In the presence of BQ788 diminished amounts of the stable prostacyclin metabolite 6-keto-PGF1alpha were detected in the perfusate. Simultaneous treatment with 8 microM BQ123 and BQ788 completely prevented the ET-1-induced vasoconstriction. Conclusions: Both ET(A)- and ET(B)-receptors contribute to ET-1-induced vasoconstriction and bronchoconstriction. The ET-1-induced vasoconstriction is attenuated by stimulation of ET(B)-receptors, a response that is partly mediated by prostacyclin. Due to the mutual interactions between ET(A)- and ET(B)-receptors, simultaneous inhibition of both receptors is required to prevent the deleterious effects of ET-1 on lung functions. AD - Biochemical Pharmacology, University of Konstanz, Germany. FAU - Uhlig, S AU - Uhlig S FAU - Featherstone, R L AU - Featherstone RL LA - eng PT - In Vitro PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - GERMANY TA - Naunyn Schmiedebergs Arch Pharmacol JT - Naunyn-Schmiedeberg's archives of pharmacology JID - 0326264 RN - 0 (BQ 788) RN - 0 (Endothelin-1) RN - 0 (Endothelins) RN - 0 (Oligopeptides) RN - 0 (Peptide Fragments) RN - 0 (Peptides, Cyclic) RN - 0 (Piperidines) RN - 0 (Receptor, Endothelin A) RN - 0 (Receptor, Endothelin B) RN - 0 (Receptors, Endothelin) RN - 136553-81-6 (cyclo(Trp-Asp-Pro-Val-Leu)) RN - 142569-99-1 (IRL 1620) RN - 58962-34-8 (6-Ketoprostaglandin F1 alpha) SB - IM MH - 6-Ketoprostaglandin F1 alpha/metabolism MH - Animals MH - Bronchoconstriction/drug effects MH - Drug Interactions MH - Endothelin-1/pharmacology MH - Endothelins/pharmacology MH - Female MH - Lung/blood supply/drug effects/*physiology MH - Muscle, Smooth/drug effects/*physiology MH - Oligopeptides/pharmacology MH - Peptide Fragments/pharmacology MH - Peptides, Cyclic/pharmacology MH - Piperidines/pharmacology MH - Rats MH - Rats, Wistar MH - Receptor, Endothelin A MH - Receptor, Endothelin B MH - Receptors, Endothelin/antagonists & inhibitors/drug effects/*physiology MH - Vasoconstriction/drug effects EDAT- 1997/09/26 MHDA- 1997/09/26 00:01 PST - ppublish SO - Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):392-7. PMID- 9358126 OWN - NLM STAT- MEDLINE DA - 19971106 DCOM- 19971106 LR - 20061115 PUBM- Print IS - 0028-4793 (Print) VI - 337 IP - 19 DP - 1997 Nov 6 TI - A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. PG - 1329-35 AB - BACKGROUND: Patients who undergo total hip replacement have a high risk of thromboembolic complications. Recombinant hirudin (desirudin), a specific inhibitor of thrombin, represents a new development in antithrombotic therapy. We compared the efficacy and safety of desirudin with those of a low-molecular-weight heparin (enoxaparin) for the prevention of thromboembolic complications in patients undergoing primary total hip replacement. METHODS: Both treatments, which were assigned in a randomized, double-blind manner, were started preoperatively: enoxaparin on the evening before surgery, and desirudin within 30 minutes before the start of surgery. The dose of desirudin was 15 mg subcutaneously twice daily, and the dose of enoxaparin was 40 mg subcutaneously once daily. The duration of treatment was 8 to 12 days. Deep-vein thrombosis was verified by bilateral venography performed at the end of the treatment period or earlier, if there were clinical signs of deep-vein thrombosis. RESULTS: At 31 centers in 10 European countries, 2079 eligible patients were randomly assigned to receive desirudin or enoxaparin. A total of 1587 patients were included in the primary analysis of efficacy. In the desirudin group, as compared with the enoxaparin group, there was a significantly lower rate of proximal deep-vein thrombosis (4.5 vs. 7.5 percent, P=0.01; relative reduction in risk, 40.3 percent) and a lower overall rate of deep-vein thrombosis (18.4 vs. 25.5 percent, P=0.001; relative reduction in risk, 28.0 percent). The safety profiles were similar in the two treatment groups. CONCLUSIONS: When administered 30 minutes before total hip replacement surgery, desirudin is more effective than enoxaparin in preventing deep-vein thrombosis. AD - Department of Orthopedics, Sahlgrenska-Ostra University Hospital, Goteborg, Sweden. FAU - Eriksson, B I AU - Eriksson BI FAU - Wille-Jorgensen, P AU - Wille-Jorgensen P FAU - Kalebo, P AU - Kalebo P FAU - Mouret, P AU - Mouret P FAU - Rosencher, N AU - Rosencher N FAU - Bosch, P AU - Bosch P FAU - Baur, M AU - Baur M FAU - Ekman, S AU - Ekman S FAU - Bach, D AU - Bach D FAU - Lindbratt, S AU - Lindbratt S FAU - Close, P AU - Close P LA - eng PT - Clinical Trial PT - Comparative Study PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - N Engl J Med JT - The New England journal of medicine JID - 0255562 RN - 0 (Anticoagulants) RN - 0 (Enoxaparin) RN - 0 (Hirudins) RN - 0 (Recombinant Proteins) RN - 120993-53-5 (desirudin) SB - AIM SB - IM CIN - N Engl J Med. 1997 Nov 6;337(19):1383-4. PMID: 9358134 CIN - N Engl J Med. 1998 Mar 26;338(13):920-1. PMID: 9518290 MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Anticoagulants/administration & dosage/*therapeutic use MH - *Arthroplasty, Replacement, Hip MH - Double-Blind Method MH - Enoxaparin/administration & dosage/*therapeutic use MH - Female MH - Hirudin Therapy MH - Hirudins/administration & dosage/*analogs & derivatives MH - Humans MH - Male MH - Middle Aged MH - Postoperative Complications/*prevention & control MH - Recombinant Proteins/administration & dosage/therapeutic use MH - Thrombophlebitis/etiology/*prevention & control MH - Treatment Outcome EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - N Engl J Med. 1997 Nov 6;337(19):1329-35. PMID- 9377034 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 1026-9428 (Print) IP - 7 DP - 1997 TI - [Clinical and functional aspects of adverse effects of toxic substance complexes in firefighters] PG - 14-8 AB - The study covered influence of combined toxic chemicals on fire extinguishers. Acute exposure of respiratory and peripheral nervous systems was demonstrated. Consequences of the exposure were proved to include polyneuropathies, neuroses and other health disorders. FAU - Potrokhov, O I AU - Potrokhov OI FAU - Dolgikh, D V AU - Dolgikh DV FAU - Kas'ianovskaia, V P AU - Kas'ianovskaia VP FAU - Shevchenko, O I AU - Shevchenko OI LA - rus PT - Comparative Study PT - English Abstract PT - Journal Article TT - Kliniko-funktsional'naia kharakteristika neblagopriiatnogo deistviia kompleksa toksicheskikh veshchestv na organizm likvidatorov pozhara. PL - RUSSIA TA - Med Tr Prom Ekol JT - Meditsina truda i promyshlennaia ekologiia JID - 9434213 RN - 0 (Hazardous Substances) SB - IM MH - Adult MH - *Fires MH - Hazardous Substances/*adverse effects MH - Humans MH - Male MH - Nervous System Diseases/*chemically induced/diagnosis MH - Neurotic Disorders/*chemically induced/diagnosis MH - Occupational Diseases/*chemically induced/diagnosis MH - *Occupations MH - Respiratory Tract Diseases/*chemically induced/diagnosis MH - Time Factors EDAT- 1997/01/01 00:00 MHDA- 1998/02/12 00:01 PST - ppublish SO - Med Tr Prom Ekol. 1997;(7):14-8. PMID- 9322672 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20041117 PUBM- Print IS - 0003-1348 (Print) VI - 63 IP - 10 DP - 1997 Oct TI - Vascular complications of thoracic outlet syndrome. PG - 913-7 AB - Vascular complications of thoracic outlet syndrome are uncommon but may result in significant long-term disability. This report documents a retrospective review of 17 such patients. Ten patients presented with acute onset of upper extremity swelling and axillosubclavian vein thrombosis. One patient presented with chronic, intermittent arm swelling and subclavian vein stenosis. Three patients presented with acute symptoms of upper extremity emboli, and three presented with chronic arm claudication. Cervical ribs were discovered in four patients with arterial symptoms and in no patients with venous symptoms. All ten patients with acute venous thrombosis underwent successful thrombolysis, with venous stenosis uncovered in 8. Thrombolysis was also performed for two patients with arterial emboli. All 17 patients underwent surgical decompression of the thoracic outlet, 16 via a supraclavicular approach and one via a transaxillary approach. One subclavian arteriotomy with endarterectomy and one resection of a subclavian artery aneurysm were performed at the time of decompression. Repeat venography after decompression demonstrated persistent venous stenosis in one patient that was treated with balloon angioplasty and stenting. After a mean of 22 months' follow-up, 12 patients had no residual symptoms, and 5 had experienced significant improvement of symptoms. In conclusion, a combined approach of thrombolysis and surgical decompression of the thoracic outlet provides a salutary outcome in a majority of patients. AD - Department of Surgery, University of Southern California School of Medicine, Los Angeles 90033, USA. FAU - Hood, D B AU - Hood DB FAU - Kuehne, J AU - Kuehne J FAU - Yellin, A E AU - Yellin AE FAU - Weaver, F A AU - Weaver FA LA - eng PT - Journal Article PL - UNITED STATES TA - Am Surg JT - The American surgeon JID - 0370522 SB - IM MH - Acute Disease MH - Adult MH - Aged MH - Aneurysm/surgery MH - Angioplasty, Balloon MH - Arm/*blood supply MH - Axillary Vein/pathology MH - Cervical Rib Syndrome/complications MH - Chronic Disease MH - Constriction, Pathologic/etiology MH - Edema/etiology MH - Embolism/drug therapy/etiology MH - Endarterectomy MH - Female MH - Follow-Up Studies MH - Humans MH - Intermittent Claudication/etiology MH - Male MH - Middle Aged MH - Peripheral Vascular Diseases/drug therapy/*etiology/radiography/surgery MH - Phlebography MH - Retrospective Studies MH - Stents MH - Subclavian Artery/pathology/surgery MH - Subclavian Vein/pathology MH - Thoracic Outlet Syndrome/*complications/surgery MH - Thrombolytic Therapy MH - Thrombosis/drug therapy/etiology MH - Treatment Outcome EDAT- 1997/10/10 MHDA- 1997/10/10 00:01 PST - ppublish SO - Am Surg. 1997 Oct;63(10):913-7. PMID- 9379505 OWN - NLM STAT- MEDLINE DA - 19971110 DCOM- 19971110 LR - 20061115 PUBM- Print IS - 0368-2811 (Print) VI - 27 IP - 4 DP - 1997 Aug TI - Association between p53 mutation and clinicopathological features of non-small cell lung cancer. PG - 211-5 AB - Genetic alterations in exons 5-8 of the p53 gene, determined by single-strand conformation polymorphism and sequencing analyses, and the clinicopathological characteristics of 108 patients with non-small cell lung cancer were compared. Mutations in this gene were found in 37 of the 108 patients (34%): in 30% (23/76) of those with adenocarcinomas, 46% (12/26) of those with squamous cell, 33% (1/3) of those with large cell and 33% (1/3) of those with adenosquamous carcinomas. No associations between the incidence of p53 mutations and the histological or cytological subtypes of adenocarcinomas were found. The analysis of types of mutations, however, showed that GC transversion was relatively common in papillary and clara subtypes, whereas it accounted for only 17% at most of p53 mutations in tubular and bronchial surface epithelial cell subtypes of adenocarcinomas. Univariate analyses revealed that large tumor size, high nodal stage and positive vascular invasion of non-small cell lung cancers, and high nodal stage and high-grade nuclear atypia of adenocarcinomas were associated significantly with p53 mutations. Multivariate analyses showed that the tumor sizes of non-small cell lung cancer correlated with p53 mutations with marginal significance (P = 0.099) whereas nuclear atypia of adenocarcinomas correlated significantly (P = 0.028). No differences between the overall or relapse-free survival rates of patients with and without p53 mutations in non-small cell lung cancers or adenocarcinomas were found. These findings indicate that p53 mutations in adenocarcinomas of the lung are associated with the malignant phenotype of tumor cells, but not with patient survival. AD - Investigative Treatment Division, National Cancer Center Research Institute East, Chiba, Japan. FAU - Guang, S G AU - Guang SG FAU - Ogura, T AU - Ogura T FAU - Sekine, I AU - Sekine I FAU - Yokozaki, M AU - Yokozaki M FAU - Esumi, H AU - Esumi H FAU - Kodama, T AU - Kodama T FAU - Nagai, K AU - Nagai K LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - JAPAN TA - Jpn J Clin Oncol JT - Japanese journal of clinical oncology JID - 0313225 RN - 0 (DNA, Neoplasm) RN - 71-30-7 (Cytosine) RN - 73-40-5 (Guanine) SB - IM MH - Adenocarcinoma/genetics/pathology MH - Adenocarcinoma, Papillary/genetics/pathology MH - Adult MH - Aged MH - Aged, 80 and over MH - Analysis of Variance MH - Base Sequence MH - Carcinoma, Adenosquamous/genetics/pathology MH - Carcinoma, Large Cell/genetics/pathology MH - Carcinoma, Non-Small-Cell Lung/genetics/*pathology MH - Carcinoma, Squamous Cell/genetics/pathology MH - Cell Nucleus/ultrastructure MH - Cytosine MH - DNA, Neoplasm/genetics MH - Disease-Free Survival MH - Epithelium/pathology MH - Exons/genetics MH - Female MH - Genes, p53/*genetics MH - Guanine MH - Humans MH - Incidence MH - Lung Neoplasms/genetics/*pathology MH - Male MH - Middle Aged MH - Multivariate Analysis MH - Mutation/*genetics MH - Neoplasm Invasiveness MH - Neoplasm Staging MH - Phenotype MH - Point Mutation MH - Polymorphism, Single-Stranded Conformational MH - Sequence Analysis, DNA EDAT- 1997/08/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Jpn J Clin Oncol. 1997 Aug;27(4):211-5. PMID- 9331500 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20060424 PUBM- Print IS - 0963-6897 (Print) VI - 6 IP - 5 DP - 1997 Sep-Oct TI - Bone marrow mononuclear cell count does not predict neutrophil and platelet recovery following autologous bone marrow transplant: value of the colony-forming unit granulocyte-macrophage (CFU-GM) assay. PG - 491-5 AB - The common use of the marrow autograft mononuclear cell (MNC) count derives from positive correlative studies following allogeneic transplantation and from earlier conflicting data regarding the value of the bone marrow autograft colony-forming unit granulocyte-macrophage (CFU-GM) assay for prediction hematologic recovery after ABMT. We conducted a retrospective analysis at our institution to determine whether autograft CFU-GM levels predict engraftment of neutrophils and platelets after ABMT in heavily pretreated patients with hematologic malignancies. Between 1 January 1993 and 1 March 1995, 58 heavily pretreated patients received only marrow cells as the autograft product. Patients with Hodgkin's disease (n = 25), acute myeloid leukemia (n = 19), and non-Hodgkin's lymphoma (n = 14) underwent intensive therapy with etoposide and melphalan. Unpurged marrow containing a minimum of 1.5 x 10(8)/kg (range: 1.5-4.8) was infused. Median time to an absolute neutrophil count > or = 0.5 x 10(9)/L was 21 days (range 10-270) and median time to a platelet count > or = 20 x 10(9)/L independent of transfusions was 44 days (range 13-317). There was no correlation between autograft MNC count and neutrophil or platelet engraftment. However, a correlation between autograft CFU-GM and both platelet and neutrophil recovery was demonstrated with a threshold CFU-GM of 3 x 10(4)/kg; delayed neutrophil recovery was observed in 79% of patients below this threshold compared to only 9% in those with an autograft CFU-GM level of more than 3 x 10(4)/kg (p = 0.0001). Similarly, platelet recovery was delayed in 76% of patients below, and 20% of those above this threshold (p = 0.003). We conclude that marrow autograft CFU-GM is predictive of engraftment of both platelets and neutrophils in heavily pretreated patients after ABMT for hematological malignancies. AD - University of Toronto Autologous Blood and Marrow Transplant Program, Toronto Hospital, Ontario, Canada. FAU - al-Fiar, F AU - al-Fiar F FAU - Prince, H M AU - Prince HM FAU - Imrie, K AU - Imrie K FAU - Stewart, A K AU - Stewart AK FAU - Crump, M AU - Crump M FAU - Keating, A AU - Keating A LA - eng PT - Journal Article PL - UNITED STATES TA - Cell Transplant JT - Cell transplantation JID - 9208854 SB - IM MH - Adolescent MH - Adult MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - *Blood Platelets MH - *Bone Marrow Transplantation MH - *Colony-Forming Units Assay MH - Combined Modality Therapy MH - Female MH - Granulocytes MH - Hodgkin Disease/drug therapy/therapy MH - Humans MH - Leukemia, Myeloid/drug therapy/therapy MH - Leukocyte Count MH - Leukocytes, Mononuclear/*cytology MH - Lymphoma, Non-Hodgkin/drug therapy/therapy MH - Macrophages MH - Male MH - Middle Aged MH - *Neutrophils MH - Predictive Value of Tests MH - Retrospective Studies MH - Transplantation, Autologous EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0963689797000535 [pii] PST - ppublish SO - Cell Transplant. 1997 Sep-Oct;6(5):491-5. PMID- 9382486 OWN - NLM STAT- MEDLINE DA - 19971107 DCOM- 19971107 LR - 20061115 PUBM- Print IS - 0273-2289 (Print) VI - 67 IP - 1-2 DP - 1997 Jul-Aug TI - Effect of different proteases on bitterness of hemoglobin hydrolysates. PG - 127-38 AB - Hemoglobin was hydrolyzed by several enzymes (Proctase, Alcalase, Neutrase, papain). Hydrolysates were analyzed (degree of hydrolysis, gel permeation on Superose 12 column, tasting) and fractionated by ultrafiltration and 2-butanol extraction. The bitter peptides were isolated and identified. The results were compared with those already obtained with peptic hemoglobin hydrolysates. All the findings were confirmed. Ultrafiltration concentrated bitter compounds in the fraction corresponding to 500-5000 Da, and these compounds were selectively extracted by 2-butanol. All the bitter peptides belonged to the same fragment of the beta-chain of bovine hemoglobin. Finally, the use of a Superose 12 chromatographic column for easy detection of bitter hydrolysates without sensory analysis could be generalized for hemoglobin hydrolysates. AD - INSA, Centre de Bioingenierie Gilbert Durand (UMR 5504, L.A. INRA), Complexe Scientifique de Rangueil, Toulouse, France. FAU - Aubes-Dufau, I AU - Aubes-Dufau I FAU - Combes, D AU - Combes D LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Appl Biochem Biotechnol JT - Applied biochemistry and biotechnology JID - 8208561 RN - 0 (Butanols) RN - 0 (Hemoglobins) RN - 0 (Peptide Fragments) RN - 78-92-2 (2-butanol) RN - EC 3.4.- (Endopeptidases) RN - EC 3.4.21.- (Subtilisins) SB - IM MH - Amino Acid Sequence MH - Animals MH - Butanols MH - Cattle MH - Chromatography, Gel MH - *Endopeptidases MH - Hemoglobins/*chemistry MH - Humans MH - Hydrolysis MH - Molecular Weight MH - Peptide Fragments/*chemistry/isolation & purification MH - Subtilisins MH - *Taste MH - Ultrafiltration EDAT- 1997/07/01 00:00 MHDA- 1997/11/05 00:01 PST - ppublish SO - Appl Biochem Biotechnol. 1997 Jul-Aug;67(1-2):127-38. PMID- 9335335 OWN - NLM STAT- MEDLINE DA - 19971103 DCOM- 19971103 LR - 20061115 PUBM- Print IS - 0092-8674 (Print) VI - 91 IP - 1 DP - 1997 Oct 3 TI - Components and dynamics of DNA replication complexes in S. cerevisiae: redistribution of MCM proteins and Cdc45p during S phase. PG - 59-69 AB - In S. cerevisiae, the chromatin structure of DNA replication origins changes as cells become competent for DNA replication, suggesting that G1 phase-specific association of replication factors with origin DNA regulates entry into S phase. We demonstrate that ORC, Cdc45p, and MCM proteins are components of prereplication complexes (pre-RC). The MCM-origin association is dependent upon ORC and Cdc6p. During S phase, MCM proteins and Cdc45p dissociate from origin DNA and associate with nonorigin DNA with similar kinetics as DNA Polymerase epsilon, which is present at DNA replication forks. Our results identify protein components of the pre-RC and a novel replication complex appearing at the G1/S transition (the RC), and suggest that after initiation MCM proteins and Cdc45p move with eukaryotic replication forks. AD - Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA. FAU - Aparicio, O M AU - Aparicio OM FAU - Weinstein, D M AU - Weinstein DM FAU - Bell, S P AU - Bell SP LA - eng GR - GM52339/GM/NIGMS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Cell JT - Cell JID - 0413066 RN - 0 (CDC45 protein, S cerevisiae) RN - 0 (CDC47 protein, S cerevisiae) RN - 0 (Carrier Proteins) RN - 0 (Cell Cycle Proteins) RN - 0 (DNA, Fungal) RN - 0 (DNA-Binding Proteins) RN - 0 (Enzyme Inhibitors) RN - 0 (Fungal Proteins) RN - 0 (Nuclear Proteins) RN - 0 (Origin Recognition Complex) RN - 0 (Saccharomyces cerevisiae Proteins) RN - 122544-18-7 (CDC6 protein, S cerevisiae) RN - 127-07-1 (Hydroxyurea) RN - EC 1.17.4.- (Ribonucleotide Reductases) SB - IM MH - Carrier Proteins/*metabolism MH - Cell Cycle/genetics MH - Cell Cycle Proteins/metabolism MH - DNA Replication/*physiology MH - DNA, Fungal/biosynthesis/*metabolism MH - DNA-Binding Proteins/*metabolism MH - Enzyme Inhibitors/pharmacology MH - Fungal Proteins/*metabolism MH - Hydroxyurea/pharmacology MH - Models, Genetic MH - Nuclear Proteins/*metabolism MH - Origin Recognition Complex MH - Replication Origin/genetics MH - Ribonucleotide Reductases/pharmacology MH - S Phase/genetics MH - Saccharomyces cerevisiae/*genetics MH - *Saccharomyces cerevisiae Proteins EDAT- 1997/10/23 MHDA- 1997/10/23 00:01 AID - S0092-8674(01)80009-X [pii] PST - ppublish SO - Cell. 1997 Oct 3;91(1):59-69. PMID- 9330258 OWN - NLM STAT- MEDLINE DA - 19971114 DCOM- 19971114 LR - 20031114 PUBM- Print IS - 0269-283X (Print) VI - 11 IP - 3 DP - 1997 Jul TI - Effects of Plasmodium yoelii nigeriensis infection on Anopheles stephensi egg development and resorption. PG - 265-9 AB - It has been shown previously that infection with Plasmodium yoelii nigeriensis reduces the number of eggs produced by female Anopheles stephensi. Here we examine the mechanism underlying fecundity reduction. Ovaries from infected and uninfected (control) female mosquitoes were examined 12, 24 or 36 h after blood-feeding during the first gonotrophic cycle (replicated) or the second gonotrophic cycle (unreplicated). Follicular development was assessed according to Christophers' stages and the proportions of developing and resorbing follicles per ovary were determined. Resorption of some follicles commenced within 12 h of blood-feeding, affecting significantly more follicles in the infected females: 1.1% v. 3.2%. The difference was greatest 36 h after blood-feeding: 25% reduction (10 v. 35%) in the first cycle; 16% reduction (9 v. 25%) in the second gonotrophic cycle. The mean speed of oogenesis was also found to be significantly retarded in infected mosquitoes. During the second gonotrophic cycle, for example, only 92-94% of follicles reached stage III by 24 h and stage IV by 36 h in infected females, whereas all the developing follicles of uninfected females reached these stages more or less synchronously in the time specified. AD - Department of Biological Sciences, Keele University, Staffordshire, U.K. FAU - Carwardine, S L AU - Carwardine SL FAU - Hurd, H AU - Hurd H LA - eng PT - Journal Article PL - ENGLAND TA - Med Vet Entomol JT - Medical and veterinary entomology JID - 8708682 SB - IM MH - Aedes/parasitology/physiology MH - Analysis of Variance MH - Animals MH - Anopheles/*parasitology/physiology MH - Female MH - *Fertility MH - Host-Parasite Relations MH - Malaria/physiopathology MH - Male MH - Mice MH - Oocytes/physiology MH - Ovary/physiology MH - *Oviposition MH - Parasitemia/physiopathology MH - Plasmodium yoelii/pathogenicity/*physiology EDAT- 1997/07/01 00:00 MHDA- 1997/10/23 00:01 PST - ppublish SO - Med Vet Entomol. 1997 Jul;11(3):265-9. PMID- 9346280 OWN - NLM STAT- MEDLINE DA - 19971121 DCOM- 19971121 LR - 20061115 PUBM- Print IS - 0014-2956 (Print) VI - 248 IP - 2 DP - 1997 Sep 1 TI - Basic residues in the 74-83 and 191-198 segments of protein kinase CK2 catalytic subunit are implicated in negative but not in positive regulation by the beta-subunit. PG - 290-5 AB - Protein kinase CK2 is a ubiquitous pleiotropic serine/threonine protein kinase whose holoenzyme is comprised of two catalytic (alpha and/or alpha') and two non-catalytic, beta-subunits. The beta-subunit possesses antagonist functions that can be physically dissected by generating synthetic fragments encompassing its N-terminal and C-terminal domains. Here we show that by mutating basic residues in the 74-77 and in the 191-198 regions of the alpha-subunit, the negative regulation by the beta-subunit and by its N-terminal synthetic fragment CK2beta-(1-77), which is observable using calmodulin as a substrate for phosphorylation, is drastically reduced. In contrast, the positive regulation by a C-terminal, CK2beta-(155-215)-peptide is unaffected or even increased. Moreover, the basal activity of alpha mutants K74-77A, K79R80K83A, and R191R195K198A toward specific peptide substrates is stimulated by the beta-subunit many fold more than that of alpha wild type, while extrastimulation by beta mutant D55L56E57A, observable with alpha wild type, is abolished with these mutants. These data support the conclusion that down regulation by the acidic residues clustered in the N-terminal moiety of beta is mediated by basic residues in the 74-83 and in the 191-198 sequences of the alpha-subunit. These are also implicated in substrate recognition consistent with the concept that the N-terminal acidic region of the beta subunit operates as a pseudosubstrate. In contrast, another CK2alpha mutant, V66A, is more sensitive to inhibition by either beta-subunit or its N-terminal, CK2beta-(1-77)-peptide, while its stimulation by the C-terminal peptide, CK2beta-(155-215), is comparable to that of alpha wild type. These observations suggest an indirect role of Val66 in conferring to the alpha-subunit a conformation less sensitive to down regulation by beta-subunit. AD - Dipartimento di Chimica Biologica, Universita' di Padova and Centro per lo Studio delle Biomembrane del Consiglio Nazionale delle Ricerche, Italy. FAU - Sarno, S AU - Sarno S FAU - Vaglio, P AU - Vaglio P FAU - Marin, O AU - Marin O FAU - Meggio, F AU - Meggio F FAU - Issinger, O G AU - Issinger OG FAU - Pinna, L A AU - Pinna LA LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - GERMANY TA - Eur J Biochem JT - European journal of biochemistry / FEBS JID - 0107600 RN - 0 (Calmodulin) RN - 0 (Peptide Fragments) RN - 9005-49-6 (Heparin) RN - EC 2.7.1.37 (Casein Kinase II) RN - EC 2.7.1.37 (Protein-Serine-Threonine Kinases) SB - IM MH - Amino Acid Sequence MH - Binding Sites MH - Calmodulin/metabolism MH - Casein Kinase II MH - Down-Regulation MH - Enzyme Activation MH - Heparin/metabolism MH - Molecular Sequence Data MH - Mutation MH - Peptide Fragments/genetics/*metabolism MH - Phosphorylation MH - Protein-Serine-Threonine Kinases/genetics/*metabolism EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Eur J Biochem. 1997 Sep 1;248(2):290-5. PMID- 9378063 OWN - NLM STAT- MEDLINE DA - 19971125 DCOM- 19971125 LR - 20061115 PUBM- Print IS - 0012-0472 (Print) VI - 122 IP - 42 DP - 1997 Oct 17 TI - [Refractory hydrothorax in primary biliary cirrhosis: successful treatment with transjugular intrahepatic portosystemic stent shunt] PG - 1275-80 AB - HISTORY AND CLINICAL FINDINGS: A 55-year-old woman with known primary biliary cirrhosis (PBC) was hospitalized because of increasing dyspnoea. A year before she had for the first time experienced a right-sided pleural effusion which had to be drained every 4 weeks. Physical examination revealed dullness on percussion and greatly decreased breath sounds on auscultation over the entire right thorax. In addition there were signs of moderate ascites and leg oedema. INVESTIGATIONS: Chest radiograph showed a homogeneous shadowing of the right thorax without mediastinal shift. Diagnostic thoracocentesis produced a serous effusion, a transudate on chemical analysis, comparable to the composition of the ascitic fluid. Bacteriological and cytological tests on both fluids were unremarkable. TREATMENT AND COURSE: The right pleural effusion was presumed to be due to a hydrothorax from the ascites caused by portal hypertension associated with the PBC. Despite continuous diuretic treatment and thoracocentesis with albumin substitution every 3 days there was no improvement and implantation of a transjugular intrahepatic portosystemic stent shunt (TIPSS) was performed. This effectively lowered portal pressure and markedly improved the patient's condition so that further thoracocentesis were no longer necessary. 3 weeks after TIPSS implantation she was discharged in good condition. Radiography 3 weeks later demonstrated continued reduction in the hydrothorax. CONCLUSION: Hydrothorax is a rare complication of liver cirrhosis. TIPSS implantation can provide lasting resolution and corresponding clinical improvement of a hydrothorax, especially in those conditions which are refractory to diuretic treatment and thoracocentesis. AD - Abteilung Gastroenterologie und Endokrinologie, Stadtische Kliniken Kassel. FAU - Nolte, W AU - Nolte W FAU - Figulla, H R AU - Figulla HR FAU - Ringe, B AU - Ringe B FAU - Wiltfang, J AU - Wiltfang J FAU - Munke, H AU - Munke H FAU - Hartmann, H AU - Hartmann H FAU - Pausch, J AU - Pausch J FAU - Ramadori, G AU - Ramadori G LA - ger PT - Case Reports PT - English Abstract PT - Journal Article TT - Refraktarer Hydrothorax bei primarer biliarer Zirrhose. Erfolgreiche Therapie durch einen transjugularen intrahepatischen portosystemischen Stent-Shunt. PL - GERMANY TA - Dtsch Med Wochenschr JT - Deutsche medizinische Wochenschrift (1946) JID - 0006723 RN - 0 (Diuretics) SB - IM MH - Diuretics/therapeutic use MH - Female MH - Humans MH - Hydrothorax/etiology/radiography/*surgery/therapy/ultrasonography MH - Liver Cirrhosis, Biliary/*complications MH - Middle Aged MH - *Portasystemic Shunt, Transjugular Intrahepatic MH - Thoracostomy EDAT- 1998/02/12 MHDA- 1998/02/12 00:01 PST - ppublish SO - Dtsch Med Wochenschr. 1997 Oct 17;122(42):1275-80. PMID- 9345446 OWN - NLM STAT- MEDLINE DA - 19971118 DCOM- 19971118 LR - 20061115 PUBM- Print IS - 1352-4585 (Print) VI - 1 IP - 3 DP - 1995 Nov TI - Cardiovascular regulation in multiple sclerosis. PG - 156-62 AB - Traditional assessments of autonomic nervous system function have depended on invasive and complex procedures. Vagal power, which is the respiratory component of heart rate variability (HRV) is an alternative and non-invasive measure for indexing autonomic nervous control of the heart. In the current study, 18 multiple sclerosis (MS) and 20 healthy subjects matched with respect to age, education and intelligence served as subjects. The MS group showed significantly lower vagal power during natural and paced breathing than healthy subjects. Importantly, heart rate did not differ between the two groups. If MS patients exhibit abnormalities in mechanisms mediating cardiac parasympathetic control, the impact on quality of life and vulnerability to adverse cardiac events need to be further evaluated. The results of this study may have implications with respect to the feasibility of using HRV as both a diagnostic and prognostic tool for evaluating parasympathetic nervous system dysfunction and in providing valuable information for developing more effective treatment and rehabilitation strategies. AD - Kessler Institute for Rehabilitation, Department of Research, West Orange, New Jersey 07052, USA. FAU - Diamond, B J AU - Diamond BJ FAU - Kim, H AU - Kim H FAU - DeLuca, J AU - DeLuca J FAU - Cordero, D L AU - Cordero DL LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. PL - ENGLAND TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 SB - IM MH - Adult MH - Analysis of Variance MH - *Cardiovascular Physiology MH - Female MH - Heart Rate/physiology MH - Humans MH - Male MH - Multiple Sclerosis/*physiopathology MH - Neuropsychological Tests MH - Reaction Time MH - Respiration/physiology MH - Spirometry MH - Vagus Nerve/physiology EDAT- 1995/11/01 00:00 MHDA- 1997/11/04 00:01 PST - ppublish SO - Mult Scler. 1995 Nov;1(3):156-62. PMID- 9316922 OWN - NLM STAT- MEDLINE DA - 19971120 DCOM- 19971120 LR - 20041117 PUBM- Print IS - 0095-1137 (Print) VI - 35 IP - 10 DP - 1997 Oct TI - Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodeficiency virus-infected patients. PG - 2639-41 AB - Cerebral toxoplasmosis is a common, opportunistic, and often life-threatening disease in HIV-infected patients. Diagnosis is supported mainly by clinical evidence and computerized tomography or magnetic resonance imaging scans, but brain images may share features with other brain diseases occurring in HIV-infected patients. To determine the diagnostic value of PCR for the detection of Toxoplasma gondii in blood from HIV-infected patients, we examined 89 blood samples from 59 HIV-infected patients. PCR and Southern blot hybridization were done with DNA extracted from blood samples from 20 patients with confirmed cerebral toxoplasmosis and from 10 patients with suspected but not confirmed cerebral toxoplasmosis. The samples were taken before and 7 to 10 days after the beginning of antiparasitic therapy. For 9 patients who suffered from cerebral toxoplasmosis more than 6 months prior to the study and for 20 patients without any evidence for toxoplasmosis only one blood sample per patient was examined. PCR gave positive results with 5 of the 20 blood samples from patients who suffered from cerebral toxoplasmosis. After 7 to 10 days of therapy PCR results became negative in all these five cases. No amplification was seen with DNA from blood samples from the other 54 patients as the target. The results presented here show that PCR testing of blood samples from HIV-infected patients is of limited value for the diagnosis of cerebral toxoplasmosis. The sensitivity was only 25%, but the specificity was very high (100%), so this technique may be useful for discriminating between cerebral toxoplasmosis and other brain diseases which may be mistaken for toxoplasmosis. AD - Department of Internal Medicine I, University of Cologne, Germany. Caspar.Franzen@Uni-Koeln.DE FAU - Franzen, C AU - Franzen C FAU - Altfeld, M AU - Altfeld M FAU - Hegener, P AU - Hegener P FAU - Hartmann, P AU - Hartmann P FAU - Arendt, G AU - Arendt G FAU - Jablonowski, H AU - Jablonowski H FAU - Rockstroh, J AU - Rockstroh J FAU - Diehl, V AU - Diehl V FAU - Salzberger, B AU - Salzberger B FAU - Fatkenheuer, G AU - Fatkenheuer G LA - eng PT - Clinical Trial PT - Journal Article PL - UNITED STATES TA - J Clin Microbiol JT - Journal of clinical microbiology JID - 7505564 SB - IM SB - X MH - HIV Infections/complications/*parasitology MH - Humans MH - Polymerase Chain Reaction/*methods MH - Predictive Value of Tests MH - Tomography MH - Toxoplasmosis, Cerebral/blood/complications/*diagnosis EDAT- 1997/10/08 MHDA- 1997/10/08 00:01 PST - ppublish SO - J Clin Microbiol. 1997 Oct;35(10):2639-41. PMID- 9296268 OWN - NLM STAT- MEDLINE DA - 19971028 DCOM- 19971028 LR - 20061115 PUBM- Print IS - 0003-9969 (Print) VI - 42 IP - 7 DP - 1997 Jul TI - Molecular cloning and characterization of the bovine tuftelin gene. PG - 489-96 AB - The bovine tuftelin gene was cloned and its structure determined by DNA sequence analysis and comparison to that of bovine tuftelin cDNA. The analyses demonstrated that the cDNA contains a 1014-bp open reading frame encoding a protein of 338 residues with a calculated mol. wt of 38,630 and an isoelectric point of 5.85. These results differ from those previously published, (1991) which contained a different conceptual amino acid sequence for the carboxy terminal region and identified a different termination codon. The protein does not appear to share homology or domain motifs with any other known protein. The gene consists of 13 exons ranging in size from 66 to 1531 bp, the latter containing the encoded carboxyterminal and 3' untranslated regions. The exons are embedded in more than 28 kbp of genomic DNA. Codons are generally not divided at exon/intron borders. Several alternatively spliced transcripts were identified by DNA sequence analysis of the isolated products produced by reverse transcriptase/polymerase chain reaction. AD - Research Center in Oral Biology, University of Pennsylvania School of Dental Medicine, Philadelphia 19104, USA. FAU - Bashir, M M AU - Bashir MM FAU - Abrams, W R AU - Abrams WR FAU - Rosenbloom, J AU - Rosenbloom J LA - eng GR - DE08239/DE/NIDCR GR - DE10620/DE/NIDCR PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - ENGLAND TA - Arch Oral Biol JT - Archives of oral biology JID - 0116711 RN - 0 (DNA, Complementary) RN - 0 (Dental Enamel Proteins) RN - 0 (tuftelin) SB - D SB - IM MH - Alternative Splicing MH - Amino Acid Sequence MH - Animals MH - Base Sequence MH - Blotting, Northern MH - Cattle MH - Cloning, Molecular/*methods MH - DNA, Complementary/genetics MH - Dental Enamel Proteins/*genetics MH - Exons/genetics MH - Genomic Library MH - Introns/genetics MH - Molecular Sequence Data MH - Sequence Analysis, DNA/methods MH - Transcription, Genetic EDAT- 1997/07/01 00:00 MHDA- 1997/09/20 00:01 AID - S0003-9969(97)00039-3 [pii] PST - ppublish SO - Arch Oral Biol. 1997 Jul;42(7):489-96. PMID- 9343165 OWN - NLM STAT- MEDLINE DA - 19971113 DCOM- 19971113 LR - 20061115 PUBM- Print IS - 0022-538X (Print) VI - 71 IP - 11 DP - 1997 Nov TI - Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. PG - 8149-56 AB - Abelson murine leukemia virus transforms pre-B cells in vitro and induces rapid-onset pre-B-cell lymphoma in vivo. Expression of an active v-Abl protein tyrosine kinase is required for the oncogenic functions of the virus. Despite the strong growth-stimulatory signal provided by v-Abl, the virus-induced tumors are clonal or oligoclonal, and changes in the growth and oncogenic potential of in vitro transformants occur during the derivation of the cell lines. Both of these features suggest that v-Abl expression must be complemented by changes in expression of one or more cellular genes for cells to acquire a fully malignant phenotype. Such genes could include other oncogenes or tumor suppressor genes. Among the latter is Tp53, a gene mutated in many spontaneous cancers. To determine if mutation of the Tp53 tumor suppressor gene plays a role in Abelson virus transformation, conformation-specific monoclonal antibodies were used to examine p53 expression in a panel of Abelson virus-transformed pre-B cells. Expression of mutant forms of p53 was detected in over 40% of the isolates. Sequence analysis revealed the presence of point mutations affecting the highly conserved central portion of the protein. These mutations interfered with the ability of p53 to activate transcription from a promoter containing p53-responsive elements and to induce apoptosis in response to DNA damage. In addition, cells expressing mutant forms of p53 induced a higher frequency of tumors with a more rapid course compared to transformants expressing wild-type p53. These data suggest that Tp53 is one important cellular gene involved in malignant transformation by Abelson virus. AD - Department of Pathology and Graduate Program in Immunology, Tufts University School of Medicine, Boston, Massachusetts 02111, USA. FAU - Thome, K C AU - Thome KC FAU - Radfar, A AU - Radfar A FAU - Rosenberg, N AU - Rosenberg N LA - eng GR - CA 33771/CA/NCI PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - J Virol JT - Journal of virology JID - 0113724 RN - 0 (Transcription Factors) RN - 0 (Tumor Suppressor Protein p53) SB - IM MH - Abelson murine leukemia virus/*genetics MH - Amino Acid Substitution MH - Apoptosis/radiation effects MH - B-Lymphocytes/virology MH - Cell Transformation, Viral/*genetics MH - Cells, Cultured MH - DNA Damage MH - Gamma Rays MH - *Genes, p53 MH - Mutation MH - Transcription Factors/genetics MH - Tumor Suppressor Protein p53/*genetics/physiology EDAT- 1997/10/29 MHDA- 1997/10/29 00:01 PST - ppublish SO - J Virol. 1997 Nov;71(11):8149-56. PMID- 9351973 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0026-895X (Print) VI - 52 IP - 5 DP - 1997 Nov TI - Phosphorylation of the Kv2.1 K+ channel alters voltage-dependent activation. PG - 821-8 AB - The voltage-gated delayed-rectifier-type K+ channel Kv2.1 is expressed in high-density clusters on the soma and proximal dendrites of mammalian central neurons; thus, dynamic regulation of Kv2.1 would be predicted to have an impact on dendritic excitability. Rat brain Kv2.1 polypeptides are phosphorylated extensively, leading to a dramatically increased molecular mass on sodium dodecyl sulfate gels. Phosphoamino acid analysis of Kv2.1 expressed in transfected cells and labeled in vivo with 32P shows that phosphorylation was restricted to serine residues and that a truncation mutant, DeltaC318, which lacks the last 318 amino acids in the cytoplasmic carboxyl terminus, was phosphorylated to a much lesser degree than was wild-type Kv2.1. Whole-cell patch-clamp studies showed that the voltage-dependence of activation of DeltaC318 was shifted to more negative membrane potentials than Kv2.1 without differences in macroscopic kinetics; however, the differences in the voltage-dependence of activation between Kv2.1 and DeltaC318 were eliminated by in vivo intracellular application of alkaline phosphatase, suggesting that these differences were due to differential phosphorylation. Similar analyses of other truncation and point mutants indicated that the phosphorylation sites responsible for the observed differences in voltage-dependent activation lie between amino acids 667 and 853 near the distal end of the Kv2.1 carboxyl terminus. Together, these parallel biochemical and electrophysiological results provide direct evidence that the voltage-dependent activation of the delayed-rectifier K+ channel Kv2. 1 can be modulated by direct phosphorylation of the channel protein; such modulation of Kv2.1 could dynamically regulate dendritic excitability. AD - Department of Biochemistry and Cell Biology and Institute for Cell and Developmental Biology, State University of New York at Stony Brook, Stony Brook, New York 11794-5215, USA. FAU - Murakoshi, H AU - Murakoshi H FAU - Shi, G AU - Shi G FAU - Scannevin, R H AU - Scannevin RH FAU - Trimmer, J S AU - Trimmer JS LA - eng GR - NS34375/NS/NINDS GR - NS34383/NS/NINDS PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Mol Pharmacol JT - Molecular pharmacology JID - 0035623 RN - 0 (Delayed Rectifier Potassium Channels) RN - 0 (Kcnb1 protein, rat) RN - 0 (Potassium Channels) RN - 0 (Potassium Channels, Voltage-Gated) RN - 0 (Shab Potassium Channels) RN - 56-45-1 (Serine) SB - IM MH - Animals MH - Brain/metabolism MH - COS Cells/metabolism MH - Delayed Rectifier Potassium Channels MH - Membrane Potentials MH - Patch-Clamp Techniques MH - Phosphorylation MH - Point Mutation MH - Potassium Channels/chemistry/genetics/metabolism/*physiology MH - *Potassium Channels, Voltage-Gated MH - Precipitin Tests MH - Rats MH - Serine/chemistry MH - Shab Potassium Channels MH - Transfection EDAT- 1997/11/14 MHDA- 1997/11/14 00:01 PST - ppublish SO - Mol Pharmacol. 1997 Nov;52(5):821-8. PMID- 9309626 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0195-9131 (Print) VI - 29 IP - 9 DP - 1997 Sep TI - Effects of estradiol on substrate turnover during exercise in amenorrheic females. PG - 1160-9 AB - The purpose of this investigation was to determine the effects of transdermal estradiol (E2) replacement on substrate utilization during exercise. Amenorrheic females (N = 6) performed three exercise trials following 72 h of placebo (C 72) and 72 and 144 h of medicated transdermal estradiol (E2) treatment (E2 72 and E2 144). Exercise involved 90 min of treadmill running at 65% VO2max followed by timed exercise to exhaustion at 85% VO2max. Resting blood samples were obtained for glucose, insulin, free fatty acids (FFA), and E2. Exercise blood samples were obtained for E2, lactate, epinephrine, and norepinephrine. Rates of appearance and disposal were calculated for glucose and glycerol using a primed, continuous infusion of [6,6-2H] glucose and [2H5] glycerol. Medicated transdermal placement increased E2 significantly at rest, before exercise (35.03 +/- 12.3, 69.5 +/- 20.1, and 73.1 +/- 31.6 pg.mL-1 for the C 72, E2 72, and E2 144 trials, respectively, P < 0.05). Resting FFA increased significantly following E2 treatment (0.28 +/- 0.16, 0.41 +/- 0.27, and 0.40 +/- 0.21 mmol.L-1 for the C 72, E2 72, and E2 144 trials, respectively, P < 0.05). Glucose Ra was significantly decreased during exercise as a result of E2 replacement (21.9 +/- 7.7, 18.9 +/- 6.2, and 18.9 +/- 5.6 mumol.kg-1.min-1 for the C 72, E2 72, and E2 144 trials, respectively, P < 0.05). Average glucose Rd also decreased during exercise as a result of E2 replacement (21.3 +/- 7.8, 18.5 +/- 6.4, and 18.6 +/- 5.8 mumol.kg-1.min-1 for the C 72, E2 72, and E2 144 trials, respectively, P < 0.05). However, the estimated relative contribution of plasma glucose and muscle glycogen to total carbohydrate oxidation was similar among the trials. Epinephrine values were significantly lower late in exercise during the E2 72 and E2 144 trials, compared with the C 72 trial (P < 0.05). These results indicate that elevated E2 levels can alter glucose metabolism at rest and during moderate intensity exercise as a result of decreased gluconeogenesis, epinephrine secretion, and/or glucose transport. AD - Center for Exercise and Applied Human Physiology, University of New Mexico, Albuquerque 87131-1258, USA. ruby@selway.umt.edu FAU - Ruby, B C AU - Ruby BC FAU - Robergs, R A AU - Robergs RA FAU - Waters, D L AU - Waters DL FAU - Burge, M AU - Burge M FAU - Mermier, C AU - Mermier C FAU - Stolarczyk, L AU - Stolarczyk L LA - eng GR - 5 M01 RR00997-18/RR/NCRR PT - Clinical Trial PT - Controlled Clinical Trial PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - UNITED STATES TA - Med Sci Sports Exerc JT - Medicine and science in sports and exercise JID - 8005433 RN - 50-28-2 (Estradiol) RN - 50-99-7 (Glucose) RN - 56-81-5 (Glycerol) SB - IM SB - S MH - Administration, Cutaneous MH - Adult MH - Amenorrhea/*physiopathology MH - Energy Metabolism MH - Estradiol/*pharmacology MH - Estrogen Replacement Therapy MH - Exercise/*physiology MH - Female MH - Glucose/*metabolism MH - Glycerol/metabolism MH - Humans MH - Sports/physiology EDAT- 1997/10/06 MHDA- 1997/10/06 00:01 PST - ppublish SO - Med Sci Sports Exerc. 1997 Sep;29(9):1160-9. PMID- 9296327 OWN - NLM STAT- MEDLINE DA - 19971030 DCOM- 19971030 LR - 20061115 PUBM- Print IS - 0306-5251 (Print) VI - 44 IP - 3 DP - 1997 Sep TI - Excretion of citalopram in breast milk. PG - 295-8 AB - AIMS: The objective of this study was to measure to secretion of the selective serotonin uptake inhibitor citalopram in breast milk. METHODS: The excretion of citalopram in breast milk was studied at steady-state conditions in two patients with depression and in one healthy volunteer after ingestion of a single dose citalopram. RESULTS: Milk/serum concentration ratios based on single pairs of samples from the two patients ranged from 1.16 to 1.88. Based on milk concentration data from the patients, the absolute dose ingested by a suckling infant would be 4.3-17.6 micrograms kg-1 day-1, and the relative dose 0.7-5.9% of the weight-adjusted maternal dose. Based on area-under-the-time-concentration curves from the healthy volunteer, the milk/serum ratio was 1.00, the absolute dose to the infant during steady-state conditions would be 11.2 micrograms kg-1 day-1 and the relative dose 1.8% of the weight-adjusted maternal dose. CONCLUSION: The study shows that the relative dose to a suckling infant is close to that reported for fluoxetine, and higher than reported for fluvoxamine, paroxetine and sertraline. AD - Division of Clinical Pharmacology, Norrland University Hospital, Umea, Sweden. FAU - Spigset, O AU - Spigset O FAU - Carieborg, L AU - Carieborg L FAU - Ohman, R AU - Ohman R FAU - Norstrom, A AU - Norstrom A LA - eng PT - Comparative Study PT - Journal Article PL - ENGLAND TA - Br J Clin Pharmacol JT - British journal of clinical pharmacology JID - 7503323 RN - 0 (Antidepressive Agents) RN - 0 (Serotonin Uptake Inhibitors) RN - 0 (Triglycerides) RN - 59729-33-8 (Citalopram) SB - IM MH - Adult MH - Antidepressive Agents/*metabolism/therapeutic use MH - Breast Feeding MH - Citalopram/*metabolism/therapeutic use MH - Depressive Disorder/drug therapy/metabolism MH - Female MH - Humans MH - Infant MH - Milk, Human/chemistry/*metabolism MH - Serotonin Uptake Inhibitors/*metabolism/therapeutic use MH - Triglycerides/chemistry EDAT- 1997/09/20 MHDA- 1997/09/20 00:01 PST - ppublish SO - Br J Clin Pharmacol. 1997 Sep;44(3):295-8. PMID- 9348196 OWN - NLM STAT- MEDLINE DA - 19971124 DCOM- 19971124 LR - 20061115 PUBM- Print IS - 0013-7227 (Print) VI - 138 IP - 11 DP - 1997 Nov TI - Simultaneous measurement of gonadotropin-releasing hormone in the third ventricular cerebrospinal fluid and hypophyseal portal blood of the ewe. PG - 4699-704 AB - GnRH is present in the hypophyseal portal blood and cerebrospinal fluid (CSF) of several species investigated, including sheep, but the precise relationship between these two compartments of GnRH is unknown. In the present study, ovariectomized steroid-treated ewes were surgically prepared for the simultaneous collection of portal blood and third ventricular CSF. Ten-minute samples were collected for pulse analysis after progesterone removal and hourly for comparisons during the estradiol-induced LH surge. The time of onset of the portal (15.3 +/- 0.5 h after estradiol) and CSF (15.9 +/- 0.2 h) GnRH surges was similar and occurred coincidentally with the LH surge (15.6 +/- 0.4 h). The period of the surge during which GnRH concentrations exceeded half-maximal levels (portal, 7.3 +/- 1.5 h; CSF, 7.3 +/- 0.3 h) was the same and outlasted the corresponding LH surge period (3.3 +/- 0.3 h). LH pulses started and peaked later than the corresponding portal GnRH pulses (onset difference, 10 +/- 1 min; peak difference, 16 +/- 1 min; P < 0.01 for both), but the times of pulse onset and peak were not significantly different from those of concomitant CSF GnRH pulses (onset difference, 8 +/- 6 min; peak difference, 8 +/- 4 min). Although the times of pulse onset and peak did not differ between the portal and CSF GnRH compartments (onset difference, 4 +/- 6 min; peak difference, 6 +/- 2 min), CSF GnRH pulses were longer than their portal counterparts (CSF, 38 +/- 3 min; portal, 15 +/- 1 min; P < 0.01). The amplitude of jugular LH pulses was strongly correlated (r2 = 0.85) with portal GnRH pulse amplitude, but not with that of CSF GnRH pulses (r2 = 0.45); there was no correlation between portal and CSF GnRH pulse amplitudes (r2 = 0.25). These data show that third ventricular CSF GnRH reliably relates neurosecretory events occurring within the hypophyseal portal system at the time of the preovulatory LH surge, but is not as precise as portal GnRH in marking a LH pulse. AD - Laboratory of Neuroendocrinology, The Babraham Institute, Cambridge, United Kingdom. skinner@tours.inra.fr FAU - Skinner, D C AU - Skinner DC FAU - Caraty, A AU - Caraty A FAU - Malpaux, B AU - Malpaux B FAU - Evans, N P AU - Evans NP LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - UNITED STATES TA - Endocrinology JT - Endocrinology JID - 0375040 RN - 33515-09-2 (Gonadotropin-Releasing Hormone) RN - 50-28-2 (Estradiol) RN - 9002-67-9 (Luteinizing Hormone) SB - AIM SB - IM MH - Animals MH - Estradiol/pharmacology MH - Female MH - Gonadotropin-Releasing Hormone/*blood/*cerebrospinal fluid MH - Luteinizing Hormone/blood MH - Ovariectomy MH - Pituitary Gland/*blood supply MH - Pulsatile Flow MH - Sheep MH - Time Factors EDAT- 1997/11/05 MHDA- 1997/11/05 00:01 PST - ppublish SO - Endocrinology. 1997 Nov;138(11):4699-704.